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ABSTRACT 
Human cytomegalovirus (HCMV) is the leading infectious cause of birth defects and 
neurodevelopmental delay, with worst outcomes in congenital infection. HCMV 
exacerbates neurological disease and progression to AIDS in HIV co-infected infants. In 
Zambia HCMV has adverse effects on growth and development even in maternally HIV-
exposed uninfected infants, affecting a third. Transmission to infants can be congenital 
or postnatal primarily through breast milk, similar to HIV. However, the route affecting 
infant development is not established, but critical to understand for deployment of 
appropriate interventions and hospital diagnostics. In this thesis, congenital HCMV 
infection was investigated in newborns using PCR and nucleotide sequencing of saliva 
and umbilical cord DNA, and showed 1% prevalence, which was too low to account for 
the widespread adverse growth effects. Therefore, maternal HCMV secretion via breast 
milk and the effects of maternal HIV were investigated. HCMV viral loads were measured 
by qPCR in 461 breast milk samples from both HIV-infected and uninfected mothers at 
postpartum day 3 and weeks 2, 4, 9, 12, and 16. Results showed higher HCMV viral loads 
and longer secretion in HIV-positive compared to negative mothers, peaking at week 4 
(p=.026) and remaining elevated at week 16 (p<.001). HCMV strains were investigated 
using the hypervariable glycoprotein gO, with all eight genotypes detected, but no 
relationship to viral load. Next, Illumina NGS was used to further analyse strains and 
mixed infections in order to assess the burden of infection. A script was developed to 
identify linked gO and gN 'Molecular tags' via analyses of FASTQ reads. In 21 samples, 
mixed infections were identified, showing 1-7 genotypes and a dominant genotype 
constituting 45-100%. ZMB240, a full-length HCMV genome - the first reference strain 
from a healthy donor representing a transmission population, and also first from Africa 
- was derived directly from breast milk DNA and found similar to elsewhere, including 
the reference Merlin. Overall, the thesis provided evidence that breast milk is the 
principal route for early HCMV infection in breastfed Zambian infants, and that maternal 
HIV increases HCMV load, burden of infection, and duration of secretion in breast milk, 
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Human Cytomegalovirus (HCMV), classified as Human betaherpesvirus 5 (HHV-5) (ICTV, 
2016), is the leading infectious cause of birth defects including intrauterine growth 
restriction, stillbirth, low birthweight, preterm birth, microcephaly, 
neurodevelopmental delay, cerebral palsy, haematological disorders, pneumonitis, 
blindness, and sensorineural hearing loss (Cheeran et al., 2009, Iwasenko et al., 2011, 
Fowler et al., 1992, Noyola et al., 2001, Pass et al., 2006, McClure et al., 2010, Pereira et 
al., 2014, Boppana and Fowler, 2007, Boppana et al., 1999, Griffiths and Walter, 2005). 
Although HCMV infection is generally clinically silent in immunocompetent hosts, 
primary infection in young adults can manifest as a transient flu-like mononucleosis 
illness. In individuals with immature or compromised immunity – neonates, the 
HIV/AIDS infected, and those on long-term immunosuppressive treatments, such as 
transplant recipients – HCMV infection often results in clinically overt disease. The worst 
outcomes, including mortality and long-term morbidity, are with congenital infection, 
which however remains challenging to detect and mitigate early, since only up to about 
10% of congenitally infected neonates are symptomatic at birth. Nevertheless, 15% of 
asymptomatic congenitally infected infants go on to develop long-term sequelae 
including progressive hearing loss and learning difficulties in later childhood (Kovacs et 
al., 1999, Rosenthal et al., 2009, Ross and Boppana, 2005). The gravity of these 
deleterious effects is compounded by HIV-1 immunosuppression, which enables new 
and reactivated HCMV infections to cause HIV/AIDS-associated disease, particularly in 
the absence of antiretroviral therapy. This is of particular relevance to Zambia, a country 
where HIV-1 is endemic. In HIV-infected infants, HCMV coinfection has been shown to 
accelerate progression to AIDS and to exacerbate neurological disease, leading to 
developmental delay and motor deficit (Kovacs et al., 1999, Doyle et al., 1996). Other 
studies, including from our laboratory, indicate highly prevalent infant HCMV infections 
and severe effects of HCMV and HIV-1 co-infection on child health, growth, 
development, and survival. The detrimental effects of HCMV have also been 
demonstrated in maternally HIV-exposed uninfected (HEU) infants, a growing cohort 
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with the largely successful implementation of prevention of mother-to-child HIV 
transmission (PMTCT) programs and widespread use of Highly Active Antiretroviral 
Therapy (HAART) in HIV-endemic regions (Bates et al., 2008, Gompels et al., 2012, Sanz-
Ramos et al., 2013, Gantt et al., 2008, Slyker et al., 2009a, van der Sande et al., 2007). 
 
In the Chilenje Infant Growth Nutrition and Infection Study (CIGNIS), a nutrition 
intervention study conducted in Zambia (ISRCTN37460449, http://www.controlled-
trials.com/mrct), our laboratory showed that 83% of infants are HCMV seropositive by 18 
months age in Zambia (Bates et al., 2008). This is similar in some developing countries 
but higher than in many global regions (van der Sande et al., 2007, Cannon et al., 2010, 
Dowd et al., 2009, Vyse et al., 2009, Bate et al., 2010). During the CIGNIS trial (Gompels 
et al., 2012), stunting was three times more prevalent among infants who were 
seropositive for HCMV compared to those seronegative. Those who were also 
maternally HIV-exposed had reduced head size and scored lower in psychomotor 
development tests. Further, HIV-exposed HCMV-viremic infants had more frequent 
hospital referrals compared to their HIV-unexposed peers. Immunological responses to 
routine childhood vaccines were assessed in the CIGNIS cohort, and sadly, HIV-exposed 
infants had weaker short-lived responses, which worsened if they were also infected 
with HCMV (Sanz-Ramos et al., 2013). These HCMV effects remained unaltered by 
dietary intervention. Since children were recruited to CIGNIS at 6 months age, the route 
of HCMV acquisition – whether congenital or postnatal – was not clear in this cohort. 
However this is important to determine so that appropriate, targeted interventions can 
be formulated to mitigate the detrimental HCMV effects highlighted above. With 40% 
(226/562) infants having HCMV DNAemia at recruitment to CIGNIS, it was unlikely that 
the observed effects could be attributed solely to congenital HCMV infection. A role for 
postnatal infection is thus implied, and investigated further in this thesis via analysis of 
breast milk. Despite the highlighted possible serious effects of HCMV, there are 
currently no routine diagnoses established for its detection in Zambia. This thesis 
therefore also trialled the use of non-invasive samples including saliva and breast milk, 
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1.2 VIRUS CLASSIFICATION AND MORPHOLOGY 
With the recent recognition of human herpesvirus 6A (HHV-6A) and human herpesvirus 
6B (HHV-6B) as distinct virus species (Ablashi et al., 2013, Adams and Carstens, 2012), 
nine distinct herpesviruses, including HCMV, are currently known to infect man. These 
viruses are grouped under the human Herpesviridae family, and on the basis of 
replication and latency, are further classified into three subfamilies – the Alpha, Beta, 
and Gammaherpesvirinae (ICTV, 2016). The Alphaherpesvirinae are mostly neurotropic, 
with a relatively short replication cycle, quick spread, and efficient cell lysis in culture. 
They exhibit a relatively broad host species range and establish latency primarily in 
neuronal ganglia. Members include herpes simplex virus types 1 and 2 (HSV-1 and HSV-
2) and varicella-zoster virus (VZV) (Roizman and Pellett, 2007). The Betaherpesvirinae, 
the topic of this thesis, have a rather restricted host range and long replication cycles. 
Infection of cell cultures is slow, and infected cells become enlarged. Viruses establish 
latency in haematopoietic cells in the bone marrow (Kondo et al., 1994, Kondo et al., 
1991, Reeves and Sinclair, 2008, Sinclair, 2008, Sinclair and Sissons, 2006, Roizman and 
Pellett, 2007). Members include HCMV, HHV-6A, HHV-6B, and human herpesvirus 7 
(HHV-7). Finally, subfamily Gammaherpesvirinae encompasses the lymphotropic 
Epstein-Barr virus (EBV) and Kaposi’s sarcoma-associated herpesvirus (KSHV), which 
infect and establish latency in lymphocytes. Both EBV and KSHV are oncogenic viruses 
(ICTV, 2016, Roizman and Pellett, 2007). 
 
The main characteristic shared by members of the Herpesviridae family is the ability to 
remain in a latent or persistent state for the lifetime of the host, with reactivations 
occurring periodically. Herpes viruses are distinctively large, double-stranded DNA 
viruses belonging to Baltimore group I (Baltimore, 1971). Virions are 150–300nm 
spherical to pleomorphic particles that possess a 240kbp monopartite double stranded 
linear DNA genome. The genome is packaged together with a lytic origin of DNA 
replication (oriLyt)-associated RNA in an icosahedral capsid, which is encased by a thick 
protein-rich amorphous tegument, in turn surrounded by a lipid bi-layer membrane, 
studded with glycoproteins (Figure 1.1A). 
 
Apart from encoding structural proteins, the HCMV genome encodes numerous non-
structural proteins and non-coding RNAs that regulate the complex viral replication cycle 
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and modulate interactions with the host’s immune system. The capsid is 110-130nm in 
diameter and constructed from mainly five herpesvirus core proteins: major capsid 
protein (MCP, the UL86 gene product), minor capsid protein (TRI1, the UL46 gene 
product), minor capsid protein binding protein (TRI2, the UL86 gene product); the 
smallest capsid protein (SCP, the UL48A gene product), and portal protein (PORT, the 
UL104 gene product). These proteins are organised into 162 capsomeres (150 hexamers 
and 12 pentamers), with 320 triplexes between the capsomeres. A portal complex 
(composed of the PORT protein) occupies one of the 12 pentamer positions, and 
facilitates viral genome entry into / exit from the capsid. Surrounding the capsid is the 
approximately 50nm thick tegument, which includes in excess of 27 relatively abundant 
virus-encoded proteins, plus a selection of cellular and viral RNAs. The tegument is 
clothed by a 10nm-thick lipid bilayer envelope derived from the host cell endoplasmic 
reticulum-Golgi intermediate compartment (ERGIC). The virion envelope contains no 
less than 20 virus-encoded glycoproteins, which serve various functions including 
adsorption to host cells. (Gibson, 2008, Mocarski Jr and Pass, 2008, Mocarski Jr et al., 
2007). With the envelope peeled back, negatively stained virions take on a characteristic 














Figure 1.1. Herpesvirus ultrastructure. [A] Key components of Cytomegalovirus virions. 
Image available online at www.viralzone.expasy.org/all_by_species/180.html [B] 
Electron micrograph of negatively stained virion showing the typical ‘fried egg’ 
appearance. Image Copyright Dr Linda M Stannard, 1995, University of Cape Town 
(accessed at http://www.virology.uct.ac.za/vir/teaching/linda-stannard/herpesvirus). 
Nucleocapsid 
Tegument 
Lipid envelope with 
glycoprotein spikes 
[B] 
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A brief historical note … 
The earliest histopathological evidence of the characteristic intranuclear inclusions 
(figure 1.2) typical of cytomegalovirus infection was by German pathologist Hugo 
Ribbert, who reported his observations in 1881 of enlarged cells with eccentrically 
placed nuclei that contained a “central nuclear body” surrounded by a clear halo in 
kidney and parotid gland sections taken from demised syphilitic infants. Later these 
intranuclear inclusions were also observed in lung and liver cells. 
 
 
Figure 1.2. Histological section of kidney showing 
HCMV-infected cells with the typical ‘Owl’s eye’ 
appearance due to intranuclear inclusions (arrows). 
Image reproduced with permission from Herriot R. 
(1994) NEJM Vol 331:649 No.10 (Herriot and Gray, 
1994), Copyright Massachusetts Medical Society. 
 
 
At that time, and for much of the early 20th century when more reports of similar 
histopathological observations continued to emerge from other scientists, the inclusion 
bodies were attributed to syphilis or protozoa. However, in 1921 Goodpasture and 
Talbert suggested that a viral agent could cause these “cytomegalic inclusions”, and with 
the independent finding of the inclusions in herpes zoster and herpes genitalis lesions, 
doubt was cast on a protozoal cause and the suggestion of a viral link strengthened. This 
was further consolidated after the development of electron microscopy in the 1930s. 
Because the pathological changes in the liver and kidney were noted to occur in the 
absence of inflammatory signs, Goodpasture and Talbert postulated that the causal 
agent could be blood-borne, and in 1950 Smith and Vellios demonstrated that the 
infection could even be spread in utero. The establishment of tissue culture systems in 
the 1950s finally led to the isolation of HCMV from salivary glands independently by 
three research teams led by Smith, Rowe, and Weller. Weller subsequently proposed 
the term “cytomegalovirus” in 1960 (Ho, 2008, Plachter et al., 1996, Riley, 1997). Since 
then the virus has been isolated from every human population group and continues to 
be topical in the medical research community. HCMV is increasingly recognized as a 
critically important, complex, and highly successful pathogen. 
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1.3 GENOME ORGANISATION AND CONTENT 
Based on a scheme proposed by Roizman and Pellet (Roizman and Pellett, 2001), 
herpesvirus genome architecture can be divided into six classes, A to F (figure 1.3), with 
typical representatives HHV-6B, herpesvirus saimiri, EBV, VZV, HCMV, and tupaia 
herpesvirus, respectively. The linear, double-stranded HCMV DNA genome comprises 
two covalently linked regions, long unique (UL) and short unique (US), each flanked by 
inverted repeats [Long Terminal Repeat (TRL) and Long Internal Repeat (IRL), and Short 
Terminal Repeat (TRS) and Short Internal Repeat (IRS) respectively]. This gives the overall 
genome configuration TRL–UL–IRL–IRS–US–TRS (Davison et al., 2003b, Dolan et al., 2004, 
Mocarski Jr et al., 2007), typical of class E herpesviral genomes. Additionally, the HCMV 
genome possesses a short region, termed the a sequence, as a direct repeat at the 
termini and also in inverse orientation at the IRL–IRS junction (figure 1.3) (Davison et al., 
2003b). The direct terminal repeats contain cis-acting signals for cleavage and packaging 
of progeny genomes during replication. Because UL and US can invert relative to each 
other by recombination between inverted repeats, four equimolar genome 
arrangements are possible in virion DNA (figure 1.4). 
 
HCMV is the largest and most complex of the nine human herpesviruses. The DNA 
sequence of strain AD169 was the first complete HCMV genome to be published (Chee 
et al., 1990). Revisions have since been made to the initial AD169 genome sequence, 
and in recent years full genome sequences for several other HCMV strains – from both 
laboratory-adapted viruses and viruses derived from pathological specimens – have 
been published. Currently, the strain Merlin (GenBank Accession number AY446894.2), 
with a genome size of 235,646bp, is widely regarded as the consensus HCMV reference 
genome. Wild type HCMV strain Merlin contains at least 170 protein-coding genes 
(Dolan et al., 2004, Gatherer et al., 2011). With technological advancement, the coding 
potential of HCMV is beginning to be understood better. Recent high-definition analyses 
of the HCMV transcriptome using RNA-Seq, RNA mapping, and ribosome profiling have 
revealed that gene expression in HCMV is even more complex than previously thought, 
in part owing to highly regulated non-canonical translation patterns, overlapping ORFs, 
and use of non-conventional initiation codons (Gatherer et al., 2011, Stern-Ginossar et 
al., 2012). One study has identified over 600 additional protein coding ORFs, the majority 
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Figure 1.3. The six classes of herpesvirus genomes, according to Roizman and Pellet 
(Roizman and Pellett, 2001). Horizontal lines represent unique / quasiunique regions, 
while rectangles depict reiterated domains. Arrows indicate the orientations of repeats. 
The nomenclature of unique and repeat regions, including the terminal redundancy (a) 
and its internal inverted copy (a’), is indicated for the class E genome. Image obtained 











Figure 1.4. Structure of the four HCMV genome isomers produced by inversion of UL 
and US regions (Landolfo et al., 2003). 
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In addition to protein coding genes, HCMV also produces polyadenylated non-coding 
RNAs, including four long non-coding RNAs – RNA2.7, RNA1.2, RNA4.9, and RNA5.0 – 
that are produced in abundance and do not overlap with protein coding regions. 
Additional non-coding RNAs are transcribed anti-sense of protein coding regions 
(Gatherer et al., 2011, Zhang et al., 2007). Non-polyadenylated HCMV RNAs include 
microRNAs, which are involved in numerous processes related to regulating host cell 
metabolism, immune evasion, and maintenance of latency (Dhuruvasan et al., 2011, 
Grey et al., 2007, Stern-Ginossar et al., 2007, Stern-Ginossar et al., 2009, Lau et al., 
2016a, Lau et al., 2016b, Poole et al., 2011, Shen et al., 2014).  
 
Overall, there are 40 core genes conserved across the human herpesvirus family. No 
additional genes are shared between HCMV and the alphaherpesviruses, but at least 7 
more genes are shared with gammaherpesviruses, and 27 are betaherpesvirus specific. 
(Mocarski Jr et al., 2007, Dolan et al., 2004, Murphy et al., 2003, Roizman and Pellett, 
2007, Davison et al., 2003b, Mocarski Jr, 2007). The number of genes shared across 
herpesvirus subfamilies is subject to revision as HCMV coding potential and gene 
function become clearer. Based on relatedness, HCMV non-core genes are grouped into 
at least 13 gene families (figure 1.5), many of which contain duplicated genes arranged 
as ‘gene accordions’. This level of gene organisation is one of the several strategies that 
enable HCMV to rapidly adapt and counteract host defences, and has also been 
demonstrated in other DNA viruses such as poxviruses (Elde et al., 2012). Functionally, 
HCMV genes can be broadly categorised into two classes: core genes, which encode 
virus structural components and key proteins involved in replication, and accessory 
genes encoding modulators of virus-host interaction. Unlike core genes, accessory genes 
are more divergent and therefore facilitate virus diversity at various levels including 




































Figure 1.5. Genetic organization and content of wild-type HCMV, based on strain 
Merlin, sequenced from the original clinical source material (urine). Image adapted from 
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1.4 REPLICATION CYCLE 
HCMV can infect various cell types including fibroblasts, endothelial cells, epithelial cells 
and cells of the monocyte-myeloid lineage (Arrode and Davrinche, 2003, DuRose et al., 
2012, O'Connor and Shenk, 2012, Bayer et al., 2013, Mocarski Jr et al., 2007). Compared 
to other herpesviruses, HCMV replicates relatively slowly, with production of progeny 
viruses peaking 72-96 hours post infection (Mocarski Jr et al., 2007). Virus-driven 
modulation of host cell gene expression, immunity, and cell survival is crucial for 
successful progression of the viral replication cycle, but the virus also has to concurrently 
regulate its own gene expression in a stringently temporal manner. 
 
The first stage in the complex HCMV replication cycle involves entry into a susceptible 
host cell, and includes several distinct steps from attachment to specific cell surface 
receptors to release of the viral genome into the nucleus (figure 1.6). Three distinct viral 
envelope glycoprotein complexes, gCI, gCII, and gCIII, are involved in recognition and 
cellular uptake of HCMV. gCI is composed of glycoprotein gB (UL55 product), while gCII 
is composed of glycoproteins gM (UL100 product) and gN (UL73 product). Two forms of 
gCIII are known to exist: a trimeric complex composed of gH (UL75 product), gL (UL115 
product), and gO (UL74 product), and a pentameric complex formed by gH, gL, pUL128, 
pUL130, and pUL131A (products of the UL128 locus). gCI and gCII mediate the initial 
binding and adsorption of HCMV to host-cell heparan sulfate glycosaminoglycans 
(Compton et al., 1993, Kari and Gehrz, 1992, Britt and Boppana, 2004). At the start of 
this thesis, additional binding of gCI to integrins (Feire et al., 2004), epidermal growth 
factor receptor (EGFR) (Wang et al., 2003, Chan et al., 2009), and platelet-derived 
growth factor receptor α (PDGFRα) (Soroceanu et al., 2008) had been shown to occur, 
although some other studies reported conflicting findings (Isaacson et al., 2007, 
Vanarsdall et al., 2012). Virus adsorption is followed by a fusion step, involving gCI and 
gCIII (Vanarsdall et al., 2008, Wille et al., 2013). In fibroblasts, this involves the trimeric 
gH/gL/gO form of the gCIII complex, followed by direct membrane fusion. In epithelial, 
endothelial and myeloid cells however, virus entry necessarily requires the pentameric 
gH/gL/pUL128/pUL130/pUL131 gCIII complex, with subsequent pH-mediated 
endocytosis (Ryckman et al., 2006, Ryckman et al., 2008b, Wang and Shenk, 2005b, 
Murrell et al., 2013, Hahn et al., 2004). Together with RL13, UL128 is among a select set 
of genes that rapidly mutate upon culture of virus in fibroblasts; this mutation appears 
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vital for optimal viral replication in fibroblasts (Stanton et al., 2010). The gCIII complex 
is therefore a major determinant for virus cell tropism (Scrivano et al., 2011, Murrell et 
al., 2013). After delivery of the nucleocapsid into the cytoplasm, it is trafficked via 
microtubules to the nucleus, into which the viral DNA is released (Dohner and Sodeik, 
2005). The large tegument protein (UL48 product) and large tegument protein binding 
protein (UL47 product) are key in nucleocapsid translocation, uncoating, and viral 
genome release (Dunn et al., 2003).  
 
In the nucleus, HCMV genes are transcribed in a temporal fashion, starting with 
immediate-early (IE), then early (E), delayed-early (DE), and finally late (L) transcripts 
(Mocarski Jr and Pass, 2008, Mocarski Jr et al., 2007). Genes UL36/UL37, UL122/UL123, 
TRS1/IRS1, and US3 encode numerous transcripts and products involved in IE gene 
regulation and evasion of cellular immune mechanisms to guarantee progression of 
replication (Mocarski Jr et al., 2007). Immune evasion mechanisms include: IE1 (UL123 
product) suppression of STAT signalling, with consequent blockade of IFN activation; cell 
death suppression by viral inhibitor of caspase 8 activation (vICA) and viral mitochondrial 
inhibitor of apoptosis (vMIA), encoded by UL36 and UL37 respectively; inhibition of IFN-
inducible protein kinase R (PKR) by IRS1 and TRS1 products; and, US3-induced disruption 
of MHC class I antigen presentation, making infected cells less attractive to cytotoxic T-
cells (Mocarski Jr et al., 2007).  
 
Figure 1.6 summarises the subsequent steps and viral products involved in the HCMV 



























Figure 1.6. Summary of HCMV replication (Mocarski Jr and Pass, 2008, Mocarski Jr et 
al., 2007). Infectious virions enter the cell via interaction of viral envelope glycoprotein 
complexes with cellular receptors. Following membrane fusion (fibroblasts) or 
endocytosis (epithelial & endothelial cells), tegument and capsid proteins are delivered 
to the cytosol, and after delivery into the nucleus, the genome is circularized. Host cell 
responses are regulated by tegument proteins, which also initiate the temporal 
expression of viral immediate early (IE) followed by delayed early (DE) genes, that 
initiate viral genome replication, and late (L) gene expression. Late gene expression gives 
rise to capsid assembly, followed by nuclear egress to the cytosol where capsids 
associate with tegument proteins and are trafficked to endoplasmic reticulum (ER) / 
Golgi assembly complexes. Capsids then acquire tegument and viral envelope 
components. Finally, enveloped infectious virus particles (VP) and non-infectious dense 
bodies (DB) are released. MT, microtubules; ERGIC, endoplasmic reticulum and Golgi 
intermediate compartment; NP, nuclear pores; INM, inner nuclear membrane; ONM, 
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1.5 HCMV LATENCY AND REACTIVATION 
The ability to establish latency is a defining characteristic of herpesviruses. HCMV can 
setup and maintain latent infection predominantly in CD14+ monocytes and CD34+ 
progenitor cells. During the latency state, only a restricted set of transcripts is expressed 
and no virion production occurs (Reeves and Sinclair, 2010, Poole et al., 2013, Goodrum 
et al., 2007, Cheung et al., 2006, Hargett and Shenk, 2010, Goodrum et al., 2002, Reeves 
et al., 2005a, Reeves et al., 2005b, Rossetto et al., 2013, Hahn et al., 1998, Mendelson 
et al., 1996). Remodelling of chromatin around the viral major immediate early 
promoter (MIEP) to a heavily repressive state is a main driver of suppression of lytic 
transcription and maintenance of latent infection (Reeves et al., 2005a, Reeves et al., 
2005b, Reeves, 2011, Murphy et al., 2002, Reeves et al., 2006). This state is enhanced 
by a deficit of viral activators (such as pp71), or in the presence of latency-associated 
repressors (such as HCMV RNA 4.9), or if cellular repressors of MIEP dominate (Saffert 
et al., 2010, Rossetto et al., 2013, Wright et al., 2005, Noriega et al., 2014). Latency is 
maintained by various cellular and virally encoded factors including the cellular 
repressor complex hDaxx:ATRX (Reeves et al., 2010, Woodhall et al., 2006, Saffert and 
Kalejta, 2007, Saffert and Kalejta, 2006, Lukashchuk et al., 2008); the latency unique 
nuclear antigen (LUNA), derived from the UL81-UL82 antisense transcript (Keyes et al., 
2012, Bego et al., 2011),; histone modifying enzymes such as histone methyltransferases 
(HMT) and histone deacetylases (HDACs) (Murphy et al., 2002); and various microRNAs. 
Virus reactivation from the latent state enables resumption of the lytic replication 
program, and is driven by various physiological and external stimuli that include cellular 
differentiation, conditions of stress, and drugs. Differentiation of progenitor cells into 
macrophages or dendritic cells alters the nuclear environment leading to changes in the 
conformation of chromatin and activation of the MIEP and the lytic replication program 
(Reeves et al., 2005a, Reeves et al., 2005b, Poole et al., 2014, Reeves, 2011) (figure 1.7). 
This can result in virus dissemination and clinically overt disease, particularly in the 
absence of robust host immunity. Histone deacetylase inhibitors such as valproic acid, 
trichostatin A, and MC1568 have been shown experimentally to alleviate the repressive 
chromatin structure, allowing IE gene expression, at least transiently (Murphy et al., 
2002). LUNA has also been shown to be in fact necessary for both the establishment of 
and successful rescue from the latency state (Keyes et al., 2012). The ability of HCMV to 
reactivate is a critical characteristic that gives rise to development of pathology at 
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individual level, and enables sustenance of virus circulation at population level. Much 
more remains to be understood regarding the precise mechanisms that regulate 
establishment and maintenance of HCMV latency in myeloid-lineage cells, as well as the 
interplay of factors governing reactivation from the latency state. Understanding these 
mechanisms is crucial for the identification of novel therapeutic targets and 












Figure 1.7. HCMV latency and reactivation. After primary HCMV infection, latency is 
established in bone marrow CD34+myeloid progenitor cells. In these cells, the viral 
genome is associated with repressive chromatin markers. Cellular differentiation into 
dendritic cells (DCs) is accompanied by chromatin remodelling, which enables the MIEP 
to associate with transcription activators, with subsequent induction of immediate early 
gene expression and reactivation of the virus (Poole et al., 2014). 
 
 
1.6 VIRUS GENE VARIATION AND STRAIN IDENTIFICATION 
In HCMV, gene variability appears to be restricted to particular genome locations, 
mostly near the ends of UL and US regions (Dolan et al., 2004). Nucleotide variation in 
genes involved in host cell entry, tissue tropism, or replication has long been thought to 
contribute to apparent differences in virulence among HCMV strains, and is a risk factor 
for subsequent infection. However no clear link has yet been shown between a 
particular HCMV genotype and clinical disease (Kari et al., 1986, Pignatelli and Dal 
Monte, 2009, Pignatelli et al., 2004, Pignatelli et al., 2010, Puchhammer-Stockl and 
Gorzer, 2011). HCMV encodes in excess of 20 membrane glycoproteins, including gB, 
gH, gL, gM, gN, and gO. Variation in these individual glycoproteins and the complexes 
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they form has been of interest because of their key role as determinants of virulence 
and tissue tropism, as exemplified by the gH/gL complex (gCIII), which forms two 
different heterologous complexes (Ryckman et al., 2008a, Ryckman et al., 2008b, 
Rasmussen et al., 2002, Mocarski Jr, 2007, Mocarski Jr et al., 2007). Other hypervariable 
HCMV surface glycoproteins that have become the subject of intense study include gO 
and gN. The genes encoding these two glycoproteins are located at the centre of the 
genome, and eight genotypes have been identified for each, with evidence for linkage 
(See Table1.1). In both gO and gN variability is highest toward the N-terminus (Bates et 
al., 2008, Dolan et al., 2004, Mattes et al., 2005, Mattick et al., 2004, Pignatelli and Dal 
Monte, 2009, Stanton et al., 2005). Because of its hypervariability and critical role in 
tissue tropism via the trimeric gCIII complex, gO is of particular interest in genotyping 
studies in this thesis. Other hypervariable genes in HCMV include UL139, which encodes 
a putative membrane glycoprotein, and for which eight genotypes are defined; and 
UL146, encoding a viral chemokine (vCXCL1), which has at least 14 distinct genotypes 
(summarised with gO genotypes in Table 1.1) (Bradley et al., 2008, Kenneson and 
Cannon, 2007, Hassan-Walker et al., 2004, Lurain et al., 2006, Dolan et al., 2004). Both 
UL139 and UL146 are components of the so called ‘virulence region’ – a 13-15kb region 
that is deleted or modified in laboratory-adapted HCMV strains and encodes at least 20 
genes, many of which are involved in immunomodulation (Cha et al., 1996, Murphy et 
al., 2003, Dolan et al., 2004). High variability also exists at the left end of UL, particularly 
in the RL11 family of genes (Davison et al., 2003a, Sekulin et al., 2007, Dolan et al., 2004). 
One RL11 member, RL13, mutates rapidly in fibroblast cultures and is therefore linked 
to a role in tissue tropism (Dargan et al., 2010, Stanton et al., 2010). Understanding the 
extent of these hypervariable genes is essential in diagnosing strain variants, their 
transmission, and disease associations. It is also necessary to investigate fully whether 
there may be restriction of strains in the various body compartments. 
 
1.7 EPIDEMIOLOGY AND TRANSMISSION 
HCMV is a ubiquitous virus found in every human population group. Globally, 
seroprevalence ranges from 60 to 100%. Infection shows no seasonality, but 
seroprevalence varies geographically and with socioeconomic status, gender, and age. 
The virus is acquired in early life in most populations except in the more economically 
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developed northern European and North American regions. Seroprevalence thus 
increases with age, is higher in developing countries, and inversely related to 
socioeconomic status (Lopo et al., 2011, Aarnisalo et al., 2003, de Ory et al., 2004, 
Kothari et al., 2002, Hecker et al., 2004, Adjei et al., 2006, Cannon et al., 2010, Dowd et 
al., 2009, van der Sande et al., 2007, Vyse et al., 2009, Crough and Khanna, 2009, Staras 
et al., 2008a, Staras et al., 2008b, Bate et al., 2010). 
 
Genotypes  Reference strain GenBank Accession No. 
gO  gN linkage   
gO1a gN1 AD169 FJ527563.1 
gO1b gN3a TR KF021605.1 
gO1c gN4c Toledo GU937742.1 
gO2a gN3b HAN38 GQ396662.1 
gO2b gN2 AF1 GU179291.1 
gO3 gN4a HAN16 JX512204.1 
gO4 gN4b Towne FJ616285.1 
gO5 gN4d Merlin AY446894.2 
    
UL139    
G1  Merlin AY446894.2 
G2  TR KF021605.1 
G3  HAN38 GQ396662.1 
G4  Toledo GU937742.1 
G5  Towne FJ616285.1 
G6  3301 GQ466044.1 
G7  AD169 FJ527563.1 
G8  AF1 GU179291.1 
    
UL146    
G1  Toledo GU937742.1 
G2  Merlin AY446894.2 
G3  KSG AY446889.1 
G4  AF1 GU179291.1 
G5  Davis JX512198.1 
G6  ML1 AY446880.1 
G7  Towne FJ616285.1 
G8  TB40/E KF297339.1 
G9  AD169 FJ527563.1 
G10  JP GQ221975.1 
G11  JHC HQ380895.1 
G12  6397 JX512197.1 
G13  HAN8 JX512202.1 
G14  HAN1 JX512199.1 
 
Table 1.1. Genotypes of selected hypervariable HCMV genes. There are eight 
genotypes each for gO and gN, and they are linked as shown in this table (Bates et al., 
2008, Dolan et al., 2004, Mattes et al., 2005, Mattick et al., 2004, Pignatelli and Dal 
Monte, 2009, Stanton et al., 2005). UL139 has eight genotypes and 14 genotypes are 
known for UL146 (Bradley et al., 2008, Kenneson and Cannon, 2007, Hassan-Walker et 
al., 2004, Lurain et al., 2006, Dolan et al., 2004). 
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In some countries, high HCMV seroprevalence has been found in women attending 
sexual health clinics and in young homosexual men (Crough and Khanna, 2009, Dowd et 
al., 2009, Boppana and Fowler, 2007, Chandler et al., 1985). In the USA, higher 
seroprevalence was found in African Americans and Hispanics compared to Caucasians 
(Boppana and Fowler, 2007, Crough and Khanna, 2009, Dowd et al., 2009). 
 
HCMV is transmitted through close personal contact via infected bodily fluids including 
oropharyngeal secretions / saliva, urine, cervical and vaginal secretions, semen, breast 
milk, tears, blood products, and allografts (Boppana and Fowler, 2007, Cannon et al., 
2011). Vertical transmission of HCMV may occur transplacentally / in utero, during 
parturition, or via breastfeeding (see section 1.8). After early infancy, young children 
acquire HCMV through horizontal transmission from other children or indirectly through 
environmental contamination. This is evidenced by the finding of higher HCMV 
seropositivity among children who attend day care centres compared to those who do 
not. Further, families living in crowded conditions also show early acquisition of the 
virus. Young children shed virus in saliva and urine, thereby facilitating virus exposure to 
other children, their parents, and to the day-care workers (Adler et al., 2004, Noyola et 
al., 2000, Boppana and Fowler, 2007). Although both children and adults can shed HCMV 
for several months following primary infection, children are particularly important as 
reservoirs of infection in communities. Some studies have demonstrated that children 
continue to shed virus in urine for as long as 9 years (Adler et al., 2004, Noyola et al., 
2000). Women of childbearing age and immunocompromised individuals are 
particularly at high risk for infection (Boppana and Fowler, 2007). In adolescence and 
early adulthood, HCMV rates continue to increase and this is attributed in part to 
increased sexual contact. The finding of HCMV in cervical and vaginal secretions and 
semen support the categorisation of HCMV as a sexually transmitted infection (Crough 
and Khanna, 2009, Chandler et al., 1985, Sohn et al., 1991). Risk factors for HCMV 
seropositivity in studies of sexual health clinic attendees include young age of sexual 
debut, recent / new sexual partners, multiple sexual partners, lack of barrier 
contraception, history of STIs, chlamydial infection, female gender, and African 
American race (Boppana and Fowler, 2007, Chandler et al., 1985, Staras et al., 2008b). 
Other occasions of HCMV infection include iatrogenic settings such as blood transfusion 
or allograft transplantation. HCMV infection is associated with transfusion of cellular 
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components of blood but not fresh-frozen plasma or cryoprecipitate (Bowden and 
Sayers, 1990). Transfusion of unscreened cellular components results in 10%–70% 
HCMV transmission largely from reactivation of latent virus from myeloid lineage cells 
(Preiksaitis et al., 1988, Wilhelm et al., 1986). The risk of transfusion associated HCMV 
infection is directly related the number of components, particularly the quantity of 
leukocytes, transfused (Boppana and Fowler, 2007). Leucocyte depletion prior to use of 
blood products has proved to be a useful strategy to limit transfusion-transmitted 
HCMV. In the transplant setting, HCMV infection may occur due to transmission from 
the transplanted organ, due to reactivation of latent infection, or following primary 
infection in a seronegative transplant recipient. Development of HCMV disease depends 
on the type of transplant, the HCMV serological match between donor and recipient, 
the immunosuppressive drug regimen used, occurrence of acute tissue rejection, donor 
and/or recipient age, HLA mismatch, genetic polymorphisms, and other concurrent 
infections. 
 
Chronic pathological conditions linked to HCMV 
Evidence continues to emerge for a role of HCMV in a range of chronic inflammatory 
conditions, autoimmune disorders, and neoplastic lesions. This is postulated to arise 
partly from the long-term immune activation and chronic inflammatory state induced 
by the frequent, albeit subclinical, HCMV reactivations. Early acquisition of HCMV is thus 
seen as a risk factor for premature aging and reduced lifespan. HCMV has been 
implicated in gliomas, some types of bowel and breast cancer, cardiovascular diseases 
(including atherosclerosis and hypertension), immune senescence, and aging 
(Söderberg-Nauclér, 2008, Barami, 2010, Soroceanu and Cobbs, 2011, Hawkins and 
Croul, 2011, Lepiller et al., 2011, Bhattacharjee et al., 2012, Fonseca et al., 2012, 
Grahame-Clarke, 2005, Cheng et al., 2009, Bishop et al., 2015, Li et al., 2015, Pawelec, 
2012, Pawelec et al., 2009, Strindhall et al., 2007, Derhovanessian et al., 2009, Stassen 
et al., 2006, Wikby et al., 2002, Roberts et al., 2010, Courivaud et al., 2013). 
 
1.8 HCMV IN EARLY CHILDHOOD 
HCMV commonly infects in childhood and then persists for life via establishing latent 
infections. The virus can be transmitted pre-, peri- or post-natally. Prenatal transmission 
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occurs transplacentally, more frequently during maternal primary infection, but can also 
occur during viral reactivation or reinfection with a different strain (Boppana and 
Fowler, 2007, Boppana et al., 1999, Boppana et al., 2001). Perinatal infection occurs 
through cervical and other genital fluids during parturition, or via milk during 
breastfeeding. Postnatally, HCMV infection occurs via infected bodily fluids, commonly 
saliva, urine, and breast milk. Children are a critical reservoir for HCMV and play a central 
role in transmission and maintenance of the virus within communities, as described in 
section 1.7 (Adler et al., 2004, Noyola et al., 2000). 
 
1.8.1 CONGENITAL HCMV 
HCMV is the most frequent cause of congenital infection, during which it can cause 
serious damage to the baby (Boppana and Fowler, 2007, Boppana et al., 1999). 
Prevalence of congenital HCMV can range from 0.2 to 5.4% (Manicklal et al., 2013, van 
der Sande et al., 2007, Dar et al., 2008, Manicklal et al., 2014), although one study found 
a prevalence of 29% in a limited sample of HIV-infected infants (Slyker et al., 2009a). 
Studies have shown that prevalence is highest, at around 1–5% of births, in populations 
with high maternal seroprevalence, commonly in the developing world, compared to 
developed countries with low maternal seroprevalence, where incidence is 0.2–1.8% of 
births (Fowler and Boppana, 2006, Fowler et al., 1999, Fowler et al., 2003, Kaye et al., 
2008, Yamamoto et al., 2013, Yamamoto et al., 2010). HCMV remains the leading non-
genetic cause of childhood hearing loss. The incidence of HCMV-related hearing loss 
among infants born in populations of high maternal seroprevalence is similar to or even 
higher than that reported in populations from developed countries (Boppana, 1999; 
2001; Dar, 2008; Kenneson, 2007; Manicklal, 2013; Mussi-Pinhata, 2009; Sohn, 1992; 
van der Sande, 2007). Congenital HCMV infection has been shown to occur in up to 40% 
of cases following primary maternal infection during pregnancy (Liesnard et al., 2000, 
Revello and Gerna, 2002), while in non-primary maternal infection, it occurs in 2.2% of 
cases (Revello and Gerna, 2002, Fowler et al., 2003, Kenneson and Cannon, 2007), but 
can approach 20%, as reported in one Israeli study (Rahav et al., 2007). Congenital HCMV 
from non-primary maternal infection occurs if the mother has a reactivation of virus or 
gets re-infected with a new strain. HCMV is therefore unique, in that unlike all other 
known congenital pathogens, it can even be transmitted by women with pre-existing 
immunity (Mussi-Pinhata et al., 2009, Boppana and Fowler, 2007, Boppana et al., 1999, 
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Boppana et al., 2001). Although congenital infection leading to long-term sequelae can 
result from maternal primary infection during any stage of pregnancy, primary infection 
in the first trimester is associated with a higher rate of foetal damage (Foulon et al., 
2008, Pass et al., 2006). However, transmission rates are reportedly lower in early 
compared to later stages of pregnancy (Revello and Gerna, 2004, Gindes et al., 2008, 
Enders et al., 2011, Daiminger et al., 2005, Bodeus et al., 2010). During delivery, neonatal 
HCMV infection can occur by virus shedding in the birth canal followed by ingestion of 
infected secretions by the neonate (Boppana and Fowler, 2007). Diagnosis of congenital 
HCMV requires virus isolation (Gold standard) or PCR using saliva, urine or other samples 
collected within two weeks of birth (Ross et al., 2011, de Vries et al., 2012). Beyond this 
two-week window, congenital infection cannot be reliably distinguished from 
postnatally acquired virus. Breastfeeding and intimate nursing can profoundly confound 
the diagnosis of congenital HCMV. 
 
1.8.2 POSTNATAL HCMV INFECTION 
Although breastfeeding has been recognised as a route for postnatal HCMV transmission 
for several decades (Hayes et al., 1972, Stagno et al., 1980, Schleiss, 2006b, Schleiss, 
2006a), it is traditionally believed that HCMV transmitted through this route carries no 
major health risks except in very low birthweight preterm infants, where acute 
deleterious effects have been widely documented (Hamprecht et al., 2005, Hamprecht 
et al., 2008, Hamprecht et al., 2004b, Hamprecht et al., 2001, Maschmann et al., 2006, 
Jim et al., 2004). Nevertheless, long-term follow-up of preterm infants infected with 
HCMV via milk demonstrates that breastmilk-acquired HCMV infection has detrimental 
effects on intellectual development (Goelz et al., 2013). Possible severe life-threatening 
effects of breastmilk-transmitted HCMV in term babies have been highlighted by a 
recent German case of severe colitis (Novakova et al., 2014). Early studies of HCMV in 
breast milk in Africa suggest differences with data in other regions. In Europe and the 
far East, studies indicate HCMV is generally absent in colostrum and ‘early milk’, being 
only detectable in the milk from 2‐4 weeks postpartum, with peak viral load around the 
fourth postpartum week, before waning and finally disappearing by week 12. It has been 
shown that HCMV in breast milk results from local virus reactivation within the 
mammary gland and that cell-free virus, frequently shed into the whey, is of greater 
importance for vertical transmission than the infrequently occurring virus within milk 
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cells (Asanuma et al., 1996, Hamprecht et al., 1998, Hamprecht et al., 2001, Jim et al., 
2009). A Zimbabwean study showed that HCMV and EBV interact locally with HIV‐1 
within breast tissue, and associate with higher HIV‐1 viral loads, thereby impacting on 
HIV‐1 transmission via breast milk (Gantt et al., 2008). As described earlier in this 
chapter, widespread negative effects of HCMV on child health and development have 
also been demonstrated in Zambia where breastfeeding is widely practiced, including 
among otherwise healthy children, suggesting again more widespread pathological 
effects of postnatal infection (Gompels et al., 2012, Sanz-Ramos et al., 2013). 
 
1.8.3 HCMV AND HIV/AIDS INFECTION IN CHILDHOOD 
In the setting of HIV-1 infection, HCMV is the most common viral opportunistic infection, 
with severe sight- and life-threatening effects, especially in the absence of antiviral 
therapy. Children co-infected with HIV‐1 and HCMV suffer greater morbidity and 
mortality compared to those infected with either virus alone (Kovacs et al., 1999, Slyker 
et al., 2009b). Concomitant HCMV in HIV‐1 infection accelerates progression to AIDS 
(Kovacs et al., 1999, Slyker et al., 2009b, Marinda et al., 2007, Ross and Boppana, 2005). 
This phenomenon was also noted among haemophiliacs co-infected with HIV and HCMV 
(Webster et al., 1989). On the other hand, HIV‐1 infection increases the likelihood of 
HCMV infection and/or reactivation (Slyker et al., 2009a, Slyker et al., 2009b). In Zambia, 
a lung necropsy study ranked HCMV among the top three causes of death among HIV‐1 
infected children dying of respiratory illness (Chintu et al., 2002). In the CIGNIS cohort, 
even maternal HIV‐1 exposure without child infection increased the negative effects of 
HCMV on child psychomotor development, reduced infant growth in a third of the 
cohort, and markedly reduced immunological responses to the polio vaccine (Gompels 
et al., 2012, Sanz-Ramos et al., 2013). 
 
Although infant HCMV infection was assessed in Zambia through the Chilenje Infant 
Growth and Nutrition Study (CIGNIS) (Sanz-Ramos et al., 2013, Gompels et al., 2012), 
neither the actual route of transmission (congenital or postnatal) was established, nor 
how maternal HIV affects this, and therefore is a key premise for studies in this thesis. 
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1.9 HCMV CONTROL 
1.9.1 HYPERIMMUNE GLOBULIN 
Passive immunization using anti-HCMV hyperimmune globulin (HIG) – an 
immunoglobulin preparation pooled from healthy blood donors with high titers – has 
been of interest as a potentially safe intervention, particularly in women at risk of 
transmitting HCMV during pregnancy, and as prophylaxis in solid organ transplant 
recipients. Active research is ongoing, but some early reports indicate beneficial 
outcomes. For instance, in a group of ‘at risk‘ women who received HIG, there were 
significant reductions in placental pathology, markedly less incidences of congenital 
HCMV in neonates, and reversal of foetal cerebral abnormalities compared to peers who 
did not receive HIG (Nigro et al., 2005, Nigro et al., 2008, La Torre et al., 2006, Buxmann 
et al., 2012). Improved infant neurodevelopmental outcomes have also been associated 
with maternal use of HIG during pregnancy (Visentin et al., 2012). 
 
1.9.2 DRUGS 
There are four anti-HCMV drugs currently in use for prevention and treatment of HCMV 
infection/disease: Ganciclovir (GCV), Valganciclovir (vGCV), Cidofovir (CDV) and 
Foscarnet (FOS) (figure 1.8). These drugs have tremendously improved HCMV 
management and outcomes, particularly in adults in the transplantation setting. 
However, the usefulness of these antivirals is restricted by their low bioavailability 
(except for vGCV, which has good oral bioavailability), toxicities, and the emergence of 
resistance mutations. There are currently no suitable anti-HCMV drugs for neonates, 
although GCV and vGCV have been undergoing clinical trials in the context of 
symptomatic congenital infection, and have shown good efficacy in improving 
neurodevelopmental outcomes, particularly with longer (6 months versus 6 weeks) drug 
treatment (Oliver et al., 2009, Acosta et al., 2007, Kimberlin et al., 2003, Kimberlin et al., 
2015, Nassetta et al., 2009).  
 
Ganciclovir (GCV) and Valganciclovir (vGCV) 
GCV (9-[1, 3-dyhydroxy-2-propoxymethyl] guanine) was the first antiviral approved for 
HCMV treatment in 1989 (Chou, 2008). GCV is a guanosine analogue and homologue of 
acyclovir (ACV). It is activated to its triphosphate form by sequential phosphorylation 
involving both viral and cellular kinases. UL97 (serine/threonine phosphokinase) and 
 Page 37 of 338 
UL54 (DNA polymerase) are two key viral molecules involved in GCV metabolism. In its 
active form as GCV triphosphate, the drug competitively inhibits viral DNA 
polymerisation, leading to chain termination. The requirement for hospitalization to 
administer the drug intravenously, and the associated need for intravenous 
catheterisation for six weeks of therapy limit GCV use. Furthermore, utility of GCV is 
hampered by the serious hematologic side effects that can occur, particularly 
neutropenia and thrombocytopenia, and by the development of drug resistance 
mutations (Biron, 2006, Chou, 2008). In the 1990s, vGCV, an orally administered L-valyl 
ester prodrug of GCV, was developed. Following oral administration vGCV is rapidly 
metabolized in the intestinal wall and liver and achieves up to 10 times the 
bioavailability of GCV. vGCV has a similar toxicity profile as GCV. Because of its 
convenient mode of administration, vGCV is now more widely used in the transplant 
setting (Biron, 2006, Len et al., 2008). 
 
Foscarnet (FOS) 
Foscarnet (FOS), generic name phosphonoformic acid, is a pyrophosphate analogue, 
used as second-line therapy in cases of GCV/vGCV drug-resistance. FOS does not require 
activation. It non-competitively inhibits HCMV DNA polymerase activity by reversibly 
blocking the pyrophosphate binding site, thereby inhibiting cleavage of pyrophosphate 
from deoxynucleoside triphosphates. The main adverse effects associated with FOS are 
nephrotoxicity, metabolic toxicity, and electrolyte imbalance (hypocalcemia, 
hypomagnesemia and hypophosphatemia). FOS is particularly useful in 
myelosuppressed patients, in haematopoietic stem cell transplant (HSCT) recipients 
with weak grafts, in HIV/AIDS associated HCMV retinitis, and in those with leucopenia. 
FOS has also been used as maintenance therapy to prevent HCMV relapse or progression 
(Biron, 2006, Tan, 2014). 
 
Cidofovir (CDV) 
CDV ([S]-1-[3-hydroxy-2-phosphonylmethoxypropyl] cytosine) is a monophosphate 
nucleotide analogue, which is used as third line treatment for HCMV infection. Because 
it inherently possesses a phosphate-like group, CDV does not require initial 
phosphorylation by the viral phosphokinase. However, it still requires activation 
(diphosphorylation) by cellular kinases. Like GCV, the incorporation of CDV-diphosphate 
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into viral DNA leads to termination of HCMV DNA replication. CDV is approved as a 
broad-spectrum antiviral for treatment of infections caused by various DNA viruses, 
including members of all three herpesvirus subfamilies. It has been used effectively to 
treat HCMV retinitis in HIV/AIDS patients. CDV has a relatively long intracellular half-life 
compared to GCV and FOS, but similar to FOS, its main adverse effects are nephrotoxicity 


















Figure 1.8. Approved anti-HCMV drugs. Addition of the first phosphate to Ganciclovir 
(GCV) (and its prodrug valganciclovir, vGCV) is performed by the HCMV UL97 
serine/threonine phosphokinase. Following addition of two further phosphates by 
cellular kinases, GCV triphosphate – the active form of the drug – is incorporated into 
nascent DNA by the viral DNA polymerase (UL54). Resistance results from UL97 and/or 
UL54 mutations. Cidofovir (CDV), a monophosphate analog, does not require initial viral 
kinase activity; two phosphates are added by cellular kinases to produce the active form 
of the drug. Resistance to CDV is conferred only by DNA polymerase mutations. 
Foscarnet (FOS) is a pyrophosphate analog, which does not require activation. 
Resistance is conferred only by DNA polymerase mutations. The DNA polymerase is the 
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Other drug candidates 
The following are among several new drugs (Biron, 2006, Tan, 2014) being actively 
assessed for treatment of HCMV disease. 
Maribavir (MBV), a benzimidazole antiviral agent, targets the viral pUL97 
phosphokinase and acts by inhibiting viral encapsidation and nuclear egress of progeny 
viral particles. MBV has been used with some success as salvage therapy in selected 
patients with multidrug-resistant HCMV (Avery et al., 2010). However, it has not been 
successful as prophylaxis in allogeneic stem cell or in liver transplant recipients (Marty 
et al., 2011), although this has been attributed in part to suboptimal dosing (Marty and 
Boeckh, 2011). The main side effects reported are taste disturbance and skin eruptions. 
CMX001 (hexadecyloxypropyl-cidofovir), a lipid ester of CDV (Williams-Aziz et al., 2005, 
Tan, 2014), remains intact in plasma and delivers the active compound (CDV) directly to 
target cells, resulting in enhanced cellular uptake and high intracellular levels of CDV 
diphosphate. CDV diphosphate competitively inhibits the viral DNA polymerase driven 
incorporation of deoxycytidine triphosphate into viral DNA, thereby terminating chain 
elongation. CMX001 has been considered for use in ganciclovir-resistant CMV disease 
(Price and Prichard, 2011). Side effects are mild and include abdominal discomfort and 
stomatitis (Hostetler, 2009). 
Letermovir (AIC246), a 3,4-dihydroquinazoline, is a terminase inhibitor which targets 
viral pUL56 (large terminase subunit), thereby inhibiting the cleavage of concatemeric 
progeny DNA to unit-length genomes that must be packaged into capsids. AIC246 
therefore blocks viral replication without inhibiting the synthesis of progeny HCMV DNA 
or viral proteins (Verghese and Schleiss, 2013). It has shown high efficacy in multidrug-
resistant disseminated HCMV infection in a lung transplant patient (Kaul et al., 2011). So 
far, no toxicities have been reported (Melendez and Razonable, 2015). 
Leflunomide, a pyrimidine synthesis inhibitor (Torres-Madriz and Boucher, 2008), is 
approved for use in some autoimmune conditions, but has also shown anti-HCMV 
efficacy. It acts by disrupting progeny virion assembly. Successful use has been 
demonstrated in solid organ transplant recipients, but not in hematopoietic stem cell 
transplant recipients (Battiwalla et al., 2007). Anaemia and hepatotoxicity are the drug’s 
main adverse effects. 
Artesunate (ART), a commonly used antimalarial in endemic countries, has shown some 
anti-HCMV activity in vitro, and is undergoing extensive investigation for use in some 
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HCMV infection settings. Some research groups have shown that ART enhances activity 
of commonly used anti-HCMV antivirals when used in combination. However, conflicting 
outcomes have reported (Gantt et al., 2013, Germi et al., 2014, Kaptein et al., 2006, Lau 
et al., 2011, Schnepf et al., 2011, Shapira et al., 2008, Wolf et al., 2011, Zeng et al., 2015). 
The dose and duration of use of artesunate may be contributory factors to the variation 
in reported results, and need further investigation. 
 
1.9.3 VACCINES 
Owing to the significant morbidity and mortality associated with HCMV, and resultant 
decrease in quality of life, particularly in congenital infection and transplant settings, at 
the onset of the 21st Century an American Institute of Medicine report designated HCMV 
a level I (highest priority) vaccine target (Stratton et al., 2000). Although an effective 
vaccine remains elusive, there has been some good efficacy demonstrated by some 
formulations such as the gB subunit vaccine (Griffiths et al., 2011, Pass, 2009). Other 
vaccines are at various stages of development. Further trials have been planned in 
paediatric groups, or to block maternal transmission (Emery, 2011, Emery et al., 2013, 
Griffiths, 2002, Griffiths, 2012, Griffiths, 2014, Griffiths et al., 2011, Schleiss and 
Heineman, 2005, Schleiss, 2013, Sung and Schleiss, 2010, Zhong and Khanna, 2007, Pass, 
2009, Pass et al., 2009). Vaccine formulations incorporate different viral immunogens 
which can elicit adequate humoral and/or cellular responses. This includes HCMV 
surface glycoproteins, which can be immunogenic and therefore form attractive targets 
for vaccine development. For instance, gB has been a focus of several anti‐HCMV vaccine 
development efforts because it is relatively conserved, highly immunogenic and an 
important target for both humoral and cellular immune responses (Rasmussen and 
Cowan, 2003, Rasmussen et al., 1985, Rasmussen et al., 1988, Gretch et al., 1988a, 
Gretch et al., 1988b, Chandler and McDougall, 1986). More recent vaccine development 
efforts also include the gCIII complexes due to their role in host cell tropism and disease, 
and the highly potent neutralising antibody responses induced (Lilleri et al., 2013, Fouts 
et al., 2012, Cui et al., 2013, Macagno et al., 2010, Saccoccio et al., 2011). Anti-HCMV 
vaccines currently being assessed can be broadly categorised as follows (Rieder and 
Steininger, 2014, McVoy, 2013). 
 
 
 Page 41 of 338 
Live attenuated vaccines  
Since virtually all antigens can be expressed, live attenuated vaccines have the inherent 
potential of inducing both humoral and cellular immune responses close to levels 
induced by natural infection. A major disadvantage however, borders around safety, 
particularly if the vaccine is administered in pregnancy. One promising live vaccine is 
based on an isolate of HCMV strain Towne that was attenuated by serial passage in 
human fibroblasts. It has been reported to induce both cellular and humoral responses 
in what appears to be a dose-dependent manner (Adler et al., 1995). The vaccine has 
undergone enhancement, including the generation of chimeras that incorporate 
portions of the HCMV strain Toledo. Preliminary reports among seropositive volunteers 
indicate no improvement in baseline immunity; effects in seronegative participants are 
awaited (Heineman et al., 2006). 
 
Subunit vaccines  
These are targeted at inducing robust immune responses to selected immunogens. 
Commonly, the vaccine is a combination of an immunogenic molecule and an adjuvant. 
Two subunit vaccines currently in trials are the gB/MF59 vaccine (Sanofi) and the 
gB/AS01 vaccine (GlaxoSmithKline). Both vaccines are targeted at eliciting antibody 
responses. The gB/MF59 vaccine has so far gone through phase 2 trials, where it showed 
50% efficacy in reducing incidence of primary HCMV infection in one cohort, while in a 
cohort of renal and liver transplant recipients use of gB/MF59 led to reduced duration 
of viremia and shorter periods of antiviral treatment (Griffiths et al., 2011, Pass, 2009). 
There have also been encouraging reports for the gB/AS01 vaccine from phase 1 trials, 
where its safety and immunogenicity have been confirmed (Schleiss et al., 2014). 
 
Plasmid DNA Vaccines 
In this category of vaccines, a portion of DNA encoding an immunogenic molecule is 
delivered into host cells, which then express the immunogen of interest in vivo. 
Examples are the TransVax vaccine developed for use as a therapeutic vaccine in the 
transplant setting, and CyMVectin targeting congenital HCMV. TransVax contains pp65 
and gB plasmid DNAs with poloxamer adjuvant whereas CyMVectin has pp65 and gB 
plasmid DNAs with Vaxfectin adjuvant. TransVax has undergone phase 2 trials in HSCT 
recipients, where it is reported to have reduced post-transplant viremia (Kharfan-Dabaja 
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et al., 2012, Wloch et al., 2008). Another plasmid DNA vaccine in phase 2 trials is the 
trivalent CL-CT02 composed of gB/pp65/IE1 (Jacobson et al., 2009). 
 
Virus–Vectored Vaccines 
An example in this group is AVX601, an RNA virus–vectored vaccine which utilises 
replication-defective Venezuelan equine encephalitis virus for expression of a pp65/IE1 
and gB fusion protein (Reap et al., 2007a, Reap et al., 2007b). 
 
The quest for an efficacious HCMV vaccine continues to gather momentum as more 
breakthroughs are made in understanding the virus and its multi-tier arsenal used to 
evade our immune defences. Vaccine development efforts require multi-pronged, multi-
disciplinary approaches encompassing a wide spectrum of expertise from basic science 
to social science and economics. A particular bottleneck that remains to be overcome is 
the low public awareness of HCMV and its devastating impact on childhood and quality 
of life in general. 
 
1.9.4 NON-PHARMACOLOGICAL CONTROL METHODS 
Several non-pharmacological strategies have been investigated with the view of limiting 
infectious HCMV load, particularly in breast milk in the context of preterm and very low 
birthweight infants. These include freeze-thawing (Hamprecht et al., 2004b, 
Maschmann et al., 2006), pasteurisation (Hamprecht et al., 2004b, Stock et al., 2015, 
Ewaschuk et al., 2011a, Ewaschuk et al., 2011b, Hamprecht et al., 2004a), and UV 
irradiation (Christen et al., 2013, Christen, 2014). These techniques show good promise, 
although varied outcomes have been obtained with some approaches, particularly 
freeze-thawing (Maschmann et al., 2006, Chiavarini et al., 2011). Concerns linger, such 
as the retention of nutritional and immunological qualities in milk following application 
of treatments; however techniques continue to be improved to address these concerns 
(Goelz et al., 2009, Czank et al., 2009, Hamprecht et al., 2004a). Other challenges border 
on logistics for large-scale (community-level) implementation. These include the 
requirement for specialised equipment and infrastructure such as the pasteurisation 
equipment or UV source, electricity/energy source, and fridge/freezers for storage of 
treated milk to ensure that an adequate supply of safe milk is available to the baby ‘on 
demand’. As technology advances and costs reduce, some of these challenges are being 
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overcome. In the context of Sub-Saharan Africa, where multiple pathogens can afflict 
concurrently, efforts that eliminate or reduce pathogen load in breast milk can markedly 
improve early child health. Apart from HCMV, HIV, Hepatitis B virus, EBV, and various 
bacteria are transmissible through milk. Therefore milk treatment can potentially limit 
the transmission of a variety of pathogens. 
 
Public health promotion efforts are now increasingly being made to promote basic 
personal hygiene practices such as handwashing to limit transmission of HCMV. Hand 
hygiene has been shown to be a very effective and cost-effective strategy for blocking 
the HCMV transmission cycle, particularly in hospitals and childcare settings (Stowell et 
al., 2014, Cannon and Davis, 2005). 
 
 
1.10 THESIS AIMS 
Previous studies in our laboratory showed widespread adverse effects of HCMV 
infection on growth and development of Zambian infants, particularly the HEU (Gompels 
et al., 2012, Sanz-Ramos et al., 2013), but the route of HCMV infection associated with 
these effects was undefined. Building upon these previous studies, the overarching aims 
of this thesis were therefore to explore congenital and breast milk HCMV transmission 
in Zambia, and to genetically characterise locally circulating HCMVs, in order to establish 
the transmission route(s) responsible for the widespread negative effects of HCMV on 
child wellbeing. Crucially, our studies took into account maternal HIV infection by 
comparing HIV-infected and uninfected mothers, thereby clarifying HIV influence on 
HCMV infection burden and transmission dynamics. Our studies sought to utilise non-
invasive samples (saliva, umbilical tissue, breast milk) for possible future routine 
application to HCMV detection in the local setting. It is envisaged that findings presented 
in this thesis will ultimately help inform clinical practice and add fundamental 
information, including on virus genetic diversity, to help direct the deployment of anti-
HCMV drugs, vaccines, and other interventions in Zambia.  
 
Specific Objectives 
To accomplish the above aims, the following objectives were set: 
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1) To investigate the birth prevalence of HCMV among new-borns in Zambia, using non-
invasive samples;  
2) To analyse HCMV shedding and viral DNA load kinetics in breast milk from both HIV-
infected and uninfected Zambian mothers; 
3) To analyse HCMV genotype variants in saliva and breast milk by sequencing the 
hypervariable gO and gN genes; 
4) To assess HCMV infection burden by investigating mixed-genotype infections using 
NGS deep sequencing and novel in silico methods for detecting and enumerating 
genotypes; and, 
5) To assemble and characterise a reference complete HCMV genome from DNA 
extracted directly from breast milk in Africa. 
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Chapter 2 
METHODS 
2.1  ETHICAL CONSIDERATIONS  
Studies undertaken as part of this thesis were reviewed and approved by the LSHTM 
Research Ethics Committee (LSHTM REC No. 6456, appendix 1) and the University of 
Zambia Biomedical Research Ethics Committee (UNZABREC No. 010-06-13, appendix 2). 
 
Study participants were free to decline or withdraw from their participation in the study 
at any time and this did not disadvantage them in any way. Confidentiality was 
maintained at all stages of the study. All samples were coded with a unique study ID and 
no personal identifiers were used during sample processing or data analysis. In case 
evidence of congenital HCMV infection was identified during the study, arrangements 
were in place for referral to locally available specialist assessment and follow-up services 
including neurological, psychosocial, and audiometry at Zambia’s largest tertiary 
hospital, the University Teaching Hospital (UTH), where part of the study was based.  
 
2.2  STUDY COHORTS AND SAMPLE COLLECTION 
HCMV was investigated in two settings:  
1) Congenital infection, in a prospective cross sectional study of new-borns at UTH. For 
this part of the study, we collected saliva and leftover umbilical tissue (which is normally 
discarded after delivery) as the non-invasive samples for virus diagnosis and analysis. 
Parents were also given the option of either finger/toe nails or hair follicles if they were 
uncomfortable with use of umbilical tissue (see participants’ information sheet, 
appendix 5). HCMV analyses focused primarily on use of saliva, while the other sample 
types were used to screen for congenital HHV-6A/B, which are known to integrate 
chromosomally and therefore potentially present in every body cell.  
 
2) Postnatal infection transmission, via retrospective study of breast milk, detailed in 
section 2.2.2.  
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The roseoloviruses HHV-6A and HHV-6B, which are closely related to HCMV but have 
unique pathological, clinical and epidemiological characteristics, were also evaluated 
where appropriate as experimental controls. 
 
2.2.1 NEONATAL COHORT  
Study Setting and Participants  
This aspect of the study was cross-sectional, and conducted at UTH, in Lusaka, Zambia. 
As Zambia’s largest tertiary hospital, UTH is a 1800-bed government-run referral centre 
providing specialist health care including clinical, radiological, laboratory, and 
rehabilitation services, and also serves as the country’s main training institution for 
various levels of healthcare cadres including Doctors, Nurses, Pharmacists, Biomedical 
Scientists, and Physiotherapists. UTH has an immediate catchment population of over 2 
million people, and nationally serves Zambia’s population of 15 million. Various 
healthcare services ranging from primary to tertiary are provided to in- and out-patients 
under four main clinical departments: Paediatrics & Child Health, Obstetrics & 
Gynaecology, Internal Medicine, and Surgery, which are complemented by 
Pathology/Microbiology, Radiology, Pharmacy, and Physiotherapy departments. 
Participants in our neonatal study were drawn from the Labour Ward (LW) and the 
Neonatal Intensive Care Unit (NICU). All neonates born in the UTH LW, and all neonates 
referred to NICU for specialised neonatal care, whether born at UTH or elsewhere, were 
eligible for inclusion in the study provided they were 14 days or younger, and a parent / 
guardian consented to participation by signing a consent form (appendix 6). Exclusion 
criteria were: being above 14 days old, having received a blood transfusion, and refusal 
of consent by parent / guardian. The study was introduced by a research nurse to 
parents / guardians of prospective participants who met the inclusion criteria, with 
detailed explanation and a copy of the study Information Sheet (appendix 5) provided. 
On obtaining written consent, relevant demographic and medical information was 
collected on a standardized data capture form (appendix 7).  
 
For this study, our target sample size was 200 neonates. Recruitments were however 
hampered by protracted industrial action taken by nursing staff during the period of our 
field study. Between 1st August and 15th September 2013, 117 neonates were recruited 
to the study: 101 from LW and 16 from NICU. In LW all neonates were recruited within 
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1 hour of birth (median 10min, IQR 5 – 26min) and in all cases but one, saliva samples 
were collected before initiation of breastmilk feeding. There were four cases of 
stillbirths. In NICU, the median postnatal age at recruitment was 4 days (IQR 1.0 – 9.3 
days). At recruitment half (8/16) of the participants had already commenced breastmilk 
feeding.  
 
Specimen Collection and Handling 
Saliva was collected by swabbing the neonate’s mouth with a sterile polyester-tipped 
swab (Peel pouch Dryswab™, Medical Wire & Equipment), which was air-dried then 
placed in a separate, labelled grip seal bag. Additionally, approximately 1cm3 of umbilical 
tissue was collected using a sterile surgical blade shortly after birth in LW or from above 
the umbilical cord clamp in NICU. Where collection of umbilical tissue was declined or 
not feasible, parents could opt for nail clippings or hair follicles to be collected. Nail 
clippings were obtained using sterilized nail clippers. Hair follicles were plucked from the 
scalp. Overall, we collected saliva from 116 participants, umbilical tissue from 115, hair 
from one, and nail clippings from one participant, as outlined in table 2.1. Prior to DNA 
extraction, saliva, nail, and hair specimens were stored securely in a locked cabinet at 
room temperature, while umbilical tissue was frozen at –20°C at the UTH Virology 
Laboratory (UTHVL) located within the UTH grounds.  
 
Sample Type LW NICU Total 
Saliva  100 16 116 
Umbilical tissue 101 14 115 
Hair - 01 01 
Nails - 01 01 
 
Table 2.1: Type of sample collected by ward. Saliva and umbilical tissue were the 
preferred non-invasive sample types by parents/guardians in this study. 
 
 
2.2.2 BREASTFEEDING COHORT 
The second arm of this thesis analysed available breast milk samples remaining from the 
Breast Feeding and Postpartum Maternal Health (BFPH) study (Collin et al., 2006), and 
stored at the Institute of Child Health, University College London, London. BFPH was 
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conducted in Lusaka, Zambia from June 2001 to July 2003 as a longitudinal cohort study 
that recruited 429 (218 HIV-negative, 211 HIV-positive) women to examine factors 
associated with postpartum physical and mental morbidity. Maternal and infant health 
and infant feeding data were collected from 34 weeks gestation to 16 weeks 
postpartum. At 11 separate postnatal visits (days [D] 3, 7, 10, 14, and weeks [W] 3, 4, 5, 
6, 9, 12, 16) spot milk samples were collected for measurement of inflammation markers 
and HIV-1 viral load. HIV-positive mothers and their new-borns received single-dose 
nevirapine as per local prevention of mother to child HIV transmission (PMTCT) policy 
(Collin et al., 2006, Kasonka et al., 2006, Phiri et al., 2006).  
 
Breast milk samples for present study 
For this current study, 261 milk samples (118 HIV-positive and 143 HIV-negative) 
collected at W16, were available in sufficient volume. In order to gain insight into the 
kinetics of HCMV shedding in breast milk in this population, we also examined all 
available milk sets with D3, W2, W4, W9, and W12 samples. Forty such sets, from 20 
HIV-negative and 20 HIV-positive women, were available for analysis in the kinetics 
studies. All available milk samples were stored at –80°C. 
 
2.3  DNA EXTRACTION AND PCR 
2.3.1 DNA EXTRACTION 
DNA utilised in analyses including qualitative and quantitative PCR and genome 
sequencing assays for HCMV, HHV-6A, HHV-6B, and GAPDH was extracted from saliva, 
umbilical tissue, nails, hair or breast milk using the QIAamp® DNA Mini kit (QIAGEN®), 
following manufacturers’ instructions, as follows in brief.  
 
Saliva 
Here the ‘DNA Purification from Buccal Swabs’ spin protocol was used. Each polyester 
swab tip was separated from the stick and placed in 400μl of PBS in a sterile 2ml 
microcentrifuge tube. 20μl of proteinase K and 400μl of Buffer AL were then added and 
immediately mixed thoroughly by vortexing for 15s prior to incubation at 56°C for 
10min. The tube was then centrifuged briefly to remove drops from inside the lid, and 
400μl of molecular biology grade 100% ethanol added to the sample, mixed by pulse-
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vortexing for 15s, followed by brief centrifugation to remove drops from inside the lid. 
Binding of sample to the QIAamp Mini spin column membrane was achieved in two 
successive steps, each involving the application of up to 700μl of sample mixture to a 
QIAamp Mini spin column in a 2ml collection tube followed by centrifugation at 
8000rpm for 1min. The filtrate with collection tube was discarded and spin column 
placed in another clean 2ml collection tube. Wash steps involved addition of 500μl of 
Buffer AW1, centrifugation at 8000rpm for 1min, followed by 500μl of Buffer AW2 and 
centrifugation at 14,000rpm for 3min, with change of collection tube at the end of each 
centrifugation step. Additional centrifugation was performed at 14,000rpm for 1min 
before the elution step. DNA was eluted into 50μl molecular biology grade water added 
to the spin column placed in a sterile 1.5ml microcentrifuge tube. Following incubation 
at room temperature for 5min, final centrifugation at 8000rpm for 1min was performed 
to recover the DNA. DNA yield and quality were measured on a NanoDrop™ 
spectrophotometer (Thermo Fisher Scientific Inc), and extracted DNA samples were 
stored at –20°C at UTHVL and LSHTM, prior to downstream analysis.  
 
Umbilical tissue, Nails, and Hair 
For these samples types, the ‘DNA Purification from Tissues’ protocol was used. Up to 
25mg of each sample was cut up into small pieces using a sterile disposable blade and 
placed in a sterile 1.5ml microcentrifuge tube. 180μl of Buffer ATL and 20μl of proteinase 
K were added and the mixture was vortexed for 15s before incubation at 56°C for 3hrs, 
during which occasional vortexing was done to disperse the sample. At the end of the 
incubation period, the microcentrifuge tube was centrifuged briefly to remove drops 
from the inside of the lid. 200μl Buffer AL was then added to the sample, mixed by pulse-
vortexing for 15s, and incubated at 70°C for 10min. 200μl of molecular biology grade 
100% ethanol was added to the sample, mixed by pulse-vortexing for 15s, and tube 
briefly centrifuged to remove drops from inside of the lid. The mixture was then carefully 
applied to a QIAamp Mini spin column in a 2ml collection tube and cap closed before 
centrifugation at 8000rpm for 1min. The filtrate with collection tube was discarded and 
spin column placed in another clean 2ml collection tube. Wash, elution, yield 
quantification, and DNA sample storage steps were the same as for DNA extraction from 
saliva, outlined in the previous section.  
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Breast milk 
DNA was extracted from breast milk using the ‘DNA Purification from Blood or Body 
Fluids’ spin column protocol. In readiness for DNA extraction, each milk sample was 
thawed and gently mixed to homogeneity. 20μl of proteinase K was pipetted into the 
bottom of a sterile 1.5ml microcentrifuge tube followed by 200μl of breast milk sample, 
and then 200μl of Buffer AL. Tube contents were mixed thoroughly by pulse-vortexing 
for 15s to yield a homogeneous solution, which was incubated at 56°C for 10min. At the 
end of incubation, the tube was centrifuged briefly to remove drops from inside of the 
lid. 200μl of molecular biology grade 100% ethanol was then added to the sample, mixed 
by pulse-vortexing for 15s, and then the tube was briefly centrifuged to remove drops 
from inside of the lid. The mixture was then carefully applied into a QIAamp Mini spin 
column in a 2ml collection tube and cap closed before centrifugation at 8000rpm for 
1min. Wash, elution, yield quantification, and DNA sample storage steps were the same 
as for DNA extraction from saliva, outlined earlier.  
 
2.3.2 QUALITATIVE PCR 
All PCR experiments were conducted in three separate dedicated areas to minimise 
contamination, as follows. Reagents were stored and prepared in a dedicated ‘clean’ 
room located on a separate floor of the laboratory building, and using dedicated 
instruments and laboratory personal protective equipment (PPE, i.e. laboratory coats 
and gloves). Clinical samples were stored and added to reaction mixtures in another 
room, again with dedicated instruments and PPE. Amplification and gel electrophoresis 
were then conducted in a separate third room. The principle of unidirectional workflow 
was observed, and reaction tubes/plates were sealed prior to loading into the 
thermocycler. All PCR reactions included appropriate positive controls and two negative 
controls: reagent control (i.e. no template) and water as template. 
 
Targets and Oligonucleotide Primers 
Conserved genes HCMV UL55 and HHV-6A/B U38, encoding HCMV gB and the HHV-6A/B 
polymerase respectively, were targeted for virus screening, while hypervariable HCMV 
UL73 and HCMV UL74 genes encoding HCMV gN and gO respectively were used in 
genotyping assays as defined previously in the Gompels research laboratory (Bates et 
al., 2008, Mattick et al., 2004, Bates et al., 2009, Mattes et al., 2005). For HHV6-A/B, 
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additional PCR targets included the viral chemokine encoded by U83 and the chemokine 
receptor encoded by U51. To validate the DNA extraction protocol, we amplified a 
104bp fragment of the human housekeeping gene encoding glyceraldehyde-3-
phosphate dehydrogenase (GAPDH), as previously described (Asahi-Ozaki et al., 2006, 
Bates et al., 2009, Bates et al., 2008). Oligonucleotide primers used are detailed in table 
2.2. All primers were synthesised by Sigma-Aldrich Co. Ltd., UK. The same primer sets 
were also used in sequencing PCR reactions (section 2.5.1).  
 
PCR setup and thermal cycling conditions 
Qualitative PCR reactions were in 25μl volumes consisting of 12μl of Promega’s GoTaq® 
Green Master Mix (containing 50 units/ml of Taq DNA polymerase, 400μM dATP, 400μM 
dGTP, 400μM dCTP, 400μM dTTP, 3mM MgCl2), 2.5μl each of forward and reverse 
primer (10μM), 7μl nuclease-free water (Promega), and 1μl of template DNA. Each 
reaction had a final primer concentration of 1μM. For HCMV gB, HCMV gO, HCMV gN, 
and GAPDH amplification, thermal cycling conditions were: 95°C for 2min, then 40 cycles 
of 95°C for 30s, 59°C for 30s, and 72°C for 2min, followed by final extension at 72°C for 
5min, and holding at 4°C. For HHV-6A/B U38 amplification, only annealing temperature 
differed, at 55°C. PCR was performed using a DYAD™ DNA Engine Dual Block Peltier 
Thermocycler (MJ research). 
 
Agarose Gel Electrophoresis 
Agarose gel electrophoresis used 1X Tris base/Boric acid/EDTA (TBE) buffer to separate 
PCR amplification products loaded in 1% agarose gels (1g genetic analysis grade agarose 
(Fisher scientific, UK) in 100ml 1X TBE). Agarose gels were stained with ethidium 
bromide (5μg/ml) to aid visualisation of DNA bands under UV illumination in a UV box. 
Because GoTaq® Green Master Mix (Promega) used in our PCR reactions contained 
loading dye, amplification products were loaded directly onto gels. Electrophoresis was 
carried out at 100 Volts until the leading edge of dye neared the base of the gel to 
maximise band separation (approximately 45-60min). Gels were viewed on the 
GeneGenius SYDR2 Gel Bioimaging Unit (Syngene), with GeneSnap software, which 
enabled digital images of the DNA bands to be captured. 
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Target Oligo Name Sequence (5' to 3') Product size (bp) Reference 
HCMV UL55 (gB) gB1 GAGGACAACGAAATCCTGTTGGGCA 149 (Bates et al., 2008, 
Mattes et al., 2005, 
Mattick et al., 2004) 
gB2 TCGACGGTGGAGATACTGCTGAGG 
  gB-P3 [FAM]CAATCATGCGTTTGAAGAGGTAGTCCACG[TAMRA]  
 UL73 (gN) gNup TGGTGTGATGGAGTGGAAC 411-420 (Bates et al., 2008, 
Mattick et al., 2004) 
 gNlw TAGCCTTTGGTGGTGGTTGC 
 UL74 (gO) GO-up CGACCAGAATCAGCAGTGAG 742 (Bates et al., 2008, 
Mattick et al., 2004) 
 GO-lw TGTACAGTTGCGTTGTGCGTA 
HHV-6A/B U38 (Pol) MaSu38F AAGACGGGTTATTATGCTGTG 566 Gompels lab, 
(unpublished) MaSu38R ACAGACATAAAGATGCTATCC 
 U51  
(Chemokine receptor) 
U51MF1 TATGGTTGGGTATTTATTTTTTCGTC 867 Gompels lab, 
(unpublished)  U51MR1 ACTCTCGAGTCATTTTAACATTTTTATTCCAACCTCTAAATCC 
 U83 (Chemokine) U83FP1 AAGTTAACACGACGGGAACAA 339 Gompels lab, 
(unpublished)  U83RP1 TGCCATATCACACATCGAG 
Human GAPDH GAPup GCTCCCTCTTTCTTTGCAGCAAT 104 (Asahi-Ozaki et al., 
2006, Bates et al., 2008)   GAPdown TACCATGAGTCCTTCCACGATAC 
  GAP Probe [FAM]TCCTGCACCACCAACTGCTTAGCACC[TAMRA] 
pGEM-T 
Vector 
Insert of interest SP6 GCTCCCTCTTTCTTTGCAGCAAT (Insert size + 46) Promega Corp.,  
TM042 rev. May 2007 T7 TACCATGAGTCCTTCCACGATAC 
 
Table 2.2: Oligonucleotide primers and probes used in our PCR and qPCR assays. The table outlines the sequences of primers and probes used in 
this study, and size of amplification products. All primers and probes were synthesised and supplied by Sigma-Aldrich Co. Ltd., UK. 
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2.3.3 QUANTITATIVE REAL-TIME PCR 
DNA copy numbers were computed in a TaqMan® Real-Time assay run on the Applied 
Biosystems® 7500 Fast Real-Time PCR System (Applied Biosystems® Inc.) as described 
for HCMV gB (Bates et al., 2008, Mattes et al., 2005) and GAPDH (Bates et al., 2008, 
Asahi-Ozaki et al., 2006). The assay used the 5’-6FAM / 3’-TAMRA – labelled 
oligonucleotide probes (Sigma-Aldrich Co. Ltd., UK) gB-P3 or GAPprobe with the gB1/gB2 
and GAPup/GAPdown primer sets (table 2.2) for HCMV and GAPDH respectively. 
Standard curves were generated from 10-fold serial dilutions (in triplicate) of plasmid-
cloned DNA standards (table 2.3) spanning 100 to 106 concentrations. Each qPCR 
reaction was in a 25μl volume consisting of 10μl KAPA PROBE FAST Universal qPCR 
Master Mix (Kapa Biosystems), 1μl probe (5mM), 1μl each of forward and reverse 
primers (10 mM), 0.4μl ROX Low, 7μl nuclease-free water, and 5μl template DNA. All 
standards and samples were run in triplicate. Cycling conditions were 95°C for 10min, 
followed by 45 cycles of 95°C for 15s and 60°C for 1min. Our in-house plasmid reference 
standards derived from cloned gB amplicons (see section 2.4) were normalised to the 
HCMV 09/162 International Clinical Reference Standard (National Institute of Biological 
Standards, Potters Barr, UK). 
 
2.4  PLASMID CLONING 
Generation of plasmid clones  
To generate plasmid clones with GAPDH and HCMV gB inserts, the pGEM®-T Easy Vector 
Systems cloning kit (Promega Corporation) was used, in accordance with manufacturers’ 
instructions (Promega Corporation, TM042 revised May 2007) as follows. PCR product 
or control DNA insert, pGEM®-T Easy Vector and T4 DNA ligase were added to a 
microcentrifuge tube at PCR product to vector ratios of 3:1 and 1:1. The PCR product 
concentration was determined using a NanoDrop™ spectrophotometer (Thermo 
Scientific™) after purifying DNA bands of interest from agarose gels following 
electrophoresis. To calculate the amount of PCR product (insert) to include in the 




ng of insert =  
ng of vector X kb size of insert 
X insert:vector molar ratio 
kb size of vector 
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Ligation reactions were performed for one hour at room temperature. After thawing on 
ice, 50μl of JM109 competent cells were added to microcentrifuge tubes containing 2μl 
of ligated vector with insert. The tubes were then gently mixed and incubated on ice for 
20min, then heat-shocked at 42°C for 45sec in a water bath before being incubated on 
ice for a further 2min. The tubes were then placed in a shaking pre-warmed 37°C 
incubator for 90min at 150rpm. Transformations were plated twice onto separate, pre-
warmed LB agar plates containing 50μg/ml ampicillin (supplemented with IPTG 0.1M/X-
Gal 20μg/ml), one with 100μl and another with 20μl. After 5 minutes, the plates were 
inverted and placed in a 37°C incubator for overnight growth. Individual white colonies 
were streaked out on new pre-warmed plates and incubated overnight at 37°C. 
Individual colonies from these second plates were selected with a sterile pipette tip and 
added to 3ml of LB broth, supplemented with 50ug/ml ampicillin, and grown overnight 
in a 37°C shaking incubator. Glycerol stocks were prepared by mixing 700μl of 
transformed bacteria stock with 700μl of 40% glycerol in a cryovial. These stocks were 
stored at –80°C. Inserts were verified by PCR and nucleotide sequencing with primers 
used during production of the insert.  
 
Isolation of Plasmid DNA 
Plasmid DNA was purified from overnight cultures of transformed bacteria in LB broth, 
supplemented with 50ug/ml ampicillin, using the PureLink® HiPure Plasmid Miniprep kit 
(Invitrogen™/Life Technologies™). For each sample, cells were harvested from 3ml of an 
overnight LB culture by centrifuging at 4000×g for 5min, followed by removal of all 
medium. Cells were resuspended in 0.4ml of Resuspension Buffer (R3) with RNase A in 
a microcentrifuge tube until homogeneous. Thereafter 0.4ml of Lysis Buffer (L7) were 
added, and contents mixed gently by inverting the capped tube (avoiding vortexing) 
until the lysate mixture was thoroughly homogenous. The mixture was incubated at 
room temperature for 5min, followed by addition of 0.4ml of Precipitation Buffer (N3), 
and mixing immediately by inverting the tube (avoiding vortexing) until the mixture was 
thoroughly homogeneous. The lysate was then centrifuged at >12,000×g for 10min at 
room temperature, the clear lysate transferred into another sterile tube and centrifuged 
at >12,000×g for a further 5min at room temperature to remove any remaining cellular 
debris. The supernatant was then loaded onto a column and allowed to drain by gravity. 
The column was washed twice with 2.5ml Wash Buffer (W8), allowing the solution in the 
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column to drain by gravity and discarding the flow-through after each wash. To elute 
and precipitate the DNA, a sterile microcentrifuge (elution) tube was placed under the 
column, and 0.9ml Elution Buffer (E4) added to the column, allowing the solution to 
drain by gravity. 0.63ml of isopropanol were added to the elution tube and mixed 
thoroughly before centrifuging the elution tube at >12,000×g for 30min at 4°C. The 
supernatant was carefully removed and discarded, and the DNA pellet resuspend in 1ml 
of 70% ethanol before additional centrifugation at >12,000×g for 5min at 4°C. Again, the 
supernatant was carefully removed and discarded. The DNA pellet was air-dried for 
10min before being resuspended in 50μL of nuclease-free water. The DNA yield and 
quality were measured on a NanoDrop™ spectrophotometer (Thermo Fisher Scientific 
Inc), and aliquots made for storage at –20°C pending further use. Inserts were verified 
by PCR amplification across the insertion site using the SP6 and T7 promoter primers 
(Promega Corporation, TM042 revised May 2007, see table 2.2), followed by nucleotide 
sequencing with primers used during production of the insert. Serial 10-fold dilutions 
containing 1X1010 to 1X100 DNA copies/μl were made, and aliquots of each 
concentration stored at -20°C. Table 2.3 outlines characteristics of the plasmid clones. 
 
  GAPDH HCMV gB 
Plasmid designation G2-4 B2-8 
Insert gene source Human saliva DNA HCMV strain AD169 
Vector pGEM®-T Easy pGEM®-T Easy 
Vector size (bp) 3015 3015 
Insert size (bp)  104 149 
Miniprep yield (ng/μl)  73.2 82.5 
Stock concentration (copies/μl) 2.14 X 1010 2.38 X 1010 
 
Table 2.3: Characteristics of plasmid clones. pGEM®-T Easy plasmids with GAPDH and 
HCMV gB inserts were designated G2-4 and B2-8 respectively as characterised here, 
for use as in-house standards in qPCR experiments. 
 
 
2.5  NUCLEOTIDE SEQUENCING  
2.5.1 GEL DNA PURIFICATION 
Following qualitative PCR runs, DNA was purified from gels using the Zymoclean™ Gel 
DNA Recovery Kit (Zymo Research Corp.). Bands of interest were excised from gels using 
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a clean scalpel and transferred to a 1.5ml microcentrifuge tube. To this, buffer ADB was 
added at a rate of three times the volume of the agarose slice. The tube was incubate at 
37-55°C for 5-10min until the gel slice completely dissolved, and the melted agarose 
solution was then transferred to a Zymo-Spin™ column in a collection tube. This was 
centrifuged at 14,000rpm for 60s, flow-through discarded, and then washed twice with 
200μl of Wash Buffer, each time centrifuging at 14,000rpm for 30s and discarding the 
filtrate. Finally, 15μl of nuclease-free water were added directly to the column placed 
into a sterile 1.5ml tube, and incubated for 2-5minbefore centrifugation at 14,000rpm 
for 60s to recover DNA. The DNA yield and quality were measured on a NanoDrop™ 
spectrophotometer (Thermo Fisher Scientific Inc.) before samples were sequenced or 
stored at -20°C. 
 
2.5.2 SANGER SEQUENCING  
Nucleotide sequences were determined by capillary electrophoresis using Sanger 
methods to define the PCR amplicons derived from HCMV and HHV-6A/6B amplified 
directly from clinical samples as previously described (Bates, 2008 & 2009). Sequencing 
reactions were performed in-house or outsourced from Source BioScience, Oxford, UK. 
The in-house method used the BigDye® Terminator v3.1 (Applied Biosystems) kit, 
following manufacturer’s instructions to directly sequence both sense and antisense 
strands from gel-extracted DNA. Sequencing reactions were in 10μl volumes consisting 
of 3μl dilution buffer, 1μl primer (1μM), 4μl nuclease-free water, 1μl big dye, and 1μl 
template (10-20ng of DNA). Amplification reactions were performed in a DYAD™ DNA 
Engine Dual Block Peltier Thermocycler (MJ Research). Sample tubes were loaded into 
the thermocycler, preheated to 96°C for 4 minutes, followed by 25 cycles of 
denaturation at 96°C for 20sec, annealing at 50°C for 10sec, and extension at 60°C for 
2min. There was then a final extension step at 60°C for 5min. Samples were then kept 
at 4°C pending DNA extraction, which involved precipitation with 0.1M sodium acetate 
/ 68% ethanol. After this, samples were incubated on ice for 20 min, and then 
centrifuged at 3000xg for 30min at 4°C. Supernatant was then removed; ice-cold 70% 
ethanol was added and the samples were centrifuged at 3000xg for 10min prior to 
removal of supernatant. Finally, samples were re-suspended in Hi-di formamide 
(Applied Biosciences). Nucleotide sequences were then determined by capillary 
electrophoresis on an automated ABI3730 sequencer (Applied Biosystems). In some 
 Page 57 of 338 
cases, Sanger sequencing was outsourced from Source BioScience UK Ltd 
(http://www.lifesciences.sourcebioscience.com/genomic-services/sanger-sequencing-
service/). Nucleotide sequences were compiled using ChromasPro software version 1.7 
(Technelysium). 
 
2.5.3 ILLUMINA NEXT GENERATION SEQUENCING  
For further genomic analyses using Illumina platforms, six extracted DNA samples with 
viral loads characterised were selected from HIV-positive as well as HIV-negative W4, 
12, and 16 milk samples. The SureSelect system (Agilent Technologies Inc.) (Depledge et 
al., 2011) was used for HCMV target amplification direct from the clinical samples 
described above, then genome libraries were prepared by clonal amplification and 
paired-end sequenced on the MiSeq™ (Illumina®) platform by our collaborators, the 
Andrew Davison group at the MRC Center for Virus Research, University of Glasgow. 
Resultant FASTQ reads were delivered using Dropbox (Dropbox Inc., San Francisco) then 
analysed as described in section 2.6 (Bioinformatics, NGS analyses). 
 
2.6  BIOINFORMATICS  
Phylogenetic analysis  
Forward and reverse sequence chromatograms were analysed using ChromasPro 
software version 1.7 (Technelysium) and compiled to generate contiguous sequences 
which were then checked against archived sequences using the NCBI Basic Local 
Alignment Search Tool (BLAST) (http://blast.ncbi.nlm.nih.gov/Blast.cgi). The ExPASy 
bioinformatics resource portal (http://www.expasy.org/resources) and its suite of tools 
was also utilised. Multiple alignments were performed using Clustal Omega 
(http://www.ebi.ac.uk/Tools/msa/clustalo/) and phylogenetic analyses conducted via 
maximum-likelihood methods in MEGA version 6.06 (Tamura et al., 2013). The Jones-
Taylor-Thornton (JTT) model was used, with phylogenies tested by 1,000 bootstrap 
replications. Tree inference was made by the Nearest-Neighbour-Interchange (NNI) 
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NGS data analysis 
Raw NGS reads were checked for quality using FASTQC 
(http://www.bioinformatics.babraham.ac.uk/projects/fastqc/) and trimmed to a 
minimum length of 100 bases using Trimmomatic (Bolger et al., 2014). The NGS reads 
were optimised by VelvetOptimiser for reference-independent de novo assembly with 
Velvet (Zerbino and Birney, 2008) and ABACAS (Assefa et al., 2009), and contigs were 
verified by employing the consensus sequence as mapping reference using the Burrows-
Wheeler Aligner, BWA (Li and Durbin, 2009, Li and Durbin, 2010), SAMtools / BCFtools 
(Li et al., 2009) and GATK (McKenna et al., 2010) for alignment, indexing, mapping, and 
variant calling. Artemis was employed for visualisation (Rutherford et al., 2000). 
Genome annotations were transferred from the HCMV reference strain Merlin 
(AY446894.2) using the Rapid Annotation Transfer Tool, RATT (Otto et al., 2011).  
 
Molecular tags for strain identification 
Genotype-specific nucleotide sequences (‘Molecular tags’) were developed (see Chapter 
5) for the HCMV hypervariable genes UL73 and UL74 (Dolan et al., 2004, Pignatelli et al., 
2004, Puchhammer-Stockl et al., 2006). The molecular tags were validated against all 
publicly available relevant HCMV sequences in GenBank Flat File Release 211 (National 
Center for Biotechnology Information (NCBI), 2015). Custom perl scripts were then 
developed to interrogate FASTQ reads in order to quantify mixed infections by 
enumerating the proportions of individual molecular tags in relation to representative 
read depths. From this information, Microsoft Excel 2013 was used to model 
proportions of each represented genotype. 
 
2.7  STATISTICAL ANALYSIS  
All data were entered into restricted, password-protected Microsoft Access 2010 
databases, and related hard copy information kept in a locked cabinet. Microsoft Excel 
2010, SPSS 21.0, and GraphPad Prism version 6.05 for Windows (GraphPad Software, La 
Jolla California USA, www.graphpad.com) were used for data analysis. Nominal data 
were analysed in contingency tables by Fisher Exact tests, while sample means were 
compared by the Student’s t test and medians analysed by the Mann-Whitney U test. p-
values were computed with significance threshold set at 0.05. 
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CHAPTER 3 
INVESTIGATION OF HCMV AT BIRTH IN ZAMBIA USING  
NON-INVASIVE SAMPLES  
3.1  INTRODUCTION 
This chapter presents findings from studies aimed at assessing congenital HCMV 
infection in Zambia, Southern Africa. At the start of this thesis, there was limited 
information on childhood infections with HCMV, particularly congenital infection in 
Zambia. Previous studies by our research group indicated that HCMV was more 
prevalent, infection occurred earlier than in other global locations, and these infections 
were associated with adverse effects on child growth and development (Bates 2008, 
2009; Gompels 2012). Studies in this chapter were thus conducted with particular 
interest to clarify the prevalence of congenital HCMV infection. We also tested for 
related betaherpesviruses, HHV-6A and HHV6-B, as controls. This was done by studying 
two neonatal groups i.e. ‘normal’ newborns delivered in the University Teaching 
Hospital (UTH) labour ward (LW), and neonates admitted to the UTH Neonatal Intensive 
Care Unit (NICU). In assessing infections, our approach was to utilise non-invasive 
samples: saliva, hair, nail clippings, or leftover umbilical tissue (which would otherwise 
be discarded following delivery), thereby minimising risk of occupational hazards, cross-
infection, or distress to the donor – which is of particular importance when dealing with 
infants, children, and their guardians. These samples have been utilised elsewhere to 
analyse various infections, including betaherpesviruses (Hall et al., 2008, Hall et al., 
2010, Morissette and Flamand, 2010, Mussi-Pinhata et al., 2009, Endo et al., 2009, 
Flamand et al., 2010, Murthy et al., 2011, Boppana et al., 2011, Arbuckle et al., 2010, 
Forman et al., 2012, Kainth and Caserta, 2011, Spano et al., 2007, Koyano et al., 2004, 
Koyano et al., 2009). Bearing in mind local cultural sensitivities associated with some of 
these sample types, parents in our studies had the option to choose which samples they 
were comfortable to be collected for testing. 
 
The first part of this chapter describes experimental setup and optimisation, and then 
results from analysis of clinical samples are presented in latter sections. I wish to 
acknowledge and thank Dr Nyaxewo Mwaanza (UTH Paediatrics and Child Health 
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Department), the UTH HERPEZ team, and donors at LSHTM for providing saliva, hair, and 
nail samples used in assay optimisation experiments. 
 
3.2  ASSAY OPTIMISATION 
3.2.1 PCR strategy and primer sensitivity  
The strategy employed in our analyses was to first screen samples using conserved gene 
targets, followed by genotyping hypervariable genes to determine strain variants. PCR 
assays and oligonucleotide primer sets previously validated and used in our laboratory 
(Bates et al., 2008, Mattick et al., 2004, Mattes et al., 2005) were adopted for studies in 
this thesis. For HCMV, screening PCR used the gB assay with the gB1/gB2 primer pair, 
while the gN and gO assays utilising gNup/gNlw and gOup/gOlw primer sets respectively 
were used for genotyping. Additionally, we used the GAPDH PCR assay with 
GAPup/GAPdown primers to validate the DNA extraction procedure (see methods, 
section 2.3). 
 
The first step was to check assay sensitivity in our hands, after which a pilot assessment 
using donor samples from the LSHTM and UTH was conducted. Finally, the methods 
were applied to samples collected from our study cohorts. To check assay sensitivity, 
serial 10-fold dilutions of plasmid-cloned target genes were used, with PCR runs setup 
in duplicate. The assay sensitivity was determined as the lowest concentration of 

























Figure 3.1. PCR primer sensitivity. Serial 10-fold dilutions of were run in duplicate for 
each gene target. The assay sensitivity was determined as the highest dilution for which 
the target sequence detection was reproducible, thus in our case 100 copies for gB and 
gN, and 10 copies for gO. 
 
 
3.2.2 Real-time quantitative PCR setup and optimisation  
Quantitative real time PCR was used to measure the HCMV viral load using the gB assay 
validated previously by our laboratory (Bates et al., 2008, Mattes et al., 2005). The setup 
and performance of the qPCR assay were in accordance with best practice as contained 
in the Minimum Information for Publication of Quantitative Real-Time PCR Experiments 
(MIQE) guidelines (Bustin et al., 2010, Bustin et al., 2009). Our TaqMan qPCR assay used 
the gB1/gB2 primer pair together with the gB3 fluorescent probe. Standard curves were 
generated by linear regression analysis of the quantification cycle (Cq) measured for 
each amplification vs. the log10 copy number for each standard dilution, which are given 
by the relationship: 
 
where:  a is the slope, b is the y-intercept, and  
x is the standard quantity 
 
 
To determine the assay limit of detection (LOD), plasmid-cloned standards were run in 
triplicate for each load level, covering seven dilution levels (106 to 100). Three trials were 
108        107        106         105        104        103         102      101     100       WC      RC 





















 108       107      106       105       104       103       102       101       100        WC      RC 
1010    109      108       107     106     105      104     103      102      101     100      WC    RC 
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performed, each on a different day. As per standard practice, the lowest concentration 
at which at least 95% of positive samples were detected was taken as the assay limit of 
detection (LOD) (Bustin et al., 2009). For the HCMV gB qPCR assay, this was 600 copies 
per 5µl template (table 3.1). For each qPCR run, standard curves were constructed and 
each ‘unknown’ sample DNA concentration was extrapolated from the regression line 
























Figure 3.2. HCMV gB qPCR [A] standard curve and [B] amplification plot. 
Representative standard curve and amplification plot obtained during a gB qPCR 
run, demonstrating good correlation among replicates, with R2 of 0.97 and run 
efficiency (Eff) of 101.7%. Standards were run in triplicate. 
 
Slope = -3.28 R2 = 0.97  Eff = 101.7% 
[A] 
[B] 





















6000000 3 3 3 9 9 100% 
600000 3 3 3 9 9 100% 
60000 3 3 3 9 9 100% 
6000 3 3 3 9 9 100% 
600 3 3 3 9 9 100% 
60 3 3 2 8 9 89% 
6 1 3 2 6 9 67% 
 
Table 3.1. HCMV gB qPCR Limit of Detection (LOD) determination. Three trials were 
performed, each consisting of a dilution series of the HCMV gB-containing plasmid. For 
each load level, three replicates were tested. The Limit of Detection (LOD) was 
determined to be 600 copies per 5µl template (highlighted). 
 
 
3.2.3 Normalisation to the HCMV 09/162 International Clinical Reference Standard 
The HCMV 09/162 International Clinical Reference Standard (ICRS) (National Institute of 
Biological Standards, Potters Barr, UK) was used to normalise our in-house plasmid-
cloned standards (see Methods section 2.3.3). The ICRS is supplied as a lyophilised 
powder, and upon reconstitution in 1ml molecular biology grade water, according to 
manufacturer’s instructions, DNA was extracted using the QIAamp® DNA Mini kit 
(QIAGEN®), following manufacturers’ instructions. Serial 10-fold dilutions of 
reconstituted HCMV ICRS, were run concurrently with our in-house standards and 
standard curve generated to determine the relationship between the primary and 
secondary standard. Based on this a conversion factor of 100 was determined. However, 
since our assay used 5µl of a 1:2 dilution of DNA from a stock that had been eluted in 
50µl but obtained from 200µl whole milk, readings per reaction were in fact equivalent 
to HCMV viral load copies per ml of whole milk. 
 
3.3 PILOT STUDIES USING NON-INVASIVE SAMPLES 
A final step in optimising our assays was to apply the assays to evaluate non-invasive 
tissue for virus diagnosis. A pilot was conducted in which saliva, nails, hair, and urine 
specimens from anonymous volunteers from LSHTM and UTH were tested. Overall these 
trials showed that sufficient DNA for virus analysis could be recovered from all these 
sample types (table 3.2). For saliva collection, the commonly available polyester-tipped 
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swabs proved effective, and adequate DNA could be recovered even when the swab 
dried, allowing flexibility for room temperature storage and transportation. During the 
pilot, we were able to amplify target genes from some of the donor samples, and derive 
nucleotide sequences (table 3.2). Figures 3.3 and 3.4 show examples of gel pictures 
demonstrating the amplification in DNA extracted from saliva of HCMV gB and HHV-









Figure 3.3. PCR amplification of HCMV gB: saliva samples. The 149bp fragment of the 
HCMV gB gene was amplified by PCR in DNA samples (labelled A-K) extracted from saliva. 
PCR products were loaded in 1% agarose gels and gel electrophoresis was performed in 
1X TBE buffer. RC, Reagent (no-template) Control; WC, Water Control; PC, Positive 











Figure 3.4. PCR amplification of HHV-6A/B U38: saliva samples. Shown is the PCR 
amplification of the 566bp fragment of the HHV-6A/B U38 gene. Samples tested (1-9) 
were DNA extracted from saliva. PCR products were loaded in 1% agarose gels and gel 
electrophoresis was performed in 1X TBE buffer. RC, Reagent (no-template) Control; 
WC, Water Control; PC, Positive Control (HHV-6A strain U1102). 
 
 
  1       2       3     4       5      6       7      8       9            RC    WC   100bp  PC 
                                                                                                                                  ladder 
566bp 
fragment 
     A          B         C         D          E         F         G         H          J          K         RC      WC      PC       100bp   
                                                                                                                                                                                                  ladder 
149bp 
fragment 
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Dry Saliva Neonate 13.6 + + - 
Nail clippings Neonate 9.1 + - - 
UN-2 
Dry Saliva Neonate 55.3 + - - 
Urine Neonate 15.1 + + 6A 
UN-3 Dry Saliva Neonate 110.4 + + 6A 
UN-4 Dry Saliva Neonate 64.7 + + 6A 
UN-5 Dry Saliva Neonate 94.8 + + 6A 
UN-5 Nail clippings Neonate 17.4 - - - 
UN-6 Dry Saliva Neonate 46.0 + + - 
UN-7 Dry Saliva Neonate 11.5 + + 6B 
UN-8 Dry Saliva Neonate 26.8 + + - 
SA Liquid Saliva Adult  15.2 - + 6B 
SB Liquid Saliva Adult  11.22 - - - 
SC Liquid Saliva Adult  24.3 - - - 
SWA Dry Saliva Adult  6.0 - - - 
SWB Dry Saliva  Adult  20.9 - - - 
SWC Dry Saliva  Adult  12.4 - - - 
CM Dry Saliva  Adult  12.9 - - - 
NM Dry Saliva  Adult  25.6 - - - 
MM Dry Saliva  Adult  44.6 - - - 
CM Hair follicles Adult  1.8 - - - 
NM Hair follicles Adult  5.7 - - - 
MM Hair follicles Adult  1.5 - - - 
CM Nail clippings Adult  13.9 - - - 
NM Nail clippings Adult  1.3 - - - 
MM Nail clippings Adult  3.8 - - - 
 
Table 3.2. Donor samples used in assay set-up and optimization. Sufficient DNA could 
be recovered from all sample types tested. HCMV, HHV-6A and HHV-6B could be 
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3.4  EVALUATION OF HCMV, HHV-6A, AND HHV-6B IN NEONATES 
A total of 117 neonates were recruited to the study: 101 from the LW and 16 from the 
NICU. In LW, all neonates were recruited within 1 hour of birth (median 10min, IQR 5 – 
26min) and in all cases but one, saliva samples were collected before initiation of breast 
milk feeding. There were four cases of stillbirths among participants from LW. In NICU 
the median postnatal age at recruitment was 4 days (IQR 1.0 – 9.3 days) and half (8/16) 
of the participants had already commenced breast milk feeding at recruitment. Table 
3.3 gives a summary of descriptive characteristics of the study participants.  
 
3.4.1 Samples 
For each participant, two samples were collected: Saliva plus either umbilical tissue, hair 
or nails. Saliva was collected by swabbing the neonate’s mouth with a sterile polyester-
tipped swab (Peel pouch Dryswab™, Medical Wire & Equipment), which was air-dried 
then placed in a separate, labelled grip seal bag. Additionally, approximately 1cm3 of 
umbilical tissue was collected using a sterile surgical blade shortly after birth in LW or 
from above the umbilical cord clamp in NICU. Where collection of umbilical tissue was 
declined or not feasible, parents could opt for nail clippings or hair follicles to be 
collected. Nail clippings were obtained using sterilized nail clippers. Hair follicles were 
plucked from the scalp. Overall, we collected saliva from 116 participants, umbilical 
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        Labour Ward         NICU        TOTAL 
  Freq % Freq % Freq % 
Breastfeeding at recruitment       
Not Breastfed 100 99.0 8 50.0 108 92.3 
Breastfed 1 1.0 8 50.0 9 7.7 
Total 101 100.0 16 100.0 117 100.0 
Gender       
Female 59 58.4 5 31.3 64 54.7 
Male 42 41.6 11 68.8 53 45.3 
Total 101 100.0 16 100.0 117 100.0 
Birth Weight (Kg)       
< 1.0 (ELBW)  4 4.0 3 18.8 7 6.0 
< 1.5 (VLBW)  3 3.0 8 50.0 11 9.4 
< 2.5 (LBW)  20 19.8 2 12.5 22 18.8 
2.5–4.5 (NBW)  74 73.3 2 12.5 76 65.0 
> 4.5 (Macrosomia) 0 0.0 1 6.3 1 0.9 
Total 101 100.0 16 100.0 117 100.0 
Mode of Delivery        
SVD 95 94.1 14 87.5 109 93.2 
CS 5 5.0 1 6.3 6 5.1 
Instr. 1 1.0 0 0.0 1 0.9 
NS 0 0.0 1 6.3 1 0.9 
Total 101 100.0 16 100.0 117 100.0 
Maternal HIV Serostatus       
Negative 83 82.2 9 56.3 92 78.6 
Positive 14 13.9 6 37.5 20 17.1 
NK 4 4.0 1 6.3 5 4.3 
Total 101 100.0 16 100.0 117 100.0 
 
Table 3.3. Neonatal cohort: descriptive statistics. VLBW, Extremely Low Birthweight; 
Very Low Birthweight; LBW, Low Birthweight; NBW, Normal Birthweight; SVD, 
Spontaneous Vaginal Delivery; CS, Caesarean section; Instr., Instrumental; NS, Not 
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[A] REASON FOR ATTENDANCE / DIAGNOSIS – LW Frequency % 
Normal labour 35 34.7 
Multiple pregnancy 8 7.9 
Raised blood pressure 8 7.9 
Preterm labour 7 6.9 
Dangerous presentation (breech / face / hand prolapse) 5 5.0 
Pre-Eclampsia 5 5.0 
Big baby 4 4.0 
Previous C/S 4 4.0 
Prolonged labour 4 4.0 
Foetal distress 3 3.0 
Post-dates 3 3.0 
IUFD / BOH 2 2.0 
Multiparity 2 2.0 
PROM 2 2.0 
Other*  7 6.9 
Not stated 2 2.0 
Total 101 100.0 
 
[B] DIAGNOSIS – NICU Frequency % 
Prematurity / Sepsis / RDS 12 75.0 
Ichthyosis Valgaris / Sepsis 1 6.3 
Macrosomia 1 6.3 
Meconium aspiration / Sepsis 1 6.3 
Meconium aspiration / SGA 1 6.3 
Total 16 100.0 
 
Table 3.4. [A] Reason for presenting to UTH labour ward (LW) and [B] infant’s 
diagnosis in NICU. C/S, Caesarean Section; IUFD, Intra-uterine foetal demise; BOH, 
Bad obstetric history; PROM, Premature rapture of membranes; RDS, Respiratory 
distress syndrome; SGA, Small for gestational age. *‘Other’ reasons for attendance 
included: elderly prime gravida, assault in pregnancy, fever, headache, vomiting, 
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Sample Type LW NICU Total 
Saliva  100 16 116 
Umbilical tissue 101 14 115 
Hair - 01 01 
Nails - 01 01 
 
Table 3.5: Type of sample collected by ward. Saliva and Umbilical tissue were accepted 
and most preferred non-invasive samples in our studies.  
 
 
3.4.2 HCMV detection 
Of 100 saliva samples collected from the LW, one sample was positive for HCMV gB by 
the screening PCR assay (figure 3.5). The sample was from an HIV-exposed female 
neonate with normal birthweight (2.8Kg). The HCMV DNA load was quantified using the 
qPCR assay and showed a high load of 2.3x107 copies/ml of saliva. Further, Sanger 
sequencing for HCMV gO and gN showed gO1c and gN4c (figure 3.6), in keeping with the 
known genotype gO1c and gN4c linkage (Bates et al., 2008, Mattick et al., 2004) (see 
table 1.1). 
 
Screening of umbilical tissue showed high background human DNA, and no HCMV DNA 









Figure 3.5. PCR amplification of HCMV gB in sample 100S. The 149bp fragment of HCMV 
gB was amplified in Sample 100S (red asterisk). PCR products were loaded in 1% agarose 
gels and gel electrophoresis was performed in 1X TBE buffer. RC, Reagent (no-template) 
Control; WC, Water Control; PC, Positive Control (HCMV strain AD169). 
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Figure 3.6. Molecular phylogenetic analyses of sample 100S [A] gO and [B] gN. The 
Maximum Likelihood method based on the JTT matrix-based model was used to infer 
relationships of the 17 amino acid sequences included in each phylogenetic analysis. 
Consensus trees were derived after applying 1000 bootstrap replicates. In each tree, 
sample 100S is indicated by the red circular marker. Analyses were conducted in MEGA 
6.06 (Tamura et al., 2013). 
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3.4.3 HHV-6A/B detection 
HHV-6A/B screening of saliva using the HHV6 U38 assay was negative for all samples 
from both the LW and NICU cohorts. However preliminary results from examination of 
umbilical tissue showed 54/117 (46.2%) probable amplifications of the U38 target. Given 
the 1% prevalence of chromosomally integrated HHV6-A/B reported elsewhere (Hall et 
al., 2004, Daibata and Miyoshi, 1999, Dahl et al., 1999, Adams et al., 1998, Hall et al., 
2008, Hall et al., 2010, De Bolle et al., 2005), our prevalence finding seemed unusually 




This chapter set out to investigate prevalence of congenital HCMV as a potential source 
and route of transmission of HCMV infection associated with the widespread 
detrimental effects of HCMV on child health and development shown earlier in Zambia 
(see introduction, chapter 1) (Gompels et al., 2012, Sanz-Ramos et al., 2013). At the start 
of this thesis, the prevalence of congenital HCMV in Zambia was unknown. Two available 
reports on congenital HCMV in sub-Saharan Africa showed 5.4% prevalence in the 
Gambia (van der Sande et al., 2007) and in a small sample, an average of about 10% 
[2.7% (1/37) among HIV-negative and 29% (4/14) among HIV-infected] in Kenya (Slyker 
et al., 2009a). Our analysis of new-borns in the normal labour ward showed congenital 
HCMV was 1% (1/100), which is consistent with rates published from other countries in 
Europe, North America and Southeast Asia (see section 1.8.1) (Fowler and Boppana, 
2006, Fowler et al., 1999, Fowler et al., 2003, Kaye et al., 2008, Yamamoto et al., 2013, 
Yamamoto et al., 2010).  
 
During the course of this thesis, three studies in sub-Saharan Africa also published 
information on prevalence of congenital HCMV. The first study analysed high-risk 
neonates under 3 weeks age at UTH neonatal intensive care unit, NICU, in Lusaka, 
Zambia, showing a prevalence of 3.8% (Mwaanza et al., 2014), and a link to maternal 
HIV infection. This was the first ever study to examine and report congenital HCMV in 
Zambia. However, in that study no measures were in place to distinguish breastmilk-fed 
from non‐breast milk-fed neonates. Given that breast milk feeding is widely practiced in 
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UTH NICU, HCMV is secreted in breast milk, and infant feeding can affect efforts to 
diagnose congenital infection (Fujisaki et al., 1998, Dunne and Jevon, 1993), it is not clear 
whether some of the HCMV infections may have been early post‐natal infections. 
Further, NICU receives births with complications, including infants with HIV-positive 
mothers, therefore may also contribute to the higher prevalence in this ward compared 
to the normal labour ward under study in this thesis. Another study published during 
the course of this thesis was conducted in South Africa among neonates born only to 
HIV infected mothers who had received prenatal ARV prophylaxis. The birth prevalence 
of congenital HCMV in that study was 2.6%, and infant HCMV was associated with 
advanced maternal immunosuppression. However, again, the study did not determine 
prevalence among ‘normal’ HIV-unexposed infants (Manicklal et al., 2014). A third study 
was conducted in Zimbabwe, among treatment-naïve HIV-infected infants, and showed 
a high rate of 11% congenital HCMV infection. In that study, other pathogens including 
EBV were also found in an unusually high prevalence congenitally (Gumbo et al., 2014). 
However, that study did not sample HIV-uninfected neonates for comparison. Unlike 
these highlighted studies, in our study presented here, both the breastfeeding status 
and maternal HIV exposure, were taken into account in investigating congenital HCMV 
infection. The neonate congenitally infected with HCMV in our study was maternally 
HIV-exposed. As described in other studies, maternal HIV is a risk factor for congenital 
HCMV transmission (Mwaanza et al., 2014, Gumbo et al., 2014, Slyker et al., 2009a) (see 
introduction section 1.8) and with the high DNA load of 2.3x107 copies/ml the neonate 
was at heightened risk of HCMV deleterious effects. Although efforts were made to trace 
the neonate and mother, in keeping with the ethical principles governing our study, 
unfortunately they could not be reached as the family was domiciled in another district 
outside Lusaka. It would have been desirable to link the neonate to available 
neurological services at UTH for assessment and follow-up clinical management, as well 
as investigate and link the mother to appropriate HIV management services, which are 
publicly available in the Zambian healthcare system. At present, therefore, in the 
maternally HIV negative group on the normal labour ward the prevalence is below 1% 
as in many other countries. 
 
In this study, it was gratifying to note that non-invasive samples were welcomed by 
parents for the investigation of infection, particularly during the culturally and clinically 
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sensitive neonatal period. We have showed that these samples can be used in the local 
setting to successfully detect, quantify, and sequence viral pathogens. In particular, use 
of saliva provides a simple, convenient, quick, pain-free, safe, and cost-effective 
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CHAPTER 4 
ANALYSIS OF HUMAN CYTOMEGALOVIRUS IN BREAST MILK 
OF HIV-POSITIVE AND NEGATIVE MOTHERS IN ZAMBIA 
4.1 INTRODUCTION 
This chapter describes results of analyses undertaken to understand the effect of 
breastfeeding duration and maternal HIV status on HCMV viral load, secretion, and 
transmission in Zambia. The CIGNIS study showed high seropositivity and early effects 
of HCMV on growth, therefore it was important to determine sources for this 
transmission and effects of maternal HIV. To do this, both HIV-positive and negative 
mothers were compared in assessing the effects of breastfeeding duration and HCMV 
viral load dynamics. Studies on HIV-negative women had showed that viral load in breast 
milk can affect infant transmission (Jim et al., 2009, van der Strate et al., 2001, 
Hamprecht et al., 2003, Yasuda et al., 2003). However, comparisons of HIV-negative to 
HIV-positive women had not yet been demonstrated. Further, the effect of virus strain 
or genotype has not yet been analysed. Furthermore, the effect of the longer 
breastfeeding duration common in the Sub-Saharan Africa region had also not been 
assessed. In order to address these critical issues, HCMV DNA loads and genotypes were 
analysed directly in breast milk from both HIV-positive and negative women in the 
previously described BFPH cohort (Collin et al., 2006, Kasonka et al., 2006) in Zambia. To 
do this DNA was extracted from all available breast milk samples collected from both 
HIV-positive and negative Zambian mothers at postpartum week (W) 16, as well as 40 
matching sets of milk collected earlier at day (D) 3, D14, W4, W9, and W12 (n=261, see 
Methods, section 2.3) were analysed. First, the samples were screened by PCR to 
determine whether in the Zambian population the duration of HCMV shedding in breast 
milk is any different from European and South East Asian populations. Next, HCMV DNA 
loads were quantified by a TaqMan® qPCR assay in breast milk samples collected 
longitudinally at 6 time-points during the first 16 weeks postpartum. Further, HCMV 
hypervariable genes encoding envelope glycoproteins gO and gN were genotyped in 
selected W4 and W16 samples so as to evaluate HCMV genotype restriction in the breast 
milk compartment. Crucially, all these analyses compared HIV-positive to HIV-negative 
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women, enabling the effect of HIV infection on HCMV viral loads and shedding dynamics 
to be defined in our study population from an HIV-endemic region of Sub-Saharan Africa. 
 
4.2 BREAST MILK DNA FROM THE BFPH COHORT  
Of the 261 W16 breast milk samples available for this study, 118 (45.2%) were from HIV-
positive while 143 (54.8%) from HIV-negative mothers. For the HCMV kinetics 
evaluation, we additionally sought out all available longitudinal sample sets collected at 
5 earlier time points (D3, D14, W4, W9, W12), which comprised 20 sets from HIV-
positive and 20 from HIV-negative mothers. DNA was extracted directly from the milk, 
as detailed in Methods section 2.3.1. Overall, DNA was extracted from a total of 461 milk 
samples for subsequent analysis. Prior to screening for HCMV, DNA extractions were 
validated (see Methods, section 2.3.2) and all extractions had good quality, with 
280nm/260nm absorbance ratios averaging 1.8 (data not shown). The 104 bp fragment 
of the housekeeping gene encoding human GAPDH (Methods section 2.3.2) was used to 
PCR-screen all DNA samples extracted from the milk, as exemplified in figure 4.1. All 
samples were positive for the GAPDH gene. Negative and positive controls were 
included with every batch of 11 samples in all assay runs, and there was no evidence for 









Figure 4.1. PCR amplification of GAPDH in breast milk. The picture shows PCR 
amplification of the 104bp GAPDH fragment in DNA samples (here labelled 1–11) 
extracted from breast milk. PCR products were loaded in 1% agarose gels, and gel 
electrophoresis was performed in 1X TBE buffer at 100V for 45 minutes. RC, Reagent 
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4.3  HCMV DETECTION IN BREAST MILK 
The breast milk DNA samples were then screened qualitatively for HCMV using our 
validated HCMV gB assay. As demonstrated in section 3.1, this assay had a sensitivity of 
100 copies per reaction and amplified a 149 bp fragment of the conserved HCMV gB 
gene. Each PCR run included 2 negative controls i.e. a no-template (reagent only) control 
and a water-as-template control, in addition to the positive control (HCMV strain 
AD169). The 40 longitudinal milk sample sets (D3, D14, W4, W9, and W12) were 100% 
positive by the HCMV gB qualitative PCR assay. Among the 261 W16 samples overall 
HCMV prevalence was 76.3% (199/261). Stratifying the complete W16 set for HIV 
showed that among HIV-positive women HCMV prevalence was 83.9% (99/118), 
compared to 63.6% (91/143) among HIV-negatives. This difference in HCMV prevalence 
in the two groups was statistically significant, p<0.001. Thus in this population of Sub-
Saharan African mothers, we detected HCMV shedding in breast milk from day 3 to week 
16 postpartum, with a significantly larger proportion of HIV-infected women having 
DNAlactia at week 16 compared to their HIV-negative counterparts. Figure 4.2 depicts 














Figure 4.2. HCMV gB amplification in breast milk. Panels show examples of the 149bp 
HCMV gB gene fragment amplified in DNA extracted from breast milk (here labelled a1–
a11 and b1–b8). PCR products were loaded in 1% agarose gels and gel electrophoresis 
performed in 1X TBE buffer at 100V for 45 minutes. RC, Reagent (no-template) Control; 
WC, Water Control; PC, Positive Control (HCMV strain AD169). 
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4.4  HCMV VIRAL LOADS IN BREAST MILK 
The qualitative assay showed differences in detection of HCMV in breast milk of HIV-
positive compared to HIV-negative mothers. In order to compare HCMV viral loads in 
breast milk from the two groups, real time qPCR was applied. This used the TaqMan® 
qPCR assay described in section 2.3.3 (Bates et al., 2008, Mattick et al., 2004) as adapted 
from Mattes (Mattes et al., 2005) and validated in section 3.2.2 on an Applied 
Biosystems® 7500 Fast Real-Time PCR System (Applied Biosystems® Inc.). Each of the 
qPCR runs were calibrated by including plasmid-cloned HCMV gB standards covering 7 
logs concentrations as well as negative (no template) controls. Samples were diluted 1:2 
in nuclease-free molecular biology grade water. Each reaction contained 5µl of sample 
or control and was run in triplicate (see Methods, sections 2.3.3 and 2.4). The in-house 
plasmid-cloned HCMV gB standards were normalised to the HCMV 09/162 International 
Clinical Reference Standard (National Institute of Biological Standards, Potters Barr, UK) 
(see methods). Using these calibration controls and standards, the assay had a limit of 
detection (LOD) of 600 copies per reaction, with 100% reproducibility in triplicate and in 
data analyses samples with viral loads below the LOD were assigned a value set at half 
the LOD. Data were log transformed and plotted using GraphPad Prism version 6.0, then 
transformed back; thus medians and geometric means are presented in comparisons 
between HIV-positive and negative groups. 
 
HCMV Viral Load Kinetics in breast milk 
The 40 sets of longitudinal breast milk samples collected at six time-points, namely D3, 
D14, W4, W9, W12, and W16, were used to investigate HCMV secretion kinetics by 
examining DNA loads over the 16-week postpartum period covered. TaqMan® realtime 
qPCR was performed for each sample (in triplicate) at each of these six time-points and 
standard curves were generated and used to compute HCMV DNA copies per reaction. 
Since each reaction contained 5µl of 1:2 diluted sample and for each sample 200µl whole 
milk were used to extract DNA, which was eluted in 50µl of nuclease-free water, the 
quantity obtained by qPCR represented HCMV DNA copies in 10µl of whole milk. This 
value was multiplied by a factor of 100 to obtain the HCMV DNA copies/ml of milk. The 
HCMV DNA copies/ml values were log10 transformed and plotted on a log linear scale 
as depicted in figures 4.3 and 4.4 for HIV-positive and HIV-negative mothers 
respectively. These data were then amalgamated and the geometric mean (gMean) at 
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each time-point was computed for each of the two groups of mothers (figures 4.5). At 
five of the six time-points, more milk samples from HIV-positive mothers had viral loads 
above the assay sensitivity cut-off compared to milk from HIV-negative women and by 
W16, 90% (18/20) of milk from HIV-positive mothers was above assay sensitivity cut-off, 
compared to 55% (11/20) from HIV-negative mothers, p = 0.031. At each of the 6 time-
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Figure 4.3. HCMV viral load kinetics in breast milk from HIV-positive mothers. Panels 
[A] to [C] show log10 HCMV DNA loads in breast milk for each of 20 HIV-positive women 
at 6 time-points during the first 16 weeks postpartum. The assay sensitivity cut-off is 
shown by the lower horizontal dotted line. Bold numbers at the top centre of each graph 
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Figure 4.4. HCMV viral load kinetics in breast milk from HIV-negative mothers. Panels 
[A] to [C] show log10 HCMV DNA loads in breast milk for each of 20 HIV-negative women 
at 6 time-points during the first 16 weeks postpartum. The assay sensitivity cut-off is 
shown by the lower horizontal dotted line. Bold numbers at the top centre of each graph 
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Comparisons of HCMV viral load and rates of secretion in breast milk from HIV-positive 
and negative women 
Overall, HCMV levels were similar at day 3, rising by W4, and then declined or persisted 
to W16. In D3 breast milk, gMean HCMV viral loads in HIV-positive and HIV-negative 
mothers were 3.88 log10 copies/ml (95% CI 3.61 – 4.15) and 3.71 log10 copies/ml (95% 
CI 3.27 – 4.15) respectively, translating into 7,568 copies/ml and 5,116 copies/ml 
respectively. These viral loads were not significantly different, p=.89. After D3, gMean 
viral loads significantly increased in both HIV-positive and negative groups and, 
interestingly, peak levels were reached at week 4 (figures 4.6 and 4.7). From D3 to W4 
there was an overall increase of 1.2 log10 copies/ml in gMean viral loads in HIV-positive 
mothers compared to only 0.5 log10 copies/ml in HIV-negative mothers. At W4 the 
gMean viral load was significantly higher in HIV-positive mothers, with 5.04 log10 
copies/ml (95% CI 4.49 – 5.58) versus 4.21 log10 copies/ml (95% CI 3.74 – 4.67) among 
HIV-negatives, p=.026 (figure 4.6). From W4 to W9 the gMean viral load declined by 0.5 
log10 copies/ml in HIV-positive mothers, and remained stable at this level until W12, 
after which there was a further decline of 0.6 log10 copies/ml to reach 3.90 log10 
copies/ml (95% CI 3.51 – 4.29), the W3 gMean level, by W16. In contrast, in HIV-negative 
mothers the gMean HCMV load plateaued from W4 to W12, averaging 4.05 log10 
copies/ml, then from W12 declined sharply by 0.7 log10 copies/ml to 2.99 log10 copies/ml 
(95% CI 2.69 – 3.29) at W16. By the last time point, W16, in HIV-negative women, the 
gMean HCMV DNA was markedly below the D3 level of 3.71 log10 copies/ml (95% CI 3.27 
– 4.15). Hence, at week 16 the gMean HCMV viral load was 0.91 log10 copies/ml higher 
in HIV-positive mothers compared to HIV-negative mothers and statistically significant, 



































Figure 4.5. Kinetics of HCMV shedding in breast milk of HIV-positive and negative 
mothers. Comparison of breast milk HCMV DNA load kinetics between HIV-positive 
(pink dots/line) and negative (black dots/line) mothers during the first 16 postpartum 
weeks. Each group consisted of 20 milk samples. [A] Scatter plot shows spread of HCMV 
viral loads at each postpartum time-point. Thick horizontal lines indicate the geometric 
means, with 95% confidence intervals indicated by the error bars. Sensitivity cut-off is 
indicated by the lower dotted line. From W4, HCMV DNA loads in milk from HIV-positive 
women were raised compared to HIV-negative women. Significant differences in 
geometric means between HIV-positive and negative mothers were at W4 and W16, 
**p=.026 and ***p<.001 respectively. [B] Shows trend of geometric means over the 16-
week time course. Error bars indicate 95% confidence intervals and the assay sensitivity 
cut-off is indicated by the lower dotted line. 
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Rate of HCMV viral load change  
To infer the average rates of change in HCMV viral loads in the two groups of mothers, 
three key time-points were considered: D3 (earliest detection of HCMV shedding), W4 
(peak HCMV viral loads), and W16 (latest time-point), and viral load kinetics taken to be 
in steady state, as depicted in figure 4.6. For HIV-positive mothers the gMean HCMV 
viral load increased at an average rate of 0.4 log10 copies/ml per week from baseline 
(D3) to peak (W4), and then declined at -0.1 log10 copies/ml per week from W4 to W16. 
In HIV-negative mothers, gMean HCMV viral load increased at a lower rate of 0.2 log10 
copies/ml per week from baseline (D3) to peak (W4), and then, similar to HIV-positive 
mothers, declined at -0.1 log10 copies/ml per week from W4 to W16. Notably, the rate 
of HCMV viral load increase from D3 to W4 was two times higher in HIV-positive 
mothers, who correspondingly also had significantly higher HCMV loads at W4 (figure 
4.5). In contrast, the overall rate of HCMV viral load decline from peak levels at W4 was 
similar in the two groups at -0.1 log10 copies/ml per week. By W16 the HIV-negative 
group had gMean lower than the D3 level (figure 4.5). Given the higher peak loads at 
W4 combined with the same rate of decline as in HIV negative women, the HIV-positive 
group would take at least 26 weeks (6 months) to lower below detection limit, therefore 





























Figure 4.6. Rate of HCMV viral load change. Geometric mean HCMV viral loads at three 
critical time-points: D3 (the earliest detection of HCMV shedding), W4 (peak HCMV viral 
loads) and W16 (latest time-point) are compared in HIV-positive (pink line) versus HIV-
negative (black line) mothers. The rate of HCMV viral load increase from D3 to W4 was 
steeper in HIV-positive women, but rate of decrease from peak W4 levels to W16 was 
comparable in the two groups of women. At D3, gMeans were comparable, but at both 
W4 and W16 were significantly higher in the HIV-positive group. The qPCR assay 
sensitivity cut-off is indicated by the lower horizontal dashed line. 
 
 
HCMV Viral Loads in W16 breast milk 
The longitudinal analyses presented in the preceding sections were from available 
samples for 40 women. However, at W16 samples were collected for the entire cohort. 
There were 205 samples at W16 with sufficient remaining volume for further analyses. 
Thus overall at W16, viral loads were measured in 205 samples: 92 (44.9%) HIV-positive 
and 113 (55.1%) HIV-negative. Of the HIV-positive mothers, 88.0% (81/92) had 
detectable HCMV DNA, compared to 59.3% (67/113) among the HIV-negative, p<.001. 
This was consistent with the earlier observation in the kinetics subset. Similar to the 
kinetics subset, gMean viral load in this larger W16 sample was significantly higher in 
the HIV-positive group, 3.9 log10 copies/ml (95% CI 3.74 – 4.13) compared to the HIV-



















Figure 4.7. HCMV viral Loads in week 16 breast milk: HIV-positive vs. HIV-negative 
mothers. Scatter plot showing HCMV viral loads in 205 available breast milk samples at 
W16 (92 HIV-positive and 113 HIV-negative). A higher proportion of breast milk from 
the HIV-positive group remained with detectable HCMV (88.0% versus 59.3%, 
***p<.001), and HIV-positive women also had nearly one log higher gMean HCMV DNA 
load than their HIV-negative counterparts, 3.93 log10 copies/ml versus 3.19 log10 
copies/ml, p<.001. These comparisons in W16 values were similar to observations in 
samples analysed in the kinetics subset (black circles). Adapted from Musonda and 
colleagues (Musonda et al., 2016). 
 
 
4.5 HCMV gO AND gN GENOTYPES IN BREAST MILK 
Having established that there are significantly different kinetics of HCMV secretion in 
HIV-positive versus HIV-negative women, the next step was to examine whether there 
is any strain restriction in the breast milk compartment or with HIV exposure among the 
Sub-Saharan African mothers under study. At the time of studies in this thesis there were 
no data on HCMV strains or isolates from breast milk. To explore the question of HCMV 
strain restriction in breast milk, the hypervariable UL74 gene, encoding gO, was targeted 
for sequencing. Additionally, UL73, which encodes gN, was also investigated. Previous 
studies from our laboratory showed that HCMV gO and gN genotypes form linkage 
groups and this was further analysed here with potential to validate the gO genotyping 
within these linkage groups. gO and gN are located adjacent to each other at the centre 
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of the linear HCMV genome, and encode glycoproteins that have a critical role in virus 
entry, spread and tropism. Because they are capable of eliciting potent neutralising 
antibodies, they have recently been targets for HCMV vaccine design studies (see 
Introduction, section 1.9) (Paterson et al., 2002, Mach et al., 2005, Mach et al., 2000, 
Dunn et al., 2003, Hobom et al., 2000, Kabanova et al., 2016, Ciferri et al., 2015a, 
Lemmermann et al., 2015, Ciferri et al., 2015b, Chiuppesi et al., 2015, Wussow et al., 
2014). Previous studies in our laboratory have demonstrated that the two genes each 
form eight genotypes, and unlike some other hypervariable HCMV genes, gO and gN 
form linkage groups (Bates et al., 2008, Mattick et al., 2004). These are represented by 
the following full-genome HCMV strains: gO1a/gN1 (AD169, FJ527563.1), gO1b/gN3a 
(TR, KF021605.1), gO1c/gN4c (Toledo, GU937742.1), gO2a/gN3b (HAN38, GQ396662.1), 
gO2b/gN2 (AF1, GU179291.1), gO3/gN4a (HAN16, JX512204.1), gO4/gN4b (Towne, 
FJ616285.1), and gO5/gN4d (Merlin, AY446894.2). In this section, results are presented 
of HCMV gO and gN sequencing in milk with sufficient remaining DNA sample for 
analysis. 
 
HCMV gO genotypes in breast milk 
HCMV gO analyses were performed for 43 available samples, of which 27 (64.3%) were 
from HIV-positive and 16 (35.7%) from HIV-negative mothers. Sequence was derived 
using Sanger methods on PCR amplification products from the variable HCMV gO N-
terminal region as described (Mattick, 2004; Bates, 2008) (see Methods section 2.3.2). 
This amplified the predominant strain in a 741bp N-terminal fragment, as shown in 
figure 4.8. Sequence analysis showed all eight gO genotypes detectable in breast milk 
(figure 4.9, table 4.1, and figure 4.10). Overall, the three most prevalent genotypes were 
gO1a, gO1b, and gO5. With our sample size, gO2a was only detected among HIV-
infected mothers, while gO1c and gO3 were detected only among HIV-uninfected 
mothers (table 4.1, and figure 4.10. Seven samples were paired at W4 and W16, and so 
these were examined to assess genotype stability at the two time-points (table 4.2). Of 
these, three pairs – all HIV-positive – had different gO genotypes detected at the two 
time points, suggesting reinfection and/or infection with mixed strains. The three 
samples were among those with high HCMV DNA loads (figure 4.3). 
 
 





Figure 4.8. PCR amplification of HCMV gO: breast milk. Picture shows PCR amplification 
of the 741bp HCMV gO gene fragment in DNA extracted from breast milk (here labelled 
e1–e12). PCR products were loaded in 1% agarose gels and gel electrophoresis was 
performed in 1X TBE buffer. RC, Reagent (no-template) Control; WC, Water Control; PC, 




















Figure 4.9. Phylogenetic analysis of gO genotypes in breast milk. Representatives of 
genotype groups defined here were analysed in comparisons to reference strains 
described previously (Bates et al., 2008, Mattick et al., 2004). Multiple alignments were 
performed using CLUSTAL in MEGA 6.06 (Tamura et al., 2013), followed by phylogenetic 
constructions inferred using the Maximum Likelihood method based on the JTT matrix-
based model. Bootstrapping values are indicated, supporting major nodes. Figure 





























































HIV-Negative HIV-Positive Total 
n % n % n % 
1a 6 37.5 7 25.9 13 30.2 
1b 3 18.8 10 37.0 13 30.2 
1c 2 12.5 0 0 2 4.7 
2a 0 0 1 3.7 1 2.3 
2b 1 6.3 2 7.4 3 7.0 
3 1 6.3 0 0 1 2.3 
4 0 0 4 14.8 4 9.3 
5 3 18.8 3 11.1 6 14.0 




[A] Table 4.1 and [B] Figure 4.10. Prevalence of HCMV gO genotypes in breast milk. 
Overall, the three most prevalent genotypes were gO1a, gO1b, and gO5. In the HIV-
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S/N ID HIV 
HCMV gO genotype 
 wk4  wk16 
1 278R Positive 1b 1b 
2 243R Positive 1a 4 
3 281R Positive 5 1b 
4 288R Positive 5 1a 
5 181L Positive 1a 1a 
6 240R Negative 1a 1a 
7 280R Negative 1a 1a 
 
Table 4.2. HCMV gO genotype in paired W4/W16 breast milk samples. Three 
(highlighted in grey shading) of seven W4/W16 paired samples had different gO 
genotypes at the two time-points. All three were from HIV-infected mothers. 
 
 
HCMV DNA Load vs. gO Genotype 
For the 43 samples for which gO was sequenced, we next investigated whether any 
particular genotype was associated with high viral load. Figure 4.11 shows the HCMV 
DNA load for each sample, and highlights the three most prevalent gO genotypes (gO1a, 
gO1b, and gO5). Although all genotypes appeared increased in HIV-positive compared 
to HIV-negative mothers, no particular genotype was associated with higher DNA loads 




























Figure 4.11. Genotype independent increases in HCMV load in breast milk from HIV-
positive and negative women. Viral loads per genotype were examined for HIV-positive 
and negative women. The main three gO genotypes gO1a, gO1b and gO5 were plotted 
and all the remaining genotypes grouped together. Genotype gO1a (black circle), gO1b 
(grey circle), gO5 (white circle), other gO genotypes (crossed circle). Geometric means 
were 5.4 and 4.8 log10 copies/ml for HIV-positive and negative women at both maximum 
and minimum secreted levels, 4 and 16 weeks postpartum respectively. Figure adapted 




HCMV gN PCR amplification in DNA extracted from breast milk 
In order to further validate the results from the gO analyses, and to examine linkage 
groups the samples were analysed with HCMV gN. Initial PCR analyses followed by 
Sanger sequencing were performed by an MSc student supervised during these studies, 
(Margaret Njenga, MSc MM, LSHTM 2015). A total of 77 samples were available for 
HCMV gN analyses. Of these, 42 (54.5%) were from HIV-positive and 35 (45.5%) from 
HIV-negative mothers. The samples included 22 collected at W4 and 56 collected at 
W16, with 21 samples paired at both time-points. The 411bp N-terminal fragment 
targeted in the HCMV gN PCR assay as described (Bates et al., 2008) (see Methods 









































Figure 4.12. PCR amplification of HCMV gN: breast milk. Representation PCR 
amplification of the 411bp HCMV gN gene fragment in DNA extracted from the breast 
milk cohort (here labelled c1–c11 and d1–d11). PCR products were loaded in 1% agarose 
gels and gel electrophoresis performed in 1X TBE buffer. RC, Reagent (no-template) 
Control; WC, Water Control; PC, Positive Control (HCMV strain AD169). 
 
 
HCMV gN genotypes recovered from breast milk 
The amplification products were purified from gels using the Zymoclean™ Gel DNA 
Recovery Kit (Zymo Research Corp.) (see Methods, section 2.5.1) and sequences derived 
by Sanger methods using the BigDye® Terminator v3.1 (Applied Biosystems) kit (see 
Methods, section 2.5.2) for 72 of the 77 samples. This included all 42 HIV-positives and 
30/35 (85.7%) of the HIV-negatives. The five unresolved HIV negative samples only 
yielded human DNA sequence and corresponded to the lowest amplification products. 
Therefore, these could be considered borderline negative reactions. Overall, we were 
able to identify seven of the eight gN genotypes in breast milk samples in our study, with 
the exception being gN2, as shown in table 4.3 and figure 4.13. There were seven 
compared to five gN genotypes identified in the HIV-positive compared to negative 
samples. Both gN4a and 4d were predominant for HIV-positive and negative samples. 
Of the 21 W4-W16 paired samples, 12 pairs were HIV-positive and nine HIV-negative. As 
shown in table 4.5, there were mixed genotypes detected in both the HIV-positive and 
negative samples, four and two respectively. Overall, there were more genotypes 
detected in HIV-positive than HIV-negative mothers. Further, more genotypes were 







   d1        d2         d3       d4        d5        d6        d7        d8        d9       d10      d11      RC       WC                   PC 
100bp 
Marker 
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detected at W16 compared to W4, possibly indicating effects of superinfection or 
reduced immunity. In comparisons at this sample size, only gN4a appeared significantly 






W4 W16  
Freq % Freq % p value 
gN1 4 18.2 8 16.0 1.0 
gN2 0 0.0 0 0.0  
gN3a 0 0.0 2 4.0  
gN3b 1 4.5 0 0.0  
gN4a 2 9.1 12 24.0 .04 
gN4b 10 45.5 13 26.0 .17 
gN4c 0 0.0 4 8.0  
gN4d 5 22.7 11 22.0 1.0 
















[A] Table 4.3 and [B] Figure 4.13. HCMV gN genotype prevalence in W4 vs. W16 breast 
milk. Compared to W4, there was loss of gN3b but additional detection of gN3a and 

























Inner Ring = W4 
Outer Ring = W16 
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[A] 
 HIV-POSITIVE HIV-NEGATIVE TOTAL  p value 
 Freq. % Freq. % Freq. %  
gN1 5 11.9 7 23.3 12 16.7 .34 
gN2 0 0 0 0 0 0  
gN3a 2 4.8 0 0 2 2.8  
gN3b 1 2.4 0 0 1 1.4  
gN4a 12 28.6 2 6.7 14 19.4 .03 
gN4b 10 23.8 13 43.3 23 31.9 .07 
gN4c 1 2.4 3 10.0 4 5.6 .30 
gN4d 11 26.2 5 16.7 16 22.2 .40 














[A] Table 4.4 and [B] Figure 4.14. HCMV gN genotype prevalence in breast milk of HIV-
positive and negative mothers. HIV-positive mothers exhibited greater diversity of 
HCMV gN genotypes, with seven of the eight genotypes detected. gN4a, gN4b, gN4c 
being the top three most predominant. Among HIV-negative mothers, only 5 of the eight 
genotypes were present, with gN4b, gN1, and gN4d being the top three most prevalent 
genotypes. There were significant differences shown in the prevalence of gN4a (p=.03) 
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   gN Genotype 
 Sample ID HIV status W4 W16 
1 181L Positive gN1 gN1 
2 237L Positive gN4d gN4d 
3 243R Positive gN4b gN4b 
4 248R Positive gN3b gN4b 
5 258R Positive gN4a gN1 
6 264R Positive gN4b gN4b 
7 277R Positive gN4d gN4c 
8 278R Positive gN4d gN4d 
9 281R Positive gN4d gN4d 
10 283L Positive gN4a gN4a 
11 288R Positive gN4d gN4a 
12 290L Positive gN4b gN4d 
1 185R Negative gN4b gN4b 
2 190L Negative gN4b gN4b 
3 197L Negative gN4b gN4d 
4 228L Negative gN4b gN4d 
5 233R Negative gN4b gN4b 
6 239R Negative gN4b gN4b 
7 240R Negative gN1 gN1 
8 263L Negative gN4b gN4b 
9 280R Negative gN1 gN1 
 
Table 4.5. HCMV gN genotypes in paired W4/W16 breast milk samples. Samples with 
gN genotype changes from W4 to W16 are highlighted in grey. There were four such 





In this chapter we examined HCMV shedding in breast milk, comparing both HIV-positive 
and negative mothers in Zambia, a Sub-Saharan African country. With additional 
epidemiological analyses which we conducted in the CIGNIS cohort, a childhood cohort 
from the same community as the breastfeeding cohort examined here, part of these 
findings were published (Musonda et al., 2016, Gompels et al., 2012, Sanz-Ramos et al., 
2013). Our studies show that HCMV infections are widespread in both HIV-positive and 
negative mothers. However, HIV-positive mothers had markedly higher HCMV levels 
secreted in their breast milk, and these higher HCMV loads persisted for longer 
compared to HIV-negative mothers. Initial HCMV levels were equal in the two groups in 
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early milk at day 3, then were higher in HIV-positive than negative mothers from 2 to 16 
weeks postpartum. These findings are in agreement with reports during the course of 
this thesis study of prolonged (>24 weeks) HCMV loads in breast milk from a cohort of 
Kenyan HIV-infected mothers (Slyker et al., 2014), although that study did not make 
comparisons to HIV-uninfected mothers. Our analysis shows peak HCMV DNA levels 
were at 4 weeks postpartum, which is similar to findings in European and South East 
Asian surveys. However, there was a difference in shedding duration, with our cohort 
continuing to shed virus in milk beyond 16 weeks postpartum compared to less than 12 
weeks in the European and Asian studies (Hamprecht et al., 2008, Hamprecht et al., 
2004b, Hamprecht et al., 2001, Jim et al., 2009, Jim et al., 2004, Yasuda et al., 2003, 
Hamprecht et al., 2003). The main difference between HIV-positive and negative 
mothers was the increased rate of HCMV secretion from reactivation at D3 to peak loads 
at W4. It has recently been shown that CD14+ leukocytes, that are susceptible to HCMV, 
increase in breast milk around three months postpartum (Maschmann et al., 2015). It is 
possible that in our cohort there may be more of these susceptible cells in the mammary 
glands of HIV-infected mothers, and coupled with higher immune dysregulation, this 
may favour HCMV proliferation in these mothers. Immune dysregulation, can be 
induced by HIV and HCMV independently, and worsens when both viruses act 
concurrently. There may also be effects from increased inflammation, given the higher 
levels of mastitis (including sub-clinical) shown among HIV-positive mothers in earlier 
analyses of this cohort (Kasonka et al., 2006). In the midst of the high HCMV levels 
demonstrated in our present study, mastitis would be an aggravating factor for breast 
milk transmission of HCMV to infants of HIV-infected mothers. 
 
Studies in Europe and Asia have shown HCMV secretion in breast milk for up to 3 months 
postpartum, with higher HCMV viral loads in milk and prolonged secretion linked to 
infant transmission (Hamprecht et al., 2003, Jim et al., 2009, Yasuda et al., 2003, van der 
Strate et al., 2001). In contrast to these regions, we have now shown prolonged HCMV 
secretion in breast milk beyond 4 months in Zambia. Furthermore, epidemiological 
analyses performed on the CIGNIS cohort show that breastfeeding for over 6 months 
among HIV-positive women, or beyond 18 months among HIV-negative women 
increased risk of infant HCMV infection (table 4.6). As described above, risk of 
transmission to infants of HIV-positive mothers may be enhanced by immune 
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impairment, a hallmark of both HIV and HCMV, and amplified by prolonged 
breastfeeding duration. In the case of HIV-negative mothers, the risk of HCMV 
transmission to their infants may be related to protracted local reactivation and 
secretion of HCMV, sustained by the much longer duration of lactation. Similar to other 
studies (Bate et al., 2010, Boppana and Fowler, 2007, Gompels et al., 2012), we found 
that low socioeconomic status and education level were associated with HCMV 
seroprevalence. However, even after controlling for these risk factors, breastfeeding up 
to 18 months remained significantly associated with HCMV infection (table 4.6). 
 
 Infant HCMV Infection (Serum Antibody) 
Months Breastfeeding  
Antibody Positive 
N (%)  
Adjusted ORa  
(95% CI)  
P Value  
HIV-Negative Mothers 
 <12b 25/32 (78.1%) 1  
 12–17 128/161 (79.5%) 0.94 (0.35–2.53)  
 18+ 110/119 (92.4%) 2.69 (0.84–8.59) .03 
HIV-Positive Mothers 
 Never 13/26 (50.0%) 1  
 <6 31/35 (88.6%) 6.83 (1.69–27.6)  
 6+ 42/44 (95.5%) 20.37 (3.71–111.7) <.001 
 
Table 4.6. Effects of maternal HIV and breastfeeding duration on infant HCMV 
infection. a Adjusted for socioeconomic status and maternal education. b Only 3 HIV-
negative mothers never breastfed and only 6 for <6 months. CI, confidence interval; 
HCMV, human cytomegalovirus; HIV, human immunodeficiency virus; OR, odds ratio. 
(Musonda et al., 2016) 
 
Slyker and co-workers showed in Kenya that mothers who transmitted HCMV had nearly 
one log higher median HCMV loads at 2 weeks postpartum compared to non-
transmitters (5.4 log copies/ml versus 4.5 log copies/ml). Further, the probability of 
infant CMV infection was modelled to be 5.5 log copies/ml at a maternal CD4 count of 
1000 cells/mm3 (Slyker et al., 2014). In our Zambian cohort, at W2 HIV-positive mothers 
also had a 1.1 log higher median HCMV load compared to their HIV-negative 
counterparts (5.1 versus 4.0 log copies/ml). Although it is difficult to directly apply the 
thresholds from the Kenyan study to ours, a basic comparison indicates that HIV-positive 
mothers would be more likely to be transmitting HCMV at this early postpartum time-
point compared to HIV-negative mothers. Between day 3 and week 16, HIV-positive 
women had 23 measurements above 5.5 log copies/ml compared with only seven for 
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HIV-negative mothers (table 4.7). However, it is likely that a lower transmission 
threshold applies and therefore many more mothers would have had readings above 
the transmission threshold, since the 5.5 log copies/ml cut-off assumes a strong 
maternal cellular immune compartment (1000 cells/mm3 CD4 cell count), which is rare 
in HIV-infected individuals, even with HAART.  
 
 HIV-positive (N=20) HIV-negative (N=20) 
 Freq % Freq % 
D3 0 0 0 0 
W2 5 25 2 10 
W4 7 35 3 15 
W9 5 25 2 10 
W12 5 25 0 0 
W16 1 5 0 0 
 
Table 4.7. Proportion of breast milk samples with HCMV DNA load above 5.5 log10 




We also assessed overall rates of change in gMean HCMV loads by considering three key 
reference points (D3 – the earliest detection of HCMV shedding; W4 – the peak HCMV 
viral loads; and W16 – the latest available time-point) (figure 4.6), and showed that while 
both HIV-infected and uninfected mothers had similar baseline levels at D3, the average 
rate of viral load increase to peak at W4 was twice as much in HIV-infected mothers as 
in the HIV-uninfected, resulting in higher peak levels at W4 in the HIV-positive group. 
Interestingly, from W4 to W16, the average rate of decline was the same in the two 
groups of mothers, with the result that HIV-negative mothers returned to baseline levels 
much quicker than the HIV-infected mothers. Assuming steady state kinetics, we thus 
estimated that it would take up to 26 weeks for HIV-positive mothers to achieve DNA 
loads below the detection limit. This gives a broader opportunity of HCMV exposure to 
their infants. The first month of life is therefore a crucial window for targeting 
interventions to limit the DNA load attained at W4, akin to the well-established concept 
of ‘viral set-point’ in HIV-1 infection (de Wolf et al., 1997, Geskus et al., 2007). Since an 
efficacious vaccine is yet to be formulated, drug administration to mothers to lower 
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HCMV load in breast milk is a possible option. However, no anti-HCMV drug is yet 
approved for use during lactation. Other measures could include heat treatment or 
irradiation of milk, which have shown success particularly in milk banks in the setting of 
very low birthweight and premature babies (Hamprecht et al., 2004b, Christen, 2014, 
Christen et al., 2013). 
 
Our analysis of HCMV genotypes found all 8 gO genotypes could be detected in breast 
milk, showing that there was no genotype restriction in the mammary gland. Mixed 
infections, suggestive of maternal reinfection, were also noted and confirmed by gN 
genotyping. However, we could not find any particular genotype linking with high HCMV 
DNA loads. Overall, the main gO genotypes were gO1a, gO1b, and gO5. This is similar to 
gO genotypes analysed in blood and respiratory compartments of HIV-infected Zambian 
children, and in various tissues from different global sources (Bates et al., 2008, Mattick 
et al., 2004). Differences in prevalence of the genotypes were not significant statistically; 













Figure 4.15. Comparison of HCMV gO genotypes prevalence in breast milk and other 
tissues. The prevalence of the eight gO genotypes in milk was similar to studies of 
genotypes from different compartments. The most predominant genotypes in the 
current study (black bars) were 1a and 1b followed by gO5. Grey bars depict gO 
genotype prevalence from our previous study of HIV-positive blood and lung tissue 
(Bates et al., 2008) in the same region, and white bars show gO prevalence in various 
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Further study of genotype ratios is essential, since the trimeric gH/gL/gO complex and 
alternate pentameric gH/gL/pUL128-131 complex affect cellular tropism, host 
transmission, as well as candidate vaccines (Paterson et al., 2002, Mach et al., 2005, 
Mach et al., 2000, Dunn et al., 2003, Hobom et al., 2000, Kabanova et al., 2016, Ciferri 
et al., 2015a, Lemmermann et al., 2015, Ciferri et al., 2015b, Chiuppesi et al., 2015, 
Wussow et al., 2014).  
 
Our study of HCMV in breast milk had three main limitations. First, the HCMV serostatus 
of the mothers was not known. Nevertheless, our HCMV DNA PCR screen showed that 
all mothers were HCMV positive. Secondly, maternal plasma CD4 cell counts were not 
available. The CD4 level can affect HCMV secretion in breast milk, as demonstrated in 
the cohort from Kenya (Slyker et al., 2014). Thirdly, we did not control for the 
contribution of other HCMV transmission routes, particularly saliva and urine from other 
children (Grosjean et al., 2014, Cannon et al., 2014) and congenital HCMV. However, we 
expect that the general background exposure would have been similar in families of 
both HIV-infected and uninfected mothers, since most mothers had children under the 
age of 5 years. Based on other studies and our own investigation of congenital infection 
(Chapter 3), the contribution from congenital HCMV infection would have been very low 
(1%.) Strengths of our study are the sizes of the maternal and infant cohorts analysed, 
and the crucial comparisons made between HIV-positive and negative groups, vividly 
showing raised levels and duration of HCMV secretion in breast milk, with 
correspondingly increased risks for infant infection in HIV-positive compared with HIV-
negative mothers. 
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CHAPTER 5: 
GENOMIC ANALYSIS OF HCMV DIVERSITY IN BREAST MILK 
5.1 INTRODUCTION 
In the previous chapter, hypervariable gO and gN genotypes were identified together 
with their use to identify mixed infections with different strains of HCMV in breast milk. 
This could be used as a marker of burden of infection in addition to the virus loads 
evaluated in the previous chapters. In order to investigate this further and understand 
the relationship to the entire HCMV genetic complement, in this chapter new methods 
of next generation deep sequencing were used to analyse these infections. Having 
established that in breast milk there is a higher HCMV viral load associated with 
maternal HIV-infection, there was preliminary evidence that some HCMV infections 
were composed of mixed genotypes, indicating repeated infections. Therefore, the high 
viral load could be compounded by a high burden of infection from repeated or mixed 
infections. The Sanger sequencing used previously has a low sensitivity to detect mixed 
infections as basically the dominant consensus sequence is identified and mixed 
infections can be detected either by multiple PCR reactions or by cloning. To investigate 
this further, new methodologies were required to sensitively detect and quantitate 
mixed infections. The hypervariable gO and gN genes served as key determinants to 
investigate this as not only could they be used to identify mixed infection, they 
themselves could also affect the infection since they are mediators of infection. 
Therefore, in this chapter analyses were undertaken using NGS deep sequencing to shed 
light on how the genotype proportions relate to viral load and HIV status. Deep 
sequencing resolves the target region typically thousands of times, enabling sensitivities 
of mixtures comprising as little as 1% of the total (Margeridon-Thermet et al., 2009, 
Mitsuya et al., 2008, Radford et al., 2012, Varghese et al., 2009). Where detected 
previously mixed-genotype infections are markers for high disease burden, severe 
infection, or persistent HCMV infection (Humar et al., 2003, Coaquette et al., 2004, Pang 
et al., 2008, Sarcinella et al., 2002, Sowmya and Madhavan, 2009, Puchhammer-Stockl 
et al., 2006). Various research groups have demonstrated occurrence of mixed-genotype 
infections from study of selected HCMV genes including gB (UL55), gN (UL73), gO (UL74), 
gH UL75), gL (UL115), UL139, and UL146 (Puchhammer-Stockl et al., 2006, Sarcinella et 
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al., 2002, Coaquette et al., 2004, Humar et al., 2003, Sowmya and Madhavan, 2009, Pang 
et al., 2008, Peek et al., 1998, Gorzer et al., 2008, Bradley et al., 2008, Hassan-Walker et 
al., 2004, Stanton et al., 2005, Bates et al., 2008, Mattick et al., 2004). These studies 
suggest that mixed HCMV genotypes exist within an infected individual, and following 
transmission, a dominant genotype may be selected in the new host. In addition, there 
is also some initial evidence for de novo mutations that may arise in each host, giving 
rise to a unique dominant genotype (Renzette et al., 2011, Renzette et al., 2013). 
However, without sufficient deep sequencing analyses, the origins of these mutations 
are not clear. With previous technology, in general, it follows that this dominant 
genotype is the one detectable by Sanger sequencing methods, leaving co-infecting 
genotypes undetected.  
 
Next Generation Sequencing (NGS) 
The original Sanger dideoxynucleotide chain termination sequencing method (Sanger 
and Coulson, 1975) revolutionised genetic studies. HCMV was one of the first complete 
genome sequences determined using the technology (Chee et al., 1990, Bankier et al., 
1991). This method was eventually automated, incorporating fluorescent markers and 
enabled the first finished-grade human genome sequence to be compiled (International 
Human Genome Sequencing Consortium, 2004). However, the original method had 
limitations including laborious bacterial/bacteriophage cloning (which may introduce 
bias) and electrophoretic separation of chain-terminated fragments, low sample 
throughput, and high cost. New technologies include ‘Next Generation Sequencing’ 
(NGS), which has transformed nucleotide sequencing by making it more accurate, 
reliable, and cheaper (and therefore more accessible), while reducing amounts of 
template DNA required. Because NGS allows combination of chain synthesis steps with 
signal detection, reactions are several fold quicker than Sanger methods. Further, the 
massively parallel sequencing setup used in many NGS platforms allows hundreds of 
gigabases of DNA to be read in a single run on a single chip, with capacity increased by 
as much as 1,000 times (Kircher and Kelso, 2010). However, as NGS technologies have 
become more advanced, challenges include storing the large quantities of data 
generated, the relatively high error rates, estimated at around 0.1–15% in different 
systems, and shorter read lengths of around 50-700 bp (Liu et al., 2012). This could 
compound analyses of, for example, mixed infection or emerging drug resistance, and 
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highlights the need for careful analysis of results, especially for variant discovery and 
clinical applications. Among the commercially available technologies, that developed by 
Illumina is currently the most widely available (Goodwin et al., 2016, Investec, 2015), 
and involves Library preparation, sequencing, and data analysis.  
 
To further address the questions of infectious burden which was limited by Sanger 
sequencing sensitivity as outlined above, this study identified ‘Molecular tags’, a type of 
barcode technology combined with computer-based customised Scripts. This facilitated 
interrogation and quantification of deeply sequenced genomes using next generation 
sequencing methods. This devised technique enabled detection and quantification of 
multiple infections using identification of HCMV gO and gN genotype variants as 
biomarkers in a sample. The method was validated on sequences publicly available in 
GenBank, and then applied to analyse Illumina NGS reads derived from DNA extracted 
from breast milk from a cohort of both HIV-infected and uninfected women who had 
been studied for post-partum health in Zambia; this cohort was also analysed in the 
previous chapter and in a publication arising from this thesis (Collin et al., 2006, Kasonka 
et al., 2006, Musonda et al., 2016). This enabled analyses of burden of infection over the 
first 16 weeks postpartum. The second part of this analyses identified samples with a 
dominant or single genotype. This would then allow unambiguous compilation of a 
complete genome, without the risk of an artefactual ‘mixed genome’ derived from 
genome compilation from a source with mixed infections. Samples with verified single 
or dominant (>90%) genotypes were then evaluated for assembly of NGS FASTQ reads 
into complete HCMV genomes. Here we characterise ZMB240, a complete HCMV 
genome similar to the reference strain Merlin, but assembled from DNA directly 
extracted from breast milk, without bias introduced from isolation or tissue culture. This 
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5.2 IDENTIFICATION OF ‘MOLECULAR TAGS’ AND DEVELOPMENT OF 
PERL SCRIPTS FOR DETECTION AND ENUMERATION OF HCMV gO 
AND gN GENOTYPES  
5.2.1 Identification of HCMV gO and gN ‘Molecular Tags’  
The first step in addressing the question of mixed-genotype infections was to develop 
tools to enable both the detection and enumeration of genotypes of a given 
hypervariable HCMV gene present in a sample. For this thesis, the focus is on the 
hypervariable HCMV gO. However, since gO forms linkage groups with gN, and both are 
hypervariable loci (Mattick et al., 2004, Bates et al., 2008), use of both gO and gN 
allowed systematic testing of this linkage, some verification of our methods, and 
identification of rare recombination at this locus. To start with, GenBank release 211 
was systematically searched for all available complete HCMV genome sequences, and 
163 complete genomes were identified and downloaded. Following extraction of the gO 
and gN nucleotide sequences from each of these genomes, MEGA 6.06 (Tamura et al., 
2013) was used for analysis, including amino acid translation and alignment using the 
in-built ClustalW tool, with default settings. The aligned amino acid sequences and 
corresponding nucleotide sequence alignments (.meg files) were saved and exported to 
Microsoft Excel format for convenient visualisation. Phylogenetic trees were also 
generated based on aligned amino acid sequences, as shown in figures 5.1 and 5.4. 
Following systematic analyses of the amino acid alignments, short stretches of amino 
acids unique to each genotype at particular loci were identified as highlighted in figures 
5.2 and 5.5, and then the corresponding back-translated nucleotide region identified in 
the nucleotide alignment (figures 5.3 and 5.6). At a nucleotide level, these ‘molecular 
tags’ were subsequently refined, taking into account the redundancy of the standard 
genetic code, to obtain sequences of 12-14 bases as optimum length. The process of 
identifying and fine-tuning the genotype-specific molecular tags was also guided by DNA 
polymorphism plots generated in DnaSP (Librado and Rozas, 2009) from the alignment 
of the 163 gO and gN nucleotide sequences (figure 5.7). For gO, three sets of tags were 
identified at three different loci: two within the hypervariable N-terminus and one 
within the C-terminus. Table 5.1 details the sequences and coordinates of each 
identified molecular tag relative to the reference strain for each gO and gN genotype. 
For HCMV gN, initial molecular tag determinations were done by Margaret Njenga 
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(MSc.MM, LSHTM 2015) using an earlier GenBank dataset with 136 complete HCMV 
genomes. This was extended to include the set of 163 as analysed for gO as available in 




Figure 5.1. Molecular phylogenetic relationship of the eight HCMV gO genotypes. This 
unrooted consensus tree was inferred from 1000 bootstrap replicates to represent the 
evolutionary history of 163 full-length HCMV gO amino acid sequences derived from 
complete HCMV genomes available in GenBank database release 211 (National Center 
for Biotechnology Information (NCBI), 2015). The evolutionary history was inferred by 
the Maximum Likelihood method based on the JTT matrix-based model and a discrete 
Gamma distribution with five categories (+G, parameter = 0.6555). Positions with less 
than 95% site coverage were eliminated, leaving 434 amino acid positions in the final 
dataset. Due to space constraints, the branches are compressed to highlight the eight 
gO genotypes (Bates et al., 2008, Mattick et al., 2004). All sequences grouped to one of 
the eight genotypes, except for BE/23.2010 (KP745697.1) discussed in the text. Analyses 
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Accession No. & Strain ID Genotype 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 
FJ527563.1 AD169 gO1a. gO1a I L R Q L E T T I - - S T K Y - - - - N 
KP745640.1 BE/22/2010. gO1a . . . . . . . . . - - . . . . - - - - . 
KP745641.1 BE/31/2011. gO1a . . . . . . . . . - - . . . . - - - - . 
KJ872542.1 PAV21. gO1a . . . . . . . . . - - . . . . - - - - . 
GU179290.1 U11. gO1a . . . . . . . . . - - . . . . - - - - . 
KP745699.1 BE/1/2012. gO1a . . . . . . . . . - - . . . . - - - - . 
KC519319.1 BE/9/2010. gO1a . . . . . . . . . - - . . . . - - - - . 
KP745657.1 BE/13/2011. gO1a . . . . . . . . . - - . . . . - - - - . 
KP745653.1 BE/22/2011. gO1a . . . . . . . . . - - . . . . - - - - . 
KC519323.1 BE/27/2010. gO1a . . . . . . . . . - - . . . . - - - - . 
KT634296.1 UKNEQAS2. gO1a . . . . . . . . . - - . . . . - - - - . 
KJ361966.1 PAV12. gO1a . . . . . . . . . - - . . . . - - - - . 
KP745674.1 BE/33/2011. gO1a . . . . . . . . . - - . . . . - - - - . 
KJ361958.1 HAN40. gO1a . . . . . . . . . - - . . . . - - - - . 
KJ361959.1 PAV1. gO1a . . . . . . . . . - - . . . . - - - - . 
KJ361950.1 HAN11. gO1a . . . . . . . . . - - . . . . - - - - . 
KJ872541.1 PAV20. gO1a . . . . . . . . . - - . . . . - - - - . 
KP745722.1 BE/40/2011. gO1a . . . . . . . . . - - . . . . - - - - . 
KP745709.1 BE/48/2011. gO1a . . . . . . . . . - - . . . . - - - - . 
KP745697.1 BE/23/2010. gO1a/1c . . K . . . R E P - - Y . . . F - - - . 
KP745652.1 BE/2/2011. gO1b . . K . . . K D . - - Y . . . F - - - . 
KP745649.1 BE/10/2012. gO1b . . K . . . K D . - - Y . . . F - - - . 
KP745634.1 BE/32/2010. gO1b . . K . . . K D . - - Y . . . F - - - . 
KJ361967.1 PAV23. gO1b . . K . . . K D . - - Y . . . F - - - . 
KP745635.1 BE/5/2012. gO1b . . K . . . K D . - - Y . . . F - - - . 
KJ361962.1 PAV6. gO1b . . K . . . K D . - - Y . . . F - - - . 
KP745639.1 BE/10/2011. gO1b . . K . . . K D . - - Y . . . F - - - . 
KP745701.1 BE/6/2010. gO1b . . K . . . K D . - - Y . . . F - - - . 
KP745703.1 BE/26/2011. gO1b . . K . . . K D . - - Y . . . F - - - . 
KP745696.1 BE/27/2011. gO1b . . K . . . K D . - - Y . . . F - - - . 
KP745698.1 BE/20/2011. gO1b . . K . . . K D . - - Y . . . F - - - . 
KP745704.1 BE/32/2011. gO1b . . K . . . K D . - - Y . . . F - - - . 
KP745725.1 BE/49/2011. gO1b . . K . . . K D . - - Y . . . F - - - . 
KP745726.1 BE/30/2010. gO1b . . K . . . K D . - - Y . . . F - - - . 
KP745713.1 BE/35/2011. gO1b . . K . . . K D . - - Y . . . F - - - . 
KP745715.1 BE/44/2011. gO1b . . K . . . K D . - - Y . . . F - - - . 
KP745691.1 CZ/1/2013. gO1b . . K . . . K D . - - Y . . . F - - - . 
KP745663.1 BE/5/2010. gO1b . . K . . . K D . - - Y . . . F - - - . 
KP745668.1 BE/18/2011. gO1b . . K . . . K D . - - Y . . . F - - - . 
KP745658.1 BE/14/2012. gO1b . . K . . . K D . - - Y . . . F - - - . 
KP745660.1 BE/6/2011. gO1b . . K . . . K D . - - Y . . . F - - - . 
KP745673.1 BE/42/2011. gO1b . . K . . . K D . - - Y . . . F - - - . 
KP745687.1 BE/36/2011. gO1b . . K . . . K D . - - Y . . . F - - - . 
KP745689.1 BE/17/2011. gO1b . . K . . . K D . - - Y . . . F - - - . 
KP745675.1 BE/23/2011. gO1b . . K . . . K D . - - Y . . . F - - - . 
KP745676.1 BE/28/2010. gO1b . . K . . . K D . - - Y . . . F - - - . 
KF021605.1 TR gO1b. gO1b . . K . . . K D . - - Y . . . F - - - . 
KJ361947.1 2CEN5. gO1b . . K . . . K D . - - Y . . . F - - - . 
KJ361948.1 2CEN15. gO1b . . K . . . K D . - - Y . . . F - - - . 
JX512207.1 HAN28. gO1b . . K . . . K D . - - Y . . . F - - - . 
KC519321.1 BE/11/2010. gO1b . . K . . . K D . - - Y . . . F - - - . 
HQ380895.1 JHC. gO1b . . K . . . K D . - - Y . . . F - - - . 
KJ361954.1 HAN32. gO1b . . K . . . K D . - - Y . . . F - - - . 
KJ872540.1 PAV18. gO1c . . K . . . R E P - - Y . . . F - - - . 
KJ361955.1 HAN33. gO1c . . K . . . R E P - - Y . . . F - - - . 
JX512201.1 HAN3. gO1c . . K . . . R E P - - Y . . . F - - - . 
KF297339.1 TB40/E Lisa. gO1c . . K . . . R E P - - Y . . . F - - - . 
GU179289.1 VR1814. gO1c . . K . . . R E P - - Y . . . F - - - . 
GU937742.1 Toledo gO1c. gO1c . . K . . . R E P - - Y . . . F - - - . 
KP745710.1 BE/2/2012. gO1c . . K . . . R E P - - Y . . . F - - - . 
GQ396663.1 HAN20. gO1c . . K . . . R E P - - Y . . . F - - - . 
KP745721.1 BE/14/2010. gO1c . . K . . . R E P - - Y . . . F - - - . 
KP745685.1 CZ/3/2012. gO1c . . K . . . R E P - - Y . . . F - - - . 
KP745724.1 BE/4/2012. gO2a . . . . . . P I P - - Y I . . P - - - Q 
KP745646.1 BE/8/2012. gO2a . . . . . . P I P - - Y I . . P - - - Q 
KP745638.1 BE/15/2010. gO2a . . . . . . P I P - - Y I . . P - - - Q 
GQ221973.1 HAN13. gO2a . . . . . . P I P - - Y I . . P - - - Q 
KP745643.1 CZ/2/2012. gO2a . . . . . . P I P - - Y I . . P - - - Q 
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KC519322.1 BE/21/2010. gO2a . . . . . . P I P - - Y I . . P - - - Q 
JX512202.1 HAN8. gO2a . . . . . . P I P - - Y I . . P - - - Q 
KP745677.1 BE/1/2010. gO2a . . . . . . P I P - - Y I . . P - - - Q 
JX512199.1 HAN1. gO2a . . . . . . P I P - - Y I . . P - - - Q 
JX512198.1 Davis. gO2a . . . . . . P I P - - Y I . . P - - - Q 
KP745712.1 BE/19/2010. gO2a . . . . . . P I P - - Y I . . P - - - Q 
KJ361968.1 PAV24. gO2a . . . . . . P I P - - Y I . . P - - - Q 
GQ396662.1 HAN38 gO2a. gO2a . . . . . . P I P - - Y I . . P - - - Q 
KP745683.1 BE/12/2011. gO2a . . . . . . P I P - - Y I . . P - - - Q 
KP745656.1 BE/2/2013. gO2b . . K . . Q S D . - - Y . . . P - - - Q 
KJ361956.1 HAN36. gO2b . . K . . Q S D . - - Y . . . P - - - Q 
JX512208.1 HAN31. gO2b . . K . . Q S D . - - Y . . . P - - - Q 
KP745667.1 BE/5/2011. gO2b . . K . . Q S D . - - Y . . . P - - - Q 
KP745686.1 BE/39/2011. gO2b . . K . . Q S D . - - Y . . . P - - - Q 
KP745716.1 BE/16/2010. gO2b . . K . . Q S D . - - Y . . . P - - - Q 
KP745654.1 BE/19/2011. gO2b . . K . . Q S D . - - Y . . . P - - - Q 
KP745705.1 BE/38/2011. gO2b . . K . . Q S D . - - Y . . . P - - - Q 
GU179288.1 U8. gO2b . . K . . Q S D . - - Y . . . P - - - Q 
KJ361951.1 HAN21. gO2b . . K . . Q S D . - - Y . . . P - - - Q 
KP745678.1 BE/25/2010. gO2b . . K . . Q S D . - - Y . . . P - - - Q 
KJ361965.1 PAV11. gO2b . . K . . Q S D . - - Y . . . P - - - Q 
JX512200.1 HAN2. gO2b . . K . . Q S D . - - Y . . . P - - - Q 
JX512203.1 HAN12. gO2b . . K . . Q S D . - - Y . . . P - - - Q 
KP745672.1 BE/29/2011. gO2b . . K . . Q S D . - - Y . . . P - - - Q 
KP745679.1 BE/24/2010. gO2b . . K . . Q S D . - - Y . . . P - - - Q 
GU179291.1 AF1 gO2b. gO2b . . K . . Q S D . - - Y . . . P - - - Q 
KJ361946.1 2CEN2. gO2b . . K . . Q S D . - - Y . . . P - - - Q 
KP745680.1 BE/11/2012. gO3 L . K . I G A S Q - D Y Y . F F T - - I 
KP745719.1 BE/26/2010. gO3 L . K . I G A S Q - D Y Y . F F T - - I 
KP745681.1 BE/43/2011. gO3 L . K . I G A S Q - D Y Y . F F T - - I 
KP745702.1 BE/21/2011. gO3 L . K . I G A S Q - D Y Y . F F T - - I 
KP745700.1 BE/4/2011. gO3 L . K . I G A S Q - D Y Y . F F T - - I 
KP745714.1 BE/29/2010. gO3 L . K . I G A S Q - D Y Y . F F T - - I 
KP745706.1 BE/41/2011. gO3 L . K . I G A S Q - D Y Y . F F T - - I 
KP745711.1 BE/24/2011. gO3 L . K . I G A S Q - D Y Y . F F T - - I 
KP745708.1 BE/8/2010. gO3 L . K . I G A S Q - D Y Y . F F T - - I 
KP745707.1 BE/13/2012. gO3 L . K . I G A S Q - D Y Y . F F T - - I 
JX512197.1 6397. gO3 L . K . I G A S Q - D Y Y . F F T - - I 
KP745688.1 BE/12/2012. gO3 L . K . I G A S Q - D Y Y . F F T - - I 
KP745684.1 BE/11/2011. gO3 L . K . I G A S Q - D Y Y . F F T - - I 
KP745692.1 BE/3/2012. gO3 L . K . I G A S Q - D Y Y . F F T - - I 
KP745718.1 CZ/1/2011. gO3 L . K . I G A S Q - D Y Y . F F T - - I 
KP745694.1 BE/12/2010. gO3 L . K . I G A S Q - D Y Y . F F T - - I 
KP745693.1 BE/15/2012. gO3 L . K . I G A S Q - D Y Y . F F T - - I 
KP745651.1 BE/9/2012. gO3 L . K . I G A S Q - D Y Y . F F T - - I 
KP745650.1 BE/1/2011. gO3 L . K . I G A S Q - D Y Y . F F T - - I 
KJ361952.1 HAN27. gO3 L . K . I G A S Q - D Y Y . F F T - - I 
KJ361964.1 PAV8. gO3 L . K . I G A S Q - D Y Y . F F T - - I 
KP745655.1 BE/3/2010. gO3 L . K . I G A S Q - D Y Y . F F T - - I 
KP745633.1 BE/45/2011. gO3 L . K . I G A S Q - D Y Y . F F T - - I 
KJ361949.1 2CEN30. gO3 L . K . I G A S Q - D Y Y . F F T - - I 
KP745636.1 BE/7/2011. gO3 L . K . I G A S Q - D Y Y . F F T - - I 
KP745645.1 BE/13/2010. gO3 L . K . I G A S Q - D Y Y . F F T - - I 
KP745642.1 CZ/1/2012. gO3 L . K . I G A S Q - D Y Y . F F T - - I 
KP745659.1 BE/3/2011. gO3 L . K . I G A S Q - D Y Y . F F T - - I 
KP745666.1 BE/7/2012. gO3 L . K . I G A S Q - D Y Y . F F T - - I 
KP745665.1 BE/16/2012. gO3 L . K . I G A S Q - D Y Y . F F T - - I 
JX512204.1 HAN16 gO3. gO3 L . K . I G A S Q - D Y Y . F F T - - I 
KJ361957.1 HAN39. gO3 L . K . I G A S Q - D Y Y . F F T - - I 
KP745670.1 BE/30/2011. gO3 L . K . I G A S Q - D Y Y . F F T - - I 
KP745723.1 BE/37/2011. gO3 L . K . I G A S Q - D Y Y . F F T - - I 
KP745661.1 BE/33/2010. gO3 L . K . I G A S Q - D Y Y . F F T - - I 
KJ361961.1 PAV5. gO3 L . K . I G A S Q - D Y Y . F F T - - I 
KJ361960.1 PAV4. gO3 L . K . I G A S Q - D Y Y . F F T - - I 
KP745664.1 CZ/2/2013. gO3 L . K . I G A S Q - D Y Y . F F T - - I 
KJ361969.1 PAV25. gO4 . . Q E I A S K T G D Y Y . F F T - - F 
GQ466044.1 3301. gO4 . . Q E I A S K T G D Y Y . F F T - - F 
KJ426589.1 HAN. gO4 . . Q E I A S K T G D Y Y . F F T - - F 
FJ616285.1 Towne gO4. gO4 . . Q E . A S K T G D Y Y . F F T - - F 
KP745690.1 BE/34/2011. gO4 . . Q E I A S K T G D Y Y . F F T - - F 
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KC519320.1 BE/10/2010. gO4 . . Q E I A S K T G D Y Y . F F T - - F 
KP745720.1 BE/15/2011. gO4 . . Q E I A S K T G D Y Y . F F T - - F 
JX512206.1 HAN22. gO4 . . Q E I A S K T G D Y Y . F L T - - F 
KP745648.1 BE/8/2011. gO4 . . Q E . A S K T G D Y Y . F F T - - F 
KP745717.1 BE/2/2010. gO4 . . Q E I A S K T G D Y Y . F L T - - F 
KP745637.1 BE/9/2011. gO4 . . Q E I A S K T G D Y Y . F L T - - F 
GQ221974.1 3157. gO5 . . K R . M S . S - - . D G . R F L M Y 
KT959235.1 DB. gO5 . . K R . M S . S - - . D G . R F L M Y 
KP745728.1 BE/4/2010. gO5 . . K R . M S . S - - . D G . R F L M Y 
AY446894.2 Merlin gO5. gO5 . . K R . M S . S - - . D G . R F L M Y 
KP745727.1 BE/17/2010. gO5 . . K R . M S . S - - . D G . R F L M Y 
KJ872539.1 PAV16. gO5 . . K R . M S . S - - . D G . R F L M Y 
KP745644.1 BE/31/2010. gO5 . . K R . M S . S - - . D G . R F L M Y 
KP745647.1 BE/18/2010. gO5 . . K R . M S . S - - . D G . R F L M Y 
KJ361971.1 UKNEQAS1. gO5 . . K R . M S . S - - . D G . R F L M Y 
KJ361963.1 PAV7. gO5 . . K R . M S . S - - . D G . R F L M Y 
KJ361953.1 HAN30. gO5 . . K R . M S . S - - . D G . R F L M Y 
KJ361970.1 PAV26. gO5 . . K R . M S . S - - . D G . R F L M Y 
KP745662.1 BE/20/2010. gO5 . . K R . M S . S - - . D G . R F L M Y 
KP745682.1 BE/46/2011. gO5 . . K R . M S . S - - . D G . R F L M Y 
KP745695.1 BE/6/2012. gO5 . . K R . M S . S - - . D G . R F L M Y 
GQ221975.1 JP. gO5 . . K R . M S . S - - . D G . R F L M Y 
JX512205.1 HAN19. gO5 . . K R . M S . S - - . D G . R F L M Y 
KP745669.1 BE/28/2011. gO5 . . K R . M S . S - - . D G . R F L M Y 
KP745671.1 BE/14/2011. gO5 . . K R . M S . S - - . D G . R F L M Y 
 
 
Figure 5.2. Amino acid sequence alignment of HCMV gO from 163 complete HCMV 
genomes. The eight gO genotypes are colour-coded, with the region showing unique 
amino acids corresponding to each genotype highlighted. The peculiar case of strain 
BE/23/2010 (KP745697.1) is discussed in section 5.2.3 ‘Unique Cases’. 
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Accession No. & Strain ID Genotype 207 208 209 210 211 212 213 214 215 216 217 218 219 220 221 222 223 224 225 226 227 228 
FJ527563.1 AD169 gO1a. gO1a A G A A A C G A C T A T T - - - - - - T C T 
KP745640.1 BE/22/2010. gO1a . . . . . . . . . A . . . - - - - - - . . . 
KP745641.1 BE/31/2011. gO1a . . . . . . . . . A . . . - - - - - - . . . 
KJ872542.1 PAV21. gO1a . . . . . . . . . . . . . - - - - - - . . . 
GU179290.1 U11. gO1a . . . . . . . . . A . . . - - - - - - . . . 
KP745699.1 BE/1/2012. gO1a . . . . . . . . . A . . . - - - - - - . . . 
KC519319.1 BE/9/2010. gO1a . . . . . . . . . . . . . - - - - - - . . . 
KP745657.1 BE/13/2011. gO1a . . . . . . . . . A . . . - - - - - - . . . 
KP745653.1 BE/22/2011. gO1a . . . . . . . . . . . . . - - - - - - . . . 
KC519323.1 BE/27/2010. gO1a . . . . . . . . . A . . . - - - - - - . . . 
KT634296.1 UKNEQAS2. gO1a . . . . . . . . . A . . . - - - - - - . . . 
KJ361966.1 PAV12. gO1a . . . . . . . . . A . . . - - - - - - . . . 
KP745674.1 BE/33/2011. gO1a . . . . . . . . . . . . . - - - - - - . . . 
KJ361958.1 HAN40. gO1a . . . . . . . . . . . . . - - - - - - . . . 
KJ361959.1 PAV1. gO1a . . . . . . . . . . . . . - - - - - - . . . 
KJ361950.1 HAN11. gO1a . . . . . . . . . A . . . - - - - - - . . . 
KJ872541.1 PAV20. gO1a . . . . . . . . . . . . . - - - - - - . . . 
KP745722.1 BE/40/2011. gO1a . . . . . . . . . . . . . - - - - - - . . . 
KP745709.1 BE/48/2011. gO1a . . . . . . . . . . . . . - - - - - - . . . 
KP745697.1 BE/23/2010. gO1a/1c . . . . . G . G A A C C . - - - - - - . A . 
KP745652.1 BE/2/2011. gO1b . . . . . A . G A . . . C - - - - - - . A . 
KP745649.1 BE/10/2012. gO1b . . . . . A . G A . . . C - - - - - - . A . 
KP745634.1 BE/32/2010. gO1b . . . . . A . G A . . . C - - - - - - . A . 
KJ361967.1 PAV23. gO1b . . . . . A . G A . . . C - - - - - - . A . 
KP745635.1 BE/5/2012. gO1b . . . . . A . G A . . . C - - - - - - . A . 
KJ361962.1 PAV6. gO1b . . . . . A . G A . . . C - - - - - - . A . 
KP745639.1 BE/10/2011. gO1b . . . . . A . G A . . . C - - - - - - . A . 
KP745701.1 BE/6/2010. gO1b . . . . . A . G A . . . C - - - - - - . A . 
KP745703.1 BE/26/2011. gO1b . . . . . A . G A . . . C - - - - - - . A . 
KP745696.1 BE/27/2011. gO1b . . . . . A . G A . . . C - - - - - - . A . 
KP745698.1 BE/20/2011. gO1b . . . . . A . G A . . . C - - - - - - . A . 
KP745704.1 BE/32/2011. gO1b . . . . . A . G A . . . C - - - - - - . A . 
KP745725.1 BE/49/2011. gO1b . . . . . A . G A . . . C - - - - - - . A . 
KP745726.1 BE/30/2010. gO1b . . . . . A . G A . . . C - - - - - - . A . 
KP745713.1 BE/35/2011. gO1b . . . . . A . G A . . . C - - - - - - . A . 
KP745715.1 BE/44/2011. gO1b . . . . . A . G A . . . C - - - - - - . A . 
KP745691.1 CZ/1/2013. gO1b . . . . . A . G A . . . C - - - - - - . A . 
KP745663.1 BE/5/2010. gO1b . . . . . A . G A . . . C - - - - - - . A . 
KP745668.1 BE/18/2011. gO1b . . . . . A . G A . . . C - - - - - - . A . 
KP745658.1 BE/14/2012. gO1b . . . . . A . G A . . . C - - - - - - . A . 
KP745660.1 BE/6/2011. gO1b . . . . . A . G A . . . C - - - - - - . A . 
KP745673.1 BE/42/2011. gO1b . . . . . A . G A . . . C - - - - - - . A . 
KP745687.1 BE/36/2011. gO1b . . . . . A . G A . . . C - - - - - - . A . 
KP745689.1 BE/17/2011. gO1b . . . . . A . G A . . . C - - - - - - . A . 
KP745675.1 BE/23/2011. gO1b . . . . . A . G A . . . C - - - - - - . A . 
KP745676.1 BE/28/2010. gO1b . . . . . A . G A . . . C - - - - - - . A . 
KF021605.1 TR gO1b. gO1b . . . . . A . G A . . . C - - - - - - . A . 
KJ361947.1 2CEN5. gO1b . . . . . A . G A . . . C - - - - - - . A . 
KJ361948.1 2CEN15. gO1b . . . . . A . G A . . . C - - - - - - . A . 
JX512207.1 HAN28. gO1b . . . . . A . G A . . . C - - - - - - . A . 
KC519321.1 BE/11/2010. gO1b . . . . . A . G A . . . C - - - - - - . A . 
HQ380895.1 JHC. gO1b . . . . . A . G A . . . C - - - - - - . A . 
KJ361954.1 HAN32. gO1b . . . . . A . G A . . . C - - - - - - . A . 
KJ872540.1 PAV18. gO1c . . . . . G . G A A C C . - - - - - - . A . 
KJ361955.1 HAN33. gO1c . . . . . G . G A A C C . - - - - - - . A . 
JX512201.1 HAN3. gO1c . . . . . G . G A A C C . - - - - - - . A . 
KF297339.1 TB40/E Lisa. gO1c . . . . . G . G A A C C . - - - - - - . A . 
GU179289.1 VR1814. gO1c . . . . . G . G A A C C . - - - - - - . A . 
GU937742.1 Toledo gO1c. gO1c . . . . . G . G A A C C . - - - - - - . A . 
KP745710.1 BE/2/2012. gO1c . . . . . G . G A A C C . - - - - - - . A . 
GQ396663.1 HAN20. gO1c . . . . . G . G A A C C . - - - - - - . A . 
KP745721.1 BE/14/2010. gO1c . . . . . G . G A A C C . - - - - - - . A . 
KP745685.1 CZ/3/2012. gO1c . . . . . G . G A A C C . - - - - - - . A . 
KP745724.1 BE/4/2012. gO2a . . . . C . T . T . C C . - - - - - - . A C 
KP745646.1 BE/8/2012. gO2a . . . . C . T . T . C C . - - - - - - . A C 
KP745638.1 BE/15/2010. gO2a . . . . C . T . T . C C . - - - - - - . A C 
GQ221973.1 HAN13. gO2a . . . . C . T . T . C C . - - - - - - . A C 
KP745643.1 CZ/2/2012. gO2a . . . . C . T . T . C C . - - - - - - . A C 
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KC519322.1 BE/21/2010. gO2a . . . . C . T . T . C C . - - - - - - . A C 
JX512202.1 HAN8. gO2a . . . . C . T . T . C C . - - - - - - . A C 
KP745677.1 BE/1/2010. gO2a . . . . C . T . T . C C . - - - - - - . A C 
JX512199.1 HAN1. gO2a . . . . C . T . T . C C . - - - - - - . A C 
JX512198.1 Davis. gO2a . . . . C . T . T . C C . - - - - - - . A C 
KP745712.1 BE/19/2010. gO2a . . . . C . T . T . C C . - - - - - - . A C 
KJ361968.1 PAV24. gO2a . . . . C . T . T . C C . - - - - - - . A C 
GQ396662.1 HAN38 gO2a. gO2a . . . . C . T . T . C C . - - - - - - . A C 
KP745683.1 BE/12/2011. gO2a . . . . C . T . T . C C . - - - - - - . A C 
KP745656.1 BE/2/2013. gO2b . C . G . G C G A C . . A - - - - - - . A C 
KJ361956.1 HAN36. gO2b . C . G . G C G A C . . A - - - - - - . A C 
JX512208.1 HAN31. gO2b . C . G . G C G A C . . A - - - - - - . A C 
KP745667.1 BE/5/2011. gO2b . C . G . G C G A C . . A - - - - - - . A C 
KP745686.1 BE/39/2011. gO2b . C . G . G C G A C . . A - - - - - - . A C 
KP745716.1 BE/16/2010. gO2b . C . G . G C G A C . . A - - - - - - . A C 
KP745654.1 BE/19/2011. gO2b . C . G . G C G A C . . A - - - - - - . A C 
KP745705.1 BE/38/2011. gO2b . C . G . G C G A C . . A - - - - - - . A C 
GU179288.1 U8. gO2b . C . G . G C G A C . . A - - - - - - . A C 
KJ361951.1 HAN21. gO2b . C . G . G C G A C . . A - - - - - - . A C 
KP745678.1 BE/25/2010. gO2b . C . G . G C G A C . . A - - - - - - . A C 
KJ361965.1 PAV11. gO2b . C . G . G C G A C . . A - - - - - - . A C 
JX512200.1 HAN2. gO2b . C . G . G C G A C . . A - - - - - - . A C 
JX512203.1 HAN12. gO2b . C . G . G C G A C . . A - - - - - - . A C 
KP745672.1 BE/29/2011. gO2b . C . G . G C G A C . . A - - - - - - . A C 
KP745679.1 BE/24/2010. gO2b . C . G . G C G A C . . A - - - - - - . A C 
GU179291.1 AF1 gO2b. gO2b . C . G . G C G A C . . A - - - - - - . A C 
KJ361946.1 2CEN2. gO2b . C . G . G C G A C . . A - - - - - - . A C 
KP745680.1 BE/11/2012. gO3 . . G T G . . . G C C A G - - - G A T . A C 
KP745719.1 BE/26/2010. gO3 . . G T G . . . G C C A G - - - G A T . A C 
KP745681.1 BE/43/2011. gO3 . . G T G . . . G C C A G - - - G A T . A C 
KP745702.1 BE/21/2011. gO3 . . G T G . . . G C C A G - - - G A T . A C 
KP745700.1 BE/4/2011. gO3 . . G T G . . . G C C A G - - - G A T . A C 
KP745714.1 BE/29/2010. gO3 . . G T G . . . G C C A G - - - G A T . A C 
KP745706.1 BE/41/2011. gO3 . . G T G . . . G C C A G - - - G A T . A C 
KP745711.1 BE/24/2011. gO3 . . G T G . . . G C C A G - - - G A T . A C 
KP745708.1 BE/8/2010. gO3 . . G T G . . . G C C A G - - - G A T . A C 
KP745707.1 BE/13/2012. gO3 . . G T G . . . G C C A G - - - G A T . A C 
JX512197.1 6397. gO3 . . G T G . . . G C C A G - - - G A T . A C 
KP745694.1 BE/12/2010. gO3 . . G T G . . . G C C A G - - - G A T . A C 
KP745684.1 BE/11/2011. gO3 . . G T G . . . G C C A G - - - G A T . A C 
KP745692.1 BE/3/2012. gO3 . . G T G . . . G C C A G - - - G A T . A C 
KP745718.1 CZ/1/2011. gO3 . . G T G . . . G C C A G - - - G A T . A C 
KP745688.1 BE/12/2012. gO3 . . G T G . . . G C C A G - - - G A T . A C 
KP745693.1 BE/15/2012. gO3 . . G T G . . . G C C A G - - - G A T . A C 
KP745651.1 BE/9/2012. gO3 . . G T G . . . G C C A G - - - G A T . A C 
KP745650.1 BE/1/2011. gO3 . . G T G . . . G C C A G - - - G A T . A C 
KJ361952.1 HAN27. gO3 . . G T G . . . G C C A G - - - G A T . A C 
KJ361964.1 PAV8. gO3 . . G T G . . . G C C A G - - - G A T . A C 
KP745655.1 BE/3/2010. gO3 . . G T G . . . G C C A G - - - G A T . A C 
KP745633.1 BE/45/2011. gO3 . . G T G . . . G C C A G - - - G A T . A C 
KJ361949.1 2CEN30. gO3 . . G T G . . . G C C A G - - - G A T . A C 
KP745636.1 BE/7/2011. gO3 . . G T G . . . G C C A G - - - G A T . A C 
KP745645.1 BE/13/2010. gO3 . . G T G . . . G C C A G - - - G A T . A C 
KP745642.1 CZ/1/2012. gO3 . . G T G . . . G C C A G - - - G A T . A C 
KP745659.1 BE/3/2011. gO3 . . G T G . . . G C C A G - - - G A T . A C 
KP745666.1 BE/7/2012. gO3 . . G T G . . . G C C A G - - - G A T . A C 
KP745665.1 BE/16/2012. gO3 . . G T G . . . G C C A G - - - G A T . A C 
JX512204.1 HAN16 gO3. gO3 . . G T G . . . G C C A G - - - G A T . A C 
KJ361957.1 HAN39. gO3 . . G T G . . . G C C A G - - - G A T . A C 
KP745670.1 BE/30/2011. gO3 . . G T G . . . G C C A G - - - G A T . A C 
KP745723.1 BE/37/2011. gO3 . . G T G . . . G C C A G - - - G A T . A C 
KP745661.1 BE/33/2010. gO3 . . G T G . . . G C C A G - - - G A T . A C 
KJ361961.1 PAV5. gO3 . . G T G . . . G C C A G - - - G A T . A C 
KJ361960.1 PAV4. gO3 . . G T G . . . G C C A G - - - G A T . A C 
KP745664.1 CZ/2/2013. gO3 . . G T G . . . G C C A G - - - G A T . A C 
KJ361969.1 PAV25. gO4 . . C G T . A . A A . C A G G T G A T . A . 
GQ466044.1 3301. gO4 . . C G T . A . A A . C A G G T G A T . A . 
KJ426589.1 HAN. gO4 . . C G T . A . A A . C A G G T G A T . A . 
FJ616285.1 Towne gO4. gO4 . . C G T . A . A A . C A G G T G A T . A . 
KP745690.1 BE/34/2011. gO4 . . C G T . A . A A . C A G G T G A T . A . 
 Page 114 of 338 
KC519320.1 BE/10/2010. gO4 . . C G T . A . A A . C A G G T G A T . A . 
KP745720.1 BE/15/2011. gO4 . . C G T . A . A A . C A G G T G A T . A . 
JX512206.1 HAN22. gO4 . . C G T . A . A A . C A G G T G A T . A . 
KP745648.1 BE/8/2011. gO4 . . C G T . A . A A . C A G G T G A T . A . 
KP745717.1 BE/2/2010. gO4 . . C G T . A . A A . C A G G T G A T . A . 
KP745637.1 BE/9/2011. gO4 . . C G T . A . A A . C A G G T G A T . A . 
GQ221974.1 3157. gO5 G A T G T . T . . A T C A - - - - - - . . . 
KT959235.1 DB. gO5 G A T G T . T . . A T C A - - - - - - . . . 
KP745728.1 BE/4/2010. gO5 G A T G T . T . . A T C A - - - - - - . . . 
AY446894.2 Merlin gO5. gO5 G A T G T . T . . A T C A - - - - - - . . . 
KP745727.1 BE/17/2010. gO5 G A T G T . T . . A T C A - - - - - - . . . 
KJ872539.1 PAV16. gO5 G A T G T . T . . A T C A - - - - - - . . . 
KP745644.1 BE/31/2010. gO5 G A T G T . T . . A T C A - - - - - - . . . 
KP745647.1 BE/18/2010. gO5 G A T G T . T . . A T C A - - - - - - . . . 
KJ361971.1 UKNEQAS1. gO5 G A T G T . T . . A T C A - - - - - - . . . 
KJ361963.1 PAV7. gO5 G A T G T . T . . A T C A - - - - - - . . . 
KJ361953.1 HAN30. gO5 G A T G T . T . . A T C A - - - - - - . . . 
KJ361970.1 PAV26. gO5 G A T G T . T . . A T C A - - - - - - . . . 
KP745662.1 BE/20/2010. gO5 G A T G T . T . . A T C A - - - - - - . . . 
KP745682.1 BE/46/2011. gO5 G A T G T . T . . A T C A - - - - - - . . . 
KP745695.1 BE/6/2012. gO5 G A T G T . T . . A T C A - - - - - - . . . 
GQ221975.1 JP. gO5 G A T G T . T . . A T C A - - - - - - . . . 
JX512205.1 HAN19. gO5 G A T G T . T . . A T C A - - - - - - . . . 
KP745669.1 BE/28/2011. gO5 G A T G T . T . . A T C A - - - - - - . . . 
KP745671.1 BE/14/2011. gO5 G A T G T . T . . A T C A - - - - - - . . . 
 
 
Figure 5.3. Nucleotide sequence alignment of HCMV gO from 163 complete HCMV 
genomes. The nucleotide sequences correspond to the amino acid region depicted in 
figure 5.2. The region showing ‘molecular tags’ unique to each genotype is highlighted. 
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Figure 5.4. Molecular phylogenetic analysis of HCMV gN genotypes. This unrooted 
consensus tree, showing the eight gN genotypes, was inferred from 1000 bootstrap 
replicates to represent the evolutionary history of 163 full-length HCMV gN amino acid 
sequences from complete HCMV genomes available in GenBank database release 211 
(National Center for Biotechnology Information (NCBI), 2015). The evolutionary history 
was inferred by the Maximum Likelihood method based on the JTT matrix-based model 
and a discrete Gamma distribution with five categories (+G, parameter = 0.8361). All 
positions with less than 95% site coverage were eliminated, leaving 135 amino acid 
positions in the final dataset. Due to space constraints, the branches are compressed. 
All sequences grouped to one of the eight HCMV gN genotypes. Analyses were 
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Accession No. & Strain ID Genotype 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 
FJ527563.1 AD169 gN1. gN1 T S K - S S A S V S T T K L T T V A T T 
KP745697.1 BE/23/2010. gN1 . . . - . . . . . . . . . . . - . . . . 
KP745641.1 BE/31/2011. gN1 . . . - . . T . . . . . . . . . . . . . 
KP745653.1 BE/22/2011. gN1 . . . - . . . . . . . . . . . . . . . . 
KP745640.1 BE/22/2010. gN1 . . . - . . . . . . . . . . . . . . . . 
KJ361966.1 PAV12. gN1 . . . - . . T . . . . . . . . . . . . . 
KP745699.1 BE/1/2012. gN1 . . . - . . T . . . . . . . . . . . . . 
KP745674.1 BE/33/2011. gN1 . . . - . . . .   . . . . . . . . . . . 
KJ361958.1 HAN40. gN1 . . . - . . . . . . . . . . . . . . . . 
KP745657.1 BE/13/2011. gN1 . . . - . . T . . . . . . . . . . . . . 
KC519319.1 BE/9/2010. gN1 . . . - . . . . . . . . . . . . . . . . 
KC519323.1 BE/27/2010. gN1 . . . - . . T . . . . . . . . . . . . . 
KJ361959.1 PAV1. gN1 . . . - . . . . . . . . . . . . . . . . 
KP745709.1 BE/48/2011. gN1 . . . - . . . . . . . . . . . . . . . . 
KJ872541.1 PAV20. gN1 . . . - . . . . . . . . . . . . . . . . 
KP745722.1 BE/40/2011. gN1 . . . - . . . . . . . . . . . . . . . . 
KJ872542.1 PAV21. gN1 . . . - . . . . . . . . . . . . . . . . 
GU179290.1 U11. gN1 . . . - . . T . . . . . . . . . . . . . 
KT634296.1 UKNEQAS2. gN1 . . . - . . T . . . . . . . . . . . . . 
GU179291.1 AF1 gN2. gN2 . P - - . P S . . . . S . P . . S V . . 
KP745654.1 BE/19/2011. gN2 . P - - . P S . . . . S . P . . S V . . 
KP745656.1 BE/2/2013. gN2 . P - - . P S . . . . S . P . . S V . . 
KP745679.1 BE/24/2010. gN2 . P - - . P S . . . . S . P . . S V . . 
KP745678.1 BE/25/2010. gN2 . P - - . P S . . . . S . P . . S V . . 
KJ361956.1 HAN36. gN2 . P - - . P S . . . . S . P . . S V . . 
KJ361951.1 HAN21. gN2 . P - - . P S . . . . S . P . . S V . . 
KP745667.1 BE/5/2011. gN2 . P - - . P S . . . . S . P . . S V . . 
KP745672.1 BE/29/2011. gN2 . P - - . P S . . . . S . P . . S V . . 
KJ361946.1 2CEN2. gN2 . P - - . P S . . . . S . P . . S V . . 
KJ361965.1 PAV11. gN2 . P - - . P S . . . . S . P . . S V . . 
JX512200.1 HAN2. gN2 . P - - . P S . . . . S . P . . S V . . 
JX512203.1 HAN12. gN2 . P - - . P S . . . . S . P . . S V . . 
KP745705.1 BE/38/2011. gN2 . P - - . P S . . . . S . P . . S V . . 
GU179288.1 U8. gN2 . P - - . P S . . . . S . P . . S V . . 
JX512208.1 HAN31. gN2 . P - - . P S . . . . S . P . . S V . . 
KP745686.1 BE/39/2011. gN2 . P - - . P S . . . . S . P . . S V . . 
KP745716.1 BE/16/2010. gN2 . P - - . P S . . . . S . P . . S V . . 
KF021605.1 TR gN3a. gN3a . L . S . . S . . . . S . . . . T . . . 
KP745639.1 BE/10/2011. gN3a . L . S . . S . . . . S . . . . T . . . 
KP745635.1 BE/5/2012. gN3a . L . S . . S . . . . S . . . . T . . . 
KP745649.1 BE/10/2012. gN3a . L . S . . S . . . . S . . . . T . . . 
KP745634.1 BE/32/2010. gN3a . L . S . . S . . . . S . . . . T . . . 
KP745652.1 BE/2/2011. gN3a . L . S . . S . . . . S . . . . T . . . 
KP745658.1 BE/14/2012. gN3a . L . S . . S . . . . S . . . . T . . . 
KP745701.1 BE/6/2010. gN3a . L . S . . S . . . . S . . . . T . . . 
KP745703.1 BE/26/2011. gN3a . L . S . . S . . . . S . . . . T . . . 
KP745696.1 BE/27/2011. gN3a . L . S . . S . . . . S . . . . T . . . 
KP745698.1 BE/20/2011. gN3a . L . S . . S . . . . S . . . . T . . . 
KP745704.1 BE/32/2011. gN3a . L . S . . S . . . . S . . . . T . . . 
KP745725.1 BE/49/2011. gN3a . L . S . . S . . . . S . . . . T . . . 
KP745726.1 BE/30/2010. gN3a . L . S . . S . . . . S . . . . T . . . 
KP745713.1 BE/35/2011. gN3a . L . S . . S . . . . S . . . . T . . . 
KP745715.1 BE/44/2011. gN3a . L . S . . S . . . . S . . . . T . . . 
KP745668.1 BE/18/2011. gN3a . L . S . . S . . . . S . . . . T . . . 
KP745673.1 BE/42/2011. gN3a . L . S . . S . . . . S . . . . T . . . 
KP745660.1 BE/6/2011. gN3a . L . S . . S . . . . S . . . . T . . . 
 Page 117 of 338 
KP745663.1 BE/5/2010. gN3a . L . S . . S . . . . S . . . . T . . . 
KP745675.1 BE/23/2011. gN3a . L . S . . S . . . . S . . . . T . . . 
KP745689.1 BE/17/2011. gN3a . L . S . . S . . . . S . . . . T . . . 
KP745691.1 CZ/1/2013. gN3a . L . S . . S . . . . S . . . . T . . . 
KP745676.1 BE/28/2010. gN3a . L . S . . S . . . . S . . . . T . . . 
KP745687.1 BE/36/2011. gN3a . L . S . . S . . . . S . . . . T . . . 
KC519321.1 BE/11/2010. gN3a . L . S . . S . . . . S . . . . T . . . 
KJ361962.1 PAV6. gN3a . L . S . . S . . . . S . . . . T . . . 
KJ361967.1 PAV23. gN3a . L . S . . S . . . . S . . . . T . . . 
JX512207.1 HAN28. gN3a . L . S . . S . . . . S . . . . T . . . 
KJ361948.1 2CEN15. gN3a . L . S . . S . . . . S . . . . T . . . 
HQ380895.1 JHC. gN3a . L . S . . S . . . . S . . . . T . . . 
KJ361950.1 HAN11. gN3a . L . S . . S . . . . S . . . . T . . . 
KJ361947.1 2CEN5. gN3a . L . S . . S . . . . S . . . . T . . . 
KJ361954.1 HAN32. gN3a . L . S . . S . . . . S . . . . T . . . 
GQ396662.1 HAN38 gN3b. gN3b . P S P P . S . . . . V . S . . S V . . 
KP745646.1 BE/8/2012. gN3b . P S P P . S . . . . V . S . . S V . . 
KP745683.1 BE/12/2011. gN3b . P S P P . S . . . . V . S . . S V . . 
KC519322.1 BE/21/2010. gN3b . P S P P . S . . . . V . S . . S V . . 
KP745677.1 BE/1/2010. gN3b . P S P P . S . . . . V . S . . S V . . 
KP745712.1 BE/19/2010. gN3b . P S P P . S . . . . V . S . . S V . . 
JX512202.1 HAN8. gN3b . P S P P . S . . . . V . S . . S V . . 
GQ221973.1 HAN13. gN3b . P S P P . S . . . . V . S . . S V . . 
KP745638.1 BE/15/2010. gN3b . P S P P . S . . . . V . S . . S V . . 
KP745724.1 BE/4/2012. gN3b . P S P P . S . . . . V . S . . S V . . 
KP745643.1 CZ/2/2012. gN3b . P S P P . S . . . . V . S . . S V . . 
JX512199.1 HAN1. gN3b . P S P P . S . . . . V . S . . S V . . 
KJ361968.1 PAV24. gN3b . P S P P . S . . . . V . S . . S V . . 
JX512198.1 Davis. gN3b . P S P P . S . . . . V . S . . S V . . 
JX512204.1 HAN16 gN4a. gN4a S . - - . T R T L T . V . A . . T . . . 
KP745702.1 BE/21/2011. gN4a S . - - . T R T L T . V . A . . T . . . 
KP745692.1 BE/3/2012. gN4a S . - - . T R T L T . V . A . . T . . . 
KJ361949.1 2CEN30. gN4a S . - - . T R T L T . V . A . . T . . . 
KP745693.1 BE/15/2012. gN4a S . - - . T R T L T . V . A . . T . . . 
KP745670.1 BE/30/2011. gN4a S . - - . T R T L T . V . A . . T . . . 
KP745706.1 BE/41/2011. gN4a S . - - . T R T L T . V . A . . T . . . 
KP745681.1 BE/43/2011. gN4a S . - - . T R T L T . V . A . . T . . . 
KP745680.1 BE/11/2012. gN4a S . - - . T R T L T . V . A . . T . . . 
KP745684.1 BE/11/2011. gN4a S . - - . T R T L T . V . A . . T . . . 
KP745700.1 BE/4/2011. gN4a S . - - . T R T L T . V . A . . T . . . 
KP745694.1 BE/12/2010. gN4a S . - - . T R T L T . V . A . . T . . . 
JX512197.1 6397. gN4a S . - - . T R T L T . V . A . . T . . . 
KP745688.1 BE/12/2012. gN4a S . - - . T R T L T . V . A . . T . . . 
KP745711.1 BE/24/2011. gN4a S . - - . T R T L T . V . A . . T . . . 
KP745714.1 BE/29/2010. gN4a S . - - . T R T L T . V . A . . T . . . 
KP745645.1 BE/13/2010. gN4a S . - - . T R T L T . V . A . . T . . . 
KJ361961.1 PAV5. gN4a S . - - . T R T L T . V . A . . T . . . 
KP745651.1 BE/9/2012. gN4a S . - - . T R T L T . V . A . . T . . . 
KP745650.1 BE/1/2011. gN4a S . - - . T R T L T . V . A . . T . . . 
KP745718.1 CZ/1/2011. gN4a S . - - . T R T L T . V . A . . T . . . 
KP745719.1 BE/26/2010. gN4a S . - - . T R T L T . V . A . . T . . . 
KP745723.1 BE/37/2011. gN4a S . - - . T R T L T . V . A . . T . . . 
KP745642.1 CZ/1/2012. gN4a S . - - . T R T L T . V . A . . T . . . 
KJ361964.1 PAV8. gN4a S . - - . T R T L T . V . A . . T . . . 
KP745636.1 BE/7/2011. gN4a S . - - . T R T L T . V . A . . T . . . 
KJ361952.1 HAN27. gN4a S . - - . T R T L T . V . A . . T . . . 
KP745707.1 BE/13/2012. gN4a S . - - . T R T L T . V . A . . T . . . 
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KP745661.1 BE/33/2010. gN4a S . - - . T R T L T . V . A . . T . . . 
KP745666.1 BE/7/2012. gN4a S . - - . T R T L T . V . A . . T . . . 
KP745665.1 BE/16/2012. gN4a S . - - . T R T L T . V . A . . T . . . 
KP745664.1 CZ/2/2013. gN4a S . - - . T R T L T . V . A . . T . . . 
KJ361957.1 HAN39. gN4a S . - - . T R T L T . V . A . . T . . . 
KP745655.1 BE/3/2010. gN4a S . - - . T R T L T . V . A . . T . . . 
KJ361960.1 PAV4. gN4a S . - - . T R T L T . V . A . . T . . . 
KP745659.1 BE/3/2011. gN4a S . - - . T R T L T . V . A . . T . . . 
KP745708.1 BE/8/2010. gN4a S . - - . T R T L T . V . A . . T . . . 
FJ616285.1 Towne gN4b. gN4b S . - - . T H T S T . V . A . . T . . . 
GQ466044.1 3301. gN4b S . - - . T H T S T . V . A . . T . . . 
KP745717.1 BE/2/2010. gN4b S . - - . T H T S T . V . A . . T . . . 
KP745720.1 BE/15/2011. gN4b S . - - . T H T S T . V . A . . T . . . 
KP745648.1 BE/8/2011. gN4b S . - - . T H T S T . V . A . . T . . . 
KC519320.1 BE/10/2010. gN4b S . - - . T H T S T . V . A . . T . . . 
KP745637.1 BE/9/2011. gN4b S . - - . T H T S T . V . A . . T . . . 
KJ426589.1 HAN. gN4b S . - - . T H T S T . V . A . . T . . . 
KJ361969.1 PAV25. gN4b S . - - . T H T S T . V . A . . T . . . 
JX512206.1 HAN22. gN4b S . - - . T H T S T . V . A . . T . . . 
KP745690.1 BE/34/2011. gN4b S . - - . T H T S T . V . A . . T . . . 
GU937742.1 Toledo gN4c. gN4c S . - - . T R T S T . V . S . A . . . . 
KJ872540.1 PAV18. gN4c S . - - . T R T S T . V . S . A . . . . 
JX512201.1 HAN3. gN4c S . - - . T R T S T . V . S . A . . . . 
KJ361955.1 HAN33. gN4c S . - - . T R T S T . V . S . A . . . . 
KP745710.1 BE/2/2012. gN4c S . - - . T R T S T . V . S . A . . . . 
GU179289.1 VR1814. gN4c S . - - . T R T S T . V . S . A . . . . 
GQ396663.1 HAN20. gN4c S . - - . T R T S T . V . S . A . . . . 
KP745685.1 CZ/3/2012. gN4c S . - - . T R T S T . V . S . A . . . . 
KF297339.1 TB40/E Lisa. gN4c S . - - . T R T S T . V . S . A . . . . 
KP745721.1 BE/14/2010. gN4c S . - - . T R T S T . V . S . A . . . . 
AY446894.2 Merlin gN4d. gN4d S . - - . T H A S T . V . A . . . . . . 
KP745633.1 BE/45/2011. gN4d S . - - . T H A S T . V . A . . . . . . 
GQ221974.1 3157. gN4d S . - - . T H A S T . V . A . . . . . . 
KJ361971.1 UKNEQAS1. gN4d S . - - . T H A S T . V . A . . . . . . 
KT959235.1 DB. gN4d S . - - . T H A S T . V . A . . . . . . 
KP745728.1 BE/4/2010. gN4d S . - - . T H A S T . V . A . . . . . . 
KJ872539.1 PAV16. gN4d S . - - . T H A S T . V . A . . . . . . 
KP745727.1 BE/17/2010. gN4d S . - - . T H A S T . V . A . . . . . . 
KJ361970.1 PAV26. gN4d S . - - . T H A S T . V . A . . . . . . 
KP745662.1 BE/20/2010. gN4d S . - - . T H A S T . V . A . . . . . . 
KJ361953.1 HAN30. gN4d S . - - . T H A S T . V . A . . . . . . 
KP745669.1 BE/28/2011. gN4d S . - - . T H A S T . V . A . . . . . . 
KP745682.1 BE/46/2011. gN4d S . - - . T H A S T . V . A . . . . . . 
KP745671.1 BE/14/2011. gN4d S . - - . T H A S T . V . A . . . . . . 
KJ361963.1 PAV7. gN4d S . - - . T H A S T . V . A . . . . . . 
JX512205.1 HAN19. gN4d S . - - . T H A S T . V . A . . . . . . 
KP745695.1 BE/6/2012. gN4d S . - - . T H A S T . V . A . . . . . . 
GQ221975.1 JP. gN4d S . - - . T H A S T . V . A . . . . . . 
KP745647.1 BE/18/2010. gN4d S . - - . T H A S T . V . A . . . . . . 
KP745644.1 BE/31/2010. gN4d S . - - . T H A S T . V . A . . . . . . 
 
Figure 5.5. Amino acid sequence alignment of HCMV gN from 163 complete HCMV 
genomes. The eight gN genotypes are colour-coded, with the region showing unique 
amino acids corresponding to each genotype highlighted.  
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Accession No. & Strain ID Genotype 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 126 127 128 129 
FJ527563.1 AD169 gN1. gN1 C T G C T A G C G T A T C A A C T A C C 
KP745697.1 BE/23/2010. gN1 . . . . . . . . . . . . . . . . . . . . 
KP745641.1 BE/31/2011. gN1 . . A . . . . . . . . . . . . . . . . . 
KP745653.1 BE/22/2011. gN1 . . . . . . . . . . . . . . . . . . . . 
KP745640.1 BE/22/2010. gN1 . . . . . . . . . . . . . . . . . . . . 
KJ361966.1 PAV12. gN1 . . A . . . . . . . . . . . . . . . . . 
KP745699.1 BE/1/2012. gN1 . . A . . . . . . . . . . . . . . . . . 
KP745674.1 BE/33/2011. gN1 . . . . . . . . . . . . . . . . . . . . 
KJ361958.1 HAN40. gN1 . . . . . . . . . . . . . . . . . . . . 
KP745657.1 BE/13/2011. gN1 . . A . . . . . . . . . . . . . . . . . 
KC519319.1 BE/9/2010. gN1 . . . . . . . . . . . . . . . . . . . . 
KC519323.1 BE/27/2010. gN1 . . A . . . . . . . . . . . . . . . . . 
KJ361959.1 PAV1. gN1 . . . . . . . . . . . . . . . . . . . . 
KP745709.1 BE/48/2011. gN1 . . . . . . . . . . . . . . . . . . . . 
KJ872541.1 PAV20. gN1 . . . . . . . . . . . . . . . . . . . . 
KP745722.1 BE/40/2011. gN1 . . . . . . . . . . . . . . . . . . . . 
KJ872542.1 PAV21. gN1 . . . . . . . . . . . . . . . . . . . . 
GU179290.1 U11. gN1 . . A . . . . . . . . . . . . . . . . . 
KT634296.1 UKNEQAS2. gN1 . . A . . . . . . . . . . . . . . . . . 
GU179291.1 AF1 gN2. gN2 . . T . . . . T . . G . . G . . G . G T 
KP745654.1 BE/19/2011. gN2 . . T . . . . T . . G . . G . . G . G T 
KP745656.1 BE/2/2013. gN2 . . T . . . . T . . G . . G . . G . G T 
KP745679.1 BE/24/2010. gN2 . . T . . . . T . . G . . G . . G . G T 
KP745678.1 BE/25/2010. gN2 . . T . . . . T . . G . . G . . G . G T 
KJ361956.1 HAN36. gN2 . . T . . . . T . . G . . G . . G . G T 
KJ361951.1 HAN21. gN2 . . T . . . . T . . G . . G . . G . G T 
KP745667.1 BE/5/2011. gN2 . . T . . . . T . . G . . G . . G . G T 
KP745672.1 BE/29/2011. gN2 . . T . . . . T . . G . . G . . G . G T 
KJ361946.1 2CEN2. gN2 . . T . . . . T . . G . . G . . G . G T 
KJ361965.1 PAV11. gN2 . . T . . . . T . . G . . G . . G . G T 
JX512200.1 HAN2. gN2 . . T . . . . T . . G . . G . . G . G T 
JX512203.1 HAN12. gN2 . . T . . . . T . . G . . G . . G . G T 
KP745705.1 BE/38/2011. gN2 . . T . . . . T . . G . . G . . G . G T 
GU179288.1 U8. gN2 . . T . . . . T . . G . . G . . G . G T 
JX512208.1 HAN31. gN2 . . T . . . . T . . G . . G . . G . G T 
KP745686.1 BE/39/2011. gN2 . . T . . . . T . . G . . G . . G . G T 
KP745716.1 BE/16/2010. gN2 . . T . . . . T . . G . . G . . G . G T 
KF021605.1 TR gN3a. gN3a G . T . . . . . . . G . . . . . A . G . 
KP745639.1 BE/10/2011. gN3a G . T . . . . . . . G . . . . . A . G . 
KP745635.1 BE/5/2012. gN3a G . T . . . . . . . G . . . . . A . G . 
KP745649.1 BE/10/2012. gN3a G . T . . . . . . . G . . . . . A . G . 
KP745634.1 BE/32/2010. gN3a G . T . . . . . . . G . . . . . A . G . 
KP745652.1 BE/2/2011. gN3a G . T . . . . . . . G . . . . . A . G . 
KP745658.1 BE/14/2012. gN3a G . T . . . . . . . G . . . . . A . G . 
KP745701.1 BE/6/2010. gN3a G . T . . . . . . . G . . . . . A . G . 
KP745703.1 BE/26/2011. gN3a G . T . . . . . . . G . . . . . A . G . 
KP745696.1 BE/27/2011. gN3a G . T . . . . . . . G . . . . . A . G . 
KP745698.1 BE/20/2011. gN3a G . T . . . . . . . G . . . . . A . G . 
KP745704.1 BE/32/2011. gN3a G . T . . . . . . . G . . . . . A . G . 
KP745725.1 BE/49/2011. gN3a G . T . . . . . . . G . . . . . A . G . 
KP745726.1 BE/30/2010. gN3a G . T . . . . . . . G . . . . . A . G . 
KP745713.1 BE/35/2011. gN3a G . T . . . . . . . G . . . . . A . G . 
KP745715.1 BE/44/2011. gN3a G . T . . . . . . . G . . . . . A . G . 
KP745668.1 BE/18/2011. gN3a G . T . . . . . . . G . . . . . A . G . 
KP745673.1 BE/42/2011. gN3a G . T . . . . . . . G . . . . . A . G . 
KP745660.1 BE/6/2011. gN3a G . T . . . . . . . G . . . . . A . G . 
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KP745663.1 BE/5/2010. gN3a G . T . . . . . . . G . . . . . A . G . 
KP745675.1 BE/23/2011. gN3a G . T . . . . . . . G . . . . . A . G . 
KP745689.1 BE/17/2011. gN3a G . T . . . . . . . G . . . . . A . G . 
KP745691.1 CZ/1/2013. gN3a G . T . . . . . . . G . . . . . A . G . 
KP745676.1 BE/28/2010. gN3a G . T . . . . . . . G . . . . . A . G . 
KP745687.1 BE/36/2011. gN3a G . T . . . . . . . G . . . . . A . G . 
KC519321.1 BE/11/2010. gN3a G . T . . . . . . . G . . . . . A . G . 
KJ361962.1 PAV6. gN3a G . T . . . . . . . G . . . . . A . G . 
KJ361967.1 PAV23. gN3a G . T . . . . . . . G . . . . . A . G . 
JX512207.1 HAN28. gN3a G . T . . . . . . . G . . . . . A . G . 
KJ361948.1 2CEN15. gN3a G . T . . . . . . . G . . . . . A . G . 
HQ380895.1 JHC. gN3a G . T . . . . . . . G . . . . . A . G . 
KJ361950.1 HAN11. gN3a G . T . . . . . . . G . . . . . A . G . 
KJ361947.1 2CEN5. gN3a G . T . . . . . . . G . . . . . A . G . 
KJ361954.1 HAN32. gN3a G . T . . . . . . . G . . . . . A . G . 
GQ396662.1 HAN38 gN3b. gN3b G . T . . . . T . . . . . . . . G G T A 
KP745646.1 BE/8/2012. gN3b G . T . . . . T . . . . . . . . G G T A 
KP745683.1 BE/12/2011. gN3b G . T . . . . T . . . . . . . . G G T A 
KC519322.1 BE/21/2010. gN3b G . T . . . . T . . . . . . . . G G T A 
KP745677.1 BE/1/2010. gN3b G . T . . . . T . . . . . . . . G G T A 
KP745712.1 BE/19/2010. gN3b G . T . . . . T . . . . . . . . G G T A 
JX512202.1 HAN8. gN3b G . T . . . . T . . . . . . . . G G T A 
GQ221973.1 HAN13. gN3b G . T . . . . T . . . . . . . . G G T A 
KP745638.1 BE/15/2010. gN3b G . T . . . . T . . . . . . . . G G T A 
KP745724.1 BE/4/2012. gN3b G . T . . . . T . . . . . . . . G G T A 
KP745643.1 CZ/2/2012. gN3b G . T . . . . T . . . . . . . . G G T A 
JX512199.1 HAN1. gN3b G . T . . . . T . . . . . . . . G G T A 
KJ361968.1 PAV24. gN3b G . T . . . . T . . . . . . . . G G T A 
JX512198.1 Davis. gN3b G . T . . . . T . . . . . . . . G G T A 
JX512204.1 HAN16 gN4a. gN4a . . C G C . C . T . . A . . . . C G T G 
KP745702.1 BE/21/2011. gN4a . . C G C . C . T . . A . . . . C G T G 
KP745692.1 BE/3/2012. gN4a . . C G C . C . T . . A . . . . C G T G 
KJ361949.1 2CEN30. gN4a . . C G C . C . T . . A . . . . C G T G 
KP745693.1 BE/15/2012. gN4a . . C G C . C . T . . A . . . . C G T G 
KP745670.1 BE/30/2011. gN4a . . C G C . C . T . . A . . . . C G T G 
KP745706.1 BE/41/2011. gN4a . . C G C . C . T . . A . . . . C G T G 
KP745681.1 BE/43/2011. gN4a . . C G C . C . T . . A . . . . C G T G 
KP745680.1 BE/11/2012. gN4a . . C G C . C . T . . A . . . . C G T G 
KP745684.1 BE/11/2011. gN4a . . C G C . C . T . . A . . . . C G T G 
KP745700.1 BE/4/2011. gN4a . . C G C . C . T . . A . . . . C G T G 
KP745694.1 BE/12/2010. gN4a . . C G C . C . T . . A . . . . C G T G 
JX512197.1 6397. gN4a . . C G C . C . T . . A . . . . C G T G 
KP745688.1 BE/12/2012. gN4a . . C G C . C . T . . A . . . . C G T G 
KP745711.1 BE/24/2011. gN4a . . C G C . C . T . . A . . . . C G T G 
KP745714.1 BE/29/2010. gN4a . . C G C . C . T . . A . . . . C G T G 
KP745645.1 BE/13/2010. gN4a . . C G C . C . T . . A . . . . C G T G 
KJ361961.1 PAV5. gN4a . . C G C . C . T . . A . . . . C G T G 
KP745651.1 BE/9/2012. gN4a . . C G C . C . T . . A . . . . C G T G 
KP745650.1 BE/1/2011. gN4a . . C G C . C . T . . A . . . . C G T G 
KP745718.1 CZ/1/2011. gN4a . . C G C . C . T . . A . . . . C G T G 
KP745719.1 BE/26/2010. gN4a . . C G C . C . T . . A . . . . C G T G 
KP745723.1 BE/37/2011. gN4a . . C G C . C . T . . A . . . . C G T G 
KP745642.1 CZ/1/2012. gN4a . . C G C . C . T . . A . . . . C G T G 
KJ361964.1 PAV8. gN4a . . C G C . C . T . . A . . . . C G T G 
KP745636.1 BE/7/2011. gN4a . . C G C . C . T . . A . . . . C G T G 
KJ361952.1 HAN27. gN4a . . C G C . C . T . . A . . . . C G T G 
KP745707.1 BE/13/2012. gN4a . . C G C . C . T . . A . . . . C G T G 
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KP745661.1 BE/33/2010. gN4a . . C G C . C . T . . A . . . . C G T G 
KP745666.1 BE/7/2012. gN4a . . C G C . C . T . . A . . . . C G T G 
KP745665.1 BE/16/2012. gN4a . . C G C . C . T . . A . . . . C G T G 
KP745664.1 CZ/2/2013. gN4a . . C G C . C . T . . A . . . . C G T G 
KJ361957.1 HAN39. gN4a . . C G C . C . T . . A . . . . C G T G 
KP745655.1 BE/3/2010. gN4a . . C G C . C . T . . A . . . . C G T G 
KJ361960.1 PAV4. gN4a . . C G C . C . T . . A . . . . C G T G 
KP745659.1 BE/3/2011. gN4a . . C G C . C . T . . A . . . . C G T G 
KP745708.1 BE/8/2010. gN4a . . C G C . C . T . . A . . . . C G T G 
FJ616285.1 Towne gN4b. gN4b . . C A C . C . T C . A . G . . C G T G 
GQ466044.1 3301. gN4b . . C A C . C . T C . A . G . . C G T G 
KP745717.1 BE/2/2010. gN4b . . C A C . C . T C . A . G . . C G T G 
KP745720.1 BE/15/2011. gN4b . . C A C . C . T C . A . G . . C G T G 
KP745648.1 BE/8/2011. gN4b . . C A C . C . T C . A . G . . C G T G 
KC519320.1 BE/10/2010. gN4b . . C A C . C . T C . A . G . . C G T G 
KP745637.1 BE/9/2011. gN4b . . C A C . C . T C . A . G . . C G T G 
KJ426589.1 HAN. gN4b . . C A C . C . T C . A . G . . C G T G 
KJ361969.1 PAV25. gN4b . . C A C . C . T C . A . G . . C G T G 
JX512206.1 HAN22. gN4b . . C A C . C . T C . A . G . . C G T G 
KP745690.1 BE/34/2011. gN4b . . C A C . C . T C . A . G . . C G T G 
GU937742.1 Toledo gN4c. gN4c . . C G C . C . T C . A . . . . C G T G 
KJ872540.1 PAV18. gN4c . . C G C . C . T C . A . . . . C G T G 
JX512201.1 HAN3. gN4c . . C G C . C . T C . A . . . . C G T G 
KJ361955.1 HAN33. gN4c . . C G C . C . T C . A . . . . C G T G 
KP745710.1 BE/2/2012. gN4c . . C G C . C . T C . A . . . . C G T G 
GU179289.1 VR1814. gN4c . . C G C . C . T C . A . . . . C G T G 
GQ396663.1 HAN20. gN4c . . C G C . C . T C . A . . . . C G T G 
KP745685.1 CZ/3/2012. gN4c . . C G C . C . T C . A . . . . C G T G 
KF297339.1 TB40/E Lisa. gN4c . . C G C . C . T C . A . . . . C G T G 
KP745721.1 BE/14/2010. gN4c . . C G C . C . T C . A . . . . C G T G 
AY446894.2 Merlin gN4d. gN4d . . C A C G C . T C . A . . . . C G T G 
KP745633.1 BE/45/2011. gN4d . . C A C G C . T C . A . . . . C G T G 
GQ221974.1 3157. gN4d . . C A C G C . T C . A . . . . C G T G 
KJ361971.1 UKNEQAS1. gN4d . . C A C G C . T C . A . . . . C G T G 
KT959235.1 DB. gN4d . . C A C G C . T C . A . . . . C G T G 
KP745728.1 BE/4/2010. gN4d . . C A C G C . T C . A . . . . C G T G 
KJ872539.1 PAV16. gN4d . . C A C G C . T C . A . . . . C G T G 
KP745727.1 BE/17/2010. gN4d . . C A C G C . T C . A . . . . C G T G 
KJ361970.1 PAV26. gN4d . . C A C G C . T C . A . . . . C G T G 
KP745662.1 BE/20/2010. gN4d . . C A C G C . T C . A . . . . C G T G 
KJ361953.1 HAN30. gN4d . . C A C G C . T C . A . . . . C G T G 
KP745669.1 BE/28/2011. gN4d . . C A C G C . T C . A . . . . C G T G 
KP745682.1 BE/46/2011. gN4d . . C A C G C . T C . A . . . . C G T G 
KP745671.1 BE/14/2011. gN4d . . C A C G C . T C . A . . . . C G T G 
KJ361963.1 PAV7. gN4d . . C A C G C . T C . A . . . . C G T G 
JX512205.1 HAN19. gN4d . . C A C G C . T C . A . . . . C G T G 
KP745695.1 BE/6/2012. gN4d . . C A C G C . T C . A . . . . C G T G 
GQ221975.1 JP. gN4d . . C A C G C . T C . A . . . . C G T G 
KP745647.1 BE/18/2010. gN4d . . C A C G C . T C . A . . . . C G T G 
KP745644.1 BE/31/2010. gN4d . . C A C G C . T C . A . . . . C G T G 
 
Figure 5.6. Nucleotide sequence alignment of HCMV gN from 163 complete HCMV 
genomes. The nucleotide sequences correspond to the amino acid region depicted in 
figure 5.5. The region showing ‘molecular tags’ unique to each genotype is highlighted. 
 

























Figure 5.7. Polymorphic sites across 163 HCMV gO and gN sequences. [A] gO and [B] 
gN nucleotide sequences of 163 complete HCMV genomes available in GenBank release 
211 (National Center for Biotechnology Information (NCBI), 2015) were aligned and 
polymorphic sites plotted in DnaSP 5.10.01 (Librado and Rozas, 2009) with a sliding 
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 Genotype Reference Strain  Nucleotide sequence Coordinates 
[A] UL74 (gO)     
     
N-terminus gO1a            :1 FJ527563.1 [AD169] AAACGACTATTT c108270-108281 
tags                      :2 KC519323.1 [BE/27/2010] AAACGACAATTT c108441-108452 
 gO1b KF021605.1 [TR] AAAAGGATATCT c108658-108669 
 gO1c GU937742.1 [Toledo] AAAGGGAACCTT c108248-108259 
 gO2a JX512198.1 [Davis] AACCTATTCCTT c103114-103125 
 gO2b GU179291.1 [AF1] AGAGCGACATAT c108478-108489 
 gO3 JX512197.1 [6397] GTAGCCAGGATT c108267-108278 
 gO4 FJ616285.1 [Towne] CGACAGGTGATT c107847-107858 
 gO5 AY446894.2 [Merlin] TGTCTACATCAT c108632-108643 
     
‘mid’-N-terminus gO1a FJ527563.1 [AD169] CCTTGTGGTACTG c108045-108057 
tags gO1b KF021605.1 [TR] TCTTGCGGTACGG c108430-108442 
 gO1c GU937742.1 [Toledo] TCTTGTGGTACAG c108020-108032 
 gO2a JX512198.1 [Davis] TCGTGTGGCGCAG c102886-102898 
 gO2b GU179291.1 [AF1] CCTTGCGGTACAG c108250-108262 
 gO3 JX512197.1 [6397] TCTTGTGGCACTG c108039-108051 
 gO4              :a FJ616285.1 [Towne] TCCTGTGGTACGA c107616-107628 
                      :b JX512206.1 [HAN22] TCCTGTGGCACGA c108469-108481 
 gO5              :a AY446894.2 [Merlin] CCTTGCGGCACAG c108395-108407 
                      :b GQ221974.1 [3157] CCTTGTGGCACAG c108218-108230 
     
C-terminus gO1a FJ527563.1 [AD169] TATTACTACCGCC c107581-107593 
tags gO1b KF021605.1 [TR] TGTTACTACCACC c107966-107978 
 gO1c GU937742.1 [Toledo] GGTTACCACCAGC c107556-107568 
 gO2a JX512198.1 [Davis] TGTTACCACCACC c102422-102434 
 gO2b GU179291.1 [AF1] TGTTACAACCACC C107786-107798 
 gO3 JX512197.1 [6397] TGCTACCACCACT c107584-107596 
 gO4 FJ616285.1 [Towne] TCCTATTGTCCCA c107164-107176 
 gO5 AY446894.2 [Merlin] TGCTACCGCTGCT c107931-107943 
     
     
[B] UL73 (gN)     
N-terminus gN1 FJ527563.1 [AD169] GCGTATCAACTACC 106804-106817 
tags gN2 GU179291.1 [AF1] GTGTGTCGACGAGT 107012-107025 
 gN3a KF021605.1 [TR] GCGTGTCAACAAGC 107201-107214 
 gN3b JX512198.1 [Davis] GTGTATCAACGGTA 101651-101664 
 gN4a JX512204.1 [HAN16] GCACCTTAACAACC 106966-106979 
 gN4b FJ616285.1 [Towne] ACACCTCAACGACC 106387-106400 
 gN4c GU937742.1 [Toledo] GCACCTCAACAACC 106779-106792 
 gN4d AY446894.2 [Merlin] ACGCCTCAACAACC 107154-107167 
 
Table 5.1. Molecular tags developed for detection of HCMV gO and gN genotypes. 
These tags were determined from amino acid and nucleotide sequence alignments of 
respective genes for 163 complete HCMV genomes available in GenBank release 211 
(National Center for Biotechnology Information (NCBI), 2015). The coordinates indicate 
the location of each tag with respect to the reference strain per respective genotype. c, 
complement. 
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5.2.2 Verification of Tags and Development of Perl Scripts 
NCBI’s nucleotide collection (nr/nt) database, organism Human Herpesvirus 5 (taxid 
10359), was queried using each molecular tag sequence via NCBI BLASTn program 
(https://blast.ncbi.nlm.nih.gov/Blast.cgi?PROGRAM=blastn&PAGE_TYPE=BlastSearch&
LINK_LOC=blasthome) (Altschul et al., 1990) with default parameters in order to verify 
that each tag was both unique to a given HCMV gO or gN genotype and also that the tag 
occurred only once within a given full HCMV genome sequence. All tags fulfilled these 
two critical criteria. To aid quick determination of which tag was present, and therefore 
which genotype a sequence belonged to, perl scripts were developed for application to 
the two commonly used sequence formats: FASTA (for archived NCBI database 
sequences) and FASTQ (for NGS reads from Illumina sequencing). The scripts search for 
multiple tags simultaneously in each FASTA sequence or set of FASTQ reads in both the 
forward and complementary / reverse orientation and return the genotype, tag 
sequence, and number of times the tag occurs in the interrogated file. The output is 
conveniently tab delimited and can easily be copied directly from a UNIX terminal or 
piped to a plain text file for easy manipulation across various word processing and data 
analysis programs including Microsoft Excel. Figure 5.8 shows screenshots of typical 
outputs. The 163 complete HCMV genomes were rechecked using the script and results 
compared to the gO genotype assignment from the phylogenetic tree construction 
(figure 5.1), with which they were completely consistent (table 5.2). As an additional 
step to validate the tags, the FASTA script was applied to all available gO sequences 
(partial or complete CDS). 195 such sequences were identified and downloaded from 
GenBank release 211 (National Center for Biotechnology Information (NCBI), 2015). The 
script correctly assigned gO genotypes to all but two sequences (table 5.3): KT988000.1 
and KT988001.1, which are incomplete gene sequences falling outside the three gO 
regions targeted by our tags. These are discussed further in section 5.2.3 ‘Unique Cases’. 
The gN tags were equally checked against all available gN sequences in GenBank release 
211, and of 465 partial and complete CDSs, the Script correctly identified gN genotypes 
for 456 sequences (table 5.4). The remaining 9 sequences could not be assigned to a 
genotype for various reasons related to the quality/nature of published sequence, as 
discussed in section 5.2.3 ‘Unique Cases’.  
 
 


























Figure 5.8. Screenshots of search results returned by perl scripts. [A]shows the typical 
output from searching FASTQ reads, while [B] depicts the typical tab delimited format 
when output from several FASTA files is piped to a plain text file. 
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 GenBank Accession No. 
& Strain ID 
gO Genotype gN Genotype 
 N-terminus mid-N- terminus C- terminus 
1 FJ527563.1_AD169 gO1a gO1a gO1a gN1 
2 GU179290.1_U11 gO1a gO1a gO1a gN1 
3 KC519319.1_BE/9/2010 gO1a gO1a gO1a gN1 
4 KC519323.1_BE/27/2010 gO1a gO1a gO1a gN1 
5 KJ361950.1_HAN11 gO1a gO1a gO1a gN3a 
6 KJ361958.1_HAN40 gO1a gO1a gO1a gN1 
7 KJ361959.1_PAV1 gO1a gO1a gO1a gN1 
8 KJ361966.1_PAV12 gO1a gO1a gO1a gN1 
9 KJ872541.1_PAV20 gO1a gO1a gO1a gN1 
10 KJ872542.1_PAV21 gO1a gO1a gO1a gN1 
11 KP745640.1_BE/22/2010 gO1a gO1a gO1a gN1 
12 KP745641.1_BE/31/2011 gO1a gO1a gO1a gN1 
13 KP745653.1_BE/22/2011 gO1a gO1a gO1a gN1 
14 KP745657.1_BE/13/2011 gO1a gO1a gO1a gN1 
15 KP745674.1_BE/33/2011 gO1a gO1a gO1a gN1 
16 KP745697.1_BE/23/2010 gO1c gO1a gO1a gN1 
17 KP745699.1_BE/1/2012 gO1a gO1a gO1a gN1 
18 KP745709.1_BE/48/2011 gO1a gO1a gO1a gN1 
19 KP745722.1_BE/40/2011 gO1a gO1a gO1a gN1 
20 KT634296.1_UKNEQAS2 gO1a gO1a gO1a gN1 
21 HQ380895.1_JHC gO1b gO1b gO1b gN3a 
22 JX512207.1_HAN28 gO1b gO1b gO1b gN3a 
23 KC519321.1_BE/11/2010 gO1b gO1b gO1b gN3a 
24 KF021605.1_TR gO1b gO1b gO1b gN3a 
25 KJ361947.1_2CEN5 gO1b gO1b gO1b gN3a 
26 KJ361948.1_2CEN15 gO1b gO1b gO1b gN3a 
27 KJ361954.1_HAN32 gO1b gO1b gO1b gN3a 
28 KJ361962.1_PAV6 gO1b gO1b gO1b gN3a 
29 KJ361967.1_PAV23 gO1b gO1b gO1b gN3a 
30 KP745634.1_BE/32/2010 gO1b gO1b gO1b gN3a 
31 KP745635.1_BE/5/2012 gO1b gO1b gO1b gN3a 
32 KP745639.1_BE/10/2011 gO1b gO1b gO1b gN3a 
33 KP745649.1_BE/10/2012 gO1b gO1b gO1b gN3a 
34 KP745652.1_BE/2/2011 gO1b gO1b gO1b gN3a 
35 KP745658.1_BE/14/2012 gO1b gO1b gO1b gN3a 
36 KP745660.1_BE/6/2011 gO1b gO1b gO1b gN3a 
37 KP745663.1_BE/5/2010 gO1b gO1b gO1b gN3a 
38 KP745668.1_BE/18/2011 gO1b gO1b gO1b gN3a 
39 KP745673.1_BE/42/2011 gO1b gO1b gO1b gN3a 
40 KP745675.1_BE/23/2011 gO1b gO1b gO1b gN3a 
41 KP745676.1_BE/28/2010 gO1b gO1b gO1b gN3a 
42 KP745687.1_BE/36/2011 gO1b gO1b gO1b gN3a 
43 KP745689.1_BE/17/2011 gO1b gO1b gO1b gN3a 
44 KP745691.1_CZ/1/2013 gO1b gO1b gO1b gN3a 
45 KP745696.1_BE/27/2011 gO1b gO1b gO1b gN3a 
46 KP745698.1_BE/20/2011 gO1b gO1b gO1b gN3a 
47 KP745701.1_BE/6/2010 gO1b gO1b gO1b gN3a 
48 KP745703.1_BE/26/2011 gO1b gO1b gO1b gN3a 
49 KP745704.1_BE/32/2011 gO1b gO1b gO1b gN3a 
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 GenBank Accession No. 
& Strain ID 
gO Genotype gN Genotype 
 N-terminus mid-N- terminus C- terminus 
50 KP745713.1_BE/35/2011 gO1b gO1b gO1b gN3a 
51 KP745715.1_BE/44/2011 gO1b gO1b gO1b gN3a 
52 KP745725.1_BE/49/2011 gO1b gO1b gO1b gN3a 
53 KP745726.1_BE/30/2010 gO1b gO1b gO1b gN3a 
54 GQ396663.1_HAN20 gO1c gO1c gO1c gN4c 
55 GU179289.1_VR1814 gO1c gO1c gO1c gN4c 
56 GU937742.1_Toledo gO1c gO1c gO1c gN4c 
57 JX512201.1_HAN3 gO1c gO1c gO1c gN4c 
58 KF297339.1_TB40/E gO1c gO1c gO1c gN4c 
59 KJ361955.1_HAN33 gO1c gO1c gO1c gN4c 
60 KJ872540.1_PAV18 gO1c gO1c gO1c gN4c 
61 KP745685.1_CZ/3/2012 gO1c gO1c gO1c gN4c 
62 KP745710.1_BE/2/2012 gO1c gO1c gO1c gN4c 
63 KP745721.1_BE/14/2010 gO1c gO1c gO1c gN4c 
64 GQ221973.1_HAN13 gO2a gO2a gO2a gN3b 
65 GQ396662.1_HAN38 gO2a gO2a gO2a gN3b 
66 JX512198.1_Davis gO2a gO2a gO2a gN3b 
67 JX512199.1_HAN1 gO2a gO2a gO2a gN3b 
68 JX512202.1_HAN8 gO2a gO2a gO2a gN3b 
69 KC519322.1_BE/21/2010 gO2a gO2a gO2a gN3b 
70 KJ361968.1_PAV24 gO2a gO2a gO2a gN3b 
71 KP745638.1_BE/15/2010 gO2a gO2a gO2a gN3b 
72 KP745643.1_CZ/2/2012 gO2a gO2a gO2a gN3b 
73 KP745646.1_BE/8/2012 gO2a gO2a gO2a gN3b 
74 KP745677.1_BE/1/2010 gO2a gO2a gO2a gN3b 
75 KP745683.1_BE/12/2011 gO2a gO2a gO2a gN3b 
76 KP745712.1_BE/19/2010 gO2a gO2a gO2a gN3b 
77 KP745724.1_BE/4/2012 gO2a gO2a gO2a gN3b 
78 GU179288.1_U8 gO2b gO2b gO2b gN2 
79 GU179291.1_AF1 gO2b gO2b gO2b gN2 
80 JX512200.1_HAN2 gO2b gO2b gO2b gN2 
81 JX512203.1_HAN12 gO2b gO2b gO2b gN2 
82 JX512208.1_HAN31 gO2b gO2b gO2b gN2 
83 KJ361946.1_2CEN2 gO2b gO2b gO2b gN2 
84 KJ361951.1_HAN21 gO2b gO2b gO2b gN2 
85 KJ361956.1_HAN36 gO2b gO2b gO2b gN2 
86 KJ361965.1_PAV11 gO2b gO2b gO2b gN2 
87 KP745654.1_BE/19/2011 gO2b gO2b gO2b gN2 
88 KP745656.1_BE/2/2013 gO2b gO2b gO2b gN2 
89 KP745667.1_BE/5/2011 gO2b gO2b gO2b gN2 
90 KP745672.1_BE/29/2011 gO2b gO2b gO2b gN2 
91 KP745678.1_BE/25/2010 gO2b gO2b gO2b gN2 
92 KP745679.1_BE/24/2010 gO2b gO2b gO2b gN2 
93 KP745686.1_BE/39/2011 gO2b gO2b gO2b gN2 
94 KP745705.1_BE/38/2011 gO2b gO2b gO2b gN2 
95 KP745716.1_BE/16/2010 gO2b gO2b gO2b gN2 
96 JX512197.1_6397 gO3a gO3 gO3 gN4a 
97 JX512204.1_HAN16 gO3a gO3 gO3 gN4a 
98 KJ361949.1_2CEN30 gO3a gO3 gO3 gN4a 
99 KJ361952.1_HAN27 gO3a gO3 gO3 gN4a 
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100 KJ361957.1_HAN39 gO3a gO3 gO3 gN4a 
101 KJ361960.1_PAV4 gO3a gO3 gO3 gN4a 
102 KJ361961.1_PAV5 gO3a gO3 gO3 gN4a 
103 KJ361964.1_PAV8 gO3a gO3 gO3 gN4a 
104 KP745633.1_BE/45/2011 gO3a gO3 gO3 gN4d 
105 KP745636.1_BE/7/2011 gO3a gO3 gO3 gN4a 
106 KP745642.1_CZ/1/2012 gO3a gO3 gO3 gN4a 
107 KP745645.1_BE/13/2010 gO3a gO3 gO3 gN4a 
108 KP745650.1_BE/1/2011 gO3a gO3 gO3 gN4a 
109 KP745651.1_BE/9/2012 gO3a gO3 gO3 gN4a 
110 KP745655.1_BE/3/2010 gO3a gO3 gO3 gN4a 
111 KP745659.1_BE/3/2011 gO3a gO3 gO3 gN4a 
112 KP745661.1_BE/33/2010 gO3a gO3 gO3 gN4a 
113 KP745664.1_CZ/2/2013 gO3a gO3 gO3 gN4a 
114 KP745665.1_BE/16/2012 gO3a gO3 gO3 gN4a 
115 KP745666.1_BE/7/2012 gO3a gO3 gO3 gN4a 
116 KP745670.1_BE/30/2011 gO3a gO3 gO3 gN4a 
117 KP745680.1_BE/11/2012 gO3a gO3 gO3 gN4a 
118 KP745681.1_BE/43/2011 gO3a gO3 gO3 gN4a 
119 KP745684.1_BE/11/2011 gO3a gO3 gO3 gN4a 
120 KP745688.1_BE/12/2012 gO3a gO3 gO3 gN4a 
121 KP745692.1_BE/3/2012 gO3a gO3 gO3 gN4a 
122 KP745693.1_BE/15/2012 gO3a gO3 gO3 gN4a 
123 KP745694.1_BE/12/2010 gO3a gO3 gO3 gN4a 
124 KP745700.1_BE/4/2011 gO3a gO3 gO3 gN4a 
125 KP745702.1_BE/21/2011 gO3a gO3 gO3 gN4a 
126 KP745706.1_BE/41/2011 gO3a gO3 gO3 gN4a 
127 KP745707.1_BE/13/2012 gO3a gO3 gO3 gN4a 
128 KP745708.1_BE/8/2010 gO3a gO3 gO3 gN4a 
129 KP745711.1_BE/24/2011 gO3a gO3 gO3 gN4a 
130 KP745714.1_BE/29/2010 gO3a gO3 gO3 gN4a 
131 KP745718.1_CZ/1/2011 gO3a gO3 gO3 gN4a 
132 KP745719.1_BE/26/2010 gO3a gO3 gO3 gN4a 
133 KP745723.1_BE/37/2011 gO3a gO3 gO3 gN4a 
134 FJ616285.1_Towne gO4 gO4 gO4 gN4b 
135 GQ466044.1_3301 gO4 gO4 gO4 gN4b 
136 JX512206.1_HAN22 gO4 gO4 gO4 gN4b 
137 KC519320.1_BE/10/2010 gO4 gO4 gO4 gN4b 
138 KJ361969.1_PAV25 gO4 gO4 gO4 gN4b 
139 KJ426589.1_HAN gO4 gO4 gO4 gN4b 
140 KP745637.1_BE/9/2011 gO4 gO4 gO4 gN4b 
141 KP745648.1_BE/8/2011 gO4 gO4 gO4 gN4b 
142 KP745690.1_BE/34/2011 gO4 gO4 gO4 gN4b 
143 KP745717.1_BE/2/2010 gO4 gO4 gO4 gN4b 
144 KP745720.1_BE/15/2011 gO4 gO4 gO4 gN4b 
145 AY446894.2_Merlin gO5 gO5 gO5 gN4d 
146 GQ221974.1_3157 gO5 gO5 gO5 gN4d 
147 GQ221975.1_JP gO5 gO5 gO5 gN4d 
148 JX512205.1_HAN19 gO5 gO5 gO5 gN4d 
149 KJ361953.1_HAN30 gO5 gO5 gO5 gN4d 
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150 KJ361963.1_PAV7 gO5 gO5 gO5 gN4d 
151 KJ361970.1_PAV26 gO5 gO5 gO5 gN4d 
152 KJ361971.1_UKNEQAS1 gO5 gO5 gO5 gN4d 
153 KJ872539.1_PAV16 gO5 gO5 gO5 gN4d 
154 KP745644.1_BE/31/2010 gO5 gO5 gO5 gN4d 
155 KP745647.1_BE/18/2010 gO5 gO5 gO5 gN4d 
156 KP745662.1_BE/20/2010 gO5 gO5 gO5 gN4d 
157 KP745669.1_BE/28/2011 gO5 gO5 gO5 gN4d 
158 KP745671.1_BE/14/2011 gO5 gO5 gO5 gN4d 
159 KP745682.1_BE/46/2011 gO5 gO5 gO5 gN4d 
160 KP745695.1_BE/6/2012 gO5 gO5 gO5 gN4d 
161 KP745727.1_BE/17/2010 gO5 gO5 gO5 gN4d 
162 KP745728.1_BE/4/2010 gO5 gO5 gO5 gN4d 
163 KT959235.1_DB gO5 gO5 gO5 gN4d 
 
Table 5.2. HCMV gO and gN genotype identification using molecular tags developed 
during this thesis. HCMV gO genotypes were correctly assigned to all 163 complete 
HCMV genomes available in GenBank release 211. The sequences were screened with 
our genotyping tags at three loci (2 in the N-terminus and one in the C-terminus) within 
the gO gene, and one locus at the N-terminus of gN. KJ361950.1 (HAN11) and 
KP745697.1 (BE/23/2010) showed peculiarities and are discussed under ‘Unique Cases’ 
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1 AF531320.1 gO1a gO1a gO1a 
2 AF531322.1 gO1a gO1a gO1a 
3 AF531325.1 gO1a gO1a gO1a 
4 AF531330.1 gO1a gO1a gO1a 
5 AF531337.1 gO1a gO1a gO1a 
6 AF531344.1 gO1a gO1a gO1a 
7 AF531346.1 gO1a gO1a gO1a 
8 AF531347.1 gO1a gO1a gO1a 
9 EU348361.1 - gO1a gO1a 
10 EU348362.1 gO1a gO1a gO1a 
11 EU348363.1 gO1a gO1a gO1a 
12 GQ227785.1 gO1a gO1a gO1a 
13 AF531316.1 gO1b gO1b gO1b 
14 AF531319.1 gO1b gO1b gO1b 
15 AF531326.1 gO1b gO1b gO1b 
16 AF531333.1 gO1b gO1b gO1b 
17 AF531334.1 gO1b gO1b gO1b 
18 AF531345.1 gO1b gO1b gO1b 
19 AF531349.1 gO1b gO1b gO1b 
20 AF531354.1 gO1b gO1b gO1b 
21 EU348351.1 gO1b gO1b gO1b 
22 EU348352.1 gO1b gO1b gO1b 
23 EU348353.1 gO1b gO1b gO1b 
24 GQ227786.1 gO1b gO1b gO1b 
25 AF531340.1 gO1c gO1c gO1c 
26 GQ227762.1 gO1c gO1c gO1c 
27 AF531315.1 gO2a gO2a gO2a 
28 AF531324.1 gO2a gO2a gO2a 
29 AF531336.1 gO2a gO2a gO2a 
30 AF531343.1 gO2a gO2a gO2a 
31 EU348354.1 gO2a gO2a gO2a 
32 AF531317.1 gO2b gO2b gO2b 
33 AF531328.1 gO2b gO2b gO2b 
34 AF531329.1 gO2b gO2b gO2b 
35 AF531335.1 gO2b gO2b gO2b 
36 AF531339.1 gO2b gO2b gO2b 
37 AF531341.1 gO2b gO2b gO2b 
38 AF531342.1 gO2b gO2b gO2b 
39 AF531353.1 gO2b gO2b gO2b 
40 EU348355.1 gO2b gO2b gO2b 
41 GQ227753.1 gO2b gO2b gO2b 
42 GQ227761.1 gO2b gO2b gO2b 
43 AF531318.1 gO3a gO3 gO3 
44 AF531327.1 gO3a gO3 gO3 
45 AF531338.1 gO3a gO3 gO3 
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46 AF531348.1 gO3a gO3 gO3 
47 AF531350.1 gO3a gO3 gO3 
48 AF531351.1 gO3a gO3 gO3 
49 AF531352.1 gO3a gO3 gO3 
50 EU348364.1 gO3a gO3 gO3 
51 GQ227765.1 gO3a gO3 gO3 
52 GQ227770.1 gO3a gO3 gO3 
53 AF531323.1 gO4 gO4 gO4 
54 AF531332.1 gO4 gO4 gO4 
55 GQ227755.1 gO4 gO4 gO4 
56 GQ227760.1 gO4 gO4 gO4 
57 AF531321.1 gO5 gO5 gO5 
58 EU348356.1 gO5 gO5 gO5 
59 EU348357.1 gO5 gO5 gO5 
60 EU348358.1 gO5 gO5 gO5 
61 EU348359.1 gO5 gO5 gO5 
62 EU348360.1 gO5 gO5 gO5 
63 GQ227780.1 gO5 gO5 gO5 
64 AY326963.1 gO1a gO1a - 
65 AY326964.1 gO1a gO1a - 
66 AY326966.1 gO1a gO1a - 
67 AY326973.1 gO1a gO1a - 
68 AY326974.1 gO1a gO1a - 
69 AY326975.1 gO1a gO1a - 
70 AY326982.1 gO1a gO1a - 
71 AY326983.1 gO1a gO1a - 
72 AY326984.1 gO1a gO1a - 
73 AY326985.1 gO1a gO1a - 
74 AY326986.1 gO1a gO1a - 
75 AY582469.1 gO1a gO1a - 
76 AY582470.1 gO1a gO1a - 
77 AY582471.1 gO1a gO1a - 
78 AY582472.1 gO1a gO1a - 
79 EU686463.1 gO1a gO1a - 
80 EU686464.1 gO1a gO1a - 
81 EU686465.1 gO1a gO1a - 
82 EU686466.1 gO1a gO1a - 
83 EU686467.1 gO1a gO1a - 
84 EU686508.1 gO1a gO1a - 
85 EU686511.1 gO1a gO1a - 
86 AY326968.1 gO1b gO1b - 
87 AY326980.1 gO1b gO1b - 
88 AY582439.1 gO1b gO1b - 
89 AY582440.1 gO1b gO1b - 
90 AY582441.1 gO1b gO1b - 
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91 AY582442.1 gO1b gO1b - 
92 AY582443.1 gO1b gO1b - 
93 AY582444.1 gO1b gO1b - 
94 AY582445.1 gO1b gO1b - 
95 AY582473.1 gO1b gO1b - 
96 EU686468.1 gO1b gO1b - 
97 EU686469.1 gO1b gO1b - 
98 EU686470.1 gO1b gO1b - 
99 EU686471.1 gO1b gO1b - 
100 EU686472.1 gO1b gO1b - 
101 EU686473.1 gO1b gO1b - 
102 EU686474.1 gO1b gO1b - 
103 EU686475.1 gO1b gO1b - 
104 EU686476.1 gO1b gO1b - 
105 EU686477.1 gO1b gO1b - 
106 EU686478.1 gO1b gO1b - 
107 EU686507.1 gO1b gO1b - 
108 EU686509.1 gO1b gO1b - 
109 EU686512.1 gO1b gO1b - 
110 EU686513.1 gO1b gO1b - 
111 EU686514.1 gO1b gO1b - 
112 EU686515.1 gO1b gO1b - 
113 EU686516.1 gO1b gO1b - 
114 AY326979.1 gO1c gO1c - 
115 AY582436.1 gO1c gO1c - 
116 AY582448.1 gO1c gO1c - 
117 AY582449.1 gO1c gO1c - 
118 AY582450.1 gO1c gO1c - 
119 AY582451.1 gO1c gO1c - 
120 EU686479.1 gO1c gO1c - 
121 EU686480.1 gO1c gO1c - 
122 AY326981.1 gO2a gO2a - 
123 EU686481.1 gO2a gO2a - 
124 EU686482.1 gO2a gO2a - 
125 EU686510.1 gO2a gO2a - 
126 AY326962.1 gO2b gO2b - 
127 AY326971.1 gO2b gO2b - 
128 AY326972.1 gO2b gO2b - 
129 AY326978.1 gO2b gO2b - 
130 AY582447.1 gO2b gO2b - 
131 AY582480.1 gO2b gO2b - 
132 AY582481.1 gO2b gO2b - 
133 EU686483.1 gO2b gO2b - 
134 EU686484.1 gO2b gO2b - 
135 EU686485.1 gO2b gO2b - 
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136 EU686486.1 gO2b gO2b - 
137 EU686517.1 gO2b gO2b - 
138 AY582437.1 gO3 gO3 - 
139 AY582438.1 gO3 gO3 - 
140 AY582461.1 gO3 gO3 - 
141 AY582464.1 gO3 gO3 - 
142 AY582465.1 gO3 gO3 - 
143 AY582466.1 gO3 gO3 - 
144 AY582467.1 gO3 gO3 - 
145 AY582468.1 gO3 gO3 - 
146 AY582482.1 gO3 gO3 - 
147 EU686487.1 gO3 gO3 - 
148 EU686488.1 gO3 gO3 - 
149 EU686489.1 gO3 gO3 - 
150 EU686490.1 gO3 gO3 - 
151 EU686491.1 gO3 gO3 - 
152 EU686492.1 gO3 gO3 - 
153 EU686493.1 gO3 gO3 - 
154 EU686494.1 gO3 gO3 - 
155 EU686495.1 gO3 gO3 - 
156 EU686496.1 gO3 gO3 - 
157 AY326967.1 gO4 gO4 - 
158 AY326969.1 gO4 gO4 - 
159 AY326970.1 gO4 gO4 - 
160 EU686497.1 gO4 gO4 - 
161 EU686498.1 gO4 gO4 - 
162 EU686499.1 gO4 gO4 - 
163 EU686500.1 gO4 gO4 - 
164 AY582453.1 gO5 gO5 - 
165 AY582454.1 gO5 gO5 - 
166 AY582456.1 gO5 gO5 - 
167 AY582457.1 gO5 gO5 - 
168 AY582458.1 gO5 gO5 - 
169 AY582459.1 gO5 gO5 - 
170 AY582460.1 gO5 gO5 - 
171 AY582463.1 gO5 gO5 - 
172 AY582475.1 gO5 gO5 - 
173 AY582477.1 gO5 gO5 - 
174 AY582479.1 gO5 gO5 - 
175 EU686501.1 gO5 gO5 - 
176 EU686502.1 gO5 gO5 - 
177 EU686503.1 gO5 gO5 - 
178 EU686504.1 gO5 gO5 - 
179 EU686505.1 gO5 gO5 - 
180 EU686506.1 gO5 gO5 - 
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181 EU686518.1 gO5 gO5 - 
182 AY326977.1 gO1a - - 
183 AY326965.1 gO1b - - 
184 AY326976.1 gO2a - - 
185 AY326961.1 gO4 - - 
186 KT987996.1 - gO1a - 
187 EU377488.1 - gO1c - 
188 EU377490.1 - gO1c - 
189 KT987997.1 - gO1c - 
190 KT987998.1 - gO2b - 
191 KT987999.1 - gO2b - 
192 KT988002.1 - gO4 - 
193 KT988003.1 - gO4 - 
194 KT988000.1* - - - 
195 KT988001.1* - - - 
 
Table 5.3. HCMV gO genotype identification in HCMV sequences available in GenBank 
using molecular tags. HCMV gO genotypes were correctly assigned to 193 partial CDS 
and complete CDS sequences available in GenBank release 211. The sequences were 
screened with tags at three loci (2 in the N-terminus and one in the C-terminus) within 
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1 AF224680.1 gN1 
2 AF309969.1 gN1 
3 AF309970.1 gN1 
4 AF309971.1 gN1 
5 AF309972.1 gN1 
6 AF309973.1 gN1 
7 AF309974.1 gN1 
8 AF390755.1 gN1 
9 AF390757.1 gN1 
10 AF390758.1 gN1 
11 AF390760.1 gN1 
12 AF390766.1 gN1 
13 AF390774.1 gN1 
14 AF390775.1 gN1 
15 AF390776.1 gN1 
16 AF390778.1 gN1 
17 AF390781.1 gN1 
18 AF390783.1 gN1 
19 AF390784.1 gN1 
20 AF390786.1 gN1 
21 AF390787.1 gN1 
22 AF390788.1 gN1 
23 AF390789.1 gN1 
24 AF390796.1 gN1 
25 AF390799.1 gN1 
26 AF390804.1 gN1 
27 AF390806.1 gN1 
28 AF390817.1 gN1 
29 AF390818.1 gN1 
30 AF390826.1 gN1 
31 AF390827.1 gN1 
32 AF390829.1 gN1 
33 AF390830.1 gN1 
34 AF390831.1 gN1 
35 AF390843.2 gN1 
36 AF390844.2 gN1 
37 AF390845.2 gN1 
38 AF390846.2 gN1 
39 AF390847.2 gN1 
40 AF390851.1 gN1 
41 AF390852.1 gN1 
42 AF390854.1 gN1 
43 AF395121.1 gN1 
44 AF396713.1 gN1 
45 AF396714.1 gN1 
46 AF396715.1 gN1 
47 AF396716.1 gN1 
48 AF396723.1 gN1 
49 AF396725.1 gN1 
 GenBank Accession No. Genotype 
50 AF396726.1 gN1 
51 AF396735.1 gN1 
52 AF396738.1 gN1 
53 AY326987.1 gN1 
54 AY326988.1 gN1 
55 AY326989.1 gN1 
56 AY326990.1 gN1 
57 AY326991.1 gN1 
58 AY326992.1 gN1 
59 AY326993.1 gN1 
60 AY326998.1 gN1 
61 AY327000.1 gN1 
62 AY327001.1 gN1 
63 AY327002.1 gN1 
64 AY327003.1 gN1 
65 AY327004.1 gN1 
66 AY327005.1 gN1 
67 AY327006.1 gN1 
68 AY327007.1 gN1 
69 AY327010.1 gN1 
70 AY327014.1 gN1 
71 AY327016.1 gN1 
72 AY327017.1 gN1 
73 AY327018.1 gN1 
74 AY327019.1 gN1 
75 AY327020.1 gN1 
76 AY327024.1 gN1 
77 AY327025.1 gN1 
78 AY327026.1 gN1 
79 AY327029.1 gN1 
80 AY327030.1 gN1 
81 AY327031.1 gN1 
82 EU377503.1 gN1 
83 EU686416.1 gN1 
84 EU686417.1 gN1 
85 EU686418.1 gN1 
86 EU686419.1 gN1 
87 EU686451.1 gN1 
88 EU686454.1 gN1 
89 EU686458.1 gN1 
90 EU686459.1 gN1 
91 EU686460.1 gN1 
92 EU686461.1 gN1 
93 EU686462.1 gN1 
94 GQ227785.1 gN1 
95 GU441773.1 gN1 
96 GU583628.1 gN1 
97 GU583629.1 gN1 
98 GU583630.1 gN1 
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99 GU583631.1 gN1 
100 GU583642.1 gN1 
101 GU583646.1 gN1 
102 GU583647.1 gN1 
103 KF875976.1 gN1 
104 KF875977.1 gN1 
105 KR992948.1 gN1 
106 KR992949.1 gN1 
107 KR992950.1 gN1 
108 KR992952.1 gN1 
109 KR992954.1 gN1 
110 KR992956.1 gN1 
111 KR992967.1 gN1 
112 KR992968.1 gN1 
113 KR992970.1 gN1 
114 KR992983.1 gN1 
115 KR992990.1 gN1 
116 KR992993.1 gN1 
117 KR992994.1 gN1 
118 KR992996.1 gN1 
119 KR993000.1 gN1 
120 KR993007.1 gN1 
121 KR993008.1 gN1 
122 KR993019.1 gN1 
123 KR993025.1 gN1 
124 KR993027.1 gN1 
125 KR993035.1 gN1 
126 KR993041.1 gN1 
127 KR993059.1 gN1 
128 KT987979.1 gN1 
129 KT987980.1 gN1 
130 AF309975.1 gN2 
131 AF309976.1 gN2 
132 AF309977.1 gN2 
133 AF309978.1 gN2 
134 AF309979.1 gN2 
135 EU686420.1 gN2 
136 EU686421.1 gN2 
137 EU686422.1 gN2 
138 GQ227753.1 gN2 
139 GQ227761.1 gN2 
140 GU376725.1 gN2 
141 KF875978.1 gN2 
142 KF875979.1 gN2 
143 KR992958.1 gN2 
144 KR992972.1 gN2 
145 KR992976.1 gN2 
146 KR992995.1 gN2 
147 KR992998.1 gN2 
 GenBank Accession No. Genotype 
148 KR993002.1 gN2 
149 KR993006.1 gN2 
150 KR993012.1 gN2 
151 KR993036.1 gN2 
152 KR993042.1 gN2 
153 KR993043.1 gN2 
154 KR993046.1 gN2 
155 KR993050.1 gN2 
156 KR993052.1 gN2 
157 KR993056.1 gN2 
158 KR993057.1 gN2 
159 AF309980.1 gN3a 
160 AF309981.1 gN3a 
161 AF309982.1 gN3a 
162 AF309983.1 gN3a 
163 AF309984.1 gN3a 
164 AF309985.1 gN3a 
165 AF309986.1 gN3a 
166 AF390794.1 gN3a 
167 AF390825.1 gN3a 
168 AF390841.2 gN3a 
169 AF390842.2 gN3a 
170 AF390856.1 gN3a 
171 AF396717.1 gN3a 
172 AF396718.1 gN3a 
173 AF396719.1 gN3a 
174 AF396720.1 gN3a 
175 AF396732.1 gN3a 
176 AF396734.1 gN3a 
177 AF396745.1 gN3a 
178 AY326994.1 gN3a 
179 AY326995.1 gN3a 
180 AY326996.1 gN3a 
181 AY326997.1 gN3a 
182 AY326999.1 gN3a 
183 AY327008.1 gN3a 
184 AY327009.1 gN3a 
185 AY327015.1 gN3a 
186 AY327027.1 gN3a 
187 AY327028.1 gN3a 
188 AY327032.1 gN3a 
189 EU686423.1 gN3a 
190 EU686424.1 gN3a 
191 EU686425.1 gN3a 
192 EU686426.1 gN3a 
193 EU686427.1 gN3a 
194 EU686428.1 gN3a 
195 EU686429.1 gN3a 
196 EU686446.1 gN3a 
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197 EU686447.1 gN3a 
198 EU686448.1 gN3a 
199 EU686449.1 gN3a 
200 EU686450.1 gN3a 
201 EU686452.1 gN3a 
202 EU686455.1 gN3a 
203 EU686457.1 gN3a 
204 GQ227786.1 gN3a 
205 GU376726.1 gN3a 
206 GU583636.1 gN3a 
207 KR992951.1 gN3a 
208 KR992960.1 gN3a 
209 KR992966.1 gN3a 
210 KR992975.1 gN3a 
211 KR992977.1 gN3a 
212 KR992979.1 gN3a 
213 KR992980.1 gN3a 
214 KR992987.1 gN3a 
215 KR992991.1 gN3a 
216 KR993005.1 gN3a 
217 KR993021.1 gN3a 
218 KR993031.1 gN3a 
219 KR993033.1 gN3a 
220 KR993038.1 gN3a 
221 KR993045.1 gN3a 
222 KR993053.1 gN3a 
223 KR993058.1 gN3a 
224 KR993060.1 gN3a 
225 KT987981.1 gN3a 
226 KT987982.1 gN3a 
227 AF390770.1 gN3b 
228 AF390773.1 gN3b 
229 AF390802.1 gN3b 
230 AF390812.1 gN3b 
231 AF390823.1 gN3b 
232 AF390835.2 gN3b 
233 AY327013.1 gN3b 
234 AY327021.1 gN3b 
235 EU377506.1 gN3b 
236 EU686430.1 gN3b 
237 GU376720.1 gN3b 
238 KF875980.1 gN3b 
239 KF875981.1 gN3b 
240 KR992971.1 gN3b 
241 KR992974.1 gN3b 
242 KR992984.1 gN3b 
243 KR992997.1 gN3b 
244 KR992999.1 gN3b 
245 KR993010.1 gN3b 
 GenBank Accession No. Genotype 
246 KR993011.1 gN3b 
247 KR993020.1 gN3b 
248 KR993023.1 gN3b 
249 KR993029.1 gN3b 
250 KR993030.1 gN3b 
251 KR993040.1 gN3b 
252 KR993047.1 gN3b 
253 KR993048.1 gN3b 
254 KR993049.1 gN3b 
255 KT987983.1 gN3b 
256 AF224679.1 gN4a 
257 AF309987.1 gN4a 
258 AF309988.1 gN4a 
259 AF309989.1 gN4a 
260 AF309990.1 gN4a 
261 AF309991.1 gN4a 
262 AF309992.1 gN4a 
263 AF309993.1 gN4a 
264 AF309994.1 gN4a 
265 AF390752.1 gN4a 
266 AF390753.1 gN4a 
267 AF390762.1 gN4a 
268 AF390767.1 gN4a 
269 AF390768.1 gN4a 
270 AF390769.1 gN4a 
271 AF390779.1 gN4a 
272 AF390782.1 gN4a 
273 AF390785.1 gN4a 
274 AF390791.1 gN4a 
275 AF390792.1 gN4a 
276 AF390793.1 gN4a 
277 AF390795.1 gN4a 
278 AF390801.1 gN4a 
279 AF390813.1 gN4a 
280 AF390815.1 gN4a 
281 AF390819.1 gN4a 
282 AF390821.1 gN4a 
283 AF390836.2 gN4a 
284 AF390837.2 gN4a 
285 AF390848.1 gN4a 
286 AF390849.1 gN4a 
287 AF390855.1 gN4a 
288 AF396721.1 gN4a 
289 AF396722.1 gN4a 
290 AF396724.1 gN4a 
291 AF396727.1 gN4a 
292 AF396730.1 gN4a 
293 AF396731.1 gN4a 
294 AF396739.1 gN4a 
 Page 138 of 338 
 GenBank Accession No. Genotype 
295 AF396741.1 gN4a 
296 AF396743.1 gN4a 
297 EU377505.1 gN4a 
298 EU377509.1 gN4a 
299 EU686431.1 gN4a 
300 EU686432.1 gN4a 
301 EU686453.1 gN4a 
302 GQ227765.1 gN4a 
303 GQ227770.1 gN4a 
304 GU376721.1 gN4a 
305 GU376722.1 gN4a 
306 GU583637.1 gN4a 
307 GU583644.1 gN4a 
308 KR992957.1 gN4a 
309 KR992959.1 gN4a 
310 KR992962.1 gN4a 
311 KR992981.1 gN4a 
312 KR992982.1 gN4a 
313 KR992985.1 gN4a 
314 KR992988.1 gN4a 
315 KR993003.1 gN4a 
316 KR993013.1 gN4a 
317 KR993015.1 gN4a 
318 KR993016.1 gN4a 
319 KR993018.1 gN4a 
320 KR993024.1 gN4a 
321 KR993032.1 gN4a 
322 KR993051.1 gN4a 
323 KR993054.1 gN4a 
324 KR993055.1 gN4a 
325 KT987984.1 gN4a 
326 KT987985.1 gN4a 
327 AF309995.1 gN4b 
328 AF309996.1 gN4b 
329 AF309997.1 gN4b 
330 AF309998.1 gN4b 
331 AF309999.1 gN4b 
332 AF390749.1 gN4b 
333 AF390750.1 gN4b 
334 AF390751.1 gN4b 
335 AF390754.1 gN4b 
336 AF390756.1 gN4b 
337 AF390765.1 gN4b 
338 AF390780.1 gN4b 
339 AF390797.1 gN4b 
340 AF390810.1 gN4b 
341 AF390816.1 gN4b 
342 AF390820.1 gN4b 
343 AF390832.1 gN4b 
 GenBank Accession No. Genotype 
344 AF390834.1 gN4b 
345 AF390850.1 gN4b 
346 AF390857.1 gN4b 
347 AF396733.1 gN4b 
348 AF396736.1 gN4b 
349 EU377510.1 gN4b 
350 EU686433.1 gN4b 
351 EU686434.1 gN4b 
352 EU686435.1 gN4b 
353 GQ227755.1 gN4b 
354 GQ227760.1 gN4b 
355 GU376723.1 gN4b 
356 GU583632.1 gN4b 
357 GU583634.1 gN4b 
358 GU583638.1 gN4b 
359 GU583640.1 gN4b 
360 GU583641.1 gN4b 
361 GU583645.1 gN4b 
362 KR261654.1 gN4b 
363 KR992955.1 gN4b 
364 KR992963.1 gN4b 
365 KR992964.1 gN4b 
366 KR992989.1 gN4b 
367 KR993014.1 gN4b 
368 KR993022.1 gN4b 
369 KR993026.1 gN4b 
370 KR993028.1 gN4b 
371 KR993039.1 gN4b 
372 KT987986.1 gN4b 
373 KT987987.1 gN4b 
374 AF390748.1 gN4c 
375 AF390761.1 gN4c 
376 AF390790.1 gN4c 
377 AF390805.1 gN4c 
378 AF390814.1 gN4c 
379 AF390838.2 gN4c 
380 AF395119.1 gN4c 
381 AF395120.1 gN4c 
382 AF396728.1 gN4c 
383 AF396737.1 gN4c 
384 EU686436.1 gN4c 
385 EU686437.1 gN4c 
386 GQ227762.1 gN4c 
387 GU647095.1 gN4c 
388 KR992965.1 gN4c 
389 KR992973.1 gN4c 
390 KR992992.1 gN4c 
391 KR993001.1 gN4c 
392 KR993004.1 gN4c 
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393 KR993009.1 gN4c 
394 KR993044.1 gN4c 
395 KT987988.1 gN4c 
396 KT987989.1 gN4c 
397 AF224681.1 gN4d 
398 AF224682.1 gN4d 
399 AF224683.1 gN4d 
400 AF224684.1 gN4d 
401 AF224685.1 gN4d 
402 AF224686.1 gN4d 
403 AF224687.1 gN4d 
404 AF310000.1 gN4d 
405 AF310001.1 gN4d 
406 AF310002.1 gN4d 
407 AF310003.1 gN4d 
408 AF310004.1 gN4d 
409 AF310005.1 gN4d 
410 AF310006.1 gN4d 
411 AF390759.1 gN4d 
412 AF390763.1 gN4d 
413 AF390764.1 gN4d 
414 AF390771.1 gN4d 
415 AF390772.1 gN4d 
416 AF390798.1 gN4d 
417 AF390800.1 gN4d 
418 AF390803.1 gN4d 
419 AF390807.1 gN4d 
420 AF390808.1 gN4d 
421 AF390809.1 gN4d 
422 AF390811.1 gN4d 
423 AF390822.1 gN4d 
424 AF390824.1 gN4d 
425 AF390828.1 gN4d 
426 AF390833.1 gN4d 
427 AF390840.2 gN4d 
428 AF395118.1 gN4d 
429 AF395122.1 gN4d 
430 AF396729.1 gN4d 
431 AF396740.1 gN4d 
432 AF396742.1 gN4d 
433 AF396744.1 gN4d 
434 EU686438.1 gN4d 
435 EU686439.1 gN4d 
436 EU686440.1 gN4d 
437 EU686441.1 gN4d 
438 EU686442.1 gN4d 
439 EU686443.1 gN4d 
440 EU686444.1 gN4d 
441 EU686456.1 gN4d 
 GenBank Accession No. Genotype 
442 GQ227780.1 gN4d 
443 GU376724.1 gN4d 
444 GU376727.1 gN4d 
445 GU583633.1 gN4d 
446 GU583635.1 gN4d 
447 GU583643.1 gN4d 
448 KF875982.1 gN4d 
449 KF875983.1 gN4d 
450 KR992953.1 gN4d 
451 KR992969.1 gN4d 
452 KR992978.1 gN4d 
453 KR992986.1 gN4d 
454 KR993017.1 gN4d 
455 KR993034.1 gN4d 
456 KR993037.1 gN4d 
457 AF224688.1* - 
458 AF390777.1* - 
459 AF390853.1* - 
460 AY327011.1* - 
461 AY327022.1* - 
462 AY327023.1* - 
463 EU686445.1* - 
464 GU583639.1* - 




Table 5.4. HCMV gN genotype 
identification using molecular tags. 
HCMV gN genotypes were correctly 
assigned to 456 out of 465 partial or 
complete CDSs available in GenBank 
release 211. * Nine sequences could not 
be assigned a genotype by our tags for 
various reasons discussed in section 
5.2.3 ‘Unique Cases’. 
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5.2.3 Unique Cases  
1. KP745697.1 (HCMV strain BE/23/2010) – potential recombinant 
This sequence is from urine-derived virus passaged four times in human fibroblasts. UL1 
and UL9 are mutated (https://www.ncbi.nlm.nih.gov/nuccore/822901463). The 
BE/23/2010 gO sequence shares similarities with both gO1c and gO1a. Amino acid 
sequence alignment (figure 5.9) shows that the first 140 amino acid residues are 
identical to gO1c reference strain Toledo (GU937742.1) while the remaining 324 
residues are identical to gO1a reference strain AD169 (FJ527563.1). However, at 
nucleotide level the similarity with gO1a is earlier at base 294 [codon 98] (figure 5.10). 
These observations suggest that strain BE/23/2010 is a gO1a/gO1c recombinant or a 
compilation error from mixed infection. 
 
 
FJ527563.1_AD169 [gO1a] MGRKEMMVRDVPKMVFLISISFLLVSFINCKVMSKALYNRPWRGLVLSKIGKYKLDQLKL 60 
GU937742.1_Toledo [gO1c] MGRKGD-MRSISKLFFIISLTVLLFSIINCKVVRP--PGRYWLGTVLSTIGKQKLDKFKL 57 
KP745697.1_BE/23/2010  MGRKGD-MRSISKLFFIISLTVLLFSIINCKVVRP--PGRYWLGTVLSTIGKQKLDKFKL 57 
                         ****   :*.: *:.*:**::.**.*:*****:      * * * ***.*** ***::** 
 
FJ527563.1_AD169 [gO1a]   EILRQLETTISTKY-NVSKQPVKNLTMNMTEFPQYYILAGPIQNYSITYLWFDFYSTQLR 119 
GU937742.1_Toledo [gO1c]  EILKQLEREPYTKYFNMTRQHVKNLTMNMTQFPQYYILAGPIRNDSITYLWFDFYSTQLR 117 
KP745697.1_BE/23/2010  EILKQLEREPYTKYFNMTRQHVKNLTMNMTQFPQYYILAGPIRNDSITYLWFDFYSTQLR 117 
                         ***:***    *** *:::* *********:***********:* *************** 
 
FJ527563.1_AD169 [gO1a] KPAKYVYSQYNHTAKTITFRPPPCGTVPSMTCLSEMLNVSKRNDTGEQGCGNFTTFNPMF 179 
GU937742.1_Toledo [gO1c] KPAKYVYSQYNHTAKTITFRPPSCGTVPSMTCLSEMLNVSKRNDTGEQGCGNFTTFNPMF 177 
KP745697.1_BE/23/2010  KPAKYVYSQYNHTAKTITFRPPPCGTVPSMTCLSEMLNVSKRNDTGEQGCGNFTTFNPMF 177 
                         ********************** ************************************* 
 
FJ527563.1_AD169 [gO1a] FNVPRWNTKLYVGPTKVNVDSQTIYFLGLTALLLRYAQRNCTHSFYLVNAMSRNLFRVPK 239 
GU937742.1_Toledo [gO1c] FNVPRWNTKLYVGPTKVNVDSQTIYFLGLTALLLRYAQRNCTHSFYLVNAMSRNLFRVPK 237 
KP745697.1_BE/23/2010  FNVPRWNTKLYVGPTKVNVDSQTIYFLGLTALLLRYAQRNCTHSFYLVNAMSRNLFRVPK 237 
                         ************************************************************ 
 
FJ527563.1_AD169 [gO1a] YINGTKLKNTMRKLKRKQAPVKEQFEKKAKKTQSTTTPYFSYTTSAALNVTTNVTYSITT 299 
GU937742.1_Toledo [gO1c] YINGTKLKNTMRKLKRKQAPVKEQLEKKTKKSQSTTTPYFSYTTSTALNVTTNATYKVTT 297 
KP745697.1_BE/23/2010  YINGTKLKNTMRKLKRKQAPVKEQFEKKAKKTQSTTTPYFSYTTSAALNVTTNVTYSITT 297 
                         ************************:***:**:*************:*******.**.:** 
 
FJ527563.1_AD169 [gO1a] AARRVSTSTIAYRPDSSFMKSIMATQLRDLATWVYTTLRYRQNPFCEPSRNRTAVSEFMK 359 
GU937742.1_Toledo [gO1c] SAKRIPTSTIAYRPDSSFMKSIMATQLRDLATWVYTTLRYRNEPFCKPDRNRTAVSEFMK 357 
KP745697.1_BE/23/2010  AARRVSTSTIAYRPDSSFMKSIMATQLRDLATWVYTTLRYRQNPFCEPSRNRTAVSEFMK 357 
                         :*:*: ***********************************::***:*.*********** 
 
FJ527563.1_AD169 [gO1a] NTHVLIRNETPYTIYGTLDMSSLYYNETMFVENKTASDSNKTTPTSPSMGFQRTFIDPLW 419 
GU937742.1_Toledo [gO1c] NTHVLIRNETPYTIYGTLDMSSLYYNETMSVENETASDNNETTPTSPSTRFQKTFIDPLW 417 
KP745697.1_BE/23/2010  NTHVLIRNETPYTIYGTLDMSSLYYNETMFVENKTASDSNKTTPTSPSMGFQRTFIDPLW 417 
                         ***************************** ***:****.*:*******  **:******* 
 
FJ527563.1_AD169 [gO1a] DYLDSLLFLDEIRNFSLRSPTYVNLTPPEHRRAVNLSTLNSLWWWLQ 466 
GU937742.1_Toledo [gO1c] DYLDSLLFLDKIRNFSLQLPAYGNLTPPEHRRAVNLSTLNSLWWWSQ 464 
KP745697.1_BE/23/2010  DYLDSLLFLDEIRNFSLRSPTYVNLTPPEHRRAVNLSTLNSLWWWLQ 464 
                         **********:******: *:* ********************** * 
 
Figure 5.9. Full-length HCMV gO amino acid sequence alignment of BE/23/2010, 
AD169 (gO1a reference strain) and Toledo (gO1c reference strain). The red box 
indicates the position where sequence similarity of BE/23/2010 switches from gO1c to 
gO1a (residue 140). Alignment was done using CLUSTAL Omega version 1.2.2. 
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FJ527563.1_AD169.[gO1a] ATGGGGAGAAAAGAGATGATGGTGAGAGACGTCCCTAAGATGGTGTTTCTAATATCTATA 60 
GU937742.1_Toledo.[gO1c] ATGGGGAGAAAA---GGAGACATGAGAAGCATTTCTAAATTATTCTTTATTATATCACTG 57 
KP745697.1_BE/23/2010. ATGGGGAGAAAA---GGAGACATGAGAAGCATTTCTAAATTATTCTTTATTATATCACTA 57 
       ************          *****  * *  ****  *  * *** * *****  *  
 
FJ527563.1_AD169.[gO1a] TCTTTCTTGCTTGTTTCTTTCATAAACTGTAAAGTTATGTCAAAAGCGCTTTATAATCGT 120 
GU937742.1_Toledo.[gO1c] ACTGTCCTGTTATTTTCTATAATAAACTGTAAGGTCGTCAGACCACC------GGGACGT 111 
KP745697.1_BE/23/2010. ACTGTCCTGTTATTTTCTATAATAAACTGTAAGGTCGTCAGACCACC------GGGACGT 111 
        ** ** ** *  ***** * *********** **  *   *  * *          *** 
 
FJ527563.1_AD169.[gO1a] CCTTGGAGGGGCTTGGTACTGTCTAAGATAGGCAAATATAAATTAGATCAGCTTAAGTTA 180 
GU937742.1_Toledo.[gO1c] TACTGGTTAGGTACAGTACTTTCTACGATAGGCAAGCAAAAACTAGATAAATTCAAGTTA 171 
KP745697.1_BE/23/2010. TACTGGTTAGGTACAGTACTTTCTACGATAGGCAAGCAAAAACTAGATAAATTCAAGTTA 171 
          ***   **    ***** **** *********  * *** ***** *  * ****** 
 
FJ527563.1_AD169.[gO1a] GAAATTTTGAGACAACTAGAAACGACTATTTCTA---CAAAATACAATGTAAGTAAACAA 237 
GU937742.1_Toledo.[gO1c] GAGATTTTAAAACAATTAGAAAGGGAACCTTATACAAAATACTTCAATATGACTAGACAA 231 
KP745697.1_BE/23/2010. GAGATTTTAAAACAATTAGAAAGGGAACCTTATACAAAATACTTCAATATGACTAGGCAA 231 
       ** ***** * **** ****** *     ** **    * * * **** * * **  *** 
 
FJ527563.1_AD169.[gO1a] CCGGTTAAAAATCTCACTATGAACATGACAGAGTTTCCACAATACTACATTTTAGCGGGC 297 
GU937742.1_Toledo.[gO1c] CACGTTAAAAATCTTACTATGAATATGACCCAGTTTCCACAATACTACATTCTAGCAGGT 291 
KP745697.1_BE/23/2010. CACGTTAAAAATCTTACTATGAATATGACCCAGTTTCCACAATACTACATTCTAGCGGGC 291 
       *  *********** ******** *****  ******************** **** **  
 
FJ527563.1_AD169.[gO1a] CCCATTCAGAATTATAGTATAACCTATCTGTGGTTTGATTTTTATAGTACCCAGCTTAGA 357 
GU937742.1_Toledo.[gO1c] CCCATTCGAAACGATAGTATAACCTATCTGTGGTTCGATTTTTATAGTACCCAGCTTAGA 351 
KP745697.1_BE/23/2010. CCCATTCGAAATGATAGTATAACCTATCTGTGGTTCGATTTTTATAGTACCCAGCTTAGA 351 
       *******  **  ********************** ************************ 
 
FJ527563.1_AD169.[gO1a] AAACCCGCAAAATACGTTTACTCACAGTACAATCATACGGCTAAAACGATAACATTCAGA 417 
GU937742.1_Toledo.[gO1c] AAACCCGCCAAATACGTCTACTCACAGTACAATCATACGGCTAAAACGATAACATTCAGA 411 
KP745697.1_BE/23/2010. AAACCCGCAAAATACGTCTACTCACAGTACAATCATACGGCTAAAACGATAACATTCAGA 411 
       ******** ******** ****************************************** 
 
FJ527563.1_AD169.[gO1a] CCCCCACCTTGTGGTACTGTGCCTTCCATGACTTGTCTTTCCGAAATGCTAAACGTTTCC 477 
GU937742.1_Toledo.[gO1c] CCCCCATCTTGTGGTACAGTGCCTTCAATGACTTGTCTTTCCGAAATGTTAAACGTTTCC 471 
KP745697.1_BE/23/2010. CCCCCACCTTGTGGTACTGTGCCTTCCATGACTTGTCTTTCCGAAATGCTAAACGTTTCC 471 
       ****** ********** ******** ********************* *********** 
 
FJ527563.1_AD169.[gO1a] AAACGTAATGATACTGGCGAACAAGGTTGCGGTAATTTCACCACGTTCAACCCCATGTTT 537 
GU937742.1_Toledo.[gO1c] AAACGTAATGATACTGGCGAACAAGGCTGCGGTAATTTTACCACGTTCAACCCCATGTTT 531 
KP745697.1_BE/23/2010. AAACGTAATGATACTGGCGAACAAGGTTGCGGTAATTTCACCACGTTCAACCCCATGTTT 531 
       ************************** *********** ********************* 
 
FJ527563.1_AD169.[gO1a] TTCAATGTACCGCGTTGGAACACCAAATTGTACGTGGGTCCGACTAAGGTTAACGTAGAT 597 
GU937742.1_Toledo.[gO1c] TTCAATGTACCACGTTGGAATACCAAATTGTACGTGGGTCCGACTAAAGTTAACGTAGAT 591 
KP745697.1_BE/23/2010. TTCAATGTACCGCGTTGGAACACCAAATTGTACGTGGGTCCGACTAAGGTTAACGTAGAT 591 
       *********** ******** ************************** ************ 
 
FJ527563.1_AD169.[gO1a] AGTCAAACGATTTATTTTCTAGGTTTAACCGCCCTGCTTTTACGTTACGCACAACGCAAC 657 
GU937742.1_Toledo.[gO1c] AGTCAAACGATTTATTTTTTGGGTTTAACCGCCCTACTTCTACGTTACGCACAACGCAAC 651 
KP745697.1_BE/23/2010. AGTCAAACGATTTATTTTCTAGGTTTAACCGCCCTGCTTTTACGTTACGCACAACGCAAC 651 
       ****************** * ************** *** ******************** 
 
FJ527563.1_AD169.[gO1a] TGTACACACAGTTTCTACCTGGTTAACGCCATGAGCCGGAATCTATTTCGCGTCCCCAAG 717 
GU937742.1_Toledo.[gO1c] TGCACACACAGTTTCTACCTGGTTAACGCCATGAGCCGGAATCTATTCCGCGTCCCCAAG 711 
KP745697.1_BE/23/2010. TGTACACACAGTTTCTACCTGGTTAACGCCATGAGCCGGAATCTATTTCGCGTCCCCAAG 711 
       ** ******************************************** ************ 
 
FJ527563.1_AD169.[gO1a] TATATTAACGGCACCAAGTTAAAAAACACTATGCGAAAACTAAAACGTAAACAAGCGCCC 777 
GU937742.1_Toledo.[gO1c] TATATTAACGGCACCAAGTTGAAAAACACTATGCGAAAACTAAAACGTAAACAAGCGCCA 771 
KP745697.1_BE/23/2010. TATATTAACGGCACCAAGTTAAAAAACACTATGCGAAAACTAAAACGTAAACAAGCGCCC 771 
       ******************** **************************************  
 
FJ527563.1_AD169.[gO1a] GTTAAGGAACAATTCGAAAAAAAAGCTAAGAAAACTCAGAGTACTACTACGCCATACTTT 837 
GU937742.1_Toledo.[gO1c] GTCAAAGAACAATTAGAAAAAAAGACTAAAAAATCTCAGAGTACTACTACGCCATATTTT 831 
KP745697.1_BE/23/2010. GTTAAGGAACAATTCGAAAAAAAGGCTAAGAAAACTCAGAGTACTACTACGCCATACTTT 831 
       ** ** ******** ********  **** *** ********************** *** 
 
FJ527563.1_AD169.[gO1a] TCCTATACAACGTCTGCCGCTCTCAACGTCACTACTAACGTGACTTATAGTATTACTACC 897 
GU937742.1_Toledo.[gO1c] TCCTATACAACGTCTACCGCTCTCAACGTCACTACTAACGCGACTTATAAGGTTACCACC 891 
KP745697.1_BE/23/2010. TCCTATACAACGTCTGCCGCTCTCAACGTCACTACTAACGTGACTTATAGTATTACTACC 891 
       *************** ************************ ********   **** *** 
 
FJ527563.1_AD169.[gO1a] GCCGCAAGGCGGGTTTCCACGTCTACAATTGCTTATCGTCCTGATAGCAGCTTTATGAAG 957 
GU937742.1_Toledo.[gO1c] AGCGCAAAGCGGATTCCCACATCTACGATTGCTTATCGTCCTGATAGCAGCTTTATGAAG 951 
KP745697.1_BE/23/2010. GCCGCAAGGCGGGTTTCCACGTCTACAATTGCTTATCGTCCTGATAGCAGCTTTATGAAG 951 
         ***** **** ** **** ***** ********************************* 
 
FJ527563.1_AD169.[gO1a] TCCATTATGGCCACACAGTTAAGGGACCTAGCAACGTGGGTGTATACCACTCTACGTTAC 1017 
GU937742.1_Toledo.[gO1c] TCCATTATGGCCACGCAGTTAAGGGATCTAGCGACATGGGTGTATACTACTCTACGGTAT 1011 
KP745697.1_BE/23/2010. TCCATTATGGCCACACAGTTAAGGGACCTAGCAACGTGGGTGTATACCACTCTACGTTAC 1011 
       ************** *********** ***** ** *********** ******** **  
 
 Page 142 of 338 
FJ527563.1_AD169.[gO1a] CGGCAAAATCCTTTTTGTGAACCAAGCCGCAACCGAACCGCCGTGTCAGAATTTATGAAA 1077 
GU937742.1_Toledo.[gO1c] CGGAATGAACCCTTTTGTAAACCAGACCGTAACCGTACCGCCGTGTCAGAATTTATGAAA 1071 
KP745697.1_BE/23/2010. CGGCAAAATCCTTTTTGTGAACCAAGCCGCAACCGAACCGCCGTGTCAGAATTTATGAAA 1071 
       *** *  * ** ****** *****  *** ***** ************************ 
 
FJ527563.1_AD169.[gO1a] AACACGCACGTACTAATCCGTAACGAAACGCCGTACACTATTTACGGTACTCTCGACATG 1137 
GU937742.1_Toledo.[gO1c] AACACGCACGTATTGATTCGTAACGAAACACCGTACACTATTTACGGCACTCTTGACATG 1131 
KP745697.1_BE/23/2010. AACACGCACGTACTAATCCGTAACGAAACGCCGTACACTATTTACGGTACTCTTGACATG 1131 
       ************ * ** *********** ***************** ***** ****** 
 
FJ527563.1_AD169.[gO1a] AGCTCCTTATATTACAACGAAACCATGTTCGTGGAAAACAAAACAGCTTCCGATAGTAAC 1197 
GU937742.1_Toledo.[gO1c] AGCTCCTTATACTACAACGAAACCATGTCCGTGGAAAACGAAACGGCTTCCGATAATAAC 1191 
KP745697.1_BE/23/2010. AGCTCCTTATATTACAACGAAACCATGTTCGTGGAAAACAAAACAGCTTCCGATAGTAAC 1191 
       *********** **************** ********** **** ********** **** 
 
FJ527563.1_AD169.[gO1a] AAAACTACACCTACGTCACCATCAATGGGGTTTCAGAGAACATTTATAGATCCCCTGTGG 1257 
GU937742.1_Toledo.[gO1c] GAAACTACACCTACGTCACCATCGACGAGGTTTCAGAAAACGTTTATAGATCCCTTATGG 1251 
KP745697.1_BE/23/2010. AAAACTACACCTACGTCACCATCAATGGGGTTTCAGAGAACATTTATAGATCCCCTGTGG 1251 
        ********************** * * ********* *** ************ * *** 
 
FJ527563.1_AD169.[gO1a] GACTATCTAGACTCGCTGCTGTTTCTAGATGAGATTCGTAACTTTAGCCTCCGGTCACCC 1317 
GU937742.1_Toledo.[gO1c] GACTATCTAGACTCGCTGCTGTTTCTAGATAAAATCCGTAACTTTAGCCTCCAATTACCC 1311 
KP745697.1_BE/23/2010. GACTATCTAGACTCGCTGCTGTTTCTAGATGAGATTCGTAACTTTAGCCTCCGGTCACCC 1311 
       ****************************** * ** ****************  * **** 
 
FJ527563.1_AD169.[gO1a] ACGTATGTAAACCTTACCCCGCCGGAACACCGCCGGGCTGTAAATCTGTCCACCCTCAAT 1377 
GU937742.1_Toledo.[gO1c] GCGTATGGAAATCTTACCCCGCCGGAACACCGCCGGGCTGTAAATCTATCCACCCTCAAT 1371 
KP745697.1_BE/23/2010.  ACGTATGTAAACCTTACCCCGCCGGAACACCGCCGGGCTGTAAATCTGTCCACCCTCAAT 1371 
        ****** *** *********************************** ************ 
 
FJ527563.1_AD169.[gO1a] AGCCTTTGGTGGTGGTTGCAGTAA  1401 
GU937742.1_Toledo.[gO1c] AGCCTTTGGTGGTGGTCGCAGTAA  1395 
KP745697.1_BE/23/2010. AGCCTTTGGTGGTGGTTGCAGTAA  1395 
       **************** ******* 
 
Figure 5.10. Full-length HCMV gO nucleotide sequence alignment of BE/23/2010, 
AD169 (gO1a reference strain) and Toledo (gO1c reference strain). The red box 
indicates the position where sequence similarity of BE/23/2010 switches from gO1c to 





2. KJ361950.1 (HCMV strain HAN 11) – potential recombinant 
HCMV strain HAN 11 was sequenced from virus isolated from a bronchoalveolar lavage 
sample and passaged 3 times in human fibroblasts. It contains three mutated genes 
(RL5A, UL150 and US9) (https://www.ncbi.nlm.nih.gov/nuccore/586833288). HAN 11 
has gN of genotype gN3a (figure 5.5) and gO of genotype gO1 (figure 5.2). As previously 
shown, genotype gN3a forms a linkage group with gO3, while gO1 links with gN1a (Bates 
et al., 2008). The unusual combination of gN3a and gN1, as seen here for HAN 11, is to 
our knowledge the only case where the established gN/gO linkage relationship is 
abrogated, and indicates a recombination point in between these genes, or again the 
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3. KT988000.1 and KT988001.1 – incomplete sequences, do not include tags 
Sequences KT988000.1 (isolate human-wt/ITA/PR206/1995) and KT988001.1 (isolate 
human-wt/ITA/PR2197/2012) were derived from urine in a cohort of congenitally and 
postnatally infected children (Arcangeletti et al., 2015). Both sequences are relatively 
short, each being 267bp in length, spanning base positions 439 to 705 relative to the gO 
sequence of strain HAN16 (gO3). This region falls outside the three loci targeted by our 
tags. However phylogenetic tree construction confirms both KT988000.1 and 




4. Partial gN CDSs with Unassigned Genotype – possible sequencing errors 
Nine partial gN CDSs could not be assigned a genotype by our script and tags (table 5.4). 
Of these, seven were found to contain substitutions that gave rise to mismatches with 
our tags; one has unresolved ambiguous bases; and one has a 3bp deletion, as 
summarised in table 5.5. These could be sequencing errors or variants. 
 
Accession No. Isolate ID Reason gN genotype unassigned by Molecular tag 
AF224688.1 E16 A to G substitution at position 104 (1st base of gN4d tag) w.r.t reference strain Merlin 
AF390777.1 RV 3nt (ACC) deletion at position 115-117 (last 3 bases of gN4d tag) w.r.t reference strain 
Merlin 
AF390853.1 C9 Contains 4 unresolved ambiguous (‘N’) bases , including at position 110, G to A-
substitution at position 106, and A to G-substitution at position 114 w.r.t gN4d 
reference strain Merlin 
AY327011.1 Riu GCT to ACT and A to C substitutions at positions 120-122 and 126 respectively w.r.t 
gN3a reference strain TR 
AY327022.1 U1r C to T substitution at position 122 w.r.t gN3a reference strain TR 
AY327023.1 U3r C to T substitution at position 122 w.r.t gN3a reference strain TR 
EU686445.1 35M6 C to A substitution at position 124 w.r.t gN3a reference strain TR 
GU583639.1 323F C to T substitution at position 117 w.r.t gN4d reference strain Merlin 
KR992961.1 9C GC to AT substitution at position 104-105 w.r.t gN4c reference strain Toledo 
 
Table 5.5. Partial HCMV gN CDSs that could not be assigned genotypes by our 
molecular tags. The nine partial HCMV gN CDSs detailed here could not be assigned to 
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5.2.4 Genotype Detection Rate 
Overall the tags for gO combined with the script was able to genotype gO 356/358 
(99.4%) and gN 619/628 (98.6%) correctly, demonstrating that the tags were robust to 
genotype and the perl Script could be employed to analyse NGS data. Therefore, this 
method could now be applied to clinical samples and NGS data for quantification of 
mixed infections and evaluation of infection burden.  
 
 
5.3 ANALYSIS OF HCMV NGS SEQUENCES FROM BREAST MILK  
5.3.1 NGS Data Pre-processing  
We sequenced twenty-one DNA samples (17 HIV-positive and 4 HIV-negative) which had 
sufficient remaining volume for NGS. The DNA was extracted from breast milk collected 
at weeks (W), W4, W12, and W16 postpartum from 12 women – eight HIV-positive and 
four HIV-negative. HCMV target amplification using the SureSelect system (Agilent 
Technologies Inc.), library preparation and Illumina® MiSeq™ paired-end sequencing 
were performed by our collaborating partners, the Andrew Davison group at the MRC 
Center for Virus Research, University of Glasgow. Upon obtaining the FASTQ read files 
(see Methods Section 2.6), we used FASTQC 
(http://www.bioinformatics.babraham.ac.uk/projects/fastqc/) to analyse read quality, 
and Trimmomatic (Bolger et al., 2014) to trim adaptors and filter the reads. 
Trimmomatic was used in standard format (phred+33) with the following settings: 
LEADING:3 TRAILING:3 SLIDINGWINDOW:4:20 MINLEN:100. Table 5.7 summarises key 
outputs from this pre-processing step. 
 
5.3.2 Application of perl script to analyse genotype variants  
Having validated the molecular tags and perl script as described in section 5.2, the next 
step was to apply these tools to directly analyse FASTQ reads from NGS sequences from 
our 21 clinical (breast milk) samples collected from 12 individuals – four HIV-negative 
and eight HIV-positive. Milk samples included four from the HIV-negative and 17 from 
HIV-positive mothers. Overall, four samples were collected at week (W) 4, five at W12, 
and ten at W16 postpartum, as detailed in table 5.6. In figures presented in this section, 
the point of sample collection is designated as a subscript to the sample ID, thus 240R12. 
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The primary focus of this analysis was on gO genotypes; however, each sample was also 
checked for gN genotypes (Table 5.8). Verification was performed by mapping the 
FASTQ reads to the appropriate reference for each gO genotype and then calculating 
the read depth using the SAMtools mpileup tool or the GATK DepthofCoverage tool. In 
all cases, this was consistent with the number of variants detected by our perl Script 
approach. Although it was possible to detect gO genotypes present to as low as 0.2%, 
we set a cut-off of 1% and minimum read depth of 10, consistent with previously 
established thresholds in our laboratory for analyses of Illumina based sequence reads 
for a related human betaherpesvirus to detect minor variants (Tweedy et al., 2015a, 
Tweedy et al., 2015b, Tweedy et al., 2016), and as established elsewhere for other 
genomic systems (Depledge et al., 2011). 
 
 




Sample Collection time-point (postpartum) 
W4 W12 W16 
1 141 Positive Right    
2 158 Negative Left    
3 174 Positive Left    
   Right    
4 232 Negative Right    
5 240 Negative Right    
6 243 Positive Left    
   Right    
7 248 Positive Right    
8 259 Positive Left    
   Right    
9 278 Positive Left    
   Right    
10 280 Negative Right    
11 281 Positive Right    
12 288 Positive Right    
 
Table 5.6. Breast milk samples analysed by NGS. Twenty-one samples collected from 
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Figures 5.11 and 5.12 chart the gO genotype proportions in milk from HIV-negative (N=4) 
and HIV-positive (N=17) mothers respectively, showing vividly that in both groups there 
were multiple genotypes present. With our cut-offs multiple infections were detected 
in all but four samples: 234R16, 243R4, 243R16, and 248R4. For visual clarity and 
consistency, the eight gO genotypes are colour-coded: gO1a (grey); gO1b (black); gO1c 
(magenta); gO2a (orange); gO2b (dark red); gO3 (yellow); gO4 (green); and gO5 (blue). 
Notably, gO2b was not detected among HIV-negative samples.  
 
In figure 5.13, comparison was made between the gO proportions in three HIV-positive 
and three HIV-negative samples collected at the same time point, week 16. In these six 
samples between 2 and 7 different genotypes were detected per sample, irrespective of 
HIV status.  
 
In Figure 5. 14, further comparisons were made, in this case genotype variants in 4 
individuals who had samples collected from both the left (L) and right (R) breast at the 
same time point. All four individuals for whom such sample pairs were available were 
HIV-positive. There was striking concordance between the gO genotype proportions in 
samples from the two sides (figure 5.14) indicating similarity in the routes of infection 
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Number Number % Number % Number % Number % Number % 
141R16 Positive  1,146,537   890,615  77.68  178,153  15.54  26,676  2.33 1,095,444 95.55  51,093  4.46 
174L16 Positive  916,944   737,347  80.41  118,244  12.9  23,979  2.62 879,570 95.93  37,374  4.08 
174R16 Positive  1,083,750   827,817  76.38  186,721  17.23  21,513  1.99 1,036,051 95.6  47,699  4.4 
243L16 Positive  1,132,222   847,209  74.83  174,948  15.45  25,436  2.25 1,047,593 92.53  84,629  7.47 
243R4 Positive  1,473,048   1,006,620  68.34  327,497  22.23  24,086  1.64 1,358,203 92.21  114,845  7.8 
243R12 Positive  1,400,640   1,145,618  81.79  133,375  9.52  43,541  3.11 1,322,534 94.42  78,106  5.58 
243R16 Positive  886,331   685,668  77.36  136,340  15.38  21,640  2.44 843,648 95.18  42,683  4.82 
248R4 Positive  854,330   657,792  77.0  138,720  16.24  17,525  2.05 814,037 95.29  40,293  4.72 
259L16 Positive  1,620,030   1,067,874  65.92  401,160  24.76  23,079  1.42 1,492,113 92.1  127,917  7.9 
259R16 Positive  1,451,513   909,158  62.64  383,704  26.43  23,133  1.59 1,315,995 90.66  135,518  9.34 
278L16 Positive  1,480,282   975,707  65.91  365,136  24.67  20,927  1.41 1,361,770 91.99  118,512  8.01 
278R4 Positive  1,752,804   1,208,782  68.96  384,070  21.91  29,648  1.69 1,622,500 92.56  130,304  7.43 
278R12 Positive  1,947,062   1,685,104  86.55  126,845  6.51  59,910  3.08 1,871,859 96.14  75,203  3.86 
278R16 Positive  1,483,322   949,871  64.04  389,601  26.27  19,995  1.35 1,359,467 91.66  123,855  8.35 
281R4 Positive  2,718,523   2,020,988  74.34  449,676  16.54  67,925  2.5 2,538,589 93.38  179,934  6.62 
288R4 Positive  1,486,816   992,768  66.77  346,684  23.32  27,013  1.82 1,366,465 91.91  120,351  8.09 
288R12 Positive  1,521,583   1,263,945  83.07  145,835  9.58  40,457  2.66 1,450,237 95.31  71,346  4.69 
158L16 Negative  885,658   675,776  76.3  132,258  14.93  28,493  3.22 836,527 94.45  49,131  5.55 
232R12 Negative  1,732,535   1,409,192  81.34  169,036  9.76  55,011  3.18 1,633,239 94.28  99,296  5.73 
240R12 Negative 1,499,202 1,256,577 83.82 127,782 8.52 44,586 2.97 1,428,945 95.31 70,257 4.69 
280R12 Negative  1,561,860   1,305,644  83.6  135,680  8.69  45,835  2.93 1,487,159 95.22  74,701  4.78 
 
Table 5.7. Summary of FASTQ reads pre-processing for DNA derived from 21 breast milk samples. Trimmomatic (Bolger et al., 2014) in standard 
format (phred+33) was used to filter the reads. Only reads with a minimum length of 100 bases were retained for further analysis. 
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ID HIV Status gO genotype proportion (%)  gN genotype proportion (%) 
  gO1a gO1b gO1c gO2a gO2b gO3 gO4 gO5 gN1 gN2 gN3a gN3b gN4a gN4b gN4c gN4d 
141R16 Positive  48.9  1.3 48.8  1.0   25.0 75.0      
158L16 Negative 2.4 12.6 6.9 6.9  60.1 4.8 6.2     100.0    
174L16 Positive     26.4 68.1 5.5  5.1 33.9 3.8  54.1 3.1   
174R16 Positive  2.9   31.8 63.6 1.6  1.7 14.8 1.4  82.1    
232R12 Negative  62.8      37.2   57.9     42.1 
240R12 Negative 5.5 3.6 15.9 1.8  17.4 13.4 42.4 4.1    3.1 9.3  83.5 
243L16 Positive       100    6.5   93.5   
243R4 Positive       100       100.0   
243R12 Positive  4.3    1.6 94.1    2.7   97.3   
243R16 Positive       100       100.0   
248R4 Positive    100.0        100.0     
259L16 Positive 8.8    38.1  53.1  21.0 36.9    42.1   
259R16 Positive 9.5    23.2  67.3  14.9 22.8    62.3   
278L16 Positive  88.5      11.5   79.2     20.8 
278R4 Positive  76.0 0.8 0.7  1.3 0.8 20.3   71.6     28.4 
278R12 Positive 9.0 9.7 41.2 1.5  21.8 14.8 2.0         
278R16 Positive  88.1      11.9   84.8     15.2 
280R12 Negative 58.5 2.3 16.1 1.2  14.3 7.6  100.0        
281R4 Positive 0.7 11.8 1.5 1.4  4.0 2.0 78.5   4.9     95.1 
288R4 Positive 3.4 2.0 1.0 0.8  2.1 9.2 81.5 13.0    4.6  8.2 74.2 
288R12 Positive 9.4 10.4 29.3 8.1  26.4 12.9 3.6    100.0     
 
Table 5.8. Confirmation of HCMV gO and gN genotype linkage in breast milk samples analysed by NGS. The table summarises the proportions of gO 
and gN variants analysed using our tags and perl script. Highlighted in grey are the dominant variants, showing correlation between the linked gN/gO 
genotype. 







Figure 5.11. HCMV gO genotype proportions in four breast milk samples from HIV-
negative mothers. Sample IDs are indicated in the centre of each doughnut, with the 
subscript indicating the time-point in weeks postpartum when the milk sample was 
collected. Genotypes are colour-coded as follows: gO1a – grey; gO1b – black; gO1c – 




















































































































































































Figure 5.12. HCMV gO genotype proportions in 17 breast milk samples from HIV-
positive mothers. Sample IDs are indicated in the centre of each doughnut, with the 
subscript indicating the time-point in weeks postpartum when the milk sample was 
collected. Genotypes are colour-coded as follows: gO1a – grey; gO1b – black; gO1c – 



































































































Figure 5.13. HCMV gO genotypes in breast milk from three HIV-positive and three HIV-negative mothers at postpartum week 12. Sample IDs are 
indicated in the centre of each doughnut, with HIV-positive samples in shown red font and HIV-negative in black. Genotypes are colour-coded as 



































































































Figure 5.14. HCMV gO genotypes in breast milk from four mothers with milk samples 
collected from both left (L) and right (R) breasts at week 16 postpartum. Sample IDs 
are indicated in the centre of each doughnut. All four mothers were HIV-positive. 
Genotypes are colour-coded as follows: gO1a – grey; gO1b – black; gO1c – magenta; 
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5.3.3 HCMV gO genotype, mixed infections kinetics, and viral load  
In order to compare the burden of infection with viral load, the two data sets were 
combined for samples available from this cohort. In the final dataset, there were three 
individuals for whom milk samples collected at multiple time-points were sequenced by 
NGS, and for whom HCMV viral load data were also available: 243, 278, and 288. These 
were all from HIV-positive women. The HCMV gO proportions were mapped against the 
viral load in order to assess the effect of viral load on gO genotype (figures 5.15 – 5.17). 
The data suggest that for these samples, multiple infections were already present from 
week 4 postpartum. There was an apparent ‘flaring up’ of the minor variants from W4 
to W12, and for samples 243 and 278 with available W16 data, this was followed by 
reversion to the W4 status quo. This may suggest enhanced immune pressure on the 
virus between postpartum weeks 4 and 12, viral reactivation and import of additional 





































Figure 5.15. HCMV gO genotypes and viral load: sample 243R. The lower panel is a graph of breast milk HCMV viral load kinetics from postpartum 




















































































Figure 5.16. HCMV gO genotypes and viral load: sample 278R. The lower panel is a graph of breast milk HCMV viral load kinetics from postpartum 





































































































Figure 5.17. HCMV gO genotypes and viral load: sample 288R. The lower panel is a graph of breast milk HCMV viral load kinetics from postpartum 
day (D) 3 to week (W) 16, and the top panel shows HCMV gO genotypes from NGS analysis at two time-points: W4 and W12. 
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5.3.4 Summary 
The results showed that the molecular tags and scripts could accurately genotype and 
quantify mixed infections in the breast milk samples. Mixed infections were detected in 
both HIV-positive and negative women, and the gO and gN genotypes could be used as 
markers for burden of infection. There was some evidence for wider genotypes 
indicating more HCMV infections in breast milk samples from HIV-positive women. 
Where samples were available from both breasts, we found remarkable consistency in 
genotypes prevalence. In analyses of burden of infection and viral load over time, there 
appeared in two samples increases in burden of infection after initial virus reactivation 
and replication, followed by control as the viral load decreased. In the samples analysed, 
mixed infections were detected from the earliest time point post-partum. 
 
 
5.4 ASSEMBLY OF COMPLETE HCMV GENOMES FROM BREAST MILK 
Despite the apparent global ubiquity of HCMV, scrutiny of GenBank release 211 
(National Center for Biotechnology Information (NCBI), 2015) revealed that the 163 
publicly available complete HCMV genome sequences were from just 10 countries! Six 
of the 10 countries are European, and accounted for 155/163 (95%) of the complete 
HCMV genomes, with Belgium alone contributing 95 sequences (58.3% overall). Figure 
5.18, a map constructed to depict the geographical origin of the 163 complete HCMV 
genomes, vividly shows the paucity of information from the majority of global regions, 
particularly the Southern Hemisphere. Various factors could account for this picture, 
including limited access to sequencing technology, and differences in research and 
health priorities at country / regional levels. 
 
The final part of this thesis presents compilation of complete HCMV genomes assembled 
from our NGS reads, with detailed analysis of ZMB240 as a clinical representative of the 
reference strain Merlin. Following analyses of genotype diversity, as described in section 
5.3 above, samples with a dominant gO genotype were selected for genome 
compilation. In other laboratory projects, we also analysed other hypervariable loci in 
these samples using the molecular tags approach described in Section 5.2, and multiple 
genotypes were detected for those hypervariable genes (data not shown). After the 
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initial quality checks and sequence filtering (see section 5.3.1 and table 5.7), two 
approaches were used to assemble genomes – de novo assembly and reference mapping 
– to ensure there were no gaps in the derived genomes assembly. For de novo assembly, 
FASTQ reads were optimised by VelvetOptimiser (Zerbino and Birney, 2008) and 
scaffolds were constructed from resultant contigs using SSPACE (Boetzer et al., 2011) 
and ABACAS (Assefa et al., 2009) with default settings. Contigs were verified by 
employing the consensus sequence as mapping reference. Reference mapping was 
accomplished using a variety of genomics tools including the Burrows-Wheeler Aligner, 
BWA (Li and Durbin, 2009, Li and Durbin, 2010), SAMtools / BCFtools (Li et al., 2009) and 
GATK (McKenna et al., 2010) for sequence alignment, indexing, mapping, and variant 
calling. Artemis (Rutherford et al., 2000) was employed for visualisation of mapped 
reads. Genome annotations were transferred from the genome of HCMV reference 
strain Merlin (accession number AY446894.2) using the rapid annotation transfer tool, 
RATT (Otto et al., 2011) as part of the post-assembly genome-improvement toolkit, 
PAGIT suite (Swain et al., 2012). Each annotated gene was inspected manually and using 
NCBI BLAST (Altschul et al., 1990), and where necessary, manual 






















Figure 5.18. World map showing global distribution of complete HCMV genomes by country. The number of genomes published from each country 
is indicated by a colour gradient, as shown in the legend. Data were compiled from GenBank database release 211, accessed 21st December 2015. The 
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5.4.1 HCMV strain ZMB240  
Genome Architecture 
The final compilation consensus genome was performed on ZMB240 (accession number 
TBA). This sequence was derived from DNA extracted from a breast milk sample from an 
HIV-negative mother at 12 weeks postpartum. Similar to other HCMV strains (see 
Appendix 5.1), ZMB240 is of length 236,211bp and 57.6% G+C content, with a typical 
class E herpesviral genome architecture consisting of two unique regions, long unique 






where ba/b′a′ and ca/c′a′ are the inverted repeats.  
 
The layout and coordinates of the six main regions TRL, UL, IRL, IRS, US and TRS of the 
ZMB240 genome are represented in figure 5.19, and the extent of these genome regions 




      






   







Figure 5.19. HCMV strain ZMB240 genome layout. The genome is layout is in the typical 
class E herpesviral genome architecture TRL–UL–IRL–IRS–US–TRS. Numbers indicate the 
start coordinates for each genome region. TRL, Long terminal repeat; UL, long unique 
region; IRL, long internal repeat; IRS, short internal repeat; US, unique short region, TRS, 
short terminal repeat; ba/b′a′/ca/c′a′, inverted repeats. 
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A: Genome Landmarks  
HCMV strain ZMB240 HCMV strain Merlin  
Start End Length (bp) Length (bp) 
Full sequence 1 236211 236211 235646 
'a' sequence 1 861 861 578 
TRL 1 1347 1347 1324 
UL 1348 194720 193373 193019 
OriLyt-associated repeat 94174 94313 140 140 
IRL 194721 196067 1347 1324 
'a' sequence 195207 196067 861 578 
IRS 195207 197996 2790 2537 
US 197997 233420 35424 35482 
TRS 233421 236211 2791 2538 
'a' sequence 235350 236211 862 579 
     
B: Other Features   Count Count  
CDS   169 169 
Spliced genes    16 15 
Non-spliced genes   153 154 
Repeat regions   8 8 
ncRNA regions   30 21 
GC percentage   57.6 57.5 
 
Table 5.9. Overview of HCMV strain ZMB240 genome content. Genome features are 




5.4.2 ZMB240 Genes Compared to HCMV Strain Merlin (AY446894.2) 
5.4.2.1  Gene Content 
ZMB240 includes a complement of 169 ORFs, of which eight are RL genes, 127 are UL 
genes and 34 are US genes. ZMB240 possesses an additional putative ORF, which in 
other HCMV strains including Merlin, encodes UL6. In ZMB240 however, this ORF is 
initiated by the start codon variant TTG instead of the conventional ATG, and is thus 
annotated as a “miscellaneous feature”. Bioinformatics analysis including NCBI BLAST 
searches showed that the TTG start codon in putative UL6 is documented in at least 25 
other complete-genome HCMV strains, as shown in figure 5.20. 
 
Among the 169 ORFs in ZMB240, 69 are in the forward direction and 100 in the reverse. 
Further, among the resultant gene products, 130 have the same overall length as in 
HCMV strain Merlin, including products of 35/40 core genes, 20/27 beta genes, all 7 
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betagamma genes, and the immediate early genes UL150A and US2. NCBI BLASTp 
searches showed that the variation in amino acid length due to deletions and/or 
insertions in various ZMB240 gene products including the 5 core genes (UL48, UL50, 
UL95, UL100, UL102), 7 beta genes (UL22A, UL32, UL37, UL44, UL74, UL77, UL117) and 
the spliced gene UL119 is in fact also present in other HCMV strains. For these key genes 
the number of complete HCMV genomes in GenBank release 211 with the same product 
lengths as ZMB240 is 61 (UL48), 4 (UL50), 5 (UL95), 10 (UL100), 5 (UL102), 3 (UL22A), 10 
(UL37), 14 (UL119), and one each for UL32, UL42, UL74, UL77, and UL117 as per table 
5.10. This was confirmed by protein alignments (figures 5.21 to 5.36) performed using 
NCBI’s COBALT tool (Papadopoulos and Agarwala, 2007) with default settings at 
https://www.ncbi.nlm.nih.gov/tools/cobalt/cobalt.cgi?CMD=Web.  
 
5.4.2.2  UL128 and the ULb’ Region 
The UL128 locus encodes a membrane protein which is a component of the pentameric 
complex (gH-gL-pUL128-pUL130-pUL131) critical for virus entry into non-fibroblast cells 
such as endothelial, epithelial, and myeloid cells (Hahn et al., 2004, Wang and Shenk, 
2005b, Wang and Shenk, 2005a, Ryckman et al., 2008b). HCMV strain Merlin lacks gene 
UL128 owing to the effects of selection through propagation in cell culture giving rise to 
an in-frame nucleotide substitution that introduces a stop codon leading to premature 
sequence termination (Akter et al., 2003, Dolan et al., 2004). Notably, ZMB240 – 
sequenced directly from a clinical sample – has an intact UL128, with the classical ‘C’ 
variation at nucleotide position 634 in the mature transcript. Further, as demonstrated 
in other clinical strains, the ULb’ region is intact in ZMB240 and located at the 3' end of 
UL. This 13-15kbp region, which encodes at least 20 ORFs (UL133–UL150A), has been 
termed “the virulence region” and is deleted or modified in fibroblast-cultured 
laboratory-adapted HCMV strains (Cha et al., 1996, Murphy et al., 2003, Dolan et al., 
2004).  
 
The full list of ZMB240 genes is given in table 5.12, which also highlights relative 


















Figure 5.20. Nucleotide sequence alignment of the putative UL6 ORF of strain ZMB240 
and 25 other HCMV strains. The alignment shows the first 72 nucleotides of putative 
UL6 sequences for ZMB240 and 25 other HCMV strains in GenBank release 211. In these 
strains, the ORF is initiated by TTG, compared with the conventional ATG in strains such 
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Strain Accession 
UL48 UL50 UL95 UL100 UL102 UL22A UL32 UL37 UL42 UL74 UL77 UL117 UL29 UL33 UL112 UL119 
Ͼ Ͼ Ͼ Ͼ Ͼ βṨ β βṨ β β β β Ṩ Ṩ Ṩ Ṩ 
3157 GQ221974.1 X       X         
3301 GQ466044.1      X         X  
6397 JX512197.1 X     X         X  
2CEN2 KJ361946.1    X             
2CEN5 KJ361947.1 X                
AD169 FJ527563.1  X           X X X  
AF1 GU179291.1 X              X  
BE/1/2010 KP745677.1   X              
BE/1/2011 KP745650.1 X                
BE/1/2012 KP745699.1 X                
BE/10/2011 KP745639.1 X                
BE/10/2012 KP745649.1  X             X  
BE/11/2010 KC519321.1       X  X      X  
BE/11/2012 KP745680.1 X               X 
BE/13/2010 KP745645.1 X               X 
BE/13/2012 KP745707.1 X                
BE/14/2011 KP745671.1    X             
BE/15/2010 KP745638.1 X                
BE/15/2012 KP745693.1               X X 
BE/16/2012 KP745665.1                X 
BE/17/2010 KP745727.1 X               X 
BE/17/2011 KP745689.1 X                
BE/19/2010 KP745712.1 X                
BE/19/2011 KP745654.1               X  
BE/2/2010 KP745717.1 X                
BE/2/2011 KP745652.1 X                
BE/2/2012 KP745710.1 X              X  
BE/2/2013 KP745656.1 X              X  
BE/20/2010 KP745662.1 X X               
BE/21/2010 KC519322.1                X 
BE/22/2011 KP745653.1 X              X  
BE/23/2010 KP745697.1    X             
BE/24/2011 KP745711.1 X              X  
BE/25/2010 KP745678.1               X  
BE/26/2010 KP745719.1                X 
BE/26/2011 KP745703.1 X                
BE/27/2010 KC519323.1 X                
BE/28/2010 KP745676.1 X                
BE/29/2010 KP745714.1 X                
BE/29/2011 KP745672.1               X  
BE/3/2010 KP745655.1 X                
BE/3/2011 KP745659.1 X                
BE/30/2010 KP745726.1 X                
BE/30/2011 KP745670.1                X 
BE/31/2011 KP745641.1 X     X           
BE/32/2010 KP745634.1 X                
BE/33/2011 KP745674.1 X                
BE/37/2011 KP745723.1               X  
BE/39/2011 KP745686.1               X  
BE/4/2011 KP745700.1 X   X            X 
BE/40/2011 KP745722.1 X                
BE/42/2011 KP745673.1 X                
BE/46/2011 KP745682.1  X X              
BE/49/2011 KP745725.1 X                
BE/6/2010 KP745701.1 X                
BE/6/2012 KP745695.1   X            X  
BE/7/2011 KP745636.1 X                
BE/7/2012 KP745666.1                X 
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Strain Accession 
UL48 UL50 UL95 UL100 UL102 UL22A UL32 UL37 UL42 UL74 UL77 UL117 UL29 UL33 UL112 UL119 
Ͼ Ͼ Ͼ Ͼ Ͼ βṨ β βṨ β β β β Ṩ Ṩ Ṩ Ṩ 
BE/8/2011 KP745648.1   X            X  
BE/9/2010 KC519319.1  X               
BE/9/2011 KP745637.1 X                
CZ/1/2011 KP745718.1 X                
CZ/1/2012 KP745642.1 X              X  
CZ/3/2012 KP745685.1 X               X 
HAN1 JX512199.1    X           X  
HAN11 KJ361950.1 X   X             
HAN12 JX512203.1 X                
HAN13 GQ221973.1    X           X  
HAN16 JX512204.1 X                
HAN2 JX512200.1    X           X  
HAN20 GQ396663.1 X              X  
HAN21 KJ361951.1 X              X  
HAN22 JX512206.1 X                
HAN28 JX512207.1 X    X            
HAN3 JX512201.1 X                
HAN30 KJ361953.1               X  
HAN33 KJ361955.1 X              X  
HAN38 GQ396662.1               X  
HAN40 KJ361958.1    X             
HAN8 JX512202.1 X                
JP GQ221975.1          X       
PAV11 KJ361965.1 X              X X 
PAV23 KJ361967.1 X                
PAV24 KJ361968.1               X  
PAV26 KJ361970.1 X                
PAV4 KJ361960.1 X                
PAV5 KJ361961.1 X                
PAV7 KJ361963.1               X  
PAV8 KJ361964.1 X                
Toledo GU937742.1               X X 
Towne FJ616285.1 X  X        X X     
U11 GU179290.1               X  
U8 GU179288.1 X              X X 
UKNEQAS1 KJ361971.1 X              X  
UKNEQAS2 KT634296.1 X   X             
VR1814 GU179289.1 X                
 
Table 5.10. ZMB240 Core and Beta genes whose products are of variable length 
compared to HCMV reference strain Merlin (AY446894.2). HCMV strains listed in the 
first column have amino acid products of the same length as ZMB240 for the genes 
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ZMB240     1 MARRLWILSLLAVTLTVALAAPSQKSKRSVTVEQPSTSTNSDGNNTTRNKDVTLSQGGSTTDGDEDYSGGDYDVLITDTD 80 
6397       1 MARRLWILSLLAVTLTVALAAPSQKSKRSVTVEQPSTSTNSDGNNTTRNKDVTLSQGGSTTDEDEDYSGGDYDVLITDTD 80 
BE/31/2011 1 MARRLWILSLLAVTLTVALAAPSQKSKRSVTVEQPSTSTNSDGNNTTRNKDVTLSQGGSTTDGDEDYSGEEYDVLITDGD 80 
3301       1 MARRLWILSLLAVTLTVALAAPSQKSKRSVTVEQPSTSTNSDGNNTTRNKDVTLSQGGSTTDGDEDYSGGDYDVLITDTD 80 
Merlin     1 MARRLWILSLLAVTLTVALAAPSQKSKRSVTVEQPSTSTNSDGN-TTPSKNVTLSQGGSTTDGDEDYSGGDYDVLITDTD 79 
 
ZMB240     81 GGNHQQPQKKTNEHKEEHTKENEKTQ 106 
6397       81 GGNHQQPQEKTNEHKEEHTKENEKTQ 106 
BE/31/2011 81 GSEHQQPQEKTDEHKGEHTKKNEKTQ 106 
3301       81 GGNHQQPQEKTDEHKEEHTKENEKTQ 106 
Merlin     80 GGNHQQPQEKTDEHKGEHTKENEKTQ 105 
 
Figure 5.21. ZMB240 UL22A amino acid sequence alignment. Compared to HCMV strain 
Merlin (AY446894.2), the ZMB240 UL22A amino acid sequence has an insertion after 
position 44, highlighted by the red border. This insertion is also present in HCMV strains 






ZMB240 1    MSGRRKGCSAATASSSSSSPPSRLPPLPGHARRPRRKRCLVPEVFCTRDLADLCVRRDYEGLRRYLRRFEGSCVSLGWPS  80 
AD169  1    MSGRRKGCSAATASSSSSSPPSRLPPLPGHARRPRRKRCLVPEVFCTRDLADLCVRRDYEGLRRYLRRFEGSCVSLGWPS  80 
Merlin 1    MSGRRKGCSAATASSSSSSPPSRLP-LPGHARRPRRKRCLVPEVFCTRDLADLCVRRDYEGLRRYLRRFEGSCVSLGWPS  79 
 
ZMB240 81   QCIYVVGGEHSPHSLTEIDLEHCQNDFFGEFRALHLIGTVSHATCRYQVFVDAYGAVFAYDAQEDCLYELASDLAGFFAK  160 
AD169  81   QCIYVVGGEHSPHSLTEIDLEHCQNDFFGEFRALHLIGTVSHATCRYQVFVDAYGAVFAYDAQEDCLYELASDLAGFFAK  160 
Merlin 80   QCIYVVGGEHSPHSLTEIDLEHCQNDFFGEFRALHLIGTVSHATCRYQVFVDAYGAVFAYDAQEDCLYELASDLAGFFAK  159 
 
ZMB240 161  GMIRCDPVHESICARLQPNVPLVHPDHRAELCRRSRASARGRYLRSLLAFRELLACEDTAARCAYVEAHREAQLTLIWPE  240 
AD169  161  GMIRCDPVHESICARLQPNVPLVHPDHRAELCRRSRASARGRYLRSLLAFRELLACEDTAARCAYVEAHREAQLTLIWPE  240 
Merlin 160  GMIRCDPVHESICARLQPNVPLVHPDHRAELCRRSRASARGRYLRSLLAFRELLACEDTAARCAYVEAHREAQLTLIWPE  239 
 
ZMB240 241  KHSLVLRTARDLGLSASMLRRFQRSLYTREPVMPLGEIEGAEDKTFFHRVRILCGDTGTVYAALVGQDKLVRLARDLRGF  320 
AD169  241  KHSLVLRTARDLGLSASMLRRFQRSLYTREPVMPLGEIEGAEDKTFFHRVRILCGDTGTVYAALVGQDKLVRLARDLRGF  320 
Merlin 240  KHSLVLRTARDLGLSASMLRRFQRSLYTREPVMPLGEIEGAEDKTFFHRVRILCGDTGTVYAALVGQDKLVRLSRDLRGF  319 
 
ZMB240 321  VRVGLALLIDDFRYESIGPVDRSSLYEANPELRLPFKKRRLVVGYFDSLSSLYLRGQPKFSSIWRGLRDAWTHKRPKPRE  400 
AD169  321  VRVGLALLIDDFRYESIGPVDRSSLYEANPELRLPFKKRRLVVGYFDSLSSLYLRGQPKFSSIWRGLRDAWTHKRPKPRE  400 
Merlin 320  VRVGLALLIDDFRYESIGPVDRSSLYEANPELRLPFKKRRLVVGYFDSLSSLYLRGQPKFSSIWRGLRDAWTHKRPKPRE  399 
 
ZMB240 401  RASGVHLQRYVRATAGRWLPLCWPPLHGIMLGDTQYFGVVRDHKTYRRFSCLRQAGRLYFIGLVSVYECVPDANTAPEIW  480 
AD169  401  RASGVHLQRYVRATAGRWLPLCWPPLHGIMLGDTQYFGVVRDHKTYRRFSCLRQAGRLYFIGLVSVYECVPDANTAPEIW  480 
Merlin 400  RASGVHLQRYVRATAGRWLPLCWPPLHGIMLGDTQYFGVVRDHKTYRRFSCLRQAGRLYFIGLVSVYECVPDANTAPEIW  479 
 
ZMB240 481  VSGHGHAFAYLPGEDKVYVLGLSFGEFFENGLFAVYSFFERDYVDEIVEGAWFKHTFAGMYELSQILHDRANLLRVCQLH  560 
AD169  481  VSGHGHAFAYLPGEDKVYVLGLSFGEFFENGLFAVYSFFERDYVDEIVEGAWFKHTFAGMYELSQILHDRANLLRVCQLH  560 
Merlin 480  VSGHGHAFAYLPGEDKVYVLGLSFGEFFENGLFAVYSFFERDYVDEIVEGAWFKHTFAGMYELSQILHDRANLLRVCQLH  559 
 
ZMB240 561  AGSKIRLGGSPACTFTFGSWNVAEADEANNFVIGVLEQAHFVVIGWMEPVNKAVFMDAHGGIHVLLYGTMLVKLAETLRG  640 
AD169  561  AGSKIRLGGSPACTFTFGSWNVAEADEANNFVIGVLEQAHFVVIGWMEPVNKAVFMDAHGGIHVLLYGTMLVKLAETLRG  640 
Merlin 560  AGSKIRLGGSPACTFTFGSWNVAEADEANNFVIGVLEQAHFVVIGWMEPVNKAVFMDAHGGIHVLLYGTMLVKLAETLRG  639 
 
ZMB240 641  FIRQGSFWFRCPRRFCFSPLDSSATVAAKPVSSHTSPAYDVSEYVFSGRSVLDSVSGTGAS  701 
AD169  641  FIRQGSFWFRCPRRFCFSPLDSSATVAAKPVSSHTSPAYDVSEYVFSGRSVLDSVSGTGAS  701 
Merlin 640  FIRQGSFWFRCPRRFCFSPLDSSATVAAKPVSSHTSPAYDVSEYVFSGRSVLDSVSGTGAS  700 
 
Figure 5.22. ZMB240 UL29 amino acid sequence alignment. Similar to HCMV strain 
AD169, the ZMB240 UL29 amino acid sequence has an insertion after position 25, which 
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ZMB240     1 MSLQFIGLQRRDVVALVNFLRHLTQKPDVDLEAHPKILKKCGEKRLHRRTVLFNELMLWLGYYRELRFHNPDLSSVLEEF  80 
BE/11/2010 1 MSLQFIGLQRRDVVALVNFLRHLTQKPDVDLEAHPKILKKCGEKRLHRRTVLFNELMLWLGYYRELRFHNPDLSSVLEEF  80 
Merlin     1 MSLQFIGLQRRDVVALVNFLRHLTQKPDVDLEAHPKILKKCGEKRLHRRTVLFNELMLWLGYYRELRFHNPDLSSVLEEF  80 
 
ZMB240     81 EVRCAAVARRGYTYPFGDRGKARDHLAVLDHTEFDTDVRHDAEIVERALVSAVILAKMSVRETLVTAIGQTEPIAFVHLK  160 
BE/11/2010 81 EVRCAAVARRGYTYPFGDRGKARDHLAVLDRTEFDTDVRHDAEIVERALVSAVILAKMSVRETLVTAIGQTEPIAFVHLK  160 
Merlin     81 EVRCAAVARRGYTYPFGDRGKARDHLAVLDRTEFDTDVRHDAEIVERALVSAVILAKMSVRETLVTAIGQTEPIAFVHLK  160 
 
ZMB240     161 DTEVQRIEENLEGVRRNMFCVKPLDLNLDRHANTALVNAVNKLVYTGRLIMNVRRSWEELERKCLARIQERCKLLVKELR  240 
BE/11/2010 161 DTEVQRIEENLEGVRRNMFCVKPLDLNLDRHANTALVNAVNKLVYTGRLIMNVRRSWEELERKCLARIQERCKLLVKELR  240 
Merlin     161 DTEVQRIEENLEGVRRNMFCAKPLDLNLDRHANTALVNAVNKLVYTGRLIMNVRRSWEELERKCLARIQERCKLLVKELR  240 
 
ZMB240     241 MCLSFDSNYCRNILKHAVENGDSADTLLELLIEDFDIYVDSFPQSAHTFLGARSPSLEFDDDANLLSLGGGSAFSSVPKK  320 
BE/11/2010 241 MCLSFDSNYCRNILKHAVENGDSADTLLELLIEDFDIYVDSFPQSAHTFLGARSPSLEFDDDANLLSLGGGSAFSSVPKK  320 
Merlin     241 MCLSFDSNYCRNILKHAVENGDSADTLLELLIEDFDIYVDSFPQSAHTFLGARSPSLEFDDDANLLSLGGGSAFSSVPKK  320 
 
ZMB240     321 HVPTQPLDGWSWIASPWKGHKPFRFEAHGSLAPAAEAHAARSAAVGYYDEEEKRRERQKRVDDEVVQREKQQLKAWEERQ  400 
BE/11/2010 321 HVPTQPLDGWSWIASPWKGHKPFRFEAHGSLAPAAEAHAARSAAVGYYDEEEKRRERQKRVDDEVVQREKQQLKAWEERQ  400 
Merlin     321 HVPTQPLDGWSWIASPWKGHKPFRFEAHGSLAPAAEAHAARSAAVGYYDEEEKRRERQKRVDDEVVQREKQQLKAWEERQ  400 
 
ZMB240     401 QNLQQRQQQPPPSTRKPGASRRLFGSSADE-DDDDDDDEKNIFTPIKKPGTSGKGAASGGGVSNIFSGLLSSGSQKPTSG  479 
BE/11/2010 401 QNLQQRQQQPPPPARKPSASRRLFGSSADE-DDDDDDDEKNIFTPIKKPGTSGKGAASGGGVSSIFSGLLSSGSQKPTSG  479 
Merlin     401 QNLQQRQQQPPPPTRKPGASRRLFGSSADEDDDDDDDDEKNIFTPIKKPGTSGKGAASGGGVSSIFSGLLSSGSQKPTSG  480 
 
ZMB240     480 PLNIPQQQQRHAAFSLVSPQVTKASPGRVRRDSAWDVRPLTETRGDLFSGDEDSDSSDGYPPNRQDPRFTDTLVDITDTE  559 
BE/11/2010 480 PLNIPQQQQRHAAFSLVSPQVTKASPGRVRRDSAWDVRPLTETRGDLFSGDEDSDSSDGYPPNRQDPRFTDTLVDITDTE  559 
Merlin     481 PLNIPQQQQRHAAFSLVSPQVTKASPGRVRRDSAWDVRPLTETRGDLFSGDEDSDSSDGYPPNRQDPRFTDTLVDITDTE  560 
 
ZMB240     560 TNVKPPVTTAYKFEQPTLTFGAGVNVPAGAGAAILTPTPVNPSTAPAPAPTPTFAGTQTPVNGNSPWAPTAPLPGDMNPA  639 
BE/11/2010 560 TSAKPPVTTAYKFEQPTLTFGAGVNVPAGAGAAILTPTPVNPSTAPAPAPTPTFAGTQTPVNGNSPWAPTAPLPGDMNPA  639 
Merlin     561 TSAKPPVTTAYKFEQPTLTFGAGVNVPAGAGAAILTPTPVNPSTAPAPAPTPTFAGTQTPVNGNSPWAPTAPLPGDMNPA  640 
 
ZMB240     640 NWPRERAWALKNPHLAYNPFRMPTTSTASQNTVSTTPRRPSTPRAAVTQTASQNAADEVWALRDQTAESPVEDSEEEDDD  719 
BE/11/2010 640 NWPRERAWALKNPHLAYNPFRMPTTSTASQNNVSTTPRRPSTPRAAVTQTASQNAADEVWALRDQTAESPVEDSEEEDDD  719 
Merlin     641 NWPRERAWALKNPHLAYNPFRMPTTSTASQNTVSTTPRRPSTPRAAVTQTASRDAADEVWALRDQTAESPVEDSEEEDDD  720 
 
ZMB240     720 SSDTGSVVSLGHTTPSSDY-NDVISPPSQTPEQSTPSRIRKAKLSSPMTTTSTSQKPVLGKRVATPHASARAQTVTSTPV  798 
BE/11/2010 720 SSDTGSVVSLGHTTPSSDY-NDVISPPSQTPEQSTPSRIRKAKLSSPMTTTSTSQKPVLGKRVATPHASARAQTVTSTPV  798 
Merlin     721 SSDTGSVVSLGHTTPSSDYNNDVISPPSQTPEQSTPSRIRKAKLSSPMTTTSTSQKPVLGKRVATPHASARAQTVTSTPV  800 
 
ZMB240     799 QGRLEKQVSGTPSTVPATLLQHQPASSKTTSSRNVTSGAGTSSASSARQPSASASVLSPTEDDVVSPATSPLSMLSSASP  878 
BE/11/2010 799 QGRLEKQVSGTPSTVPATLLQPQPASSKTTSSRNVTSGAGTSSASSARQPSASASVLSPTEDDVVSPATSPLSMLSSASP  878 
Merlin     801 QGRLEKQVSGTPSTVPATLLQPQPASSKTTSSRNVTSGAGTSSASSARQPSASASVLSPTEDDVVSPATSPLSMLSSASP  880 
 
ZMB240     879 SPAKSAPPSPVRGRGSRVGVVPSLKPTLGGKAVVGRPPSVPVSGSAPGRLSGTSRAASTTPTYPAVTTVYPPSSTAKSSV  958 
BE/11/2010 879 SPAKSAPPSPVKGRGSRVGVVPSLKPTLGGKAVVGRPPSVPVSGSAPGRLSGTSRAASTTPTYPAVTTVYPPSSTAKSSV  958 
Merlin     881 SPAKSAPPSPVKGRGSRVG-VPSLKPTLGGKAVVGRPPSVPVSGSAPGRLSGSSRAASTTPTYPAVTTVYPPSSTAKSSV  959 
 
ZMB240     959 SNAPPVASPSILKPGASAALQSRRSTGTAAVGSPVKSTTGMKTVAFDLSSPQKSGTGPQPGSAGMGGAKTPSDAVQNILQ  1038 
BE/11/2010 959 SNAPPVASPSILKPGASAALQSRRSTGTAAVGSLVKSTTGMKTVAFDLSSPQKSGTGPQPGSAGMGGAKTPSDAVQNILQ  1038 
Merlin     960 SNAPPVASPSILKPGASAALQSRRSTGIAAVGSPVKSTTGMKTVAFDLSSPQKSGTGPQPGSAGMGGAKTPSDAVQNILQ  1039 
 
ZMB240     1039 KIEKIKKTEE  1048 
BE/11/2010 1039 KIEKIKNTEE  1048 
Merlin     1040 KIEKIKNTEE  1049 
 
Figure 5.23. ZMB240 UL32 amino acid alignment. Relative to HCMV strain Merlin 
(AY446894.2), the ZMB240 UL32 amino acid sequence has two deletions at positions 
431 and 720 and an insertion after position 899, highlighted by the red borders. These 
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ZMB240 1    MDTIIHNTTNRSTSTPHVNSTCNMTEPLSAIRTTEAVINTFIIFVGGPLNAIVLVTQLLTNRVLGYSTPTIYMTNLYSTN  80 
AD169  1    MDTIIHNTTNRSTSTPHVNSTCNMTEPLSAIRTTEAVINTFIIFVGGPLNAIVLVTQLLTNRVLGYSTPTIYMTNLYSTN  80 
Merlin 1    MDTIIHNTTNRSTDTPHVNITCNITEPLSAIRTTEAVINTFIIFVGGPLNAIVLITQLLTNRVLGYSTPTIYMTNLYSTN  80 
 
ZMB240 81   FLTLTVLPFIVLSNQWLLPASVTSCKFLSVIYYSSCTVGFATVALIAADRYRVLHKRTYARQSYRSTYIILLLTWFAGLI  160 
AD169  81   FLTLTVLPFIVLSNQWLLPASVTSCKFLSVIYYSSCTVGFATVALIAADRYRVLHKRTYARQSYRSTYIILLLTWFAGLI  160 
Merlin 81   FLTLTVLPFIVLSNQWLLPASVASCKFLSVIYYSSCTVGFATVALIAADRYRVLHKRTYARQSYRSTYIILLLTWFAGLI  160 
 
ZMB240 161  FSMPAAVYTTVVIHNGTD-ENTNGHATCVLYFIADEVYTVLLSWKVLLTLVWGAAPVIMMTWFYAFFYSTVQRASQKQRS  239 
AD169  161  FSMPAAVYTTVVIHNGTD-ENTNGHATCVLYFIADEVYTVLLSWKVLLTLVWGAAPVIMMTWFYAFFYSTVQRASQKQRS  239 
Merlin 161  FSMPAAVYTTVVIHNGTNGQSSNGHATCVLYFIADEVYTVLLSWKVLLTLVWGAAPVIMMTWFYAFFYSTVQRASQKQRS  240 
 
ZMB240 240  RTLTFVSVLLISFVALQTPYVSIMIFNSYATAAWPMDCEHLTLRRTIGTLSRLVPHLHCLINPILYALLGHDFLQRMRQC  319 
AD169  240  RTLTFVSVLLISFVALQTPYVSIMIFNSYATAAWPMDCEHLTLRRTIGTLSRLVPHLHCLINPILYALLGHDFLQRMRQC  319 
Merlin 241  RTLTFVSVLLISFVALQTPYVSIMIFNSYATAAWPMDCEHLTLRRTIGTLSRLVPHLHCLINPILYALLGHDFLQRMRQC  320 
 
ZMB240 320  FRGQLLDRRAFLRSQQNQRATAETNLAAGNNSQSVATSLDTNSKNCNQHAKRSVSFNFPSGTWKGGQKTASNDTSTKIPH  399 
AD169  320  FRGQLLDRRAFLRSQQNQRATAETNLAAGNNSQSVATSLDTNSKNCNQHAKRSVSFNFPSGTWKGGQKTASNDTSTKIPH  399 
Merlin 321  FRGQLLDRRAFLRSQQNQRATAETNLAAGNNSQSVATSLDTSSKNCNQHAKRSVSFNFPSGTWKGGQKTASNDTSTKIPH  400 
 
ZMB240 400  RLSQSHHNLSGV  411 
AD169  400  RLSQSHHNLSGV  411 
Merlin 401  RLSQSHHNLSGV  412 
 
Figure 5.24. ZMB240 UL33 amino acid alignment. The ZMB240 UL33 amino acid 
sequence has a deletion at position 179, also present in HCMV strain AD169, relative to 








ZMB240     1   MSPVYVNLLGSVGLLAFWYFSYRWIQRKRLEDPLPPWLRKKKACALTRRSRHRLRRQHGVIDGENSETERSVDLVAALLA 80 
HAN40      1   MSPVYVNLLGSVGLLAFWYFSYRWIQRKRLEDPLPPWLRKKKACALTRRSRHRLRRQHGVIDGENSETERSVDLVAALLA 80 
HAN21      1   MSPVYVNLLGSVGLLAFWYFSYRWIQRKRLEDPLPPWLRKKKACALTRRSRHRLRRQHGVIDGENSETERSVDLVAALLA 80 
BE/29/2010 1   MSPVYVNLLGSVGLLAFWYFSYRWIQRKRLEDPLPPWLRRKKACALTRCSRHRLRRQHGVIDGENSETERSVDLVAALLA 80 
BE/1/2010  1   MSPVYVNLLGSVGLLAFWYFSYRWIQRKRLEDPLPPWLRKKKACALTRRSRHRLRRQHGVIDGENSETERSVDLVAALLA 80 
BE/10/2011 1   MSPVYVNLLGSVGLLAFWYFSYRWIQRKRLEDPLPPWLRKKKACALTRRSRHRLRRQHGVIDGENSETERSVDLVAALLA 80 
PAV20      1   MSPVYVNLLGSVGLLAFWYFSYRWIQRKRLEDPLPPWLRKKKACALTRRSRHRLRRQHGVIDGENSETERSVDLVAALLA 80 
PAV18      1   MSPVYVNLLGSVGLLAFWYFSYRWIQRKRLEDPLPPWLRKKKACALTRRSRHRLRRQHGVIDGENSETERSVDLVAALLA 80 
VR1814     1   MSPVYVNLLGSVGLLAFWYFSYRWIQRKRLEDPLPPWLRKKKACALTRRSRHRLRRQHGVIDGENSETERSVDLVAALLA 80 
3157       1   MSPVYVNLLGSVGLLAFWYFSYRWIQRKRLEDPLPPWLRKKKACALTRRSRHRLRRQHGVIDGENSETERSVDLVAALLA 80 
JP         1   MSPVYVNLLGSVGLLAFWYFSYRWIQRKRLEDPLPPWLRKKKACALTRRSRHRLRRQHGVIDGENSETERSVDLVAALLA 80 
Merlin     1   MSPVYVNLLGSVGLLAFWYFSYRWIQRKRLEDPLPPWLRKKKACALTRRSRHRLRRQHGVIDGENSETERSVDLVAALLA 80 
 
ZMB240     81  EAGEESVTEDTEREDTEEEREDEEEENEARTPEVNPIDAEGLSGLAREACEALKKALRRHRFLWQRRRRARLLQHNGPQQ 160 
HAN40      81  EAGEESVTEDTEREDTEEEREDEEEENEARTPEVNPIDAEGLSGLAREACEALKKALRRHRFLWQRRRRARLLQHNGPQQ 160 
HAN21      81  EAGEESVTEDTEREDTEEEREDEEEENEARTPEVNPIDAEGLSGLAREACEALKKALRRHRFLWQRRRRAQLLQHNGPQQ 160 
BE/29/2010 81  EAGEESVTEDTEREDTEEEREDEEEENEARTPEVNPIDAEGLSGLAREACEALKKALRRHRFLWQRRRRAQLLQHNGPQQ 160 
BE/1/2010  81  EAGEESVTEDTEREDTEEEREDEEEENEARTPEVNPIDAEGLSGLAREACEALKKALRRHRFLWQRRRRARLLQHNGPQQ 160 
BE/10/2011 81  EAGEESVTEDTEREDTEEEREDEEEENEARTPEVNPIDAEGLSGLAREACEALKKALRRHRFLWQRRRRARLLQHNGPQQ 160 
PAV20      81  EAGEESVTEDTEREDTEEEREDEEEENEARTPEVNPIDAEGLSGLAREACEALKKALRRHRFLWQRRRRARLLQHNGPQQ 160 
PAV18      81  EAGEESVTEDTEREDTEEEREDEEEENEARTPEVNPIDAEGLSGLAREACEALKKALRRHRFLWQRRRRAQLLQHNGPQQ 160 
VR1814     81  EAGEESVTEDTEREDTEEEREDEEEENEARTPEVNPIDAEGLSGLAREACEALKKALRRHRFLWQRRRRAQLLQHNGPQQ 160 
3157       81  EAGEESVTEDTEREDTEEEREDEEEENEARTPEVNPIDAEGLSGLAREACEALKKALRRHRFLWQRRQRARMLQHNGPQQ 160 
JP         81  EAGEESVTEDTEREDTEEEREDEEEENEARTPEVNPIDAEGLSGLAREACEALKKALRRHRFLWQRRRQARLLQHNGPQQ 160 
Merlin     81  EAGEESVTEDTEREDTEEEREDEEEENEARTPEVNPMDAEGLSGLAREACEALKKALRRHRFLWQRRRRARLLQHNGPQQ 160 
 
ZMB240     161 SHHAAVFCRVHGLRGFQVSVWLLLTLLWSTGNGVSVRCTYHGTDINITSNTTSMNCQLNCTCNNTQIYNGPCVGTEARLP 240 
HAN40      161 SHHAAVFCRVHGLRGFQVSVWLLLTLLWSTGNGVSVRCTYHGTDINITSNTTSMNCQLNCTCNNTQIYNGPCVGTEARLP 240 
HAN21      161 SHHAAGFCRVHGLRGFQVSVWLLLTLLWSTGNGVSVRCTYHGTDINITSNTTSMNCHLNCTCNNTQIYNGPCVGTEARLP 240 
BE/29/2010 161 SHHAAVFCRVHGLRGFQVSVWLLLTLFLSTGHGVSVRCTYHGTDINVTSNTTSMNCQLNCTCNNTQIYNGPCVGTEARLP 240 
BE/1/2010  161 SHHAAVFCRVHGLRGFQVSVWLLLTLLWSTGNGVSVRCTYHGTDINITSNTTSMNCQLNCTCNNTQIYNGPCVGTEARLP 240 
BE/10/2011 161 FHHAAVFCRVHGLRGFQVSVWLLLTLLWSTGNGVSVRCTYHGTDINITSNTTSMNCQLNCTCNNTQIYNGPCVGTEARLP 240 
PAV20      161 SHHAAVFCRVHGLRGFQVSVWLLLTLLWNTGNGVSVRCTYHGTDINITSNTTSMNCQLNCTCNNTQIYNGPCVGTEARLP 240 
PAV18      161 SHHAAVFCRVHGLRGFQVSVWLLLTLLWSTGNGVSVRCTYHGTDINITSNTTSMNCQLNCTCNNTQIYNGPCVGTEARLP 240 
VR1814     161 SHHAAVFCRVHGLRGFQVSVWLLLTLLWSTGNGVSVRCTYHGTDINITSNTTSMNCQLNCTCNNTQIYNGPCVGTEARLP 240 
3157       161 FHHAAGFCRVHGLRGFQVSVWLLLTLLWSTGNGVSVRCTYHGTDINITSNTTSMNCQLNCTCNNTQIYNGPCVGTEARLP 240 
JP         161 SHHAAVFCRVHGLRGFQVSVWLLLTLLWSTGNGVSVRCTYHGTDINITSNTTSMNCQLNCTCNNTQIYNGPCVGTEARLP 240 
Merlin     161 SHHAAVFCRVHGLRGFQVSVWLLLTLFWSTGYGVSVRCTYHGTDINVTSNATSMNCRLNCTCNHTQIYNGPCAGAESKLP 240 
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ZMB240     241 LNVTFNQSRRQWHSVMLKFGFQYHLEGWFPLRVLNESHETNVTEVHGEVACFKNDTNITVGQLMLNFTGHSYVLRAVAHT 320 
HAN40      241 LNVTFNQSRRQWHSVMLKFGFQYHLEGWFPLRVLNESHETNVTEVHGEVACFKNDTNITVGQLMLNFTGHSYVLRAVAHT 320 
HAN21      241 LNVTFNQSRRQWHSVMLKFGFQYHLEGWFPLRVLNESHETNVTEVRGEIACFTNDTNVTVGQLMLNFTGHSYVLQAVAHT 320 
BE/29/2010 241 LNVTFQQSRRQWHSVMLKFGFQYHLEGWFPLRVLNESRETNVTEVRGEIACFTNDTNVTVGQLMLNFTGHSYVLQAVAHT 320 
BE/1/2010  241 LNVTFNQSRRQWHSVMLKFGFQYHLEGWFPLRVLNESHETNVTEVHGEVACFKNDTNITVGQLMLNFTGHSYVLRAVAHT 320 
BE/10/2011 241 LNVTFNQSRRQWHSVMLKFGFQYHLEGWFPLRVLNESHETNVTEVHGEVACFKNDTNITVGQLMLNFTGHSYVLRAVAHT 320 
PAV20      241 LNVTFNQSRRQWHSVMLKFGFQYHLEGWFPLRVLNESHETNVTEVHGEVACFKNDTNITVGQLMLNFTGHSYVLRAVAHT 320 
PAV18      241 LNVTFNQSRRQWHSVMLKFGFQYHLEGWFPLRVLNESHETNVTEVHGEVACFKNDTNITVGQLMLNFTGHSYVLRAVAHT 320 
VR1814     241 LNVTFNQSRRQWHSVMLKFGFQYHLEGWFPLRVLNESHETNVTEVHGEVACFKNDTNITVGQLMLNFTGHSYVLRAVAHT 320 
3157       241 LNVTFNQSRRQWHSVMLKFGFQYHLEGWFPLRVLNESHETNVTEVHGEVACFKNDTNITVGQLMLNFTGHSYVLRAVAHT 320 
JP         241 LNVTFNQSRRQWHSVMLKFGFQYHLEGWFPLRVLNESHETNVTEVHGEVACFKNDTNITVGQLMLNFTGHSYVLRAVAHT 320 
Merlin     241 LNVTFRQSRRQWHSVMLTFGFQYHLEGWFPLRILNESRDINVTEVYGEVACFTNDTNITMGQLTLNLTGRSYVLRALART 320 
 
ZMB240     321 SPFESYVHWEETNATSNMTSNVTSLENTTTVMLTLAKYAESDYIFLQDMCPRFLRRTLKITKRKTINATFTGTNVTSLPM 400 
HAN40      321 SPFESYVHWEETNATSNMTSNVTSLENTTTVMLTLAKYAESDYIFLQDMCPRFLRRTLKITKRKTINATFTGTNVTSLPM 400 
HAN21      321 SPFESYVHWEETNVTSDVTSNVTSLENTTTVMLILTKYAESDYIFLQDMCPRFLRKTLKLTRNKKRNSTFTGTNVTSLPM 400 
BE/29/2010 321 SPFESYVHWEETNVTSNVTSNVTSVENTTTVMLILTKYAESDYIFLQDMCPRFLRRTLKLTRNKKRNSTFTGTNVTSLPM 400 
BE/1/2010  321 SPFESYVHWEETNATSNMTSNVTSLENTTTVMLTLAKYAESDYIFLQDMCPRFLRRTLKITKRKTINATFTGTNVTSLPM 400 
BE/10/2011 321 SPFESYVHWEETNATSNMTSNVTSLENTTTVMLTLAKYAESDYIFLQDMCPRFLRRTLKITKRKTINATFTGTNVTSLPM 400 
PAV20      321 SPFESHVHWEETNATSNITSNVTSLENTTTVMLTLAKYAESDYIFLQDMCPRFLRRTLKLTKNKTRNATFTGTNVTSLPM 400 
PAV18      321 SPFESYVHWEETNATSNMTSNVTSLENTTTVMLTLAKYAESDYIFLQDMCPRFLRRTLKITKRKTINATFTGTNVTSLPM 400 
VR1814     321 SPFESHVHWEETNATSNITSNVTSLENTTTVMLTLAKYAESDYIFLQDMCPRFLRRTLKLTKNKTRNATFTGTNVTSLPM 400 
3157       321 SPFESHVHWEETNATSNITSNVTSLENTTTVMLTLAKYAESDYIFLQDMCPRFLRRTLKLTKKKTRNATFTGTNVTSLPM 400 
JP         321 SPFESHVHWEETNATSNITSNVTSLENTTTVMLTLAKYAESDYIFLQDMCPRFLRRTLKLTKNKTRNATFTGTNVTSLPM 400 
Merlin     321 SPFESSVNWEETNVTDNATS---SENNTVTVMSVLTVYAESDYIFLQDMCPRFLKRSVKLAKNNRRNTTFTGTNVTSLPE 397 
 
ZMB240     401 WT-PECEGWKYWTTLSIMWKNRRSALLRAKSRALGHWALLSICTVAAGSIALLSLFCILLIGLRRDLLEDFRYICRDEGS 479 
HAN40      401 WT-PECEGWKYWTTLSIMWKNRRSALLRAKSRALGHWALLSICTVAAGSIALLSLFCILLIGLRRDLLEDFRYICRDEGS 479 
HAN21      401 WT-PECEGWKYWTTLSVMWRNRRSALLRAKSRALGHWALLSICTVAAGSIALLSLFCILLIGLRRDLLEDFRYICRDEGS 479 
BE/29/2010 401 WT-PECEGWKYWITLSTMWKNRRSALLRAKSRALGHWALLSICTVAAGSIALLSLFCILLIGLRRDLLEDFRYICRDEGS 479 
BE/1/2010  401 WT-PECEGWKYWTTLSIMWKNRRSDLLRAKSRALGHWALLSICTVAAGSIALLSLFCILLIGLRRDLLEDFRYICRDEGS 479 
BE/10/2011 401 WT-PECEGWKYWTTLSIMWKNRRSALLRAKSRALGHWALLSICTVAAGSIALLSLFCILLIGLRRDLLEDFRYICRDEGS 479 
PAV20      401 WT-PKCDGWKYWITLSMMWRNRRSALLRAKSRALGHWALLSICTVAAGSIALLSLFCILLIGLRRDLLEDFRYICRDEGS 479 
PAV18      401 WT-PECEGWKYWTTLSIMWKNRRSALLRAKSRALGHWALLSICTVAAGSIALLSLFCILLIGLRRDLLEDFRYICRDEGS 479 
VR1814     401 WT-PKCDGWKYWITLSMMWRNRRSALLRAKSRALGHWALLSICTVAAGSIALLSLFCILLIGLRRDLLEDFRYICRDEGG 479 
3157       401 WT-PQCEGWKYWITLSMMWRNRRSALLRAKSRALGHWALLSICTVAAGSIALLSLFCILLIGLRRDLLEDFRYICRDEGS 479 
JP         401 WT-PKCDGWKYWITLSMMWRNRRSALLRAKSRALGHWALLSICTVAAGSIALLSLFCILLIGLRRDLLEDFRYICRDEGG 479 
Merlin     398 WTLQQCQGWKYWTTLSIMWKNRRSALLRAKSRALGHWALLSICTVAAGSIALLSLFCILLIGLRRDLLEDFRYICRDEGS 477 
 
ZMB240     480  SSTKNDVHRIV  490 
HAN40      480  SSTKNDVHRIV  490 
HAN21      480  SSTKNDVHRIV  490 
BE/29/2010 480  SSTKNDVHRIV  490 
BE/1/2010  480  SSTKNDVHRIV  490 
BE/10/2011 480  SSTKNDVHRIV  490 
PAV20      480  SSTKNDVHRIV  490 
PAV18      480  SSTKNDVHRIV  490 
VR1814     480  SSTKNDVHRIV  490 
3157       480  SSTKNDVHRIV  490 
JP         480  SSTKNDVHRIV  490 
Merlin     478  SSTKNDVHWIV  488 
 
Figure 5.25. ZMB240 UL37 amino acid alignment. The sequence has three amino acids 
inserted after position 340, giving an additional glycosylation site (NVT). Further, one 
residue is deleted at position 400. These sequence differences – relative to HCMV strain 
Merlin AY446894.2 – are highlighted by the red borders, and also present in the 10 




ZMB240     1 MEPTPMLRDRDHDDAPPTYEQAMGLCPTTVSTPPPPPPDCSPPPYRPPYCLVSSPSPRHTFDMDMMEMPATMHPTTGAYF 80 
BE/11/2010 1 MEPTPMLRDRDHDDAPPTYEQAMGLCPTTVSTPPPPPPDCSPPPYRPPYCLVSSPSPRHTFDMDMMEMPATMHPTTGAYF 80 
Merlin     1 MEPTPMLRDRDHDDAPPTYEQAMGLCPTTVSTPPPPPPDCSPPPYRPPYCLVSSPSPRHTFDMDMMEMPATMHPTTGAYF 80 
 
ZMB240     81 DNGWKWTFALLVVAILGIIFLAVVFTVVINRDNST-TTGT--TSG 122 
BE/11/2010 81 DNGWKWTFALLVVAILGIIFLAVVFTVVINRDNST-TTGT--TSG 122 
Merlin     81 DNGWKWTFALLVVAILGIIFLAVVFTVVINRDSANITTGTQASSG 125 
 
Figure 5.26. ZMB242 UL42 amino acid alignment. There are three deletions in the 
ZMB240 sequence at positions 116, 121, and 122, highlighted by the red borders, 
relative to HCMV strain Merlin AY446894.2. The deletions are also present in HCMV 
strain BE/11/2010, as shown here.  
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ZMB240 1    MKVTQASCHQGDIARFGARAGNQCVCNGIMFLHALHLGGTSAVLQTEALDAIMEEGARLDARLERELQKKLPAGGRLPVY  80 
Towne  1    MKVTQASCHQGDIARFGARAGNQCVCNGIMFLHALHLGGTSAVLQTEALDAIMEEGARLDARLERELQKKLPAGGRLPVY  80 
3157   1    MKVTQASCHQGDIARFGARAGNQCVCNGIMFLHALHLGGTSAVLQTEALDAIMEEGARLDARLERELQKKLPAGGRLPVY  80 
HAN20  1    MKVTQASCHQGDIARFGARAGNQCVCNGIMFLHALHLGGTSAVLQTEALDAIMEEGARLDARLERELQKKLPAGGRLPVY  80 
VR1814 1    MKVTQASCHQGDIARFGARAGNQCVCNGIMFLHALHLGGTSAVLQTEALDAIMEEGARLDARLERELQKKLPAGGRLPVY  80 
U8     1    MKVTQASCHQGDIARFGARAGNQCVCNGIMFLHALHLGGTSAVLQTEALDAIMEEGARLDARLERELQKKLPAGGRLPVY  80 
Merlin 1    MKVTQASCHQGDIARFGARAGNQCVCNGIMFLHALHLGGTSAVLQTEALDAIMEEGARLDARLERELQKKLPAGGRLPVY  80 
 
ZMB240 81   RLGDEVPRRLESRFGRTVHALSRPFNGTTETCDLDGYMCPGIFDFLRYAHAKPRPTYVLVTVNSLARAVVFTEDHMLVFD  160 
Towne  81   RLGDEVPRRLESRFGRTVHALSRPFNGTTETCDLDGYMCPGIFDFLRYAHAKPRPTYVLVTVNSLARAVVFTEDHMLVFD  160 
3157   81   RLGDEVPRRLESRFGRTVHALSRPFNGTTETCDLDGYMCPGIFDFLRYAHAKPRPTYVLVTVNSLARAVVFTEDHMLVFD  160 
HAN20  81   RLGDEVPRRLESRFGRTVHALSRPFNGTTETCDLDGYMCPGIFDFLRYAHAKPRPTYVLVTVNSLARAVVFTEDHMLVFD  160 
VR1814 81   RLGDEVPRRLESRFGRTVHALSRPFNGTTETCDLDGYMCPGIFDFLRYAHAKPRPTYVLVTVNSLARAVVFTEDHMLVFD  160 
U8     81   RLGDEVPRRLESRFGRTVHALSRPFNGTTETCDLDGYMCPGIFDFLRYAHAKPRPTYVLVTVNSLARAVVFTEDHMLVFD  160 
Merlin 81   RLGDEVPRRLESRFGRTVHALSRPFNGTTETCDLDGYMCPGIFDFLRYAHAKPRPTYVLVTVNSLARAVVFTEDHMLVFD  160 
 
ZMB240 161  PHSSAECHNAAVYHCEGLHQVLMVLTGFGVQLSPAFYYEALFLYMLDVATVPEAEIAARLVSTYRDRDIDLTGVVRESAD  240 
Towne  161  PHSSAECHNAAVYHCEGLHQVLMVLTGFGVQLSPAFYYEALFLYMLDVATVPEAEIAARLVSTYRDRDIDLTGVVRESAD  240 
3157   161  PHSSAECHNAAVYHCEGLHQVLMVLTGFGVQLSPAFYYEALFLYMLDVATVPEAEIAARLVSTYRDRDIDLTGVVRESAD  240 
HAN20  161  PHSSAECHNAAVYHCEGLHQVLMVLTGFGVQLSPAFYYEALFLYMLDVATVPEAEIAARLVSTYRDRDIDLTGVVRESAD  240 
VR1814 161  PHSSAECHNAAVYHCEGLHQVLMVLTGFGVQLSPAFYYEALFLYMLDVATVPEAEIAARLVSTYRDRDIDLTGVVRESAD  240 
U8     161  PHSSAECHNAAVYHCEGLHQVLMVLTGFGVQLSPAFYYEALFLYMLDVATVPEAEIAARLVSTYRDRDIDLTGVVRESAD  240 
Merlin 161  PHSSAECHNAAVYHCEGLHQVLMVLTGFGVQLSPAFYYEALFLYMLDVATVPEAEIAARLVSTYRDRDIDLTGVVRESAD  240 
 
ZMB240 241  TAATTTTAAPSLPPLPDPIVDPGCPPGVAPSIPVYDPSSSPKKTPDKRRKDLSGSKHGGKKKPPSTTSKTLATASSS-SA  319 
Towne  241  TAATTTTAAPSLPPLPDPIVDPGCPPGVAPSIPVYDPSSSPKKTPEKRRKDLSGSKHGGKKKPPSTTSKTLATASSS-SA  319 
3157   241  TAATTTTAAPSLPPLPDPIVDPGCPPGVAPSIPVYDPSSSPKKTPEKRRKDLSGSKHGGKKKPPSTTSKTLATASSS-SA  319 
HAN20  241  TAATTTTAAPSLPPLPDPIVDPGCPPGVAPSIPVYDPSSSPKKTPEKRRKDLSGSKHGGKKKPPSTTSKTLATASSS-SA  319 
VR1814 241  TAATTTTAAPSLPPLPDPIVDPGCPPGVAPSIPVYDPSSSPKKTPEKRRKDLSGSKHGGKKKPPSTTSKTLATASSS-SA  319 
U8     241  TAATTTTAAPSLPPLPDPIVDPGCPPGVAPSIPVYDPSSSPKKTPEKRRKDLSGSKHGGKKKPPSTTSKTLATASSS-SA  319 
Merlin 241  TAATTTTAAPSLPPLPDPIVDPGCPPGVAPSIPVYDPSSSPKKTPEKRRKDLSGSKHGGKKKPPSTTSKTLATASSSPSA  320 
 
ZMB240 320  IAAASSSSAVPPSYSCGEGALPALGRYQQLVDEVEQELKALTLPPLPANTSAWTLHAAGTESGANAATATAPSFDEAFLT  399 
Towne  320  IAAASSSSAVPPSYSCGEGALPALGRYQQLVDEVEQELKALTLPPLPANTSAWTLHAAGTESGANAATATAPSFDEAFLT  399 
3157   320  IAAASSSSAVPPSYSCGEGALPALGRYQQLVDEVEQELKALTLPPLPANTSAWTLHAAGTESGANAATATAPSFDEAFLT  399 
HAN20  320  IAAASSSSAVPPSYSCGEGALPALGRYQQLVDEVEQELKALTLPPLPANTSAWTLHAAGTESGANAATATAPSFDEAFLT  399 
VR1814 320  IAAASSSSAVPPSYSCGEGALPALGRYQQLVDEVEQELKALTLPPLPANTSAWTLHAAGTESGANAATATAPSFDEAFLT  399 
U8     320  IAAASSSSAVPPSYSCGEGALPALGRYQQLVDEVEQELKALTLPPLPANTSAWTLHAAGTESGANAATATAPSFDEAFLT  399 
Merlin 321  IAAASSSSAVPPSYSCGEGALPALGRYQQLVDEVEQELKALTLPPLPANTSAWTLHAAGTESGANAATATAPSFDEAFLT  400 
 
Figure 5.27. ZMB240 UL48 amino acid alignment. There is an amino acid deletion at 
position 318 (red border) relative to HCMV strain Merlin AY446894.2. This deletion is 
also present in 61 full genome HCMV strains (table 5.10), five of which are included in 
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ZMB240     1   MEINKVLHQDLVQATRRILKLGPSELRVTDAGLICKNPNYSVCDAMLKTDTVYCVEYLLSYWESRTDHVPCFIFKNTGCA 80 
AD169      1   MEMNKVLHQDLVQATRRILKLGPSELRVTDAGLICKNPNYSVCDAMLKTDTVYCVEYLLSYWESRTDHVPCFIFKNTGCA 80 
BE/46/2011 1   MEMNKVLHQDLVQATRRILKLGPSELRVTDAGLICKNPNYSVCDAMLKTDTVYCVEYLLSYWESRTDHVPCFIFKNTGCA 80 
BE/10/2010 1   MEMNKVLHQDLVQATRRILKLGPSELRVTDAGLICKNPNYSVCDAMLKTDTVYCVEYLLSYWESRTDHVPCFIFKNTGCA 80 
BE/9/2010  1   MEMNKVLHQDLVQATRRILKLGPSELRVTDAGLICKNPNYSVCDAMLKTDTVYCVEYLLSYWESRTDHVPCFIFKNTGCA 80 
Merlin     1   MEMNKVLHQDLVQATRRILKLGPSELRVTDAGLICKNPNYSVCDAMLKTDTVYCVEYLLSYWESRTDHVPCFIFKNTGCA 80 
 
ZMB240     81  VSLCCFVRAPVKLVSPARHVGEFNVLKVNESLIVTLKDIEEIKPSAYGVLTKCVVRKSNSASVFNIELIAFGPENEGEYE 160 
AD169      81  VSLCCFVRAPVKLVSPARHVGEFNVLKVNESLIVTLKDIEEIKPSAYGVLTKCVVRKSNSASVFNIELIAFGPENEGEYE 160 
BE/46/2011 81  VSLCCFVRAPVKLVSPARHVGEFNVLKVNESLIVTLKDIEEIKPSAYGVLTKCVVRKSNSASVFNIELIAFGPENEGEYE 160 
BE/10/2010 81  VSLCCFVRAPVKLVSPARHVGEFNVLKVNESLIVTLKDIEEIKPSAYGVLTKCVVRKSNSASVFNIELIAFGPENEGEYE 160 
BE/9/2010  81  VSLCCFVRAPVKLVSPARHVGEFNVLKVNESLIVTLKDIEEIKPSAYGVLTKCVVRKSNSASVFNIELIAFGPENEGEYE 160 
Merlin     81  VSLCCFVRAPVKLVSPARHVGEFNVLKVNESLIVTLKDIEEIKPSAYGVLTKCVVRKSNSASVFNIELIAFGPENEGEYE 160 
 
ZMB240     161 NLLRELYAKKAASTSLAVRNHVTVSSHSGSGPSLWRARMSAALTRTAGKRSSRTAS-PPPPPRHPSCSPTMVAAGGAAAG 239 
AD169      161 NLLRELYAKKAASTSLAVRNHVTVSSHSGSGPSLWRARMSAALTRTAGKRSSRTAS-PPPPPRHPSCSPTMVAAGGAAAG 239 
BE/46/2011 161 NLLRELYAKKAASTSLAVRNHVTVSSHSGSGPSLWRARMSAALTRTAGKRSSRTAS-PPPPPRHPSCSPTMVAAGGAAAG 239 
BE/10/2010 161 NLLRELYAKKAASTSLAVRNHVTVSSHSGSGPSLWRARMSAALTRTAGKRSSRTAS-PPPPPRHPSCSPTMVAAGGAAAG 239 
BE/9/2010  161 NLLRELYAKKAASTSFAVRNHVTVSSHSGSGPSLWRARMSAALTRTAGKRSSRTAS-PPPPPRHPSCSPTMVAAGGAAAG 239 
Merlin     161 NLLRELYAKKAASTSLAVRNHVTVSSHSGSGPSLWRARMSAALTRTAGKRSPRTASPPPPPPRHPSCSPTMVAAGGAAAG 240 
 
ZMB240     240 PRPPPPPMAAGSWRLCRCEACMGRCGCASEGDADEEEEELLALAGEGKAAAAAAGQDVGGSARRPLEEHVSRRRGVSTHH 319 
AD169      240 PRPPPPPMAAGSWRLCRCEACMGRCGCASEGDADEEEEELLALAGEGKAAAAAAGQDVGGSARRPLEEHVSRRRGVSTHH 319 
BE/46/2011 240 PRPPPPPMAAGSWRLCRCEACMGRCGCASEGDADEEEEELLALAGEGKAAAAAAGQDVGGSARRPLEEHVSRRRGVSTHH 319 
BE/10/2010 240 PRPPPPPMAAGSWRLCRCEACMGRCGCASEGDADEEEEELLALAGEGKAATAAAGQDVGGSARRPLEEHVSRRRGVSTHH 319 
BE/9/2010  240 PRPPPPPMAAGSWRLCRCEACMGRCGCASEGDADEEEEELLALAGEGKAAAAAAGQDVGGSARRPLEEHVSRRRGVSTHH 319 
Merlin     241 PRPPPPPMAAGSWRLCRCEACMGRCGCASEGDADEEEEELLALAGEGKAAAAAAGQDIGGSARRPLEEHVSRRRGVSTHH 320 
 
ZMB240     320 RHPPSPPCAPSLERTGYRWAPSSWWRARSGPSRPQSGPWLPARFAILGPLVLALLLVLALLWRGHGQSSSPTRSAHRD 397 
AD169      320 RHPPSPPCAPSLERTGYRWAPSSWWRARSGPSRPQSGPWLPARFATLGPLVLALLLVLALLWRGHGQSSSPTRSAHRD 397 
BE/46/2011 320 RHPPSPPCAPSLERTGYRWAPSSWWRARSGSSRPQSGPWLPARFATLGPLVLALLLVLALLWRGHGQSSSPTRSAHRD 397 
BE/10/2010 320 RHPPSPPCAPSLERTGYRWAPSSWWRARSGPSRPQSGPWLPARFATLGPLVLALLLVLALLWRGHGQSSSPTRSAHRD 397 
BE/9/2010  320 RHPPSPPCAPSLERTGYRWAPSSWWRARSGPSRPQSGPWLPARFATLGPLVLALLLVLALLWRGHGQSSSPTRSAHRD 397 
Merlin     321 RHPPSPPCTPSLERTGYRWAPSSWWRARSGPSRPQSGPWLPARFATLGPLVLALLLVLALLWRGHGQSSSPTRSAHRD 398 
 
Figure 5.28. ZMB240 UL50 amino acid alignment. Similar to the four HCMV strains 
included in this alignment, the ZMB240 UL50 product has a single residue deleted at 





ZMB240 1    -----MIMVKGIPKIMLLISITFLLLSLINCNVLVNSRGTRRSWPYTVLSYRGKEILKKQKEDILKRLMSTSSDGYRFLM  75 
JP     1    -----MIMVKGIPKIMLLISITFLLLSLINCNVLVNSRGTRRSWPYTVLSYRGKEILKKQKEDILKRLMSTSSDGYRFLM  75 
Merlin 1    MGKKEMIMVKGIPKIMLLISITFLLLSLINCNVLVNSRGTRRSWPYTVLSYRGKEILKKQKEDILKRLMSTSSDGYRFLM  80 
 
ZMB240 76   YPSQQKFHAIVISMDKFPQDYILAGPIRNDSITHMWFDFYSTQLRKPAKYVYSEYNHTAHKITLRPPPCGTVPSMNCLSE  155 
JP     76   YPSQQKFHAIVISMDKFPQDYILAGPIRNDSITHMWFDFYSTQLRKPAKYVYSEYNHTAHKITLRPPPCGTVPSMNCLSE  155 
Merlin 81   YPSQQKFHAIVISMDKFPQDYILAGPIRNDSITHMWFDFYSTQLRKPAKYVYSEYNHTAHKITLRPPPCGTVPSMNCLSE  160 
 
ZMB240 156  MLNVSKRNDTGEKGCGNFTTFNPMFFNVPRWNTKLYIGSNKVNVDSQTIYFLGLTALLLRYAQRNCTRSFYLVNAMSRNL  235 
JP     156  MLNVSKRNDTGEKGCGNFTTFNPMFFNVPRWNTKLYIGSNKVNVDSQTIYFLGLTALLLRYAQRNCTRSFYLVNAMSRNL  235 
Merlin 161  MLNVSKRNDTGEKGCGNFTTFNPMFFNVPRWNTKLYIGSNKVNVDSQTIYFLGLTALLLRYAQRNCTRSFYLVNAMSRNL  240 
 
ZMB240 236  FRVPKYINGTKLKNTMRKLKRKQALVKEQPQKKNKKSQSTTTPYLSYTTSTAFNVTTNVTYSATAAVTRVATSTTGYRPD  315 
JP     236  FRVPKYINGTKLKNTMRKLKRKQALVKEQPQKKNKKSQSTTTPYLSYTTSTAFNVTTNVTYSATAAVTRVATSTTGYRPD  315 
Merlin 241  FRVPKYINGTKLKNTMRKLKRKQALVKEQPQKKNKKSQSTTTPYLSYTTSTAFNVTTNVTYSATAAVTRVATSTTGYRPD  320 
 
ZMB240 316  SNFMKSIMATQLRDLATWVYTTLRYRNEPFCKPDRNRTAVSEFMKNTHVLIRNETPYTIYGTLDMSSLYYNETMSVENET  395 
JP     316  SNFMKSIMATQLRDLATWVYTTLRYRNEPFCKPDRNRTAVSEFMKNTHVLIRNETPYTIYGTLDMSSLYYNETMSVENET  395 
Merlin 321  SNFMKSIMATQLRDLATWVYTTLRYRNEPFCKPDRNRTAVSEFMKNTHVLIRNETPYTIYGTLDMSSLYYNETMSVENET  400 
 
ZMB240 396  ASDNNETTPTSPSTRFQRTFIDPLWDYLDSLLFLDKIRNFSLQLPAYGNLTPPEHRRAANLSTLNSLWWWSQ  467 
JP     396  ASDNNETTPTSPSTRFQRTFIDPLWDYLDSLLFLDKIRNFSLQLPAYGNLTPPEHRRAANLSTLNSLWWWSQ  467 
Merlin 401  ASDNNETTPTSPSTRFQRTFIDPLWDYLDSLLFLDKIRNFSLQLPAYGNLTPPEHRRAANLSTLNSLWWWSQ  472 
 
Figure 5.29. ZMB240 UL74 amino acid alignment. Compared to HCMV strain Merlin 
(AY446894.2), the first five amino acids are deleted in HCMV genotype gO5 strains 
ZMB240 and JP as highlighted by the red border.  
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ZMB240 1    MSLLHTFWRLPVAVFFEPHEENVLRCPERVLRRLLEDAAVAMRGGGWREDVLMDRVRKRYLRQELRDLGHRVQTYCEDLE  80 
Towne  1    MSLLHTFWRLPVAVFFEPHEENVLRCPERVLRRLLEDAAVAMRGGGWREDVLMDRVRKRYLRQELRDLGHRVQTYCEDLE  80 
Merlin 1    MSLLHTFWRLPVAVFFEPHEENVLRCPERVLRRLLEDAAVAMRGGGWREDVLMDRVRKRYLRQELRDLGHRVQTYCEDLE  80 
 
ZMB240 81   GRVSEAEALLNQQCELDEGPSPRTLLQPPCRPRSSSPGTGVAGASAVPHGLYSRHDAITGP-ATPSDAATASAAAGASST  159 
Towne  81   GRVSEAEALLNQQCELDEGPSPRTLLQPPCRPRSSSPGTGVAGASAVPHGLYSRHDAITGP-ATPSDAATASAAAGASST  159 
Merlin 81   GRVSEAEALLNQQCELDEGPSPRTLLQPPCRPRSSSPGTGVAGASAVPHGLYSRHDAITGPVAAPSDAVAASAAAGASST  160 
 
ZMB240 160  WLAQCAERPLPGNVPSYFGITQNDPFIRFHTDFRGEVVNTMFENASTWTFSFGIWYYRLKRGLYTQPRWKRVYHLAQMDN  239 
Towne  160  WLAQCAERPLPGNVPSYFGITQNDPFIRFHTDFRGEVVNTMFENASTWTFSFGIWYYRLKRGLYTQPRWKRVYHLAQMDN  239 
Merlin 161  WLAQCAEQPLPGNVPNYFGITQNDPFIRFHTDFRGEVVNTMFENASTWTFSFGIWYYRLKRGLYTQPRWKRVYHLAQMDN  240 
 
ZMB240 240  FSISQELLLGVVNALENVTVYPTYDCVLSDLEAAACLLAAYGHALWEGRDPPDSVATVLGELPQLLPRLADDVSREIAAW  319 
Towne  240  FSISQELLLGVVNALENVTVYPTYDCVLSDLEAAACLLAAYGHALWEGRDPPDSVATVLGELPQLLPRLADDVSREIAAW  319 
Merlin 241  FSISQELLLGVVNALENVTVYPTYDCVLSDLEAAACLLVAYGHALWEGRDPPDSVTAVLSELPQLLPRLADDVSREIAAW  320 
 
ZMB240 320  EGPVAAGNNYYAYRDSPDLRYYMPLSGGRHYHPGTFDRHVLVRLFHKRGVIQHLPGYGTITEELVQERLSGQVRDDVLSL  399 
Towne  320  EGPVAAGNNYYAYRDSPDLRYYMPLSGGRHYHPGTFDRHVLVRLFHKRGVIQHLPGYGTITEELVQERLSGQVRDDVLSL  399 
Merlin 321  EGPVAAGNNYYAYRDSPDLRYYMPLSGGRHYHPGTFDRHVLVRLFHKRGVLQHLPGYGTITEELVQERLSGQVRDDVLSL  400 
 
ZMB240 400  WSRRLLVGKLGRDVPVFVHEQQYLRSGLTCLAGLLLLWKVTNADSVFAPRTGKFTLADLLGSDAVAGGGLPGGRAGGEEE  479 
Towne  400  WSRRLLVGKLGRDVPVFVHEQQYLRSGLTCLAGLLLLWKVTNADSVFAPRTGKFTLADLLGSDAVAGGGLPGGRAGGEEE  479 
Merlin 401  WSRRLLVGKLGRDVPVFVHEQQYLRSGLTCLAGLLLLWKVTNADSVFAPRTGKFTLADLLGSDAVAGGGLPGGRAGGEEK  480 
 
ZMB240 480  GYGGRHGRVRNFEFLVQYYIGPWYARDPAVTLSQLFPGLALLAVTESVRSGWDPSRREDSAGGGDGGGAVLMQLSKSNPV  559 
Towne  480  GYGGRHGRVRNFEFLVQYYIGPWYARDPAVTLSQLFPGLALLAVTESVRSGWDPSRREDSAGGGDGGGAVLMQLSKSNPV  559 
Merlin 481  GYGGRHGRVRNFEFLVQYYIGPWYARDPAVTLSQLFPGLALLAVTESVRSGWDPSRREDSAGGGDGGGAVLMQLSKSNPV  560 
 
ZMB240 560  ADYMFAQSSKQYGDLRRLEVHDALLFHYEHGLGRLLSVTLPRHRVSTLGSSLFNVNDIYELLYFLVLGFLPSVAVL  635 
Towne  560  ADYMFAQSSKQYGDLRRLEVHDALLFHYEHGLGRLLSVTLPRHRVSTLGSSLFNVNDIYELLYFLVLGFLPSVAVL  635 
Merlin 561  ADYMFAQSSKQYGDLRRLEVHDALLFHYEHGLGRLLSVTLPRHRVSTLGSSLFNVNDIYELLYFLVLGFLPSVAVL  636 
 
Figure 5.30. ZMB240 UL77 amino acid alignment. Like HCMV strain Towne, ZMB240 
UL77 has an amino acid deletion at position 142, highlighted by the red border, relative 





ZMB240     1    MMAAAVVRAEVRRQRREERKKMAAARTTEDPPENDVVADVACGTGAVTRSSSSSLVVSSSSASGSDESSSASPLSFPVSS  80 
BE/6/2012  1    MMAAAVVRAEVRRQRREERKKMAAARTTEDPPENHVVADVACGTGAVTRSSSSSLVVSSSSASGSDESSSASPLSFPVCS  80 
BE/46/2011 1    MMAAAVVRAEVRRQRREERKKMAVARTTEDPPENHVVADVACGTGAVTRSSSSSLVVSSSSASGSDEPSSASPLSFPVCS  80 
BE/1/2010  1    MMAAAVVRAEVRRQRREERKKMAAARTTEDPPENHVVADVVCGTGAVTRSSSSSLVVSSSSASGSDEPSSASPLSFPVCS  80 
BE/8/2011  1    MMAAAVVRAEVRRQRREERKKMAAARTTEDPPENHVVADVACGTGAVTRSSSSSLVVSSSSASGSDESSSASPLSFPVSS  80 
Towne      1    MMAAAVVRAEVRRQRREERKKMAAARTTEDPPENHVVADVACGTGAVTRSSSSSLVVSSSSASGSDEPSSASPLSFPVCS  80 
Merlin     1    MMAAAVVRAEVRRQRREERKKMASARTTEDPPENHVVADVACGTGAVTRSSSSSLVVSSSSASGSDESSSASPLSFPVSS  80 
 
ZMB240     81   PSTAVRSPGSAGVSTSLCSVERMVELSAQSPAADFSVSEAWRFEEAVNMALVACEAVSPYDRFRLIETPDENFLLVTNVI  160 
BE/6/2012  81   PSTAVRSPGSAGVSTSLCSVERMVELSAQSPAADFSVSEAWRFEEAVNMALVACEAVSPYDRFRLIETPDENFLLVTNVI  160 
BE/46/2011 81   PSTAVRSPGSAGVSTSLCSVERMVELSAQSPAADFSVSEAWRFEEAVNMALVACEAVSPYDRFRLIETPDENFLLVTNVI  160 
BE/1/2010  81   PSTAVRSPGSAGVSTSLCSVERMVELSAQSPAADFSVSEAWRFEEAVNMALVACEAVSPYDRFRLIETPDENFLLVTNVI  160 
BE/8/2011  81   PSTAVRSPGSAGVSTSLCSVERMVELSAQSPAADFSVSEAWRFEEAVNMALVACEAVSPYDRFRLIETPDENFLLVTNVI  160 
Towne      81   PSTAVRSPGSAGVSTSLCSVERMVELSAQSPAADFSVSEAWRFEEAVNMALVACEAVSPYDRFRLIETPDENFLLVTNVI  160 
Merlin     81   PSTAVRSPGSAGVSTSLCSVERMVELSAQSPAADFSVSEAWRFEEAVNMALVACEAVSPYDRFRLIETPDENFLLVTNVI  160 
 
ZMB240     161  PRESAEVPVLDSSSSGGDSGPEDKKKNVGNKTAGEKNGGGSRAKRRRRRRAPKNDAATPSFLRRHDVLERFAAAAEPLPS  240 
BE/6/2012  161  PRESAEVPVLDSSSSGGDSGPEDKKKNVGNKTAGEKNGGGSRAKRRRRRRAPKNDAATPSFLRRHDVLERFAAAAEPLPS  240 
BE/46/2011 161  PRESAEVPVLDSSSSGGDSGPEDKKKNVGNKTAGEKNGGGSRAKRRRRRRAPKNDAATPSFLRRHDVLERFAAAAEPLPS  240 
BE/1/2010  161  PRESAEVPVLDSSSSGGDSGPEDKKKNVGNKTAGEKNGGGSRAKRRRRRRAPKNDAATPSFLRRHDVLERFAAAAEPLPS  240 
BE/8/2011  161  PRESAEVPVLDSSSSGGDSGPEDKKKNVGNKTAGEKNGGGSRAKRRRRRRAPKNDAATPSFLRRHDVLERFAAAAEPLPS  240 
Towne      161  PRESAEVPVLDSSSSGGDSGPEDKKKNVGNKTAGEKNGGGSRAKRRRRRRAPKNDAATPSFLRRHDVLERFAAAAEPLPS  240 
Merlin     161  PRESAEVPVLDSSSSGGDSGPEDKKKNVGNKTAGEKNGGGSRAKRRRRRRAPKNDAATPSFLRRHDVLERFAAAAEPLPS  240 
 
ZMB240     241  LCVRDYALRNADRVTYDGELIYGSYLLYRKAHVELSLSSNKVQHVEAVLRQVYTPGLLDHHNVCDVEALLWLLYCGPRSF  320 
BE/6/2012  241  LCVRDYALRNADRVTYDGELIYGSYLLYRKAHVELSLSSNKVQHVEAVLRQVYTPGLLDHHNVCDVEALLWLLYCGPRSF  320 
BE/46/2011 241  LCVRDYALRNADRVTYDGELIYGSYLLYRKAHVELSLSSNKVQHVEAVLRQVYTPGLLDHHNVCDVEALLWLLYCGPRSF  320 
BE/1/2010  241  LCVRDYALRNADRVTYDGELIYGSYLLYRKAHVELSLSSNKVQHVEAVLRQVYTPGLLDHHNVCDVEALLWLLYCGPRSF  320 
BE/8/2011  241  LCVRDYALRNADRVTYDGELIYGSYLLYRKAHVELSLSSNKVQHVEAVLRQVYTPGLLDHHNVCDVEALLWLLYCGPRSF  320 
Towne      241  LCVRDYALRNADRVTYDGELIYGSYLLYRKAHVELSLSSNKVQHVEAVLRQVYTPGLLDHHNVCDVEALLWLLYCGPRSF  320 
Merlin     241  LCVHDYALRNADRVTYDGELIYGSYLLYRKAHVELSLSSNKVQHVEAVLRQVYTPGLLDHHNVCDVEALLWLLYCGPRSF  320 
 
ZMB240     321  CARDTCFGREKNGCPFPALLPKLFYEPVRDYMTYMNLAELYVFVWYRGYEFPAPTPQATTA------GSGGGGGAGACAV  394 
BE/6/2012  321  CARDTCFGREKNGCPFPALLPKLFYEPVRDYMTYMNLAELYVFVWYRGYEFPAPTPQATTA------GSGGGGGAGACAV  394 
BE/46/2011 321  CARDTCFGREKNGCPFPALLPKLFYEPVRDYMTYMNLAELYVFVWYRGYEFPAPTPQATTA------GSGGGGGAGACAV  394 
BE/1/2010  321  CARDTCFGREKNGCPFPALLPKLFYEPVRDYMTYMNLAELYVFVWYRGYEFPAPTPQATTA------GSGGGGGAGACAV  394 
BE/8/2011  321  CARDTCFGREKNGCPFPALLPKLFYEPVRDYMTYMNLAELYVFVWYRGYEFPAPTPQATTA------GSGGGGGAGACAV  394 
Towne      321  CARDTCFGREKNGCPFPALLPKLFYEPVRDYMTYMNLAELYVFVWYRGYEFPAPTPQATTA------GSGGGGGAGACAV  394 
Merlin     321  CARDTCFGREKNGCPFPALLPKLFYEPVRDYMTYMNLAELYVFVWYRGYEFPAPTPQATTAGGGGGGGSGGGGGAGACAV  400 
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ZMB240     395  ETSASAGRVDDAGDEVHLPLKPVSLDRLREVLQAVRGRFSGREVPAWPASSRTCLLCALYSQNRLCLDLARDEARTVSYS  474 
BE/6/2012  395  ETSASAGRVDDAGDEVHLPLKPVSLDRLREVLQAVRGRFSGREVPAWPASSRTCLLCALYSQNRLCLDLARDEARTVSYS  474 
BE/46/2011 395  ETSASAGRVDDAGDEVHLPLKPVSLDRLREVLQAVRGRFSGREVPAWPASSRTCLLCALYSQNRLCLDLARDEARTVSYS  474 
BE/1/2010  395  ETSASAGRVDDAGDEVHLPLKPVSLDRLREVLQAVRGRFSGREVPAWPASSRTCLLCALYSQNRLCLDLARDEARTVSYS  474 
BE/8/2011  395  ETSASAGRVDDAGDEVHLPLKPVSLDRLREVLQAVRGRFSGREVPAWPASSRTCLLCALYSQNRLCLDLARDEARTVSYS  474 
Towne      395  ETSASAGRVDDAGDEVHLPLKPVSLDRLREVLQAVRGRFSGREVPAWPASSRTCLLCALYSQNRLCLDLARDEARTVSYS  474 
Merlin     401  ETSASAGRVDDAGDEVHLPLKPVSLDRLREVLQAVRGRFSGREVPAWPASSRTCLLCALYSQNRLCLDLARDEARTVSYS  480 
 
ZMB240     475  PIVIQDCAAAVTDVTLSHILPGQSTVSLFPVYHVGKLLDALSLNDAGLITLNL  527 
BE/6/2012  475  PIVIQDCAAAVTDVTLSHILPGQSTVSLFPVYHVGKLLDALSLNDAGLITLNL  527 
BE/46/2011 475  PIVIQDCAAAVTDVTLSHILPGQSTVSLFPVYHVGKLLDALSLNDAGLITLNL  527 
BE/1/2010  475  PIVIQDCAAAVTDVTLSHILPGQSTVSLFPVYHVGKLLDALSLNDAGLITLNL  527 
BE/8/2011  475  PIVIQDCAAAVTDVTLSHILPGQSTVSLFPVYHVGKLLDALSLNDAGLITLNL  527 
Towne      475  PIVIQDCAAAVTDVTLSHILPGQSTVSLFPVYHVGKLLDALSLNDAGLITLNL  527 
Merlin     481  PIVIQDCAAAVTDVTLSHILPGQSTVSLFPVYHVGKLLDALSLNDAGLITLNL  533 
 
Figure 5.31. ZMB242 UL95 amino acid alignment. Relative to HCMV strain Merlin 
AY446894.2, ZMB240 UL95 has 6 deletions spanning positions 382-387, highlighted by 









ZMB240     1   MAPSHVDKVNTRTWSASIVFMVLTFVNVSVHLVLSNFPHLGYPCVYYHVVDFERLNMSAYNVMHLHTPMLFLDSVQLVCY  80 
HAN40      1   MAPSHVDKVNTRTWSASIVFMVLTFVNVSVHLVLSNFPHLGYPCVYYHVVDFERLNMSAYNVMHLHTPMLFLDSVQLVCY  80 
HAN11      1   MAPSHVDKVNTRTWSASIVFMVLTFVNVSVHLVLSNFPHLGYPCVYYHVVDFERLNMSAYNVMHLHTPMLFLDSVQLVCY  80 
HAN2       1   MAPSHVDKVNTRTWSASIVFMVLTFVNVSVHLVLSNFPHLGYPCVYYHVVDFERLNMSAYNVMHLHTPMLFLDSVQLVCY  80 
HAN1       1   MAPSHVDKVNTRTWSASIVFMVLTFVNVSVHLVLSNFPHLGYPCVYYHVVDFERLNMSAYNVMHLHTPMLFLDSVQLVCY  80 
2CEN2      1   MAPSHVDKVNTRTWSASIVFMVLTFVNVSVHLVLSNFPHLGYPCVYYHVVDFERLNMSAYNVMHLHTPMLFLDSVQLVCY  80 
UKNEQAS2   1   MAPSHVDKVNTRTWSASIVFMVLTFVNVSVHLVLSNFPHLGYPCVYYHVVDFERLNMSAYNVMHLHTPMLFLDSVQLVCY  80 
BE/4/2011  1   MTPSHVDKVNTRTWSASIVFMVLTFVNVSVHLVLSNFPHLGYPCVYYHVVDFERLNMSAYNVMHLHTPMLFLDSVQLVCY  80 
BE/23/2010 1   MAPSHVDKVNTRTWSASILFMVLTFVNVSVHLVLSNFPHLGYPCVYYHVVDFERLNMSAYNVMHLHTPMLFLDSVQLVCY  80 
BE/14/2011 1   MAPSHVDKVNTRTWSASIVFMVLTFVNVSVHLVLSNFPHLGYPCVYYHVVDFERLNMSAYNVMHLHTPMLFLDSVQLVCY  80 
HAN13      1   MAPSHVDKVNTRTWSASIVFMVLTFVNVSVHLVLSNFPHLGYPCVYYHVVDFERLNMSAYNVMHLHTPMLFLDSVQLVCY  80 
Merlin     1   MAPSHVDKVNTRTWSASIVFMVLTFVNVSVHLVLSNFPHLGYPCVYYHVVDFERLNMSAYNVMHLHTPMLFLDSVQLVCY  80 
 
ZMB240     81  AVFMQLVFLAVTIYYLVCWIKISMRKDKGMSLNQSTRDISYMGDSLTAFLFILSMDTFQLFTLTMSFRLPSMIAFMAAVH  160 
HAN40      81  AVFMQLVFLAVTIYYLVCWIKISMRKDKGMSLNQSTRDISYMGDSLTAFLFILSMDTFQLFTLTMSFRLPSMIAFMAAVH  160 
HAN11      81  AVFMQLVFLAVTIYYLVCWIKISMRKDKGMSLNQSTRDISYMGDSLTAFLFILSMDTFQLFTLTMSFRLPSMIAFMAAVH  160 
HAN2       81  AVFMQLVFLAVTIYYLVCWIKISMRKDKGMSLNQSTRDISYMGDSLTAFLFILSMDTFQLFTLTMSFRLPSMIAFMAAVH  160 
HAN1       81  AVFMQLVFLAVTIYYLVCWIKISMRKDKGMSLNQSTRDISYMGDSLTAFLFILSMDTFQLFTLTMSFRLPSMIAFMAAVH  160 
2CEN2      81  AVFMQLVFLAVTIYYLVCWIKISMRKDKGMSLNQSTRDISYMGDSLTAFLFILSMDTFQLFTLTMSFRLPSMIAFMAAVH  160 
UKNEQAS2   81  AVFMQLVFLAVTIYYLVCWIKISMRKDKGMSLNQSTRDISYMGDSLTAFLFILSMDTFQLFTLTMSFRLPSMIAFMAAVH  160 
BE/4/2011  81  AVFMQLVFLAVTIYYLVCWIKISMRKDKGMSLNQSTRDISYMGDSLTAFLFILSMDTFQLFTLTMSFRLPSMIAFMAAVH  160 
BE/23/2010 81  AVFMQLVFLAVTIYYLVCWIKISMRKDKGMSLNQSTRDISYMGDSLTAFLFILSMDTFQLFTLTMSFRLPSMIAFMAAVH  160 
BE/14/2011 81  AVFMQLVFLAVTIYYLVCWIKISMRKDKGMSLNQSTRDISYMGDSLTAFLFILSMDTFQLFTLTMSFRLPSMIAFMAAVH  160 
HAN13      81  AVFMQLVFLAVTIYYLVCWIKISMRKDKGMSLNQSTRDISYMGDSLTAFLFILSMDTFQLFTLTMSFRLPSMIAFMAAVH  160 
Merlin     81  AVFMQLVFLAVTIYYLVCWIKISMRKDKGMSLNQSTRDISYMGDSLTAFLFILSMDTFQLFTLTMSFRLPSMIAFMAAVH  160 
 
ZMB240     161 FFCLTIFNVSMVTQYRSYKRSLFFFSRLHPKLKGTVQFRTLIVNLVEVALGFNTTVLAMALCYGFGNNFFVRTGHMVLAV  240 
HAN40      161 FFCLTIFNVSMVTQYRSFKRSLFFFSRLHPKLKGTVQFRTLIVNLVEMALGFNTTVVAMALCYGFGNNFFVRTGHMVLAV  240 
HAN11      161 FFCLTIFNVSMVTQYRSYKRSLFFFSRLHPKLKGTVQFRTLIVNLVEMALGFNTTVVAMALCYGFGNNFFVRTGHMVLAV  240 
HAN2       161 FFCLTIFNVSIVTQYRSFKRSLFFFSRLHPKLKGTVQFRTLIVNLVEMALGFNTTVVAMALCYGFGNNFFVRTGHMVLAV  240 
HAN1       161 FFCLTIFNVSMVTQYRSFKRSLFFFSRLHPKLKGTVQFRTLIVNLVEMALGFNTTVVAMALCYGFGNNFFVRTGHMVLAV  240 
2CEN2      161 FFCLTIFNVSIVTQYRSFKRSLFFFSRLHPKLKGTVQFRTLIVNLVEMALGFNTTVVAMALCYGFGNNFFVRTGHMVLAV  240 
UKNEQAS2   161 FFCLTIFNVSMVTQYRSFKRSLFFFSRLHPKLKGTVQFRTLIVNLVEMALGFNTTVVAMALCYGFGNNFFVRTGHMVLAV  240 
BE/4/2011  161 FFCLTIFNVSMVTQYRSFKRSLFFFSRLHPKLKGTVQFRTLIVNLVEMALGFNTTVVAMALCYGFGNNFFVRTGHMVLAV  240 
BE/23/2010 161 FFCLTIFNVSMVTQYRSFKRSLFFFSRLHPKLKGTVQFRTLIVNLVEMALGFNTTVIAMALCYGFGNNFFVRTGHMVLAV  240 
BE/14/2011 161 FFCLTIFNVSMVTQYRSFKRSLFFFSRLHPKLKGTVQFRTLIVNLVEMALGFNTTVVAMALCYGFGNNFFVRTGHMVLAV  240 
HAN13      161 FFCLTIFNVSMVTQYRSFKRSLFFFSRLHPKLKGTVQFRTLIVNLVEMALGFNTTVVAMALCYGFGNNFFVRTGHMVLAV  240 
Merlin     161 FFCLTIFNVSMVTQYRSYKRSLFFFSRLHPKLKGTVQFRTLIVNLVEVALGFNTTVVAMALCYGFGNNFFVRTGHMVLAV  240 
 
ZMB240     241 FVVYAIISIIYFLLIEAVFFQYVKVQFGYHLGAFFGLCGLIYPIVQYGAFTIGDDYRTGISWSFGMLFFIWAMFTTCRAV  320 
HAN40      241 FVVYAIISIIYFLLIEAVFFQYVKVQFGYHLGAFFGLCGLIYPIVQYGAFTIGDDYRTGISWSFGMLFFIWAMFTTCRAV  320 
HAN11      241 FVVYAIISIIYFLLIEAVFFQYVKVQFGYHLGAFFGLCGLIYPIVQYGAFTIGDDYRTGISWSFGMLFFIWAMFTTCRAV  320 
HAN2       241 FVVYAIISIIYFLLIEAVFFQYVKVQFGYHLGAFFGLCGLIYPIVQYGAFTIGDDYRTGISWSFGMLFFIWAMFTTCRAV  320 
HAN1       241 FVVYAIISIIYFLLIEAIFFQYVKVQFGYHLGAFFGLCGLIYPIVQYGAFTIGDDYRTGISWSFGMLFFIWAMFTTCRAV  320 
2CEN2      241 FVVYAIISIIYFLLIEAVFFQYVKVQFGYHLGAFFGLCGLIYPIVQYGAFTIGDDYRTGISWSFGMLFFIWAMFTTCRAV  320 
UKNEQAS2   241 FVVYAIISIIYFLLIEAVFFQYVKVQFGYHLGAFFGLCGLIYPIVQYGAFTIGDDYRTGISWSFGMLFFIWAMFTTCRAV  320 
BE/4/2011  241 FVVYAIISIIYFLLIEAVFFQYVKVQFGYHLGAFFGLCGLIYPIVQYGAFTIGDDYRTGISWSFGMLFFIWAMFTTCRAV  320 
BE/23/2010 241 FVVYAIISIIYFLLIEAVFFQYVKVQFGYHLGAFFGLCGLIYPIVQYGAFTIGDDYRTGISWSFGMLFFIWAMFTTCRAV  320 
BE/14/2011 241 FVVYAIISIIYFLLIEAVFFQYVKVQFGYHLGAFFGLCGLIYPIVQYGAFTIGDDYRTGISWSFGMLFFIWAMFTTCRAV  320 
HAN13      241 FVVYAIISIIYFLLIEAVFFQYVKVQFGYHLGAFFGLCGLIYPIVQYGAFTIGDDYRTGISWSFGMLFFIWAMFTTCRAV  320 
Merlin     241 FVVYAIISIIYFLLIEAVFFQYVKVQFGYHLGAFFGLCGLIYPIVQYDTF-LSNEYRTGISWSFGMLFFIWAMFTTCRAV  319 
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ZMB240     321 RYFRGRGSGSVKYQALATASGEEVAALSHHDSLESRRLREEEDDDDDEDFEDA  373 
HAN40      321 RYFRGRGSGSVKYQALATASGEEVAALSHHDSLESRRLREEEDDDDDDDFEDA  373 
HAN11      321 RYFRGRGSGSVKYQALATASGEEVAALSHHDSLESRRLREEEDDDDDEDFEDA  373 
HAN2       321 RYFRGRGSSSVKYQALATASGEEVAALSHHDSLESRRLREEEDDDDDEDFEDA  373 
HAN1       321 RYFRGRGSGSVKYQALATASGEEVAALSHHDSLESRRLREEEDDDDDEDFEDA  373 
2CEN2      321 RYFRGRGSGSVKYQALATASGEEVAALSHHDSLESRRLREEEDDDDDEDFEDA  373 
UKNEQAS2   321 RYFRGRGSGSVKYQALATASSEEVAALSHHDSLESRRLREEEDDDDDEDFEDA  373 
BE/4/2011  321 RYFRGRGSGSVKYQALATASGEEVAALSHHDSLESRRLREEEDDDDDDDFEDA  373 
BE/23/2010 321 RYFRGRGSGSVKYQALATASGEEVAALSHHDSLESRRLREEEDDDDDEDFEDA  373 
BE/14/2011 321 RYFRGRGSGSVKYQALATASGEEVAALSHHNSLESRRLREEEDDDDDEDFEDA  373 
HAN13      321 RYFRGRGSGSVKYQALATASGEEVAALSHHDSLESRRLREEEDDDDDEDFEDA  373 
Merlin     320 RYFRGRGSGSVKYQALATASGEEVAALSHHDSLESRRLREEE-DDDDEDFEDA  371 
 
Figure 5.32. ZMB242 UL100 amino acid alignment. Relative to HCMV strain Merlin 
AY446894.2, ZMB240 UL100 has two insertions after positions 290 and 361, highlighted 







ZMB240 1    MTAQPPLHHRHHPYTLFGTSCHLSWYGLLEASVPIVQCLFLDLGGGRAEPRLHTFVVRGDRLPPAEVRAVHRASYAALAS  80 
HAN28  1    MTAQPPLHHRHHPYTLFGTSCHLSWYGLLEASVPIVQCLFLDLGGGRAEPRLHTFVVRGDRLPPAEVRVVHRASYAALAS  80 
Merlin 1    MTAQPPLHHRHHPYTLFGTSCHLSWYGLLEASVPIVQCLFLDLGGGRAEPRLHTFVVRGDRLPPAEVRAVHRASYAALAS  80 
 
ZMB240 81   AVTTDADERRRGLEQRSAVLARVLLEGSALIRVLARTFTPVQIQTDASGVEILEAAPALGVETAALSNALSLFHVAKLVV  160 
HAN28  81   AVTTDADERRRGLEQRSAVLARVLLEGSALIRVLARTFTPVQIQTDASGVEILEAAPALGVETAALSNALSLFHVAKLVV  160 
Merlin 81   AVTTDADERRRGLEQRSAVLARVLLEGSALIRVLARTFTPVQIQTDASGVEILEAAPALGVETTALSNALSLFHVAKLVV  160 
 
ZMB240 161  IGSYPEVHEPRVVTHAAERVSEEYGTHAHKKLRRGYYAYDLAMSFRVGTHKYVLERDDEAVLARLFEVREVCFLRTCLRL  240 
HAN28  161  IGSYPEVHEPRVVTHAAERVSEEYGTHAHKKLRRGYYAYDLAMSFRVGTHKYVLERDDEAVLARLFEVREVCFLRTCLRL  240 
Merlin 161  IGSYPEVHEPRVVTHAAERVSEEYGTHAHKKLRRGYYAYDLAMSFRVGTHKYVLERDDEAVLARLFEVREVCFLRTCLRL  240 
 
ZMB240 241  VTPVGFVAVAVTDEQCCLLLQSAWTHLYDVLFRGFAGQPPLRDYLGPDLFETGAARSFFFPGFPPVPVYAVHGLHTLMRE  320 
HAN28  241  VTPVGFVAVAVTDEQCCLLLQSAWTHLYDVLFRGFAGQPPLRDYLGPDLFETGAARSFFFPGFPPVPVYAVHGLHTLMRE  320 
Merlin 241  VTPVGFVAVAVTDEQCCLLLQSAWTHLYDVLFRGFAGQPPLRDYLGPDLFETGAARSFFFPGFPPVPVYAVHGLHTLMRE  320 
 
ZMB240 321  TALDAAAEVLSWCGLPDIVGSAGKLEVEPCALSLGVPEDEWQVFGTEAGGGAVRLNATAFRERPAGGDRRWLLPPLPRDD  400 
HAN28  321  TALDAAAEVLSWCGLPDIVGSAGKLEVEPCALSLGVPEDEWQVFGTEAGGGAVRLNATAFRERPAGGDRRWLLPPLPRDD  400 
Merlin 321  TALDAAAEVLSWCGLPDIVGSAGKLEVEPCALSLGVPEDEWQVFGTEAGGGAVRLNATAFRERPAGGDRRWLLPPLPRDD  400 
 
ZMB240 401  GDGENNVVEVSSSTGGAHPPSDDATFTVHVRDATLHRVLIVDLVERVLAKCVRARDFNPYVRYSHRLHTYAVCEKFIENL  480 
HAN28  401  GDGENNVVEVSSSTGGAHPPSDDATFTVHVRDATLHRVLIVDLVERVLAKCVRARDFNPYVRYSHRLHTYAVCEKFIENL  480 
Merlin 401  GDGENNVVEVSSSTGGAHPPSDDATFTVHVRDATLHRVLIVDLVERVLAKCVRARDFNPYVRYSHRLHTYAVCEKFIENL  480 
 
ZMB240 481  RFRSRRAFWQIQSLLGYISEHVTSACASAGLLWVLSRGHREFYVYDGYSGHGPVSAEVCVRTVVDCYWRKLFGGDDPGPT  560 
HAN28  481  RFRSRRAFWQIQSLLGYISEHVTSACASAGLLWVLSRGHREFYVYDGYSGHGPVSAEVCVRTVVDCYWRKLFGGDDPGPT  560 
Merlin 481  RFRSRRAFWQIQSLLGYISEHVTSACASAGLLWVLSRGHREFYVYDGYSGHGPVSAEVCVRTVVDCYWRKLFGGDDPGPT  560 
 
ZMB240 561  CRVQESAPGVLLVWGDERLVGPFNFFYGNGGAGGSPLHGVVGGFAAGHCGGACCAGCVVTHRHSSGGGGSGVGDADHASG  640 
HAN28  561  CRVQESAPGVLLVWGDERLVGPFNFFYGNGGAGGSPLHGVVGGFAAGHCGGACCAGCVVTHRHSSGGGGSGVGDADHASG  640 
Merlin 561  CRVQESAPGVLLVWGDERLVGPFNFFYGNGGAGGSPLHGVVGGFAAGHCGGACCAGCVVTHRHSSGGGGSGVGDADHASG  640 
 
ZMB240 641  GGLDAAAGSGHNGGSDRVSPSTPPAALGGCCCAAGGDWLSAVGHVLGRLPALLRERVSVSELEAVYREILFRFVARRNDV  720 
HAN28  641  GGLDAAAGSGHNGGSDRVSPSTPPAALGGCCCAAGGDWLSAVGHVLGRLPALLRERVSVSELEAVYREILFRFVARRNDV  720 
Merlin 641  GGLDAAAGSGHNGGSDRVSPSTPPAALGGCCCAAGGDWLSAVGHVLGRLPALLRERVSVSELEAVYREILFRFVARRNDV  720 
 
ZMB240 721  DFWLLRFQPGENEVRPHAGVIDCAPFHGVWAEQGQIIVQSRDTALAADIGYGVYVDKAFAMLTACVEVWARELLSSSTAS  800 
HAN28  721  DFWLLRFQPGENEVRPHAGVIDCAPFHGVWAEQGQIIVQSRDTALAADIGYGVYVDKAFAMLTACVEVWARELLSSSTAS  800 
Merlin 721  DFWLLRFQPGENEVRPHAGVIDCAPFHGVWAEQGQIIVQSRDTALAADIGYGVYVDKAFAMLTACVEVWARELLSSSTAS  800 
 
ZMB240 801  TTAC-SSSVLSSALPSVTSSSSGTATVSPPSCSSSSATWLEERDEWVRSLAVDAQHAAKRVASEGLRFFRLNA  872 
HAN28  801  TTTC-SSSVLSSALPSVTSSSSGTATVSPPSCSSSSATWLEERDEWVRSLAVDAQHAAKRVASEGLRFFRLNA  872 
Merlin 801  TTTCSSSSVLSSALPSVTSSSSGTATVSPPSCSSSSATWLEERDEWVRSLAVDAQHAAKRVASEGLRFFRLNA  873 
 
Figure 5.33. ZMB242 UL102 amino acid alignment. Compared to HCMV strain Merlin 
AY446894.2, ZMB240 and HCMV strain HAN28 contain a deletion at position 805, 
highlighted here by the red border. 
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ZMB240 1    MDLPTTVVRKYWTFANPNRILHQSVNQTFDVRQFVFDTARLVNCVDGDGKVLHLNKGWLCATIMQHGEASAGAKTQQGFM  80 
AD169  1    MDLPTTVVRKYWTFANPNRILHQSVNQTFDVRQFVFDTARLVNCVDGDGKVLHLNKGWLCATIMQHGEASAGAKTQQGFM  80 
6397   1    MDLPTTVVRKYWTFANPNRILHQSVNQTFDVRQFVFDTARLVNCVDGDGKVLHLNKGWLCATIMQHGEASAGAKTQQGFM  80 
AF1    1    MDLPTTVVRKYWTFTNPNRILHQSVNQTFDVRQFVFDNARLVNCVDGDGKVLHLNKGWLCATIMQHGEASAGAKTQQGFM  80 
U11    1    MDLPTTVVRKYWTFTNPNRILHQSVNQTFDVRQFVFDNARLVNCVDGDGKVLHLNKGWLCATIMQHGEASAGAKTQQGFM  80 
3301   1    MDLPTTVVRKYWTFTNPNRILHQSVNQTFDVRQFVFDNARLVNCVDGDGKVLHLNKGWLCATIMQHGEASAGAKTQQGFM  80 
Merlin 1    MDLPTTVVRKYWTFTNPNRILHQSVNQTFDVRQFVFDNARLVNCVDGDGKVLHLNKGWLCATIMQHGEASAGAKTQQGFM  80 
 
ZMB240 81   SIDITGDGELQEHLFVRGGIVFNKSVSSVVGSSGPNESALLTMISENGNLQVTYVRHYLKNHGESSGGGGGCGAASTASA  160 
AD169  81   SIDITGDGELQEHLFVRGGIVFNKSVSSVVGSSGPNESALLTMISENGNLQVTYVRHYLKNHGESSSGGGGCGAASTASA  160 
6397   81   SIDITGDGELQEHLFVRGGIVFNKSVSSVVGSSGPNESALLTMISENGNLQVTYVRHYLKNHGESSGGGGGCGAASTASA  160 
AF1    81   SIDITGDGELQEHLFVRGGIVFNKSVSSVVGSSGPNESALLTMISENGNLQVTYVRHYLKNHGESSSGGGGCGAASTASA  160 
U11    81   SIDITGDGELQEHLFVRGGIVFNKSVSSVVGSSGPNESALLTMISENGNLQVTYVRHYLKNHGESSSGGGGCGAASTASA  160 
3301   81   SIDITGDGELQEHLFVRGGIVFNKSVSSVVGSSGPNESALLTMISENGNLQVTYVRHYLKNHGESSSGGGGCGAASTASA  160 
Merlin 81   SIDITGDGELQEHLFVRGGIVFNKSVSSVVGSSGPNESALLTMISENGNLQVTYVRHYLKNHGESSGGGGGCGAASTASA  160 
 
ZMB240 161  VCVSSLGGSGGTRDGPSAEEQQRRRQEQRHEERRKKSSSSAGGGGGGGAGGGGGGGGSGGQHSSDSANGLLRDPRLMNRQ  240 
AD169  161  VCVSSLGGSGGTRDGPSAEEQQRRRQEQRHEERRKKSSSSAGGGGGGGAGGGGGGGGSGGQHSSDSANGLLRDPRLMNRQ  240 
6397   161  VCVSSLGGSGGTRDGPSAEEQQRRRQEQRHEERRKKSSSSAGGGGGGGAGGGGGGGGSGGQHSSDSANGLLRDPRLMNRQ  240 
AF1    161  VCVSSLGGSGGTRDGPSAEEQQRRRQEQRHEERRKKSSSSAGGGGGGGAGGGGGGGGSGGQHSSDSANGLLRDPRLMNRQ  240 
U11    161  VCVSSLGGSGGTRDGPSAEEQQRRRQEQRHEERRKKSSSSAGGGGGGGAGGGGGGGGSGGQHSSDSANGLLRDPRLMNRQ  240 
3301   161  VCVSSLGGSGGTRDGPSAEEQQRRRQEQRHEERRKKSSSSAGGGGGGGAGGGGGGGGSGGQHSSDSANGLLRDPRLMNRQ  240 
Merlin 161  VCVSSLGGSGGTRDGPSAEEQQRRRQEQRHEERRKKSSSSAGGGGGGGASGGGGGGGSGGQHSSDSANGLLRDPRLMNRQ  240 
 
ZMB240 241  KERRPPPSSENDGSPPLREAKRQKTTAQHEGHGGGGKNETEQQSGGAGGGGGGGSGRMSLPLDTSEAVAFLNYSSSSSAV  320 
AD169  241  KERRPPPSSENDGSPPLREAKRQKTTAQHEGHGGGGKNETEQQSGGAGGGGGGGSGRMSLPLDTSEAVAFLNYSSSSSAV  320 
6397   241  KERRPPPSSENDGSPPLREAKRQKTTAQHEGHGGGGKNETEQQSGGAGGGGGGGSGCMSLPLDTSEAVAFLNYSSSSSAV  320 
AF1    241  KERRPPPSSENDGSPPLREAKRQKTTAQHEGHGGGGKNETEQQSGGAGGGGGGGSGRMSLPLDTSEAVAFLNYSSSSSAV  320 
U11    241  KERRPPPSSENDGSPPLREAKRQKTTAQHEGHGGGGKNETEQQSGGAGGGGGGGSGRMSLPLDTSEAVAFLNYSSSSSAV  320 
3301   241  KERRPPPSSENDGSPPLREAKRQKTTAQHEGHGGGGKNETEQQSGGAGGGGGGGSGRMSLPLDTSEAVAFLNYSSSSSAV  320 
Merlin 241  KERRPPPSSENDGSPPLREAKRQKTTAQHEGHGGGGKNETEQQSGGAGGGGGGGSGRMSLPLDTSEAVAFLNYSSSSSAV  320 
 
ZMB240 321  SSSSNNHHHHHHHHNAVTDVAAGTDGALLLPIERGAVVSSPSSTSPSSLLSLPRPGSAHSAGETVQESEAAATAAAAGLM  400 
AD169  321  SSSSNNHHHHHHHHNAVTDVAAGTDGALLLPIERGAVVSSPSSTSPSSLLSLPRPSSAHSAGETVQESEAAATAAAAGLM  400 
6397   321  SSSSNNHHHHHHHHNAVTDVAAGTDGALLLPIERGAVVSSPSSTSPSSLLSLPRPSSAHSAGETVQESEAAATAAAAGLM  400 
AF1    321  SSSSNNHHHHHHHHNAVTDVAAGTDGALLLPIERGAVVSSPSSTSPSSLLSLPRPSSAHSAGETVQESEAAATAAAAGLM  400 
U11    321  SSSSNNHHHHHHHHNAVTDVAAGTDGALLLPIERGAVVSSPSSTSPSSLLSLPRPSSAHSAGETVQESEAAATAAAAGLM  400 
3301   321  SSSSNNHHHHHHHHNAVTDVAAGTDGALLLPIERGAVVSSPSSTSPSSLLSLPRPSSAHSAGETVQESEAAATAAAAGLM  400 
Merlin 321  SSSSNNHHHHHHHHNAVTDVAAGTDGALLLPIERGAVVSSPSSTSPSSLLSLPRPSSAHSAGETVQESEAAATAAAAGLM  400 
 
ZMB240 401  MMRRMRRAPAEAAEAPPQSEEENDSTTPVSNCRVPPNSQESAAPQPPRSPRFDDIIQSLTKMLNDCKEKRLCDLPLVSSR  480 
AD169  401  MMRRMRRAPAEAAEAPPQSEEENDSTTPVSNCRVPPNSQESAAPQPPRSPRFDDIIQSLTKMLNDCKEKRLCDLPLVSSR  480 
6397   401  MMRRMRRAPAEAAEAPPQSEEENDSTTPVSNCRVPPNSQESAAPQPPRSPRFDDIIQSLTKMLNDCKEKRLCDLPLVSSR  480 
AF1    401  MMRRMRRAPAEAAEAPPQSEEENDSTTPVSNCRVPPNSQESAAPQPPRSPRFDDIIHSLTKMLNDCKEKRLCDLPLVSSR  480 
U11    401  MMRRMRRAPAEAAEAPPQSEEENDSTTPVSNCRVPPNSQESAAPQPPRSPRFDDIIQSLTKMLNDCKEKRLCDLPLVSSR  480 
3301   401  MMRRMRRAPAEAAEAPPQSEEENDSTTPVSNCRVPPNSQESAAPQPPRSPRFDDIIQSLTKMLNDCKEKRLCDLPLVSSR  480 
Merlin 401  MMRRMRRAPAEAAEAPPQSEEENDSTTPVSNCRVPPNSQESAAPQPPRSPRFDDIIQSLTKMLNDCKEKRLCDLPLVSSR  480 
 
ZMB240 481  LLPETSGGTVVVNHSSVARTAAAVSTAGVGPPAAACPPLVTTGVVPSGSVAGVAPVAAAVETPVAPPRPVCEIKPYVVNP  560 
AD169  481  LLPETSGGTVVVNHSSVARTAAAVSAAGVGPPAAACPPLVTTGVVPSGSVAGVAPVAAAIETPAAPPRPVCEIKPYVVNP  560 
6397   481  LLPETSGGTVVVNHSSVARTAAAVSTAGVGPPAAACPPLVTTGVVPSGSVAGVAPVAAAVETPAAPPRPVCEIKPYVVNP  560 
AF1    481  LLPETSGGTVVVNHSSVARTAAAVSTAGVGPPAAACPPLVTTGVVPSGSVAGVAPVAAAVETPAAPPRPVCEIKPYVVNP  560 
U11    481  LLPETSGGTVVVNHSSVARTAAAVSTAGVGPPAAACPPLVTTGVVPSGSVAGVAPVAAAVETPAAPPRPVCEIKPYVVNP  560 
3301   481  LLPETSGGTVVVNHSSVARTAAAVSTAGVGPPAAACPPLVTTGVVPSGSVAGVAPVAAAVETPAAPPRPVCEIKPYVVNP  560 
Merlin 481  LLPETSGGTVVVNHSSVARTAAAVSTAGVGPPAVACPPLVTTGVVPSGSVAGVAPVAAAVETPAAPPRPVCEIKPYVVNP  560 
 
ZMB240 561  VVATAAAASNSSSSSSAPLPPPPPPPSGRRGRARNNTR-GGGGGGGGRNSRRQAASSSSSSSRRSRRRNNRHEDEEDNDP  639 
AD169  561  VVATAAAASNSSSSSSAPLPPPPPPSGGRRGRARNNTR-GGGGGGGGRNSRRQAASSSSSSSRRSRRRNNRHEDEEDNDP  639 
6397   561  VVATAAAASNSSSSSSAPLPPPPPPPGGRRGRARNNTR-GGGGGGGGRNSRRQAASSSSSSSRRSRRRNNRHEDEEDNDP  639 
AF1    561  VVATAAAASNSSSSSSAPLPPPPPPPGGRRGRARNNTR-GGGGGGGGRNSRRQAASSSSSSSRRSRRRNNRHEDEEDNDP  639 
U11    561  VVATAAADSNSSSSSSAPLPPPPPPPGGRRGRARNNTR-GGGGGGGGRNSRRQAASSSSSSSRRSRRRNNRHEDEEDNDP  639 
3301   561  VVATAAAASNSSSSSSAPLPPPPPPPGGRRGRARNNTR-GGGGGGGGRNSRRQAASSSSSSSRRSRRRNNRHEDEEDNDP  639 
Merlin 561  VVATAAAASNSSSSSSAPLPPPPPPPGGRRGRARNNTRGGGGGGGGGRNSRRQAASSSSSSSRRSRRRNNRHED-EDNDP  639 
 
ZMB240 640  LLRLSQVAGSGRRRGPSFLEDGLEIIDPSEEAAIAAASIAAFFDD  684 
AD169  640  LLRLSQVAGNGRRRGPSFLEDGLEIIDPSEEAAIAAASIAAFFDD  684 
6397   640  LLRLSQVAGSGRRRGPSFLEDGLEIIDPSEEAAIAAASIAAFFDD  684 
AF1    640  LLRLSQVAGSGRRRGPSFLEDGLEIIDPSEEAAIAAASIAAFFDD  684 
U11    640  LLRLSQVAGSGRRRGPSFLEDGLEIIDPSEEAAIAAASIAAFFDD  684 
3301   640  LLRLSQVAGSGRRRGPSFLEDGLEIIDPSEEAAIAAASIAAFFDD  684 
Merlin 640  LLRLSQVAGSGRRRGPSFLEDGLEIIDPSEEAAIAAASIAAFFDD  684 
 
Figure 5.34. ZMB240 UL112 amino acid alignment. The ZMB240 UL112 product has a 
deletion at position 599 and an insertion after position 634 relative to Merlin 
(AY446894.2). These changes are also present in 34 full genome HCMV strains (table 
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ZMB240 1    MVMFSQDHVQIVYGSTRICKSLAPANKRKTHRTIVVAPRRGFLRIPPDGQDVNHVKIVPTT-SSSLAPPRDDERRPTPPL  79 
Towne  1    MVMFSQDHVQIVYGSTRICKSLAPANKRKTHRTIVVAPRRGFLRIPPDGQDVNHVKIVPTT-SSSLAPPRDDERRPTPPL  79 
Merlin 1    MVMFSQDHVQIVYGSTRICKSLAPANKRKTHRTIVVAPRRGFLRIPPDGQDVNHVKIVPTTTSSSLAPPRDDERRPTPPL  80 
 
ZMB240 80   RPPLTVYPYGTSLIRRSARDAKLRSKLIVFHITRPALGQHPQNPGISGPAAMDHSEFLTSFRREVDRQTVLTAESAPATV  159 
Towne  80   RPPLTVYPYGTSLIRRSARDAKLRSKLIVFHITRPALGQHPQNPGISGPAAMDHSEFLTSFRREVDRQTVLTAESAPATV  159 
Merlin 81   RPPLTVYPYGTSLIRRSARDAKLRSKLIVFHITRPALGQHPQNPGISGPAAMDHSEFLTSFRREVDRQTVLTAESAPATV  160 
 
ZMB240 160  EVCLGDALPGGVMGGGGLPAGVGSASAAVAAAAAAVAGVPVAANPVMPATATVTTPPMIDLTSHHRPLTLFTPASAAAAP  239 
Towne  160  EVCLGDALPGGVMGGGGLPAGVGSASAAVAAAAAAVAGVPVAANPVMPATATVTTPPMIDLTSHHRPLTLFTPASAAAAP  239 
Merlin 161  EVCLGDALPGGVMGGGGLPAGVGSASAAVAAAAAAVAGVPVAANPVMPATATVTTPPMIDLTSHHRPLTLFTPASAAAAP  240 
 
ZMB240 240  AVATNGGNATYILPADCRYAPLFASKYKYVFEEVSRLMRLHDSTAVQLQISASCGNAFQALKSALLKLHNVTVLAGQQLI  319 
Towne  240  AVATNGGNATYILPADCRYAPLFASKYKYVFEEVSRLMRLHDSTAVQLQISASCGNAFQALKSALLKLHNVTVLAGQQLI  319 
Merlin 241  AVATNGGNATYILPADCRYAPLFASKYKYVFEEVSRLMRLHDSTAVQLQISASCGNAFQALKSALLKLHNVTVLAGQQLI  320 
 
ZMB240 320  TQTMPHTPQAVATFKFFHQDPNRVLDCIRPVVPRSTSYHETGVYQMWVSGATKKDLFDAVTLCASIVEKQPDVFNINVSL  399 
Towne  320  TQTMPHTPQAVATFKFFHQDPNRVLDCIRPVVPRSTSYHETGVYQMWVSGATKKDLFDAVTLCASIVEKQPDVFNINVSL  399 
Merlin 321  TQTMPHTPQAVATFKFFHQDPNRVLDCIRPVVPRSTSYHETGVYQMWVSGATKKDLFDAVTLCASIVEKQPDVFNINVSL  400 
 
ZMB240 400  LTYPSIAAPHLPLYNEFTSFRLPTS  424 
Towne  400  LTYPSIAAPHLPLYNEFTSFRLPTS  424 
Merlin 401  LTYPSIAAPHLPLYNEFTSFRLPTS  425 
 
Figure 5.35. ZMB240 protein UL117 amino acid alignment. Like HCMV strain Towne, 
ZMB240 protein UL117 has an amino acid deletion at position 607 (highlighted by the 









ZMB240     1   MCPALAIALAAALLSNTHPGMGSSTTSAVTSP-NITVTFTTSISTPNNVTSTVTTTVQTSTFTSGSTSTSASTSVATTTQ 79 
Toledo     1   MCPALAIALAAALLSNTHPGMGSSTTSAVTSP-NITVTFTTSINTPNNVTSTVTTTVQTSTFTSGSTSTSASTSVATTTQ 79 
PAV11      1   MCPALAITLAAALLSNTHPGMGSSTKSAVTSP-NITVTSTTSISTPNNVTSTVTTTVQTSTFTSGSTSTSASTSVATTTQ 79 
BE/17/2010 1   MYPALAIALAAALLSNTHPGMGSSTTSAVTSP-NITVTSTTSISTPNNVTSTVTTTVQTSTFTSGSTSTSASTSVATTTQ 79 
BE/26/2010 1   MCPALAIALAAALLSNTHPGMGSSTTSAVTSP-NITVTSTTSISTPNNVTSTVTTTVQTSTFTSGSTSTSASTSVATTTQ 79 
BE/4/2011  1   MCPALAIALAAALLSNTHPGMGSSTTSAVTSP-NITVTSTTSISTPNNVTSTVTTTVQTSTFTSGSTSTSASTSVATTTQ 79 
BE/15/2012 1   MCPALAIALAAALLSNTHPGMGSSTTSAVTSP-NITVTSTTSISTPNNVTSTVTTTVQTSTFTSGSTSTSASTSVATTTQ 79 
CZ/3/2012  1   MCPALAIALAAALLSNTHPGMGSSTTSAVTSP-NITVTSTTSISTPNNVTSTVTTTVQTSTFTSGSTSTSASTSVATTTQ 79 
BE/11/2012 1   MCPALAIALAAALLSNTHPGMGSSTTSAVTSP-NITVTSTTSISTPNNVTSTVTTTVQTSTFTSGSTSTSASTSVATTTQ 79 
BE/30/2011 1   MCPALAIALAAALLSNTHPGMGSSTTSAVTSP-NITVTSTTSISTPNNVTSTVTTTVQTSTFTSGSTSTSASTSVATTTQ 79 
BE/7/2012  1   MCPALAIALAAALLSNTHPGMGSSTTSAVTSP-NITVTSTTSISTPNNVTSTVTTTVQTSTFTSGSTSTSASTSVATTTQ 79 
BE/16/2012 1   MCPALAIALAAALLSNTHPGMGSSTTSAVTSP-NITVTSTTSISTPNNVTSTVTTTVQTSTFTSGSTSTSASTSVATTTQ 79 
BE/13/2010 1   MCPALAIALAAALLSNTHPGMGSSTTSAVTSP-NITVTSTTSISTPNNVTSTVTTTVQTSTFTSGSTSTSASTSVATTTQ 79 
BE/21/2010 1   MCPALAIALAAALLSNTHPGMGSSTKSAVTSP-NITVTSTTSISTPNNVTSTVTTTVQTSTFTSGSTSTSASTSVATTTQ 79 
U8         1   MCPALAIALAAALLSNTHPGMGSSTTSAVTSP-NITVTSTTSISTPNNVTSTVTTTVQTSTFTSGSTSTSASTSVATTTQ 79 
Merlin     1   MCSVLAIALVVALLGDMHPGVKSSTTSAVTSPSNTTVTSTTSISTSNNVSSAVTTTVQTST-------SSASTSVIATTQ 73 
 
ZMB240     80  KEGHLYNVNCEASYSYDQVSLNATCKVNLLNNTKNPDILSVTCYARTNCKGPFIQVGYLSAFPSDDKGKLHLSYNATAQE 159 
Toledo     80  KEGHLYNVNCEASYSYDQVSLNATCKVNLLNNTKNPDILSVTCYARTNCKGPFTQVGYLSAFPSDDKGKLHLSYNATAQE 159 
PAV11      80  KEGHLYNVNCEASYSYDQVSLNATCKVNLLNNTKNPDILSVTCYARTNCKGPFTQVGYLSAFPSDDKGKLHLSYNATAQE 159 
BE/17/2010 80  KEGHLYNVNCEASYSYDQVSLNATCKVNLLNNTKNPDILSVTCYARTNCKGPFTQVGYLSAFPSDDKGKLHLSYNATAQE 159 
BE/26/2010 80  KEGHLYNVNCETSYSYDQVSLNATCKVNLLNNTKNPDILSVTCYARTNCKGPFTQVGYLSAFPSDDKGKLHLSYNATAQE 159 
BE/4/2011  80  KEGHLYNVNCEASYSYDQVSLNATCKVNLLNNTKNPDILSVTCYARTNCKGPFTQVGYLSAFPSDDKGKLHLSYNATAQE 159 
BE/15/2012 80  KEGHLYNVNCETSYSYDQVSLNATCKVNLLNNTKNPDILSVTCYARTNCKGPFTQVGYLSAFPSDDKGKLHLSYNATAQE 159 
CZ/3/2012  80  KEGHLYNVNCEASYSYDQVSLNATCKVNLLNNTKNPDILSVTCYARTNCKGPFTQVGYLSAFPSDDKGKLHLSYNATAQE 159 
BE/11/2012 80  KEGHLYNVNCETSYSYDQVSLNATCKVNLLNNTKNPDILSVTCYARTNCKGPFTQVGYLSAFPSDDKGKLHLSYNATAQE 159 
BE/30/2011 80  KEGHLYNVNCETSYSYDQVSLNATCKVNLLNNTKNPDILSVTCYARTNCKGPFTQVGYLSAFPSDDKGKLHLSYNATAQE 159 
BE/7/2012  80  KEGHLYNVNCETSYSYDQVSLNATCKVNLLNNTKNPDILSVTCYARTNCKGPFTQVGYLSAFPSDDKGKLHLSYNATAQE 159 
BE/16/2012 80  KEGHLYNVNCETSYSYDQVSLNATCKVNLLNNTKNPDILSVTCYARTNCKGPFTQVGYLSAFPSDDKGKLHLSYNATAQE 159 
BE/13/2010 80  KEGHLYNVNCEASYSYDQVSLNATCKVNLLNNTKNPDILSVTCYARTNCKGPFTQVGYLSAFPSDDKGKLHLSYNATAQE 159 
BE/21/2010 80  KEGHLYNVNCEASYSYDQVSLNATCKVNLLNNTKNPDILSVTCYARTNCKGPFTQVGYLSAFPSDDKGKLHLSYNATAQE 159 
U8         80  KEGHLYNVNCEASYSYDQVSLNATCKVNLLNNTKNPDILSVTCYARTNCKGPFTQVGYLSAFPSDDKGKLHLSYNATAQE 159 
Merlin     74  KEGHLYTVNCEASYSYDQVSLNATCKVILLNNTKNPDILSVTCYARTDCKGPFTQVGYLSAFPSNDKGKLHLSYNATAQE 153 
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ZMB240     160 LLISGLRPQETTEYTCSFFSWGRHHNATWDLFTYPIYAVYGTRLNATTMRVRVLLQEHEHCLLNGSSLYHPNSTVHLHQG 239 
Toledo     160 LLISGLRPQETTEYTCSFFSWGRHHNATWDLFTYPIYAVYGTRLNATTMRVRVLLQEHEHCLLNGSSLYHPNSTVHLHQG 239 
PAV11      160 LLISGLRPQETTEYTCSFFSWGRHHNATWDLFTYPIYAVYGTRLNATTMRVRVLLQEHEHCLLNGSSLYHPNSTVHLHQG 239 
BE/17/2010 160 LLISGLRPQETTEYTCSFFSWGRHHNATWDLFTYPIYAVYGTRLNATTMRVRVLLQEHEHCLLNGSSLYHPNSTVHLHQG 239 
BE/26/2010 160 LLISGLRPQETTEYTCSFFSWGRHHNATWDLFTYPIYAVYGTRLNATTMRVRVLLQEHEHCLLNGSSLYHPNSTVHLHQG 239 
BE/4/2011  160 LLISGLRPQETTEYTCSFFSWGRHHNATWDLFTYPIYAVYGTRLNATTMRVRVLLQEHEHCLLNGSSLYHPNSTVHLHQG 239 
BE/15/2012 160 LLISGLRPQETTEYTCSFFSWGRHHNATWDLFTYPIYAVYGTRLNATTMRVRVLLQEHEHCLLNGSSLYHPNSTVHLHQG 239 
CZ/3/2012  160 LLISGLRPQETTEYTCSFFSWGRHHNATWDLFTYPIYAVYGTRLNATTMRVRVLLQEHEHCLLNGSSLYHPNSTVHLHQG 239 
BE/11/2012 160 LLISGLRPQETTEYTCSFFSWGRHHNATWDLFTYPIYAVYGTRLNATTMRVRVLLQEHEHCLLNGSSLYHPNSTVHLHQG 239 
BE/30/2011 160 LLISGLRPQETTEYTCSFFSWGRHHNATWDLFTYPIYAVYGTRLNATTMRVRVLLQEHEHCLLNGSSLYHPNSTVHLHQG 239 
BE/7/2012  160 LLISGLRPQETTEYTCSFFSWGRHHNATWDLFTYPIYAVYGTRLNATTMRVRVLLQEHEHCLLNGSSLYHPNSTVHLHQG 239 
BE/16/2012 160 LLISGLRPQETTEYTCSFFSWGRHHNATWDLFTYPIYAVYGTRLNATTMRVRVLLQEHEHCLLNGSSLYHPNSTVHLHQG 239 
BE/13/2010 160 LLISGLRPQETTEYTCSFFSWGRHHNATWDLFTYPIYAVYGTRLNATTMRVRVLLQEHEHCLLNGSSLYHPNSTVHLHQG 239 
BE/21/2010 160 LLISGLRPQETTEYTCSFFSWGRHHNATWDLFTYPIYAVYGTRLNATTMRVRVLLQEHEHCLLNGSSLYHPNSTVHLHQG 239 
U8         160 LLISGLRPQETTEYTCSFFSWGRHHNATWDLFTYPIYAVYGTRLNATTMRVRVLLQEHEHCLLNGSSLYHPNSTVHLHQG 239 
Merlin     154 LLISGLRPQETTEYTCSFFSWGRHHNATWDLFTYPIYAVYGTRLNATTMRVRVLLQEHEHCLLNGSSLYHPNSTVHLHQG 233 
 
ZMB240     240 NQLIPPWNISNVTYNGQRLREFVFYLNGTYTVVRLHVQIAGRSFTTTYVFIKSDPLFEDRLLAYGVLAFLVFMVIILLYV 319 
Toledo     240 NQLIPPWNISNVTYNGQRLREFVFYLNGTYTVVRLHVQIAGRSFTTTYVFIKSDPLFEDRLLAYGVLAFLVFMVIILLYV 319 
PAV11      240 NQLIPPWNISNVTYNGQRLREFVFYLNGTYTVVRLHVQIAGRSFTTTYVFIKSDPLFEDRLLAYGVLAFLVFMVIILLYV 319 
BE/17/2010 240 DQLIPPWNISNVTYNGQRLREFVFYLNGTYTVVRLHVQIAGRSFTTTYVFIKSDPLFEDRLLAYGVLAFLVFMVIILLYV 319 
BE/26/2010 240 NQLIPPWNISNVTYNGQRLREFVFYLNGTYTVVRLHVQIAGRSFTTTYVFIKSDPLFEDRLLAYGVLAFLVFMVIILLYV 319 
BE/4/2011  240 DQLIPPWNISNVTYNGQRLREFVFYLNGTYTVVRLHVQIAGRSFTTTYVFIKSDPLFDDRLLAYGVLAFLVFMVIILLYV 319 
BE/15/2012 240 NQLIPPWNISNVTYNGQRLREFVFYLNGTYTVVRLHVQIAGRSFTTTYVFIKSDPLFEDRLLAYGVLAFLVFMVIILLYV 319 
CZ/3/2012  240 DQLIPPWNISNVTYNGQRLREFVFYLNGTYTVVRLHVQIAGRSFTTTYVFIKSDPLFEDRLLAYGVLAFLVFMVIILLYV 319 
BE/11/2012 240 NQLIPPWNISNVTYNGQRLREFVFYLNGTYTVVRLHVQIAGRSFTTTYVFIKSDPLFEDRLLAYGVLAFLVFMVIILLYV 319 
BE/30/2011 240 NQLIPPWNISNVTYNGQRLREFVFYLNGTYTVVRLHVQIAGRSFTTTYVFIKSDPLFEDRLLAYGVLAFLVFMVIILLYV 319 
BE/7/2012  240 NQLIPPWNISNVTYNGQRLREFVFYLNGTYTVVRLHVQIAGRSFTTTYVFIKSDPLFEDRLLAYGVLAFLVFMVIILLYV 319 
BE/16/2012 240 NQLIPPWNISNVTYNGQRLREFVFYLNGTYTVVRLHVQIAGRSFTTTYVFIKSDPLFEDRLLAYGVLAFLVFMVIILLYV 319 
BE/13/2010 240 DQLIPPWNISNVTYNGQRLREFVFYINGTYTVVRLHVQIAGRSFTTTYVFIKSDPLFEDRLLAYGVLAFLVFMVIILLYV 319 
BE/21/2010 240 NQLIPPWNISNVTYNGQRLREFVFYLNGTYTVVRLHVQIAGRSFTTTYVFIKSDPLFEDRLLAYGVLAFLVFMVIILLYV 319 
U8         240 NQLIPPWNISNVTYNGQRLREFVFYLNGTYTVVRLHVQIAGRSFTTTYVFIKSDPLFEDRLLAYGVLAFLVFMVIILLYV 319 
Merlin     234 DQLIPPWNISNVTYNGQRLREFVFYLNGTYTVVRLHVQIAGRSFTTTYVFIKSDPLFEDRLLAYGVLAFLVFMVIILLYV 313 
 
ZMB240     320  TYMLARRRDWSYKRLEEPVEEKKHPVPYFKQW  351 
Toledo     320  TYMLARRRDWSYKRLEEPVEEKKHPVPYFKQW  351 
PAV11      320  TYMLARRRDWSYKRLEEPVEEKKHPVPYFKQW  351 
BE/17/2010 320  TYMLARRRDWSYKRLEEPVEEKKHPVPYFKQW  351 
BE/26/2010 320  TYMLARRRDWSYKRLEEPVEEKKHPVPYFKQW  351 
BE/4/2011  320  TYMLARRRDWSYKRLEEPVEEKKHPVPYFKQW  351 
BE/15/2012 320  TYMLARRRDWSYKRLEEPVEEKKHPVPYFKQW  351 
CZ/3/2012  320  TYMLARRRDWSYKRLEEPVEEKKHPVPYFKQW  351 
BE/11/2012 320  TYMLARRRDWSYKRLEEPVEEKKHPVPYFKQW  351 
BE/30/2011 320  TYMLARRRDWSYKRLEEPVEEKKHPVPYFKQW  351 
BE/7/2012  320  TYMLARRRDWSYKRLEEPVEEKKHPVPYFKQW  351 
BE/16/2012 320  TYMLARRRDWSYKRLEEPVEEKKHPVPYFKQW  351 
BE/13/2010 320  TYMLARRRDWSYKRLEEPVEEKKHPVPYFKQW  351 
BE/21/2010 320  TYMLARRRDWSYKRLEEPVEEKKHPVPYFKQW  351 
U8         320  TYMLARRRDWSYKRLEEPVEEKKHPVPYFKQW  351 
Merlin     314  TYMLARRRDWSYKRLEEPVEEKKHPVPYFKQW  345 
 
Figure 5.36. ZMB240 UL119 amino acid alignment. ZMB240 protein UL119 has an amino 
acid deletion at position 35 and a block of six residues inserted after position 61 
(highlighted by the red borders) relative to HCMV strain Merlin (AY446894.2). These 






5.4.3 Non-coding RNAs 
In addition to mRNAs that encode proteins, HCMV also encodes numerous non-coding 
RNAs (ncRNAs). ncRNAs include long non-coding RNAs (lncRNAs) and microRNAs 
(miRNAs). The ZMB240 genome has at least 30 non-coding RNA regions (table 5.9) which 
comprise 4 lncRNAs and 26 microRNAs. 
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5.4.3.1  Long non-coding RNAs (lncRNAs) 
Long non-coding RNAs (lncRNAs) are found in every life form as a loosely classified 
diverse group of abundantly transcribed RNA molecules. Generally, lncRNAs are 
described as RNA transcripts >200 nucleotides in length, that do not encode proteins 
(Quinn and Chang, 2016, Mattick and Rinn, 2015). Broadly, lncRNAs are important 
regulators of gene expression, with a wide range of functions in cellular and 
developmental processes including imprinting genomic loci, shaping chromosome 
conformation and allosterically regulating enzymatic activity (Quinn and Chang, 2016). 
HCMV lncRNAs include RNA2.7, RNA1.2, RNA4.9 and RNA5.0 (Kulesza and Shenk, 2004, 
McDonough et al., 1985, Rawlinson and Barrell, 1993, Hutchinson and Tocci, 1986, 
Gatherer et al., 2011). Although they are polyadenylated and can be expressed at very 
high levels in lytic infection (Kulesza and Shenk, 2004, Gatherer et al., 2011), so far these 
lncRNAs do not appear to play protein coding functions. There is however a report 
suggesting the possibility of polypeptides being produced from lncRNAs through non-
conventional translation (Ingolia et al., 2014). Functions of the HCMV lncRNAs are 
largely unclear, but in general involve targeting of specific gene promoters mediating 
transcriptional silencing. This includes the inhibition of apoptosis (RNA2.7) (Reeves et 
al., 2007), virulence (RNA5.0) (Kulesza and Shenk, 2006), and transcriptional repression 
of viral IE gene expression during latency (RNA4.9) (Noriega et al., 2014, Rossetto et al., 
2013). Recently, a therapeutic role for RNA2.7 in Parkinson’s disease has been proposed 
(Poole et al., 2016). All four classic HCMV lncRNA regions are present in the genomes of 
both HCMV strains Merlin and ZMB240. 
 
5.4.3.2  MicroRNAs (miRNAs) 
MicroRNAs (miRNAs) are a family of single-stranded noncoding RNA molecules of 
approximatively 20-23 nucleotides length present in many multicellular organisms 
(Bartel, 2004, He and Hannon, 2004, Dunn et al., 2005). By binding to specific mRNA 
targets whose translation is consequently inhibited, miRNAs play vital roles in the post-
transcriptional regulation of gene expression (Ambros, 2004). HCMV is known to also 
encode at least 26 miRNAs (Dunn et al., 2005, Grey et al., 2005, Landgraf et al., 2007, 
Meshesha et al., 2016, Pfeffer et al., 2005, Stark et al., 2012) as curated in the microRNA 
database, miRBase release 21 (http://www.mirbase.org) (Griffiths-Jones, 2004, 
Griffiths-Jones et al., 2006, Griffiths-Jones et al., 2008, Kozomara and Griffiths-Jones, 
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2011, Kozomara and Griffiths-Jones, 2014). HCMV miRNAs are unique among human 
herpesviruses in that they are spread throughout the genome, unlike in alpha- and 
gammaherpesviruses, where the miRNA genes are clustered within defined locations 
within the genome (Buck et al., 2007, Dolken et al., 2007, Dunn et al., 2005, Pfeffer et 
al., 2005). HCMV miRNAs perform roles in complex processes including regulation of 
host cell metabolism, immune evasion, and establishment and maintenance of latency 
(Grey et al., 2007, Stern-Ginossar et al., 2007, Stern-Ginossar et al., 2009, Lau et al., 
2016a, Lau et al., 2016b, Poole et al., 2011, Shen et al., 2014). Some HCMV miRNAs have 
been shown to target both viral and host cell mRNAs (Stern-Ginossar et al., 2009). 
Interest in miRNAs has heightened in recent times due to their potential for use in 
diagnostics and as therapeutic targets, as reviewed by Ng (Ng et al., 2015). Here we 
investigated the HCMV miRNA sequences and show in table 5.11 that all 26 sequences 
are absolutely conserved in ZMB240. Of these 13 miRNAs are located within intergenic 
regions, and of 11 occurring within coding regions, nine are antisense to the coding 
region while two (hcmv-miR-UL29-5p and hcmv-miR-UL29-3p) are in the same sense as 
the coding region. A further two miRNAs (hcmv-miR-UL36-3p and hcmv-miR-UL36-5p) 
are encoded within an intron of the UL36 gene. We note that the current annotation of 
strain Merlin requires updating, as it is based on the outdated miRBase release 16 with 
only 17 miRNA sequences. 
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Micro RNA    Coordinates  
Accession No. ID Sequence Length Orientation in ZMB240 References 
MIMAT0001574 hcmv-miR-UL22A-5p TAACTAGCCTTCCCGTGAGA 20 Forward a28122–28141 (Dunn et al., 2005, Landgraf et al., 2007, Meshesha et al., 2016, Pfeffer et al., 2005, Stark et al., 2012) 
MIMAT0001575 hcmv-miR-UL22A-3p TCACCAGAATGCTAGTTTGTAG 22 Forward a28159–28180 (Dunn et al., 2005, Landgraf et al., 2007, Meshesha et al., 2016, Pfeffer et al., 2005, Stark et al., 2012) 
MIMAT0004754 hcmv-miR-UL36-3p TTTCCAGGTGTTTTCAACGTG 22 Reverse c49977–49998 (Grey et al., 2005, Landgraf et al., 2007, Meshesha et al., 2016, Pfeffer et al., 2005, Stark et al., 2012) 
MIMAT0001576 hcmv-miR-UL36-5p TCGTTGAAGACACCTGGAAAGA 22 Reverse c50021–50042 (Grey et al., 2005, Landgraf et al., 2007, Meshesha et al., 2016, Pfeffer et al., 2005, Stark et al., 2012) 
MIMAT0029122 hcmv-miR-UL59 GTTCTCTCGCTCGTCATGCCGT 22 Forward a96028–96049 (Meshesha et al., 2016) 
MIMAT0029123 hcmv-miR-UL69 CCAGAGGCTAAGCCGAAACCG 21 Forward a98330–98350 (Meshesha et al., 2016) 
MIMAT0003342 hcmv-miR-UL70-5p TGCGTCTCGGCCTCGTCCAGA 21 Forward a104511–104531 (Grey et al., 2005, Meshesha et al., 2016) 
MIMAT0003343 hcmv-miR-UL70-3p GGGGATGGGCTGGCGCGCGG 20 Forward a104552–104571 (Grey et al., 2005, Meshesha et al., 2016) 
MIMAT0026552 hcmv-miR-UL112-5p CCTCCGGATCACATGGTTACTCA 23 Forward a164588–164610 (Landgraf et al., 2007, Meshesha et al., 2016, Pfeffer et al., 2005, Stark et al., 2012) 
MIMAT0001577 hcmv-miR-UL112-3p AAGTGACGGTGAGATCCAGGCT 22 Forward a164625–164646 (Landgraf et al., 2007, Meshesha et al., 2016, Pfeffer et al., 2005, Stark et al., 2012) 
MIMAT0001578 hcmv-miR-UL148D TCGTCCTCCCCTTCTTCACCG 21 Forward a193646–193666 (Landgraf et al., 2007, Meshesha et al., 2016, Pfeffer et al., 2005, Stark et al., 2012) 
MIMAT0003341 hcmv-miR-US4-5p TGGACGTGCAGGGGGATGTCTG 22 Forward a201747–201768 (Grey et al., 2005, Meshesha et al., 2016, Stark et al., 2012) 
MIMAT0026628 hcmv-miR-US4-3p TGACAGCCCGCTACACCTCT 20 Forward a201786–201805 (Grey et al., 2005, Meshesha et al., 2016, Stark et al., 2012) 
MIMAT0001579 hcmv-miR-US5-1 TGACAAGCCTGACGAGAGCGT 21 Forward a202692–202712 (Grey et al., 2005, Landgraf et al., 2007, Meshesha et al., 2016, Pfeffer et al., 2005, Stark et al., 2012) 
MIMAT0026553 hcmv-miR-US5-2-5p CTTTCGCCACACCTATCCTGAAA 24 Forward a202784–202806 (Landgraf et al., 2007, Pfeffer et al., 2005, Stark et al., 2012) 
MIMAT0001580 hcmv-miR-US5-2-3p TATGATAGGTGTGACGATGTCT 22 Forward a202820–202841 (Landgraf et al., 2007, Pfeffer et al., 2005, Stark et al., 2012) 
MIMAT0028165 hcmv-miR-US22-5p TGTTTCAGCGTGTGTCCGCGGG 22 Forward a216476–216497 (Stark et al., 2012) 
MIMAT0028166 hcmv-miR-US22-3p TCGCCGGCCGCGCTGTAACCAGG 23 Forward a216514–216536 (Stark et al., 2012) 
MIMAT0004755 hcmv-miR-US25-1-3p GTCCGAACGCTAGGTCGGTTCT 21 Reverse c221795–221816 (Dunn et al., 2005, Landgraf et al., 2007, Meshesha et al., 2016, Pfeffer et al., 2005, Stark et al., 2012) 
MIMAT0001581 hcmv-miR-US25-1-5p AACCGCTCAGTGGCTCGGACC 21 Reverse c221838–221858 (Dunn et al., 2005, Landgraf et al., 2007, Meshesha et al., 2016, Pfeffer et al., 2005, Stark et al., 2012) 
MIMAT0001583 hcmv-miR-US25-2-3p ATCCACTTGGAGAGCTCCCGCGG 24 Reverse c221999–222021 (Landgraf et al., 2007, Meshesha et al., 2016, Pfeffer et al., 2005, Stark et al., 2012) 
MIMAT0001582 hcmv-miR-US25-2-5p AGCGGTCTGTTCAGGTGGATGA 22 Reverse c222058–222079 (Landgraf et al., 2007, Meshesha et al., 2016, Pfeffer et al., 2005, Stark et al., 2012) 
MIMAT0004756 hcmv-miR-US33-3p TCACGGTCCGAGCACATCCAA 21 Reverse c227024–227044 (Landgraf et al., 2007, Meshesha et al., 2016, Pfeffer et al., 2005, Stark et al., 2012) 
MIMAT0028167 hcmv-miR-US29-5p TGGATGTGCTCGGACCGTGACG 22 Forward a227025–227046 (Stark et al., 2012) 
MIMAT0001584 hcmv-miR-US33-5p GATTGTGCCCGGACCGTGGGCG 22 Reverse c227060–227081 (Landgraf et al., 2007, Meshesha et al., 2016, Pfeffer et al., 2005, Stark et al., 2012) 
MIMAT0028168 hcmv-miR-US29-3p CCCACGGTCCGGGCACAATCA 21 Forward a227062–227082 (Stark et al., 2012) 
 
Table 5.11. HCMV microRNAs found in the ZMB240 genome. All 26 HCMV miRNA sequences characterised in miRBase release 21 
(http://www.mirbase.org) were found conserved in the ZMB240 genome. c, complement. 
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5.4.4 Review of Anti-HCMV Drug Resistance Mutations in ZMB240 
Finally, we examined whether the ZMB240 sequence contained mutations associated 
with anti-HCMV drug resistance. Although the use of anti-HCMV drugs in the Zambian 
population is presently almost non-existent, conditions such as renal failure and liver 
failure are becoming more common in the local population and there is an increasing 
drive for access to organ transplant services. It is therefore essential that HCMV 
management and related drug resistance issues be considered. For ZMB240 we checked 
three key HCMV genes – UL97, UL54, and UL27 – that are associated with emergence of 
resistance to commonly used anti-HCMV drugs. 
 
5.4.4.1  UL97 
The UL97 gene product is a serine/threonine kinase incorporated in the mature virion 
(van Zeijl et al., 1997, Prichard et al., 2005) and has autophosphorylation capacity (He et 
al., 1997, Michel and Mertens, 2004). The kinase is vital for the initial phosphorylation 
of GCV and ACV, and is selectively inhibited by MBV. Numerous drug resistance 
mutations can develop in UL97, as reviewed by Lurain and Chou (Lurain and Chou, 2010) 
and Campos et al (Campos et al., 2016). These mutations are incorporated in the 
Mutation Resistance Analyzer (MRA) database (Chevillotte et al., 2010), an online drug 
resistance genotyping tool available at http://www.informatik.uni-
ulm.de/ni/mitarbeiter/HKestler/hcmv. ZMB240 UL97 was screened using the MRA and 
no drug resistance mutations were found. However two polymorphisms not associated 
with drug resistance, and two other changes not present in the MRA database were 
revealed (figure 5.38-A). 
 
5.4.4.2  UL54 
UL54 encodes the DNA polymerase, which in conjunction with other components of the 
viral replication complex, is responsible for viral DNA replication. The polymerase has 
both nucleotide polymerization and proofreading (3’-5’-exonuclease) activity, and is the 
ultimate target of the anti-HCMV drugs GCV/vGCV, CDV, and FOS. Drug resistance 
chiefly results from mutations that prevent drug binding to the enzyme or favour the 
enzyme’s exonuclease activity (and hence removal of the incorporated drug) (Gilbert 
and Boivin, 2005, Lurain and Chou, 2010). Screening of ZMB240 UL54 using the MRA 
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showed no drug resistance mutations, but five polymorphisms not linked to drug 
resistance were found (Figure 5.38-B). 
 
5.4.4.3  UL27 
Mutations in UL27 have are associated with relatively low-level resistance to MBV. 
Classical mutations (relative to the HCMV strain AD169, FJ527563.1) include R233S, 
W362R, A406V combined with C415stop (Chou et al., 2004), V353A, W153R, L193F, 
A269T, V353E, L426F, E22stop, W362stop, 218delC, and 301-311del (Chou, 2009). None 
of these mutations was present in ZMB240. Several polymorphisms in UL27 have also 
been observed which are not associated with conferring drug resistance. They include 
N289D, D298G, N300G, P307L, V310A, D351N, and I367V (Chou, 2009). Of these D298G 
and I367V occur in ZMB240, as highlighted in figure 5.37. 
 
MNPVDQPPPPLPTQQPEEQAKEDHDDGDERLFRDPLTTYEYLDDCRDDEEFCHQFLRAYL 
        10        20        30        40        50        60 
TPIRNRQEAVRAGLLCRTPEDLAAAGGQKKKTPAPKHPKHAMVYIRRSCLVHSACATAHG 
        70        80        90       100       110       120 
KYDIRGLTLESDLAVWAALRGVPLPPDPQHFRWLNAGAFRRLVHEAQYLPEISRAAKRIA 
       130       140       150       160       170       180 
LAVATGQYVVCTLLDYKTFGTRTHYLRQLCSMTEELYLRLDGTLCLFLEPEERELIGRCL 
       190       200       210       220       230       240 
PAALCRGLPVKYRTHRAAVFFHATFMAR AEAALKDLYAAFCECGDGRDNGGNHDGNH DGN 
       250       260       270       280       290       300 
DHSSLSPSAVASHHSRLEHAELRLERNRHLGAFHLPAIRHLTAGDVARVQDSVSRDLGFA 
       310       320       330       340       350       360 
DWSQTLVDDYFLLPAGWACANPRRGYAMYLASNAVLALRIIRLLRASIRHEYTACIRMLS 
       370       380       390       400       410       420 
GDVQRLIRLFKGEAALLRKGLAQNPVQRRELSRFRKHVHDLKRIRFTEDTFVETFCDFLE 
       430       440       450       460       470       480 
LVQRIPDYRSVSLRIKRELLCLHVFKLRRGCRAPPTPETARVQRLLWHSLRHGDAPQDRT 
       490       500       510       520       530       540 
RLPQFSSALSDAELSNHANRCRRKAPLELGPAVVAAPGPSVRYRAHIQKFERLHVRRFRP 
       550       560       570       580       590       600 
HEVGGHAT 
 
Figure 5.37. Polymorphisms in ZMB240 UL27. The full-length amino acid sequence 
shows two polymorphisms relative to HCMV strain AD169 (FJ527563.1): D298G and 




5.4.4.4  Summary 
None of the three genes associated with antiviral drug resistance in HCMV showed any 
SNPS indicative of baseline drug resistance in the ZMB240 consensus genome. 
 


















Figure 5.38. Polymorphisms in ZMB240 UL97 (Serine/Threonine Kinase) and UL54 (DNA polymerase) gene sequences. Mutation maps and drug 
resistance/sensitivity profile tables adapted from screening reports by the Mutation Resistance Analyzer (MRA) genotyping database, 
http://www.informatik.uni-ulm.de/ni/mitarbeiter/HKestler/hcmv.  
Locus  Mutation  Resistance profile Sensitivity profile Reference / Comment 
19 Q19E - GCV (Lurain et al., 2001) 
108 S108N - GCV (Lurain et al., 2001) 
75 T75A -  Not in database 
126 Q126L -  Not in database 
Locus  Mutation  Resistance profile Sensitivity profile Reference / Comment 
655 L655S - GCV, CDV, FOS (Mousavi-Jazi et al., 2001) 
685 S685N - GCV, CDV, FOS (Mousavi-Jazi et al., 2001) 
897 S897L - GCV, CDV, FOS 
(Chou et al., 1999, Mousavi-Jazi et 
al., 2001, Rodriguez et al., 2007, 
Weinberg et al., 2003) 
1122 T1122A - GCV, CDV, FOS (Chou et al., 1999) 
1164 V1164A - GCV, CDV, FOS  
[B] UL 54  
[A] UL 97  
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Gene Start End Orientation Product AA length MW Comparison to HCMV Strain Merlin (AY446894.2) 
RL1 1551 2483 Forward Protein RL1 310 34905  
RL5A 5588 5860 Reverse Protein RL5A 90 9706 5 amino acid insertions (various positions) and 10 residues deleted (various positions) 
RL8A 8036 8308 Reverse Protein RL8A 90 10168  
RL9A 8374 8517 Reverse Protein RL9A 47 5285  
RL10 8724 9236 Forward Envelope glycoprotein RL10 170 19032  
RL11 9265 9969 Forward Membrane glycoprotein RL11 234 26629  
RL12 9973 11172 Forward Membrane protein RL12 399 45369 13 amino acid insertions (various positions) and 28 residues deleted (various positions) 
RL13 11282 12205 Forward Membrane protein RL13 307 34279 22 amino acid insertions (various positions) and 8 residues deleted (various positions) 
UL1 12320 12967 Forward Membrane protein UL1 215 24378 8 amino acids inserted at positions 16 (X2), 35 (X1), 44 (X3), 189 (X2); 11 residues deleted at 140–150 
UL2 13361 13543 Reverse Protein UL2 60 6869 Single amino acid insertion after position 12 
UL4 13971 14420 Forward Envelope glycoprotein UL4 149 17140  
UL5 14511 15008 Forward Protein UL5 165 18758 Single amino acid deletion at position 28 
UL6 15119 15961 Forward Membrane protein UL6 280 30922  
UL7 16021 16689 Forward Membrane glycoprotein UL7 222 24435  
UL8 16021 17097 Forward Membrane glycoprotein UL8 324 35826  
UL9 17094 17789 Forward Membrane glycoprotein UL9 231 26621 2 amino acid insertions: at positions -1 and after 76; block of 4 residues deleted at positions 62–65  
UL10 17904 18668 Forward Membrane protein UL10 254 29037  
UL11 18770 19588 Forward Membrane glycoprotein UL11 272 30823  
UL13 19786 21204 Forward Protein UL13 472 54403 Single amino acid deletion at position 396 
UL14 21354 22337 Forward Membrane protein UL14 327 36707  
UL15A 22350 22658 Forward Protein UL15A 102 11199  
UL16 22879 23571 Forward Membrane glycoprotein UL16 230 26161  
UL17 23679 23993 Forward Protein UL17 104 12637  
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Gene Start End Orientation Product AA length MW Comparison to HCMV Strain Merlin (AY446894.2) 
UL18 24102 25205 Forward Membrane glycoprotein UL18 367 41753 Single amino acid deletion at position 34 
UL19 25202 25498 Forward Protein UL19 98 11379  
UL20 25762 26784 Forward Membrane protein UL20 340 38449  
UL21A 26929 27300 Reverse Protein UL21A 123 14216  
UL22A 27569 27972 Forward Glycoprotein UL22A 106 11575 Single amino  acid insertion after position 44 
UL23 28338 29192 Reverse Tegument protein UL23 284 32939  
UL24 29409 30485 Reverse Tegument protein UL24 358 40205  
UL25 30533 32503 Forward Tegument protein UL25 656 73540  
UL26 32690 33256 Reverse Tegument protein UL26 188 21127  
UL27 33312 35138 Reverse Protein UL27 608 69207  
UL29 35235 37486 Reverse Protein UL29 701 79053 Single amino acid insertion after position 25 
UL30 37616 37981 Reverse Protein UL30 121 13986  
UL30A 38027 38266 Reverse Protein UL30A 79 9469 Has the alternative ACG initiation codon; same as Merlin 
UL31 38460 40247 Forward Protein UL31 595 65661  
UL32 40325 43471 Reverse Tegument protein pp150 1048 112766 2 amino acid deletions at 431 and 720 and an insertion after position 899 
UL33 43542 44898 Forward Envelope glycoprotein UL33 411 46073 Single amino acid deletion at position 179 
UL34 45266 46489 Forward Protein UL34 407 45445  
UL35 46568 48493 Forward Tegument protein UL35 641 72631  
UL36 48719 50256 Reverse Tegument protein vICA 476 54950  
UL37 50390 53195 Reverse Envelope glycoprotein UL37 490 56274 Three amino acid insertions after position 340 and a deletion at position 400 
UL38 51617 52612 Reverse Protein UL38 331 36822  
UL40 53709 54374 Reverse Membrane glycoprotein UL40 221 24473  
UL41A 54536 54772 Reverse Protein UL41A 78 8953  
UL42 54878 55246 Reverse Protein UL42 122 13399 Three amino acid deletions at positions 116, 121, and 122 
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Gene Start End Orientation Product AA length MW Comparison to HCMV Strain Merlin (AY446894.2) 
UL43 55310 56581 Reverse Tegument protein UL43 423 47734  
UL44 56628 57929 Reverse DNA polymerase processivity subunit 433 46233  
UL45 58070 60790 Reverse Ribonucleotide reductase subunit 1 906 101562  
UL46 60936 61808 Reverse Capsid triplex subunit 1 290 33027  
UL47 61807 64758 Forward Tegument protein UL37 983 109990  
UL48 64755 71477 Forward Large tegument protein 2240 253115  
UL48A 71596 71823 Reverse Small capsid protein 75 8495 Single amino acid deletion at position 318 
UL49 71816 73528 Reverse Protein UL49 570 63868  
UL50 73485 74678 Reverse Nuclear egress membrane protein 397 42895 Single amino acid deletion at position 217 
UL51 74700 75173 Reverse DNA packaging protein UL33 157 17025  
UL52 75211 77217 Forward DNA packaging protein UL32 668 74146  
UL53 77210 78340 Forward Nuclear egress lamina protein 376 42303  
UL54 78318 82046 Reverse DNA polymerase catalytic subunit 1242 137160 Five polymorphisms are present: L655S, S685N, S897L, V1164A, (also present in Merlin) and T1122A 
(absent in Merlin). None confers resistance to anti-HCMV drugs. 
UL55 82188 84911 Reverse Envelope glycoprotein B 907 101954 Genotype 1 
UL56 84874 87426 Reverse DNA packaging terminase subunit 2 850 95757  
UL57 87993 91700 Reverse Single-stranded DNA-binding protein 1235 133880  
UL69 99626 101854 Reverse Multifunctional expression regulator 742 82456  
UL70 101954 104794 Reverse Helicase-primase primase subunit 946 107825  
UL71 104810 105895 Forward Tegument protein UL51 361 39870  
UL72 105976 107142 Reverse Deoxyuridine triphosphatase 388 43475  
UL73 107158 107565 Forward Envelope glycoprotein N 135 14386 Genotype gN4d 
UL74 107537 108940 Reverse Envelope glycoprotein O 467 54127 Genotype gO5; First 5 amino acids are deleted, leaving alternative internal initiation site 
UL74A 108249 109157 Forward Envelope glycoprotein 24 70 7629  
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Gene Start End Orientation Product AA length MW Comparison to HCMV Strain Merlin (AY446894.2) 
UL75 109329 111557 Reverse Envelope glycoprotein H 742 84230 Genotype 2 
UL76 111752 112729 Forward Nuclear protein UL24 325 36015  
UL77 112332 114239 Forward DNA packaging tegument protein UL25 635 70521 Single amino acid deletion at position 142 
UL78 114328 115623 Forward Envelope protein UL78 431 47369  
UL79 115678 116565 Reverse Protein UL79 295 33872  
UL80 116602 118728 Forward Capsid maturation protease 708 73862  
UL80.5 117607 118728 Forward Capsid scaffold protein 373 38222  
UL82 118888 120567 Reverse Tegument protein pp71 559 62002  
UL83 120756 122441 Reverse Tegument protein pp65 561 62883  
UL84 122712 124475 Reverse Protein UL84 587 65379  
UL85 124507 125427 Reverse Capsid triplex subunit 2 306 34595  
UL86 125589 129701 Reverse Major capsid protein 1370 153786  
UL87 129761 132586 Forward Protein UL87 941 104851  
UL88 132583 133872 Forward Tegument protein UL88 429 47631  
UL89 133869 139795 Reverse DNA packaging terminase subunit 1 674 77035  
UL91 135241 135576 Forward Protein UL91 111 12013  
UL92 135546 136151 Forward Protein UL92 201 22511  
UL93 136117 137901 Forward DNA packaging tegument protein UL17 594 68421  
UL94 137759 138796 Forward Tegument protein UL16 345 38354  
UL95 139794 141377 Forward Protein UL95 527 56911 Block of 6 amino acids deleted at position 382-387 
UL96 141374 141757 Forward Tegument protein UL14 127 14465  
UL97 141878 144001 Forward Tegument serine/threonine protein 
kinase 
707 78248 4 polymorphisms present: Q19E and S108N curated in MRA database, while T75A and Q126L 
currently not in MRA. None is known to confer resistance to anti-HCMV drugs. 
UL98 144095 145849 Forward Deoxyribonuclease 584 65331  
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Gene Start End Orientation Product AA length MW Comparison to HCMV Strain Merlin (AY446894.2) 
UL99 145786 146358 Forward Myristylated tegument protein 190 20933  
UL100 146616 147737 Reverse Envelope glycoprotein M 373 42817 2 amino acid insertions after positions 290 and 361 
UL102 147915 150533 Forward Helicase-primase subunit 872 93934 Single amino acid deletion at position 805 
UL103 150697 151446 Reverse Tegument protein UL7 249 28636  
UL104 151394 153487 Reverse Capsid portal protein 697 78521  
UL105 153315 156185 Forward Helicase-primase helicase subunit 956 106500  
UL111A 161069 161758 Forward Interleukin-10 176 20108  
UL112 161983 164194 Forward Protein UL112 684 70270 Single amino acid deletion at position 599 and an insertion after position 634  
UL114 164366 165118 Reverse Uracil-DNA glycosylase 250 28353  
UL115 165090 165926 Reverse Envelope glycoprotein L 278 30765 Genotype 3 
UL116 165926 166867 Reverse Protein UL116 313 34203  
UL117 166864 168138 Reverse Protein UL117 424 45491 Single amino acid deletion at position 607 
UL119 168251 169393 Reverse Membrane glycoprotein UL119 351 39330 Single amino acid deletion at position 35, and block of 7 residues inserted after position 61 
UL120 169448 170041 Reverse Membrane protein UL120 197 22267 Block of 5 amino acids deleted at positions 27–31, and a single residue inserted after position 145 
UL121 170092 170634 Reverse Membrane protein UL121 180 20199  
UL122 170762 174164 Reverse Regulatory protein IE2 580 63017  
UL123 172404 174164 Reverse Regulatory protein IE1 491 55038  
UL124 174197 174655 Forward Membrane protein UL124 152 15855 2 amino acid insertions: 1 after position 48 and the other after position 52 
UL128 176263 177021 Reverse Envelope protein UL128 171 19717 Intact UL128, with the classical ‘C’ variation at nucleotide position 634 of mature transcript 
UL130 177061 177705 Reverse Envelope glycoprotein UL130 214 24652  
UL131A 177726 178223 Reverse Envelope protein UL131A 129 14989  
UL132 178329 179141 Reverse Envelope glycoprotein UL132 270 29991  
UL148 179218 180168 Reverse Membrane protein UL148 316 36475  
UL147A 180237 180464 Reverse Membrane protein UL147A 75 8291  
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Gene Start End Orientation Product AA length MW Comparison to HCMV Strain Merlin (AY446894.2) 
UL147 180467 180946 Reverse Chemokine vCXCL2 159 18826  
UL146 181010 181387 Reverse Chemokine vCXCL1 125 14307 Block of 5 amino acids inserted after position 105; Genotype 3 
UL145 181668 182060 Reverse Protein UL145 130 14586  
UL144 182301 182831 Reverse Membrane glycoprotein UL144 176 19469  
UL142 183472 184392 Reverse Membrane glycoprotein UL142 306 35011 Single amino acid insertion after position 211 
UL141 184465 185481 Reverse Membrane glycoprotein UL141 338 38929  
UL140 185780 186355 Reverse Protein UL140 191 21489  
UL139 186537 186944 Reverse Membrane glycoprotein UL139 135 14025 3 amino acids deleted at positions 34–36; Genotype 4 
UL138 187507 188016 Reverse Protein UL138 169 19282  
UL136 188099 188821 Reverse Protein UL136 240 27121  
UL135 188912 189838 Reverse Protein UL135 308 33325  
UL133 190015 190788 Reverse Protein UL133 257 27689  
UL148A 190884 191123 Reverse Protein UL148A 79 8926 Single amino acid deletion at position 6 
UL148B 191253 191495 Reverse Protein UL148B 80 8869  
UL148C 191582 191815 Forward Protein UL148C 77 8527  
UL148D 192196 192384 Forward Protein UL148D 62 7065  
UL150 192400 194319 Reverse Protein UL150 639 70148  
UL150A 193259 194185 Forward Protein UL150A 271 29382  
IRS1 196313 198889 Forward Tegument protein IRS1 858 92077 Block of 11 amino acids inserted after position 368 
US1 198913 199383 Reverse Protein US1 156 17791  
US2 199701 200300 Reverse Membrane glycoprotein US2 199 23112  
US3 200715 201275 Reverse Membrane glycoprotein US3 186 21515  
US6 201987 202538 Reverse Membrane glycoprotein US6 183 20541 Single amino acid insertion after position 35 
US7 202952 203629 Reverse Membrane glycoprotein US7 225 26350  
 Page 191 of 338 
Gene Start End Orientation Product AA length MW Comparison to HCMV Strain Merlin (AY446894.2) 
US8 203832 204512 Reverse Membrane glycoprotein US8 226 26528 Single amino acid deletion at position 29 
US9 204537 205235 Reverse Membrane glycoprotein US9 232 26247 Deletion of 15 amino acids at positions 233–247  
US10 205618 206172 Reverse Membrane glycoprotein US10 184 20659 Single amino acid deletion at position 18 
US11 206248 206895 Reverse Membrane glycoprotein US11 215 25264  
US12 207081 207926 Reverse Membrane protein US12 281 32499  
US13 208006 208791 Reverse Membrane protein US13 261 29460  
US14 208860 209792 Reverse Membrane protein US14 310 34278  
US15 209837 210625 Reverse Membrane protein US15 262 29085  
US16 210685 211614 Reverse Membrane protein US16 309 34689  
US17 211759 212640 Reverse Membrane protein US17 293 31935  
US18 212908 213732 Reverse Membrane protein US18 274 30194  
US19 213870 214592 Reverse Membrane protein US19 240 26393  
US20 214639 215403 Reverse Membrane protein US20 254 28494  
US21 215510 216241 Reverse Membrane protein US21 243 27015  
US22 216418 218148 Reverse Tegument protein US22 576 65003  
US23 218262 220040 Reverse Protein US23 592 68885  
US24 220136 221641 Reverse Tegument protein US24 501 58026  
US26 222275 224086 Reverse Protein US26 603 69978  
US27 224452 225540 Forward Envelope glycoprotein US27 362 41984 2 amino acid deletions at positions 10 and 11 
US28 225748 226812 Forward Envelope protein US28 354 41020  
US29 226975 228363 Forward Membrane protein US29 462 50983  
US30 228167 229216 Forward Membrane protein US30 349 39184  
US31 229331 229816 Forward Protein US31 161 18939  
US32 229934 230485 Forward Protein US32 183 22057  
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Gene Start End Orientation Product AA length MW Comparison to HCMV Strain Merlin (AY446894.2) 
US33A 230687 230860 Forward Protein US33A 57 6874  
US34 231029 231520 Forward Protein US34 163 17741  
US34A 231514 231708 Forward Protein US34A 64 8140  
TRS1 232702 235104 Reverse Tegument protein TRS1 800 85023 12 amino acid insertions: block of 11 after position 368; 1 after 788 
 
Table 5.12. HCMV strain ZMB240 gene list. Comparisons of the 169 genes products in ZMB240 to reference strain Merlin (AY446894.2) are highlighted 
in the last column. CDS, Coding DNA Sequence; bp, base pairs; AA, amino acid; MW, molecular weight in daltons; MRA, Mutation Resistance Analyzer 
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5.5 DISCUSSION 
This chapter analyses burden of infection with HCMV in breast milk, comparing with viral 
load as well as effects of HIV infection. In order to do this, methods were established for 
the detection and quantification of HCMV genotype variants. ZMB240 – a complete 
HCMV genome sequenced from breast milk is also characterised. The genotype 
detection and enumeration method devised here utilises molecular ‘barcodes’ specific 
to each HCMV gO and gN genotype, combined with perl Scripts to interrogate NGS 
FASTQ reads. The method was tested on archived sequences in GenBank release 211 
(National Center for Biotechnology Information (NCBI), 2015) and showed high 
sensitivity of 99.4% for gO and 98.6% for gN. This however may in fact be an 
underestimate, since sequences not assigned a genotype appeared to have unresolved 
ambiguous bases and possible compilation errors, although two potential recombinants 
were detected as detailed in Section 5.2.3. The method was subsequently applied to 
NGS reads sequenced directly from 21 clinical (breast milk) samples unexposed to biases 
introduced by tissue culture. We showed that in these samples, collected from both HIV-
positive and negative women, multiple genotypes were present indicating mixed 
infections. Overall, all eight HCMV gO genotypes were detected among the HIV-positive 
samples, while among the HIV-negatives gO2b was not detected. Although this could be 
an effect of the relatively small sample, it is consistent with Sanger sequencing results 
that showed differences in the genotypes present in the two HIV groups (see Chapter 
4). Interestingly, for individuals where milk samples were available and sequenced 
independently from both breasts, there was uniformity in genotype proportions, 
suggesting a common source of virus into the mammary gland possibly from reactivation 
from latency established in another body compartment. Interestingly, the viral load and 
genotypes increased from week 4 postpartum, and this is also a documented time of 
myeloid cellular infiltration (Maschmann et al., 2015). Dynamics of genotype 
proportions were investigated by correlating the genotype prevalence to the viral load 
kinetics over the first 16 postpartum weeks. Three HIV positive women had samples 
collected at more than one time-point and were therefore used for this analysis, which 
showed that between week 4 and week 12 there was expansion in the number of 
genotypes in milk, and by week 16 the picture returned to the week 4 state. The period 
between weeks 4 and 12 coincides with the end of the puerperium and there is recovery 
from the relative immunosuppressed pregnancy state (Groer et al., 2015, Groer et al., 
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2005). The expansion of HCMV genotypes during this period may reflect the enhanced 
immune pressure on the virus leading to a phenomenon akin to “quasispecies” seen in 
RNA viruses, as has been shown previously in HCMV (Renzette et al., 2011). This 
genotype expansion may also represent new strains imported into the breast 
compartment from enhanced trafficking of macrophages and other monocytic cells 
which has been shown to peak around weeks 9 – 11 (Maschmann et al., 2015). The 
subsequent return to the week 4 genotypes points to an equilibrium state being reached 
as immune control is enhanced, as reflected by the fall in HCMV viral load by week 16. 
Humoral (antibody) responses could play a vital role in shaping this picture, as has been 
recently demonstrated in studies of HIV where antibody responses remained directed 
at the initial infecting subtype (Cornelissen et al., 2016). 
 
The final section of this chapter characterises the sequence of ZMB240, a complete 
HCMV genome derived from milk from an HIV-negative mother. This is to our knowledge 
the first complete HCMV genome from Africa. Also significant is the fact that it 
represents virus involved in the natural route of infection via breast milk. With a typical 
type E herpesviral genome architecture, 236,211 bp length, and 57.6% GC content, the 
ZMB240 genome is similar to other complete HCMV sequences (see appendix table 5.1). 
ZMB240 has a complement of 169 genes, and other genetic elements such as microRNAs 
and regulatory factors found in other HCMV strains. The only HCMV gene absent is UL6, 
which in ZMB240, like several other strains (see section 5.2), is initiated by the 
alternative TTG start codon. Core, beta, and betagamma genes, as well as all 26 currently 
verified HCMV microRNAs, are conserved in ZMB240. Although some gene products 
show differences compared to the reference strain Merlin (AY446894.2), these 
differences have been documented previously in several other HCMV strains, as detailed 
in section 5.2. Similar to the Merlin strain, ZMB240 carries the gO genotype 5 and gN 
genotype 4d. It was noted that ZMB240 gO5 is initiated from an alternative start site 5 
residues downstream relative to strain Merlin gO5 (figure 5.29). This phenomenon has 
been demonstrated in several gO5 sequences such as HCMV strain U8 (accession 
GU179288.1) (figure 5.29) and others (Bates et al., 2008). An important difference 
between ZMB240 and HCMV strain Merlin is that unlike the sequence of Merlin 
deposited in GenBank (accession number AY446894.2) ZMB240 contains intact locus 
UL128, which is a critical determinant of viral tropism as it encodes part of the 
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pentameric complex necessary for virus entry into non-fibroblast cells. HCMV strain 
Merlin later re-sequenced from the original clinical source material (urine) was also 
found to have intact UL128 (Dolan et al., 2004). Similar to other clinical strains and unlike 
laboratory-adapted HCMV strains, the ULb’ region is intact in ZMB240 and located at 
the right-hand end of the long unique region. This “virulence region” crucially encodes 
up to 20 genes essential for viral pathogenesis, immune evasion, virus dissemination, 
and latency. ULb′ is dispensable for growth and, interestingly, strains lacking ULb’ 
replicate with high efficiency and increased yields of infectious progeny virus in vitro 
compared to clinical strains with intact ULb’ (Wang et al., 2005, Goodrum et al., 2007, 
Cha et al., 1996, Dolan et al., 2004, Murphy et al., 2003). Further, there are no anti-
HCMV drug resistance mutations present in ZMB240, consistent with the fact that use 
of anti-HCMV agents is currently virtually non-existent in the Zambian population, from 
where ZMB240 originated. Currently, HCMV genomes are predominantly isolated from 
donors with pathology, commonly from urine from congenitally infected children, or 
from virus reactivations in immunosuppressed transplantation patients, or drug 
resistance variants. Overall, ZMB240 represents a reference clinical strain from the 
natural transmission medium – breast milk – from a healthy HIV-negative donor, 
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CHAPTER 6: 
SUMMARY AND CONCLUSIONS 
 
This thesis aimed to investigate and establish which route(s) of infection were associated 
with adverse childhood growth and development effects shown in previous studies 
among infants in Zambia, Sub-Saharan Africa , as well as the role of maternal HIV 
infection in the transmission of HCMV in this setting. Non-invasive approaches for 
diagnosing HCMV were also trialled in examining congenital infection via saliva, and 
postnatal transmission via breast milk. Importantly, our studies compared both HIV-
positive and negative groups inorder to delineate the role of maternal HIV in HCMV 
transmission dynamics. 
 
Our investigation of Congenital HCMV in a normal labour ward utilised PCR on neonatal 
saliva collected within the first hour of birth and before onset of breast milk feeding. The 
use of saliva to diagnose infection was warmly accepted by parents, even during this 
culturally sensitive period of life. Congenital HCMV was 1% prevalence (1/100), similar 
to surveys elsewhere. We were able to obtain nucleotide sequence and using Sanger 
sequencing determined the the gO genotype to be gO1c. This shows that use of saliva is 
sensitive for both detection and genotyping of HCMV, as well as the related 
betaherpesviries HHV-6A/B, as demonstrated in our validation experiments (section 
3.4). Our finding of 1% prevalence of congenital HCMV was lower than the 3.8% 
prevalence found by Mwaanza and co-workers among high risk neonates in the UTH 
NICU (Mwaanza et al., 2014). That study showed that HCMV prevalence was linked to 
maternal HIV seropositivity, but it did not account for possible confounding effects on 
HCMV prevalence of breast milk feeding (which mothers are encouraged to do in NICU). 
Another study published during this thesis found 2.6% congenital HCMV prevalence 
among HIV positive infants in South Africa (Manicklal et al., 2014), but no comparisons 
were made with infants unexposed to HIV. Similarly, in Zimbabwe Gumbo and 
colleagues found congenital HCMV was 11% among treatmant-naïve HIV-infected 
infants (Gumbo et al., 2014); no comparison was made to HIV-unfected infants. 
Although our congenital HCMV study was limited in the number of infants recruited due 
to industrial action by healthcare staff during the field study, we took precautions to 
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control for possible confounders including breast milk feeding by collecting samples 
within one hour of birth and before onset of feeding. Furthermore, we recruited both 
HIV-exposed and unexposed neonates. It would be interesting to study congenital 
HCMV further in LW in a larger neonatal sample. 
 
In our examination of breast milk, we found HCMV infection common among both HIV-
positive and negative mothers. Virus reactivation in milk occurred early in the 
postpartum period; infection was detected as early as day three postpartum, and HCMV 
DNA loads were comparable in both groups of mothers. However HCMV loads increased 
twice as quickly in HIV-positive mothers as it did in HIV-negative mothers, reaching peak 
levels in both groups at week 4 postpartum (figure 4.5). Interestingly, studies in Europe 
and Asia have also reported HCMV levels peaking in milk at week 4 (Hamprecht et al., 
2008, Jim et al., 2009, Yasuda et al., 2003). In our study, peak HCMV levels (at W4) were 
significantly higher in the HIV-positive group (p=.026), and remained higher to the last 
time point, week 16, where significantly more HIV-positive women remained with 
detectable HCMV in milk compared to their HIV-negative counterparts (p<.001). 
Assuming steady state HCMV dynamics, we estimated that it would take about 26 weeks 
for HCMV to reach undetectable levels from peak loads in the HIV-positive mothers. The 
high and prolonged levels of virus secretion correspond to the greater odds for HCMV 
infection for infants of HIV-positive mothers breasfed longer than 6 months or those of 
HIV-negative mothers breastfed beyond 18 months (table 4.6). Clearly, maternal HIV 
increases the load and prolongs duration of HCMV secretion, thereby increasing HCMV 
risk and exposure to infants.  
 
Although all gO genotypes were found in breast milk by Sanger sequencing, no genotype 
was associated with higher HCMV levels. Nevertheless, mixed-genotype infections were 
evident and therefore further examined by NGS deep sequencing to ascertain the 
burden of infection. This required a new analytical approach, which we devised by 
developing molecular barcodes specific to each gO genotype. Coupled with custom perl 
scripts, the barcodes were used to enumerate gO genotypes, including minor variants 
to as low as 1%, in NGS FASTA reads. In 21 breast milk-derived DNA samples analysed 
by NGS and our barcode method, we found upto seven genotypes per sample (table 
5.8). In three HIV-positive mothers with longitudinal samples analysed by NGS, we noted 
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a pattern whereby there was an expansion of genotypes present in milk between W4 
and W12 before a return to the W4 genotype(s) by W16 (figures 4.15 – 5.17). The 
genotype expansion may be due to superinfection, which commonly occurs, particularly 
if there are other young children in the family. It may also be due to enhanced immune 
activation and cellular infiltration into breast tissue similar to an immune reconstitution 
syndrome (IRIS) phenomenon as mothers during the peuperium undergo physiological 
changes returning to the pre-pregnancy state.  
 
Finally, this thesis characterised ZM240, a complete HCMV genome derived from DNA 
prepared directly from breast milk from a healthy HIV-negative mother. ZM240 has the 
architecture of a typical herpesviral class E genome and at 236,211bp length and 57.6% 
GC content is similar to other full-length HCMV genomes publicly available in GenBank. 
It contains the full gene complement but one, all regulatory elements, including 
noncoding RNAs, and is free of anti-HCMV drug resistance mutations. To our knowledge, 
ZM240 is the first complete HCMV genome from a natural route of transmission, breast 
milk, in a healthy individual, and from Africa. 
 
As endorsed by the World Health Organisation (WHO), exclusive breastfeeding for the 
first six months (Kramer and Kakuma, 2012) and continuation thereafter following 
introduction of complementary foods, remains of nutritional and immunological benefit 
for infants (http://www.who.int/nutrition/topics/infantfeeding_recommendation/en/). 
This is of particular importance where alternative feeding options are unavailable or 
cannot be safely practiced, for instance because of non-availability of safe water supply 
or due to compromised hygiene conditions. However given the detrimental effects of 
breastmilk-transmitted HCMV highlighted in this thesis, including on child health and 
development, and long-term effects on quality of life, geriatric illness, and lifespan, 
breastfeeding poses a real danger. A balanced approach is therefore necessary to retain 
the value and benefits of breast milk while limiting HCMV transmission especially in 
communities where breastfeeding is widely practiced, and therefore presents higher 
risk of infant infection. Strategies could include use of anti-HCMV drugs in mothers, 
although this would first require safety trials, since so far no anti-HCMV drugs are 
licenced for use during lactation. Treatment of milk by ultrashort heat treatment (Goelz 
et al., 2009, Stock et al., 2015, Hamprecht et al., 2004a) or irradiation (Christen et al., 
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2013, Christen, 2014) are also options that are already being applied in controlled 
hospital settings for premature and very low birthweight infants. Additionally, vaccines 
are in development by various researchers to improve maternal immunity against HCMV 
(Boppana and Britt, 2014, Fu et al., 2014, Wang and Fu, 2014). Use of hyperimmune 
globulin, which interestingly is focused on antibodies to the gH/gL complex (Fouts et al., 
2012), is another strategy for limiting infection and possible virus transmission. Other 
control efforts are targeted at addressing HCMV transmission via saliva and urine from 
young children, who serve as infection reservoirs in families and communities. These 
efforts include the promotion of good personal hygiene, particularly hand hygiene 
(Stowell et al., 2014, Cannon and Davis, 2005). 
 
FUTURE WORK 
In this thesis, we assessed postnatal and congenital HCMV infection together with 
effects of maternal HIV exposure in maternal and neonatal cohorts in Zambia. The 
results showed low levels of congenital infection in the general new-born labour ward, 
1%, compared to high levels of early postnatal infection by the age of 18 months, which 
were increased in children who were maternally HIV exposed. In order to characterise 
transmission at this early age, secretion in breast milk was examined, since this had been 
shown a major route for postnatal infection in breastfeeding populations. Viral loads, 
genotypes, and genomes were examined in DNA from breast milk from HIV–infected 
and uninfected mothers. Further, we devised a tool for assessing burden of infection via 
detecting genotype mixtures in NGS deep sequencing reads. 
 
For future studies, it would be interesting to employ the novel method developed here 
which would enable examining the burden of infection, either already present in the 
mother, or from repeated infections introduced from young siblings. Young children 
have been shown to secrete HCMV for several years (Adler et al., 2004, Noyola et al., 
2000), and in addition to breast milk, HCMV secretion in children’s saliva is likely a major 
source, although urine could also contribute depending on level of hygiene. With this 
genotyping method, all hypervariable genotype tags could be included in the script to 
provide a definitive examination of this issue of relevance for any intervention. The 
thesis developed a novel method based on molecular tags unique to each gO and gN 
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genotype. Further work could develop similar tags for detecting and quantifying other 
hypervariable HCMV genes, including members of the RL11 and US12 families, which 
are some of the most hypervariable in the genome (Dolan et al., 2004, Murphy et al., 
2003). This could be useful in rapidly constructing a viral ‘haplotype’ profile for each 
sequenced sample and in complementing approaches such as principal component 
analysis to explore and define relationships between the various hypervariable HCMV 
genes and even those with minor changes. 
 
It is also of interest to advance the concept of molecular tags further for application into 
HCMV diagnostics, which currently remain a critical bottleneck in many areas outside 
the developed world. The molecular tags have potential for incorporation into simplified 
low-cost assays. For instance, the molecular tags could potentially be fluorescently 
labelled and used as probes in real time qPCR-based assay formats to examine relative 
viral loads and kinetics over time, for example in response to vaccination or repeated 
infections. This can not only greatly improve diagnosis capability, but also serve various 
other applications, such as genotype profiling, and measurement of disease burden. 
Such multi-faceted assays would be particularly useful in settings of constrained 
resources where access to full-scale NGS facilities may not be available. 
 
Another study area that merits future consideration, and where the molecular tags have 
potential for application, is in the systematic tracking of HCMV genotypes transmitted 
by mothers to their infants and how these evolve over time in infants. Such a study 
would require a cohort of mother-infant pairs, and would help provide answers to the 
yet still open question of whether infants do re-infect their mothers during early infancy 
when there is intimate nursing, and how this affects virus dynamics and evolution in 
both mother and infant. 
 
A main limitation in our studies was that the maternal HCMV serostatus was unknown, 
and samples from other compartments such as serum or saliva were unavailable. 
However, in epidemiological follow up, almost 100% children from HIV positive mothers 
were HCMV positive, therefore the adult population is likely close to universal HCMV. It 
would have been interesting to examine HCMV genotypes secreted from saliva. 
Although this does not affect our primary goals and findings, availability of other sample 
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types would have been useful to compare the viral load and genotype kinetics in various 
body compartments to the findings in milk. This would certainly shed more light on how 
virus in breast milk relates to that in other tissues. 
 
In this thesis, ZMB240, the first complete genome from the natural transmission source, 
breast milk, in Africa was presented and extensively discussed. Future work can include 
this as a reference, since all other publicly available full HCMV genomes are from 
pathological samples and from non-African nations. Another genome was assembled 
from an HIV-positive mother and will be submitted to NCBI in addition to ZMB240. 
Further work would include comparison of all assembled genomes from this cohort to 
these reference genomes. This will not only add to the growing body of HCMV genome 
data from diverse geographical regions of the world, important for vaccine 
considerations, but also help define a fuller picture of the HCMVs circulating in settings 
where transmission occurs naturally as well as potential effects of maternal HIV 
exposure to viral load, genotype diversity and pathogenesis. 
 
CONCLUSIONS 
This study has demonstrated that at 1% the birth prevalence of HCMV in Zambia is 
similar to other world regions. We have also shown that HCMV infection in breast milk 
is common in both HIV-infected and uninfected mothers. The principal mode of early 
postnatal HCMV transmission from both HIV-infected and uninfected mothers is 
breastfeeding, with peak HCMV levels in milk occurring at one month postpartum. The 
thesis demonstrated there were significantly higher loads in breast milk from HIV-
infected mothers (p=.026) compared to HIV-negative, showing potential mechanism of 
effects of maternal HIV on postnatal transmission. Further, HCMV shedding is 
significantly prolonged beyond the fourth month in HIV-infected mothers (p<.001). All 
eight HCMV gO genotypes could be detected in breast milk, and there was evidence for 
mixed genotype infections, signifying reinfection and changes in maternal immune 
control over time. We did not find any link between HCMV load and any particular 
genotype. In our studies in this thesis, non-invasive samples including saliva and 
umbilical tissue were acceptable locally by parents of neonates for HCMV diagnosis, and 
together with breast milk, were successfully utilised to detect and sequence HCMV. 
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Additionally, we devised a new tool for detecting mixed genotypes to aid assessment of 
infection burden in NGS deep sequencing reads. The study characterised ZMB240, a 
genome sequenced from DNA prepared directly from breast milk from a healthy HIV-
negative mother, representing virus in a natural transmission setting. We showed this 
genome to be of similar size, GC content, and architecture to published HCMV genomes 
from other world regions. However, unlike laboratory-adapted strains in which several 
genes are routinely deleted or mutated through tissue culture passaging, ZMB240 
contains the full complement of HCMV genes (except for RL6, a member of the 
accordion gene family RL11), all known HCMV ncRNAs, and regulatory elements, and is 
free of anti-HCMV drug resistance mutations. On the whole, this thesis shows that 
maternal HIV infection increases HCMV load, burden, and duration of secretion in breast 
milk, and thereby can escalate the risk of early infant HCMV infection. 
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APPENDIX 5: PARTICIPANT INFORMATION SHEET – NEONATAL STUDY 
 
 
London School of Hygiene & Tropical Medicine 
Keppel Street, London WC1E 7HT United Kingdom. 
 
PARTICIPANT INFORMATION SHEET 
 
8th May 2013, version 1.0      Study protocol number: UNZABREC 010-06-13 / LSHTM REC 6456 
 
Study Title: Molecular characterisation, transmission routes, and developmental effects of 
infant infections with Human betaherpesviruses (HCMV, HHV-6A and HHV-6B) in 
Zambia: a pilot study. 
 
Principal investigator: Dr Ursula Gompels, London School of Hygiene & Tropical Medicine 
 
 
1. Invitation  
You and your child are invited to take part in this study. The following information describes the 
study to help you decide whether you would like to take part. If you need more information, a 
member of the research time will be happy to explain further. 
 
2. What is the purpose of the study?  
The purpose of this research study is to obtain information on three related viruses that can be 
contracted in early childhood. These viruses are Human Cytomegalovirus (HCMV), Human 
Herpesvirus 6A (HHV-6A) and Human Herpesvirus 6B (HHV-6B). These viruses are part of a small 
group that can infect your developing baby, called ‘congenital’ infection. They can cause disease 
then or later in childhood. This is because they infect a person for life; they remain in a dormant 
state within the body, but can periodically ‘awaken’ to cause disease symptoms. During these 
periods of awakening, they are shed through bodily fluids such as saliva, urine, breastmilk, 
genital fluids, sweat, and tears. Early infant infection with HCMV can lead to a wide range of 
conditions including deafness, blindness, mental retardation and developmental difficulties. 
HHV-6A and HHV-6B are associated with a childhood fever illness and rare severe infections with 
brain disorders including encephalitis, certain types of epilepsy, and multiple sclerosis. Our 
immune system protects us from infection. These viruses cause disease if our immune system is 
not yet developed as in babies, or not functioning well, as in individuals with HIV/AIDS. These 
viruses can be passed on from a pregnant woman to her child during pregnancy and around the 
time of delivery. HHV-6A and HHV-6B can be passed to the baby in another very unique way; in 
a few cases, they can combine with our genes (the way we inherit our characteristics from our 
parents). Such integrated virus can be detected in hair and nails, making it possible to find this 
form of infection without requiring a blood sample. Although these viruses can cause serious 
disease in babies and infants, they are not diagnosed here, so it is not possible yet to stop their 
infection. In this study, if you take part you will help put in place future screening and possible 
ways to stop infection. To do this saliva, hair, and nails will be utilized to screen for the presence 
of HCMV, HHV-6A and HHV-6B, so that we can determine in newborns: 
• how common infections with these viruses are,  
• how common the integrated form of HHV-6A and HHV-6B is, and, 
• what features can help doctors and nurses recognize early those who are infected.  
 
This will provide very important information that can be used to plan for medications or vaccines 
against these infections.  
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3. Why have I been chosen?  
You have been requested to participate in this study because you have recently had a baby. 
Approximately 200 mothers and their newborns will take part in this research. 
 
4. Do I have to take part?  
No. Your participation is absolutely voluntary. If you decide to participate, you will be asked to 
sign a consent form to record this voluntary decision.  
 
5. What will happen to me if I take part?  
We will ask you a few general questions, such as where you live, and then about your child’s 
birth and current condition. We will need to get some of this information from your medical 
records or those of your child. Next, we will collect some saliva from your child’s mouth using a 
swab, and also a few finger / toe nail clippings or hair follicles. In place of the nails or hair, a small 
piece of discarded placenta or umbilical tissue can be collected. These samples can be used for 
new virus diagnoses instead of blood; therefore no blood will be collected in this study. All this 
will be done by a trained healthcare professional and should take only a few minutes. The 



















6. Payment for participation 
There will be no payment for participating in this study.  
 
7. What are the possible disadvantages and risks of taking part?  
There may be some mild discomfort when removing hair strands and/or clipping the nails.  
 
8. What are the possible benefits of taking part?  
We cannot promise that the study will help you immediately, but it is hoped that the information 
we get will in the future help improve the diagnosis and management of children with HCMV, 
HHV-6A or HHV-6B. There will be consultation with clinicians, therefore a level of additional 
clinical care.  
 
9. Will my taking part in the study be kept confidential?  
Yes. All information about your participation in this study is confidential and will be kept securely 
in a locked cabinet; electronic records will be stored in a password-protected database. Neither 
you nor your child will be named in any reports of the study. These will only be looked at by 
Invitation to participate in study 
Accept to participate Refuse to participate 
Sign consent form 
Medical records reviewed 
Samples collected: 
1. Saliva 
2. Nails or hair or placenta or umbilical tissue 
ROUTINE HEALTHCARE …… ROUTINE HEALTHCARE …… ROUTINE HEALTHCARE 
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authorised medical staff within the hospital establishment for the purpose of providing follow-
up medical care or advice to you or your child, if necessary. 
 
10. What will happen to any samples I give?  
Samples will be examined at the UTH Virology Laboratory by highly trained and experienced 
scientists. If any material will be left over, it will be stored securely, unless you indicate that you 
would like it destroyed. For research records and samples that may require to be sent for further 
tests to co-workers outside UTH, neither you nor your child will be linked to them or identified 
by name, or address. The records and specimens will be coded.  
 
11. What if I don’t want to carry on with the study?  
You are free to withdraw from participating in the study at any time, without having to give a 
reason. You can also request that no information is used. 
 
12. Contact Details  
If you have any concerns or require further information about your participation in this study, 
you may contact:     – Dr. Kunda Musonda on 0211-253236 or 0974-136520 
 – Dr. Mwaka Monze on 0211-256078 or 0977-793654 
You may also contact:  
The Chairperson – Biomedical Research Ethics Committee, University of Zambia School of 
Medicine, Ridgeway campus, Lusaka. Telephone 0211-256067.  
 
13. What will happen to the results of the study?  
The findings of this study will be published in scientific journals. You/your child will not be 
identified in any publication unless you have agreed to release such information.  
If you would like to be told the laboratory findings from examination of your samples or those 
of your child, you may make this request to the researchers at the end of the study, using the 
contact details given above.  
  
14. Who is organising and funding the research?  
This research is part of Dr. Kunda Musonda’s PhD studies. He is a Medical Doctor based at UTH, 
and currently studying under a Commonwealth Scholarship at the London School of Hygiene and 
Tropical Medicine, University of London, in London, UK. Part of this research is supported by the 
HHV-6 Foundation. The funders have no part in the study. 
 
 15. Who has reviewed the study?  
This study has been approved by the Research Ethics Committee of the London School of 
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APPENDIX 6: INFORMED CONSENT FORM –NEONATAL STUDY 
 
London School of Hygiene & Tropical Medicine 
Keppel Street, London WC1E 7HT United Kingdom. 
 
INFORMED CONSENT FORM 
 
8th May 2013, version 1.0      Study protocol number: UNZABREC 010-06-13 / LSHTM REC 6456 
 
Study: Molecular characterisation, transmission routes, and developmental effects of infant 
infections with Human betaherpesviruses (HCMV, HHV-6A and HHV-6B) in Zambia: a 
pilot study. 
 
Principal investigator: Dr Ursula Gompels, London School of Hygiene & Tropical Medicine 
 
 
1.  I confirm that I have read the information sheet concerning this study [or have understood 
the verbal explanation] and I understand what will be required of my child and what will 
happen to her/him if she/he takes part in it. 
 
2.  My questions concerning this study have been fully answered by 
………............................................................................................(Name of person obtaining consent) 
 
3.  I understand that my child’s participation is voluntary and I may withdraw her/him from 
this study at any time without giving a reason and without affecting her/his normal medical 
care and management. 
 
4.  I understand that where it is relevant to this research, sections of any of my child’s medical 
records may be looked at by the researchers. I give permission for the researchers to access 
my child’s records.  
 
5. I understand that my child will not be named in any reports arising from this research, and 
that confidentiality shall be maintained at all times. 
 
6. I agree for my child to take part in this study. 
 
 
Name of child:_______________________________________ Date of Birth :______________ 
Name of child’s parent/guardian:__________________________________________________ 
Signature or thumb print of parent/guardian:________________________________________ 
Relationship to child_____________________________________  Date__________________ 
Name of witness:____________________________________ Signature: __________________ 
Date___________________ 
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APPENDIX 7: DATA CAPTURE FORM – NEONATAL STUDY 
 
London School of Hygiene & Tropical Medicine 
Keppel Street, London WC1E 7HT United Kingdom. 
 
8th May 2013, version 1.0      Study protocol number: UNZABREC 010-06-13 / LSHTM REC 6456 
 
Study: Molecular characterisation, transmission routes, and developmental effects of infant 
infections with Human betaherpesviruses (HCMV, HHV-6A and HHV-6B) in Zambia: a 
pilot study. 
 
Date:................................................................  Ward:........................................................................... 
Hospital No:..................................................... Study No:UTH............................................................... 
 
NEONATE 
General Information            1min    5min   10min 
1. Sex: M / F         APGAR SCORE:      _____       _____             ____ 
2. Date of Birth:.............................       
3. Time of Birth:............................. 
4. Postnatal Age at recruitment:.............................days / hours 
5. Gestational age at delivery:.............................weeks =>  Term  /  Pre-Term 
6. Mode of delivery: SVD / Instrumental / Caesarean: Indication.......................................................... 
7. Birth weight:.............•...............Kg 
8. Reason for Admission / Attendance:................................................................................................... 
9. Diagnosis:............................................................................................................................................. 
Clinical assessment 
10. Jaundice    Y / N            13. Hepatomegaly    Y / N 
11. Petechiae    Y / N            14. Splenomegaly    Y / N 
12. Purpura      Y / N            15. Microcephaly     Y / N 
16. Convulsions  Y / N 
17. Congenital malformation / Other findings:........................................................................................ 
Laboratory Results 
18. Hemoglobin level     :...................... g/dL   = Anaemia     Y / N  
19. Platelet count       :......................X109 /L  = Thrombocytopenia Y / N  
20. ALT          :....................../L    = Elevated   Y / N 
21. AST          :....................../L    = Elevated    Y / N 
22. Bilirubin:   a) Conjugated   :....................../L    = Elevated    Y / N 
       b) Unconjugated :....................../L    = Elevated    Y / N 
23. HIV Exposed: Y / N / U             24. HIV PCR Result: P / N / U 
Samples Collected 
Saliva   Nails   Hair   Umbilical ts   
Initials   
Time  Time  Time  Time  
Breastfed: Y / N / U      
MOTHER 
1. Date of Birth:...................................................   2. Age: ...............................years 
3. Residential area:..............................................   4. Occupation:..................................................... 
5. Marital Status: Married / Single        6. Children: Alive..........Dead..........Miscarried.......... 
7. Education:  Primary / Secondary / Tertiary / Never   8. HIV: P / N / U   9. HAART/PMTCT: Y / N 
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Appendix 8 is an alignment of representative complete HCMV genome sequences. Highlighted are the locations of oligonucleotide primers (gB1 and 
gB2) and labelled probe (gB-P3) used for HCMV UL55 (gB) detection and quantification in this thesis. 
gB2 gB-P3 
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Appendix 9 is an alignment of representative complete HCMV genome sequences. Highlighted are the locations of oligonucleotide primers (gO-up 
and gO-lw) used for amplification and Sanger sequencing of HCMV UL74 (gO) in this thesis.
gO-lw 
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APPENDIX 10: CHARACTERISTICS OF COMPLETE HCMV GENOMES USED IN THIS STUDY. 
Accession num._Strain Size (bp) Isolation Tissue Source Description Source Age Date collected Country Notes 
KT634296.1_UKNEQAS2 234,873 Amniotic fluid Fetus 20 weeks  2013 Australia Sequenced directly from clinical specimen; sequenced from enriched 
viral DNA (SureSelect); 2 genes are mutated (RL6, RL9) 
KC519319.1_BE/9/2010 235,631 Urine - - 09-Apr-10 Belgium Passaged two times in human fibroblasts;  
KC519320.1_BE/10/2010 235,215 Urine - - 22-Apr-10 Belgium Passaged two times in human fibroblasts; gene UL9 is mutated;  
KC519321.1_BE/11/2010 235,061 Urine - - 27-Apr-10 Belgium Passaged two times in human fibroblasts; two genes are mutated (RL5A 
and UL1);  
KC519322.1_BE/21/2010 235,722 Urine - - 26-Jul-10 Belgium Sequenced directly from clinical material, no cell culture passage; three 
genes are mutated (RL5A, UL9 and UL150);  
KC519323.1_BE/27/2010 234,810 Urine - - 21-Oct-10 Belgium Passaged four times in human fibroblasts; four genes are mutated (RL5A, 
UL1, UL9 and UL111A);  
KP745633.1_BE/45/2011 235,352 NPA - - 27-Jan-11 Belgium Passaged one time in human fibroblasts 
KP745634.1_BE/32/2010 235,205 Amniotic fluid - - 29-Dec-10 Belgium Passaged one time in human fibroblasts; genes RL5A and US9 are 
mutated 
KP745635.1_BE/5/2012 235,184 Urine - - 22-Jan-12 Belgium Passaged two times in human fibroblasts 
KP745636.1_BE/7/2011 237,117 Urine - - 17-Mar-11 Belgium Passaged two times in human fibroblasts; genes RL12 and UL148 are 
mutated 
KP745637.1_BE/9/2011 235,865 Urine - - 14-Apr-11 Belgium Passaged two times in human fibroblasts; gene UL9 is mutated 
KP745638.1_BE/15/2010 235,514 Urine - - 31-May-10 Belgium Passaged three times in human fibroblasts; genes RL1, UL9 and UL111A 
are mutated; mutations were confirmed in original clinical material 
KP745639.1_BE/10/2011 235,054 Urine - - 15-Apr-11 Belgium Passaged two times in human fibroblasts; gene UL1 is mutated, mutation 
confirmed in original clinical material 
KP745640.1_BE/22/2010 235,632 Urine - - 31-Aug-10 Belgium Passaged four times in human fibroblasts 
KP745641.1_BE/31/2011 235,844 Urine - - 27-Oct-11 Belgium Passaged four times in human fibroblasts 
KP745644.1_BE/31/2010 236,028 Urine - - 16-Dec-10 Belgium Passaged four times in human fibroblasts 
KP745645.1_BE/13/2010 236,032 Urine - - 06-May-10 Belgium Passaged three times in human fibroblasts; gene US9 is mutated, 
mutation confirmed in original clinical material 
KP745646.1_BE/8/2012 235,889 Urine - - 14-Feb-12 Belgium Passaged three times in human fibroblasts; gene RL13 is mutated 
KP745647.1_BE/18/2010 235,871 Urine - - 20-Jun-10 Belgium Passaged five times in human fibroblasts 
KP745648.1_BE/8/2011 235,111 Urine - - 13-Apr-11 Belgium Passaged two times in human fibroblasts; gene US9 is mutated 
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Accession num._Strain Size (bp) Isolation Tissue Source Description Source Age Date collected Country Notes 
KP745649.1_BE/10/2012 234,754 Urine - - 02-Apr-12 Belgium Passaged two times in human fibroblasts 
KP745650.1_BE/1/2011 235,833 Urine - - 14-Jan-11 Belgium Passaged three times in human fibroblasts; genes UL1 and UL9 are 
mutated 
KP745651.1_BE/9/2012 235,836 Urine - - 26-Mar-12 Belgium Passaged two times in human fibroblasts; genes UL1 and UL9 are 
mutated 
KP745652.1_BE/2/2011 235,810 Urine - - 06-Jan-11 Belgium Passaged four times in human fibroblasts 
KP745653.1_BE/22/2011 235,612 Urine - - 18-Jul-11 Belgium Passaged two times in human fibroblasts; genes RL6 and UL9 are 
mutated 
KP745654.1_BE/19/2011 235,446 Urine - - 05-Jul-11 Belgium Passaged two times in human fibroblasts; genes RL6 and UL9 are 
mutated 
KP745655.1_BE/3/2010 236,597 Urine - - 18-Mar-10 Belgium Passaged two times in human fibroblasts; genes RL5A and UL9 are 
mutated 
KP745656.1_BE/2/2013 235,156 Urine - - 17-Jan-13 Belgium Passaged three times in human fibroblasts; genes RL5A, UL128 and US9 
are mutated 
KP745657.1_BE/13/2011 235,713 Urine - - 10-May-11 Belgium Passaged two times in human fibroblasts; genes RL5A, UL1, UL9 and US7 
are mutated, mutations confirmed in original clinical material 
KP745658.1_BE/14/2012 234,931 Urine - - 14-May-12 Belgium Passaged one time in human fibroblasts; genes RL6, UL9, UL40 and US7 
are mutated, RL6, UL9 and US7 mutations confirmed in original clinical 
material 
KP745659.1_BE/3/2011 235,726 Urine - - 14-Jan-11 Belgium Passaged four times in human fibroblasts 
KP745660.1_BE/6/2011 235,101 Urine - - 10-Mar-11 Belgium Passaged two times in human fibroblasts; gene UL9 is mutated, mutation 
confirmed in original clinical material 
KP745661.1_BE/33/2010 235,605 NPA - - 27-Dec-10 Belgium Passaged one time in human fibroblasts; genes RL6, UL9 and US9 are 
mutated 
KP745662.1_BE/20/2010 235,516 Urine - - 20-Jul-10 Belgium Passaged four times in human fibroblasts; genes RL5A and UL9 are 
mutated, UL9 mutation was confirmed in original clinical material 
KP745663.1_BE/5/2010 236,345 Urine - - 25-Mar-10 Belgium Passaged two times in human fibroblasts; genes RL6 and US9 are 
mutated 
KP745665.1_BE/16/2012 235,910 Urine - - 24-May-12 Belgium Passaged one time in human fibroblasts; gene UL150 is mutated, 
mutation confirmed in original clinical material 
KP745666.1_BE/7/2012 236,053 Urine - - 14-Feb-12 Belgium Passaged three times in human fibroblasts; genes RL13 and UL150 are 
mutated, UL150 mutation confirmed in original clinical material 
KP745667.1_BE/5/2011 235,621 Urine - - 07-Mar-11 Belgium Passaged seven times in human fibroblasts 
KP745668.1_BE/18/2011 235,416 Urine - - 22-Jun-11 Belgium Passaged two times in human fibroblasts 
KP745669.1_BE/28/2011 235,732 NPS - - 20-Oct-11 Belgium Passaged two times in human fibroblasts; gene UL40 is mutated 
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Accession num._Strain Size (bp) Isolation Tissue Source Description Source Age Date collected Country Notes 
KP745670.1_BE/30/2011 235,350 Urine - - 26-Oct-11 Belgium Passaged two times in human fibroblasts; gene UL150 is mutated 
KP745671.1_BE/14/2011 235,498 Urine - - 12-May-11 Belgium Passaged nine times in human fibroblasts; genes UL9, UL11 and US6 are 
mutated 
KP745672.1_BE/29/2011 236,364 Urine - - 20-Oct-11 Belgium Passaged two times in human fibroblasts; genes RL5A and UL9 are 
mutated 
KP745673.1_BE/42/2011 235,462 NPA - - 09-Jan-11 Belgium Passaged one time in human fibroblasts; gene RL5A is mutated 
KP745674.1_BE/33/2011 235,276 Urine - - 22-Nov-11 Belgium Passaged two times in human fibroblasts 
KP745675.1_BE/23/2011 235,425 NPS - - 19-Jul-11 Belgium Passaged two times in human fibroblasts; gene UL9 is mutated 
KP745676.1_BE/28/2010 235,974 Urine - - 15-Oct-10 Belgium Passaged four times in human fibroblasts; genes RL5A and UL9 are 
mutated 
KP745677.1_BE/1/2010 235,705 Urine - - 18-Jan-10 Belgium Passaged two times in human fibroblasts; genes RL5A and US9 are 
mutated 
KP745678.1_BE/25/2010 235,904 Urine - - 09-Sep-10 Belgium Passaged two times in human fibroblasts; gene UL111A is mutated 
KP745679.1_BE/24/2010 235,744 Urine - - 07-Sep-10 Belgium Passaged two times in human fibroblasts; gene UL9 is mutated 
KP745680.1_BE/11/2012 235,893 Urine - - 10-Apr-12 Belgium Passaged two times in human fibroblasts; gene UL150 is mutated, 
mutation confirmed in original clinical material 
KP745681.1_BE/43/2011 235,100 NPA - - 19-Jan-11 Belgium Passaged one time in human fibroblasts; genes RL5A, RL6 and UL133 are 
mutated 
KP745682.1_BE/46/2011 236,239 NPA - - 07-Mar-11 Belgium Passaged one time in human fibroblasts; gene US9 is mutated 
KP745683.1_BE/12/2011 235,258 Urine - - 09-May-11 Belgium Passaged two times in human fibroblasts; genes RL6 and US9 are 
mutated, mutations confirmed in original clinical material 
KP745684.1_BE/11/2011 234,806 Urine - - 18-Apr-11 Belgium Passaged four times in human fibroblasts; gene RL6 is mutated 
KP745686.1_BE/39/2011 235,982 NPA - - 01-Jan-11 Belgium Passaged one time in human fibroblasts; genes UL9, UL111A, US9 are 
mutated 
KP745687.1_BE/36/2011 234,373 Urine - - 02-Dec-11 Belgium Passaged two times in human fibroblasts; genes RL6, UL9 and UL40 are 
mutated, mutations confirmed in original clinical material 
KP745688.1_BE/12/2012 235,362 NPS - - 21-Apr-12 Belgium Passaged two times in human fibroblasts; gene RL6 is mutated 
KP745689.1_BE/17/2011 235,827 Urine - - 20-May-11 Belgium Passaged two times in human fibroblasts; genes UL1 and UL9 are 
mutated 
KP745690.1_BE/34/2011 235,290 Urine - - 28-Nov-11 Belgium Passaged two times in human fibroblasts 
KP745692.1_BE/3/2012 236,051 Urine - - 09-Jan-12 Belgium Passaged two times in human fibroblasts; gene US13 is mutated 
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Accession num._Strain Size (bp) Isolation Tissue Source Description Source Age Date collected Country Notes 
KP745693.1_BE/15/2012 235,508 Urine - - 24-May-12 Belgium Passaged one time in human fibroblasts; genes UL150 and US7 are 
mutated 
KP745694.1_BE/12/2010 235,195 Urine - - 29-Apr-10 Belgium Passaged eight times in human fibroblasts; gene RL5A is mutated 
KP745695.1_BE/6/2012 235,164 Urine - - 31-Jan-12 Belgium Passaged five times in human fibroblasts; genes RL6, US9 and US27 are 
mutated 
KP745696.1_BE/27/2011 235,392 Urine - - 13-Sep-11 Belgium Passaged five times in human fibroblasts; gene UL9 is mutated 
KP745697.1_BE/23/2010 236,066 Urine - - 09-Sep-10 Belgium Passaged four times in human fibroblasts; genes UL1 and UL9 are 
mutated 
KP745698.1_BE/20/2011 235,272 Urine - - 05-Jul-11 Belgium Passaged two times in human fibroblasts; gene US7 is mutated 
KP745699.1_BE/1/2012 235,150 Urine - - 02-Jan-12 Belgium Passaged two times in human fibroblasts; genes UL1 and UL136 are 
mutated 
KP745700.1_BE/4/2011 235,808 Urine - - 03-Mar-11 Belgium Passaged two times in human fibroblasts 
KP745701.1_BE/6/2010 235,329 Urine - - 23-Mar-10 Belgium Passaged two times in human fibroblasts; genes RL5A, UL9 and US7 are 
mutated 
KP745702.1_BE/21/2011 235,849 Urine - - 15-Jul-11 Belgium Passaged five times in human fibroblasts 
KP745703.1_BE/26/2011 234,902 Urine - - 23-Aug-11 Belgium Passaged two times in human fibroblasts 
KP745704.1_BE/32/2011 235,633 Urine - - 17-Nov-11 Belgium Passaged two times in human fibroblasts; gene UL150 is mutated 
KP745705.1_BE/38/2011 235,775 NPS - - 12-Dec-11 Belgium Passaged two times in human fibroblasts; genes RL6 and UL9 are 
mutated 
KP745706.1_BE/41/2011 235,332 BAL - - 07-Jan-11 Belgium Passaged one time in human fibroblasts; genes UL9 and UL111A are 
mutated 
KP745707.1_BE/13/2012 235,015 Urine - - 23-Apr-12 Belgium Passaged two times in human fibroblasts; gene UL9 is mutated 
KP745708.1_BE/8/2010 235,964 Urine - - 12-Apr-10 Belgium Passaged one time in human fibroblasts; gene UL9 is mutated, mutation 
confirmed in original clinical material 
KP745709.1_BE/48/2011 235,747 NPA - - 28-Mar-11 Belgium Passaged one time in human fibroblasts; genes UL40 and US9 are 
mutated 
KP745710.1_BE/2/2012 236,100 Urine - - 09-Jan-12 Belgium Passaged two times in human fibroblasts; genes RL5A and UL133 are 
mutated 
KP745711.1_BE/24/2011 235,745 Urine - - 04-Aug-11 Belgium Passaged two times in human fibroblasts 
KP745712.1_BE/19/2010 235,365 Urine - - 06-Jul-10 Belgium Passaged five times in human fibroblasts; genes UL9 and UL136 are 
mutated 
KP745713.1_BE/35/2011 235,941 Urine - - 30-Nov-11 Belgium Passaged two times in human fibroblasts; genes UL142 and US9 are 
mutated, UL142 mutation confirmed in original clinical material 
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Accession num._Strain Size (bp) Isolation Tissue Source Description Source Age Date collected Country Notes 
KP745714.1_BE/29/2010 234,922 Urine - - 07-Dec-10 Belgium Passaged seven times in human fibroblasts 
KP745715.1_BE/44/2011 235,301 NPA - - 27-Jan-11 Belgium Passaged one time in human fibroblasts; genes RL5A, UL150A, IRS1 and 
US9 are mutated 
KP745716.1_BE/16/2010 235,366 NPS - - 06-Jun-10 Belgium Passaged five times in human fibroblasts; genes UL1, UL111A and US9 
are mutated 
KP745717.1_BE/2/2010 235,138 NPS - - 16-Mar-10 Belgium Passaged two times in human fibroblasts; genes UL9 and UL111A are 
mutated 
KP745719.1_BE/26/2010 235,908 Urine - - 15-Sep-10 Belgium Passaged two times in human fibroblasts; gene UL150 is mutated 
KP745720.1_BE/15/2011 235,905 Urine - - 13-May-11 Belgium Passaged five times in human fibroblasts; genes RL5A and UL9 are 
mutated, mutations confirmed in original clinical material 
KP745721.1_BE/14/2010 234,537 NPS - - 11-May-10 Belgium Passaged two times in human fibroblasts; genes RL6, UL9 and UL40 are 
mutated 
KP745722.1_BE/40/2011 235,716 NPA - - 04-Jan-11 Belgium Passaged one time in human fibroblasts; gene RL6 is mutated 
KP745723.1_BE/37/2011 234,858 NPS - - 05-Dec-11 Belgium Passaged five times in human fibroblasts; gene RL6 is mutated 
KP745724.1_BE/4/2012 234,950 Urine - - 16-Jan-12 Belgium Passaged two times in human fibroblasts; gene RL5A is mutated, 
mutation confirmed in original clinical material 
KP745725.1_BE/49/2011 235,317 NPA - - 26-Apr-11 Belgium Passaged one time in human fibroblasts; gene RL5A is mutated 
KP745726.1_BE/30/2010 235,642 Urine - - 08-Dec-10 Belgium Passaged two times in human fibroblasts; genes UL9, US9 and US27 are 
mutated, US27 mutation confirmed in original clinical material 
KP745727.1_BE/17/2010 235,836 Urine - - 14-Jun-10 Belgium Passaged four times in human fibroblasts; genes RL5A, RL12 and UL111A 
are mutated 
KP745728.1_BE/4/2010 236,428 Urine - - 22-Mar-10 Belgium Passaged two times in human fibroblasts; genes RL5A and UL111A are 
mutated 
KJ426589.1_isolate HAN 236,144 - - - 10-Jan-07 China - 
KP745642.1_CZ/1/2012 235,030 Urine - - 23-May-12 Czech Republic Passaged two times in human fibroblasts; gene UL9 is mutated 
KP745643.1_CZ/2/2012 235,226 Urine - - 15-Oct-12 Czech Republic Passaged two times in human fibroblasts; gene US13 is mutated 
KP745664.1_CZ/2/2013 235,191 Blood - - 01-Mar-13 Czech Republic Passaged two times in human fibroblasts; genes RL6, UL9 and UL40 are 
mutated 
KP745685.1_CZ/3/2012 234,598 Urine - - 05-Nov-12 Czech Republic Passaged two times in human fibroblasts; gene UL145 is mutated 
KP745691.1_CZ/1/2013 235,139 Blood - - 22-Feb-13 Czech Republic Passaged two times in human fibroblasts; gene UL111A is mutated 
KP745718.1_CZ/1/2011 234,758 Urine - - 20-May-11 Czech Republic Passaged two times in human fibroblasts; gene UL9 is mutated 
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Accession num._Strain Size (bp) Isolation Tissue Source Description Source Age Date collected Country Notes 
KT959235.1_DB 235,512 Cervical swab Pregnant woman 30 years 2009 France Passaged 3 times in monocyte-derived human macrophages; 2 genes are 
mutated (RL13, UL9); 1 gene has disabling SNPS (UL130); 1 gene has an 
SNP (UL100); US9 is the short form 
GQ221973.1_HAN13 236,219 BAL - - 2007 Germany Passaged 3 times in human fibroblasts; 1 gene is mutated (RL5A) 
GQ396662.1_HAN38 236,112 BAL - - 2007 Germany Passaged twice in human fibroblasts; 2 genes are mutated (RL6 and US9) 
GQ396663.1_HAN20 235,728 BAL - - 2007 Germany Passaged twice in human fibroblasts 
JX512199.1_HAN1 235,006 BAL - - 2007 Germany Acronym:  
JX512200.1_HAN2 232,940 BAL - - 2007 Germany Passaged 3 times in human fibroblasts; 7 genes are mutated (UL1, UL6, 
UL7, UL8, UL9, UL30 and US7); except for the UL6-UL9 deletion, these 
mutations are also present in the original clinical specimen 
JX512201.1_HAN3 235,703 BAL - - 2007 Germany Passaged 3 times in human fibroblasts 
JX512202.1_HAN8 234,951 BAL - - 2007 Germany Passaged 3 times in human fibroblasts; 1 gene is mutated (UL111A); this 
mutation is also present in the original clinical specimen 
JX512203.1_HAN12 236,006 BAL - - 2007 Germany Passaged 3 times in human fibroblasts; 1 gene is lacking (RL6) and 1 gene 
is mutated (UL9); this mutation is also present in the original clinical 
specimen; most of the population contains an unannotated deletion 
extending from TRL into the left end of UL 
JX512204.1_HAN16 235,112 Urine  Infant - 2007 Germany Passaged twice in human fibroblasts; 2 genes are mutated (US7 and 
US12) 
JX512205.1_HAN19 235,810 BAL - - 2007 Germany Passaged twice in human fibroblasts; 1 gene is mutated (RL5A) 
JX512206.1_HAN22 236,379 BAL - - 2007 Germany Passaged twice in human fibroblasts 
JX512207.1_HAN28 236,017 BAL - - 2007 Germany Passaged 3 times in human fibroblasts 
JX512208.1_HAN31 235,720 BAL - - 2007 Germany Passaged twice in human fibroblasts; 1 gene is mutated (UL1) 
KF297339.1_TB40/E Lisa 237,683 Throat wash BMT recipient - 1999 Germany Generated on human fibroblasts by passaging strain TB40/E once, plaque 
purifying three times, and passaging once more; 5 genes are mutated 
(RL13, UL128, IRS1, US1 and US2); US33A, US34, US34A and TRS1 are 
duplicated in place of IRS1, US1 and part of US2 
KJ361946.1_2CEN2 235,360 BAL - - 2009 Germany Passaged once in human fibroblasts; 2 genes are mutated (UL1 and UL9) 
KJ361947.1_2CEN5 235,567 BAL - - 2009 Germany Passaged once in human fibroblasts; 1 gene is mutated (RL5A) 
KJ361948.1_2CEN15 234,949 BAL - - - Germany Passaged once on human fibroblasts; genome sequence derived directly 
from clinical specimen is identical; 1 gene is mutated (UL97) 
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KJ361949.1_2CEN30 236,168 BAL - - - Germany Passaged once on human fibroblasts; genome sequence derived directly 
from clinical specimen is identical; 3 genes are mutated (UL1, UL9 and 
UL14) 
KJ361950.1_HAN11 235,276 BAL - - 2007 Germany Passaged 3 times in human fibroblasts; 3 genes are mutated (RL5A, 
UL150 and US9) 
KJ361951.1_HAN21 235,834 BAL - - 2006 Germany Passaged 3 times in human fibroblasts 
KJ361952.1_HAN27 235,861 BAL - - 2007 Germany Passaged twice in human fibroblasts; 2 genes are mutated (RL12 and 
UL133) 
KJ361953.1_HAN30 235,483 BAL - - 2006 Germany Passaged twice in human fibroblasts 
KJ361954.1_HAN32 235,458 BAL - - 2007 Germany Passaged twice in human fibroblasts; 1 gene is mutated (UL9) 
KJ361955.1_HAN33 235,512 BAL - - 2007 Germany Passaged 3 times in human fibroblasts; 1 gene is mutated (UL9) 
KJ361956.1_HAN36 234,844 BAL - - 2007 Germany Passaged twice in human fibroblasts; 1 gene is mutated (UL20) 
KJ361957.1_HAN39 235,056 BAL - - 2007 Germany Passaged once in human fibroblasts; 1 gene is mutated (UL1) 
KJ361958.1_HAN40 235,763 BAL - - 2007 Germany Passaged twice in human fibroblasts; 2 genes are mutated (RL1 and 
US13) 
GU179288.1_U8 235,709 Urine Congenitally infected 
infant 
- 2003 Italy Unpassaged strain in the original clinical sample 
GU179289.1_VR1814 235,233 Cervical 
secretions 
Pregnant woman with 
primary HCMV 
- 1996 Italy Unpassaged strain in the original clinical sample 
GU179291.1_AF1 235,937 Amniotic fluid - - 2003 Italy Unpassaged strain in the original clinical sample; 2 genes are mutated 
(RL6 and UL9) 
KJ361959.1_PAV1 235,815 Amniotic fluid - - 2005 Italy Sequenced directly from clinical specimen; 1 gene is mutated (RL5A) 
KJ361960.1_PAV4 235,272 Amniotic fluid - - 2006 Italy Sequenced directly from clinical specimen; 3 genes are mutated (RL5A, 
UL150 and US7) 
KJ361961.1_PAV5 235,485 Amniotic fluid - - 2006 Italy Sequenced directly from clinical specimen; 1 gene is mutated (US8) 
KJ361962.1_PAV6 235,432 Amniotic fluid - - 2007 Italy Sequenced directly from clinical specimen; 2 genes are mutated (RL1 and 
US7) 
KJ361963.1_PAV7 235,142 Amniotic fluid - - 2007 Italy Sequenced directly from clinical specimen; 1 gene is mutated (US7) 
KJ361964.1_PAV8 235,432 Amniotic fluid - - 2007 Italy Sequenced directly from clinical specimen; 1 gene is mutated (UL9) 
KJ361965.1_PAV11 236,310 Amniotic fluid - - - Italy Sequenced directly from clinical specimen 
KJ361966.1_PAV12 235,616 Amniotic fluid - - - Italy Sequenced directly from clinical specimen; 1 gene is mutated (RL5A) 
 Page 259 of 338 
Accession num._Strain Size (bp) Isolation Tissue Source Description Source Age Date collected Country Notes 
KJ361967.1_PAV23 235,700 Amniotic fluid - - 2012 Italy Sequenced directly from clinical specimen; 2 genes are mutated (RL1 and 
RL5A) 
KJ361968.1_PAV24 235,361 Amniotic fluid - - 2012 Italy Sequenced directly from clinical specimen; 1 gene is mutated (UL30) 
KJ361969.1_PAV25 235,902 Amniotic fluid - - 2013 Italy Sequenced directly from clinical specimen; 2 genes are mutated (UL9 and 
UL150) 
KJ361970.1_PAV26 236,180 Amniotic fluid - - 2013 Italy Sequenced directly from clinical specimen; 2 genes are mutated (UL1 and 
UL9) 
KJ872539.1_PAV16 236,240 Amniotic fluid - - 2009 Italy Sequenced directly from clinical specimen; sequenced from enriched 
viral DNA (SureSelect); 3 genes are mutated (RL5A, UL9 and UL111A) 
KJ872540.1_PAV18 234,739 Amniotic fluid - - 2008 Italy Sequenced directly from clinical specimen; sequenced from enriched 
viral DNA (SureSelect) 
KJ872541.1_PAV20 236,293 Amniotic fluid - - 2013 Italy Sequenced directly from clinical specimen; sequenced from enriched 
viral DNA (SureSelect); 1 gene is mutated (RL5A) 
KJ872542.1_PAV21 235,901 Amniotic fluid - - 2013 Italy Sequenced directly from clinical specimen; sequenced from enriched 
viral DNA (SureSelect); 2 genes are mutated (UL1 and UL9); 1 gene is 
mutated in a proportion of genomes (RNA4.9) 
HQ380895.1_JHC 235,476 Blood BMT recipient - 2003 South Korea - 
GQ221974.1_3157 235,154 Urine Congenitally infected 
infant 
- 2001 United Kingdom Sequenced at passage 3 in human fibroblasts; three genes are mutated 
(RL13, UL40 and UL128) 
GQ221975.1_JP 236,375 Prostate tissue 
(post mortem) 
AIDS patient - 2001 United Kingdom Sequenced directly from patient material, not passaged in cell culture; 
two genes are mutated (RL5A and UL111A) 
GQ466044.1_3301 235,703 Urine Congenitally infected 
infant 
- 2001 United Kingdom Sequenced directly from patient material; not passaged in cell culture 
GU179290.1_U11 234,732 Urine Congenitally infected 
infant 
- 2003 United Kingdom Unpassaged strain in the original clinical sample; 1 gene is mutated (UL9) 
JX512197.1_6397 235,870 Urine Congenitally infected 
infant 
- 2001 United Kingdom Passaged 3 times in human fibroblasts; 12 genes are mutated (RL13, UL9, 
UL130, UL131A, IRS1, US1, US2, US3, US6, US7, US8 and US9); region 
normally at left end of US replaced by inverted copy of region from right 
end of US, resulting in longer TRS/IRS; TRL/IRL is very short probably 
owing to deletion at UL junction 
KJ361971.1_UKNEQAS1 235,190 Urine Congenitally infected 
infant 
- 2012 United Kingdom Passaged twice in human fibroblasts; sequenced from enriched viral DNA 
(SureSelect); 1 gene is mutated (RL5A) 
AY446894.2_Merlin 235,646 Urine Congenitally infected 
child 
- 1999 United Kingdom: 
Cardiff 
Originally named strain 742; passaged 3 times in human fibroblasts; gene 
UL128 is mutated; populations of mutants in RL13 predominate, but the 
consensus sequence of this gene is not mutated;  
FJ527563.1_AD169 231,781 Adenoids Girl 7 years  1956 USA Passaged in human fibroblasts; contains most of UL/b' region, which is 
absent from other AD169 substrains, and instead contains smaller 
deletion that affects genes UL144, UL142, UL141 and UL140; contains 
 Page 260 of 338 
Accession num._Strain Size (bp) Isolation Tissue Source Description Source Age Date collected Country Notes 
mutations in genes RL5A, RL13, and UL131A; majority population 
contains deletion that affects IRS1, US1 and US2 
FJ616285.1_Towne 235,147 Urine Infant with 
microcephaly and 
hepatosplenomegaly 
2 months 1970 USA Passaged many times in human fibroblasts; contains mutations in genes 
RL13, UL1, UL40, UL130 and US1; majority population contains large 
deletion in UL/b' region associated with inverted duplication of sequence 
from near left genome end 
GU937742.1_Toledo 235,398 Urine Congenitally infected 
infant 
- 1984 USA Passaged several times in human fibroblasts; contains inversion of 14336 
bp region (genes UL128 to UL133); 3 genes are mutated (RL13, UL9 and 
UL128) 
JX512198.1_Davis 229,768 Liver biopsy Congenitally infected 
infant 
- 1957 USA Passaged many times in human fibroblasts; 10 genes are mutated (RL5A, 
RL12, RL13, UL1, UL2, UL4, UL5, UL6, UL99 and UL130); a 472 bp region is 
deleted from the region between genes US34A and TRS1; the population 
possibly contains various unannotated deletions extending from TRL into 
the left end of UL 
KF021605.1_TR 235,681 Vitreous humor HIV-positive male - 1996 USA Passaged several times in human fibroblasts 
 
Appendix 10. This table outlines key features of the 163 complete HCMV genome sequences in GenBank database release 211 that were used for 
reference in this thesis. BAL, Bronchoalveolar lavage; BMT, Bone marrow transplant; NPA, Nasopharyngeal aspirate; NPS, Nasopharyngeal swab. 
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 Accession num._Strain/Isolate Size (bp) Isolation source Date collected Country Notes 
1 AF531315.1_1176  1,389 - - - - 
2 AF531316.1_122  1,392 - - - - 
3 AF531317.1_1276  1,398 - - - - 
4 AF531318.1_1960  1,395 - - - - 
5 AF531319.1_279  1,392 - - - - 
6 AF531320.1_298  1,401 - - - - 
7 AF531321.1_3052  1,419 - - - - 
8 AF531322.1_4088  1,401 - - - - 
9 AF531323.1_452  1,374 - - - - 
10 AF531324.1_540  1,389 - - - - 
11 AF531325.1_6444  1,401 - - - - 
12 AF531326.1_650  1,392 - - - - 
13 AF531327.1_7614  1,395 - - - - 
14 AF531328.1_7868  1,398 - - - - 
15 AF531329.1_791  1,398 - - - - 
16 AF531330.1_851  1,401 - - - - 
17 AF531332.1_DM13  1,374 - - - - 
18 AF531333.1_DM2  1,389 - - - - 
19 AF531334.1_DM7  1,392 - - - - 
20 AF531335.1_DM8  1,398 - - - - 
21 AF531336.1_SW1758  1,389 - - - - 
22 AF531337.1_SW1  1,401 - - - - 
23 AF531338.1_SW1020  1,395 - - - - 
24 AF531339.1_SW1102  1,398 - - - - 
25 AF531340.1_SW1324  1,395 - - - - 
26 AF531341.1_SW1701  1,398 - - - - 
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27 AF531342.1_SW1715  1,398 - - - - 
28 AF531343.1_1736  1,389 - - - - 
29 AF531344.1_SW1762  1,401 - - - - 
30 AF531345.1_SW2  1,392 - - - - 
31 AF531346.1_SW3  1,401 - - - - 
32 AF531347.1_SW4  1,401 - - - - 
33 AF531348.1_SW475  1,395 - - - - 
34 AF531349.1_SW490  1,389 - - - - 
35 AF531350.1_SW5  1,395 - - - - 
36 AF531351.1_SW6  1,395 - - - - 
37 AF531352.1_SW7  1,395 - - - - 
38 AF531353.1_SW8  1,398 - - - - 
39 AF531354.1_SW990  1,392 - - - - 
40 AY326961.1_Air  421 Mouth rinse - Malawi - 
41 AY326962.1_Aiu  430 Urine - Malawi - 
42 AY326963.1_Bir  433 Mouth rinse - Malawi - 
43 AY326964.1_Biu  433 Urine - Malawi - 
44 AY326965.1_B1u  433 Urine - Malawi - 
45 AY326966.1_B4r  433 Mouth rinse - Malawi - 
46 AY326967.1_B4u  421 Urine - Malawi - 
47 AY326968.1_Cir  433 Mouth rinse - Malawi - 
48 AY326969.1_Eir  421 Mouth rinse - Malawi - 
49 AY326970.1_E4u  421 Urine - Malawi - 
50 AY326971.1_Fiu  430 Urine - Malawi - 
51 AY326972.1_F1u  430 Urine - Malawi - 
52 AY326973.1_F2u  433 Urine - Malawi - 
53 AY326974.1_G3u  433 Urine - Malawi - 
54 AY326975.1_G3r  433 Mouth rinse - Malawi - 
55 AY326976.1_H3u  425 Urine - Malawi - 
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56 AY326977.1_L1r  433 Mouth rinse - Malawi - 
57 AY326978.1_Mir  430 Mouth rinse - Malawi - 
58 AY326979.1_M1r  427 Mouth rinse - Malawi - 
59 AY326980.1_Riu  433 Urine - Malawi - 
60 AY326981.1_R2r  424 Mouth rinse - Malawi - 
61 AY326982.1_T3u  433 Urine - Malawi - 
62 AY326983.1_T4r  433 Mouth rinse - Malawi - 
63 AY326984.1_T4u  433 Urine - Malawi - 
64 AY326985.1_Xir  433 Mouth rinse - Malawi - 
65 AY326986.1_Zir  433 Mouth rinse - Malawi - 
66 AY582436.1_K1  460 - - United Kingdom - 
67 AY582437.1_A1  469 - - United Kingdom - 
68 AY582438.1_A2  469 - - United Kingdom - 
69 AY582439.1_B1  466 - - United Kingdom - 
70 AY582440.1_B2  466 - - United Kingdom - 
71 AY582441.1_B3  466 - - United Kingdom - 
72 AY582442.1_B4  466 - - United Kingdom - 
73 AY582443.1_B5  466 - - United Kingdom - 
74 AY582444.1_B6  466 - - United Kingdom - 
75 AY582445.1_B7a  466 - - United Kingdom - 
76 AY582447.1_C1a  463 - - United Kingdom - 
77 AY582448.1_C1b  460 - - United Kingdom - 
78 AY582449.1_C2  460 - - United Kingdom - 
79 AY582450.1_C3  460 - - United Kingdom - 
80 AY582451.1_C4a  460 - - United Kingdom - 
81 AY582453.1_D1  484 - - United Kingdom - 
82 AY582454.1_D2a  484 - - United Kingdom - 
83 AY582456.1_D3  484 - - United Kingdom - 
84 AY582457.1_D4  484 - - United Kingdom - 
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85 AY582458.1_D5  484 - - United Kingdom - 
86 AY582459.1_D6  484 - - United Kingdom - 
87 AY582460.1_D7  484 - - United Kingdom - 
88 AY582461.1_D8a  469 - - United Kingdom - 
89 AY582463.1_D9a  484 - - United Kingdom - 
90 AY582464.1_D9b  469 - - United Kingdom - 
91 AY582465.1_E1  469 - - United Kingdom - 
92 AY582466.1_E2  469 - - United Kingdom - 
93 AY582467.1_E3  469 - - United Kingdom - 
94 AY582468.1_E4  469 - - United Kingdom - 
95 AY582469.1_F1  466 - - United Kingdom - 
96 AY582470.1_F2  466 - - United Kingdom - 
97 AY582471.1_F3  466 - - United Kingdom - 
98 AY582472.1_F4  466 - - United Kingdom - 
99 AY582473.1_G1a  466 - - United Kingdom - 
100 AY582475.1_G2a  484 - - United Kingdom - 
101 AY582477.1_G3  484 - - United Kingdom - 
102 AY582479.1_H3  484 - - United Kingdom - 
103 AY582480.1_I1  463 - - United Kingdom - 
104 AY582481.1_I5  463 - - United Kingdom - 
105 AY582482.1_J1  469 - - United Kingdom - 
106 EU348351.1_C177  1,392 - - Japan - 
107 EU348352.1_C83  1,392 - - Japan - 
108 EU348353.1_Y01  1,392 - - Japan - 
109 EU348354.1_FUK19U  1,389 - - Japan - 
110 EU348355.1_C164  1,398 - - Japan - 
111 EU348356.1_ASA1  1,419 - - Japan - 
112 EU348357.1_C95  1,419 - - Japan - 
113 EU348358.1_C149  1,419 - - Japan - 
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114 EU348359.1_FUK28  1,419 - - Japan - 
115 EU348360.1_N62  1,419 - - Japan - 
116 EU348361.1_C154  1,401 - - Japan - 
117 EU348362.1_FUK16  1,401 - - Japan - 
118 EU348363.1_S01  1,401 - - Japan - 
119 EU348364.1_C49  1,395 - - Japan - 
120 EU377488.1_M5509/05  326 Clinical specimen - India - 
121 EU377490.1_VRF3053/06  326 Clinical specimen - India - 
122 EU686463.1_N5bb  445 - - Zambia Genotype: gO1a 
123 EU686464.1_N6bb  445 - - Zambia Genotype: gO1a 
124 EU686465.1_N14a  445 - - Zambia Genotype: gO1a 
125 EU686466.1_N17bb  445 - - Zambia Genotype: gO1a 
126 EU686467.1_N33bb  445 - - Zambia Genotype: gO1a 
127 EU686468.1_N2a  445 - - Zambia Genotype: gO1b 
128 EU686469.1_N9a  445 - - Zambia Genotype: gO1b 
129 EU686470.1_N15cc  445 - - Zambia Genotype: gO1b 
130 EU686471.1_N18bb  445 - - Zambia Genotype: gO1b 
131 EU686472.1_N19a  445 - - Zambia Genotype: gO1b 
132 EU686473.1_N23a  445 - - Zambia Genotype: gO1b 
133 EU686474.1_N24bb  445 - - Zambia Genotype: gO1b 
134 EU686475.1_N25a  445 - - Zambia Genotype: gO1b 
135 EU686476.1_N27bb  445 - - Zambia Genotype: gO1b 
136 EU686477.1_N34a  445 - - Zambia Genotype: gO1b 
137 EU686478.1_N36bb  445 - - Zambia Genotype: gO1b 
138 EU686479.1_N31a  439 - - Zambia Genotype: gO1c 
139 EU686480.1_N32a  439 - - Zambia Genotype: gO1c 
140 EU686481.1_N8bb  436 - - Zambia Genotype: gO2a 
141 EU686482.1_N29cc  436 - - Zambia Genotype: gO2a 
142 EU686483.1_N7bb  442 - - Zambia Genotype: gO2b 
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143 EU686484.1_N10a  442 - - Zambia Genotype: gO2b 
144 EU686485.1_N11bb  442 - - Zambia Genotype: gO2b 
145 EU686486.1_N21a  442 - - Zambia Genotype: gO2b 
146 EU686487.1_N6a  448 - - Zambia Genotype: gO3 
147 EU686488.1_N7a  448 - - Zambia Genotype: gO3 
148 EU686489.1_N8a  448 - - Zambia Genotype: gO3 
149 EU686490.1_N11a  448 - - Zambia Genotype: gO3 
150 EU686491.1_N12a  448 - - Zambia Genotype: gO3 
151 EU686492.1_N17a  448 - - Zambia Genotype: gO3 
152 EU686493.1_N20bb  448 - - Zambia Genotype: gO3 
153 EU686494.1_N26a  448 - - Zambia Genotype: gO3 
154 EU686495.1_N27b  448 - - Zambia Genotype: gO3 
155 EU686496.1_N35bb  448 - - Zambia Genotype: gO3 
156 EU686497.1_N12cc  433 - - Zambia Genotype: gO4 
157 EU686498.1_N26bb  433 - - Zambia Genotype: gO4 
158 EU686499.1_N28a  433 - - Zambia Genotype: gO4 
159 EU686500.1_N33a  433 - - Zambia Genotype: gO4 
160 EU686501.1_N3aa  461 - - Zambia Genotype: gO5 
161 EU686502.1_N13bb  461 - - Zambia Genotype: gO5 
162 EU686503.1_N29b  461 - - Zambia Genotype: gO5 
163 EU686504.1_N30bb  461 - - Zambia Genotype: gO5 
164 EU686505.1_N35aa  461 - - Zambia Genotype: gO5 
165 EU686506.1_N36a  461 - - Zambia Genotype: gO5 
166 EU686507.1_37M18  445 - 14-Nov-06 Zambia Genotype: gO1b 
167 EU686508.1_40M6  445 - 21-Nov-05 Zambia Genotype: gO1a 
168 EU686509.1_263M6  445 - 30-Aug-06 Zambia Genotype: gO1b 
169 EU686510.1_178M18  436 - 05-Jul-07 Zambia Genotype: gO2a 
170 EU686511.1_K60  445 - - Zambia Genotype: gO1a 
171 EU686512.1_K33  445 - - Zambia Genotype: gO1b 
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172 EU686513.1_K57  445 - - Zambia Genotype: gO1b 
173 EU686514.1_K67  445 - - Zambia Genotype: gO1b 
174 EU686515.1_K86  445 - - Zambia Genotype: gO1b 
175 EU686516.1_K142  445 - - Zambia Genotype: gO1b 
176 EU686517.1_K61  442 - - Zambia Genotype: gO2b 
177 EU686518.1_K141  461 - - Zambia Genotype: gO5 
178 GQ227753.1_HAN15  2,843 Bronchoalveolar lavage 2007 Germany Passaged twice in human fibroblasts; acronym: HCMV; 
acronym: HHV-5 
179 GQ227755.1_HAN17  2,813 Bronchoalveolar lavage 2007 Germany Passaged twice in human fibroblasts; acronym: HCMV; 
acronym: HHV-5 
180 GQ227760.1_HAN23  2,813 Bronchoalveolar lavage 2007 Germany Passaged 3 times in human fibroblasts; acronym: HCMV; 
acronym: HHV-5 
181 GQ227761.1_HAN24  2,841 Bronchoalveolar lavage 2007 Germany Passaged 3 times in human fibroblasts; acronym: HCMV; 
acronym: HHV-5 
182 GQ227762.1_HAN25  2,837 Bronchoalveolar lavage 2007 Germany Passaged twice in human fibroblasts; acronym: HCMV; 
acronym: HHV-5 
183 GQ227765.1_HAN29  2,841 Bronchoalveolar lavage 2007 Germany Passaged twice in human fibroblasts; acronym: HCMV; 
acronym: HHV-5 
184 GQ227770.1_HAN34  2,841 Bronchoalveolar lavage 2007 Germany Passaged twice in human fibroblasts; acronym: HCMV; 
acronym: HHV-5 
185 GQ227780.1_U4  2,859 Urine from a congenitally infected infant 2003 United Kingdom Passaged 10 times in human fibroblasts; acronym: HCMV; 
acronym: HHV-5 
186 GQ227785.1_W1  2,852 Post mortem lung tissue from an AIDS patient 2001 United Kingdom Sequenced directly from patient material, not passaged in 
cell culture; two strains (W1 and W2) were detected in the 
same material; acronym: HCMV; acronym: HHV-5 
187 GQ227786.1_W2  2,843 Post mortem lung tissue from an AIDS patient 2001 United Kingdom Sequenced directly from patient material, not passaged in 
cell culture; two strains (W1 and W2) were detected in the 
same material; acronym: HCMV; acronym: HHV-5 
188 KT987996.1_human-wt/ITA/PR184/2010  267 Urine 2010 Italy Genotype: gO1a 
189 KT987997.1_human-wt/ITA/PR1343/1995  267 Urine 1995 Italy Genotype: gO1c 
190 KT987998.1_human-wt/ITA/PR817/1998  267 Urine 1998 Italy Genotype: gO2b 
191 KT987999.1_human-wt/ITA/PR217/1997  267 Urine 1997 Italy Genotype: gO2b 
192 KT988000.1_human-wt/ITA/PR206/1995  267 Urine 1995 Italy Genotype: gO3 
193 KT988001.1_human-wt/ITA/PR2197/2012  267 Urine 2012 Italy Genotype: gO3 
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194 KT988002.1_human-wt/ITA/PR2115/2001  267 Urine 2001 Italy Genotype: gO4 
195 KT988003.1_human-wt/ITA/PR2528/1998  267 Urine 1998 Italy Genotype: gO4 
 
Appendix 11. This table depicts key features of the 195 partial and complete HCMV gO CDSs sequences available in GenBank release 211 that were 
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 Accession num._Strain/Isolate Isolation source Date collected Country Notes 
1 AF224679.1_E1 - - - - 
2 AF224680.1_E4 - - - - 
3 AF224681.1_E5 - - - - 
4 AF224682.1_E8 - - - - 
5 AF224683.1_E10 - - - - 
6 AF224684.1_E11 - - - - 
7 AF224685.1_E13 - - - - 
8 AF224686.1_E14 - - - - 
9 AF224687.1_E15 - - - - 
10 AF224688.1_E16 - - - - 
11 AF309969.1_LN - - - - 
12 AF309970.1_GR - - - - 
13 AF309971.1_DB - - - - 
14 AF309972.1_SB - - - - 
15 AF309973.1_HDs - - - - 
16 AF309974.1_HR - - - - 
17 AF309975.1_DL - - - - 
18 AF309976.1_Can2 - - - - 
19 AF309977.1_Can4 - - - - 
20 AF309978.1_Can7 - - - - 
21 AF309979.1_Can8 - - - - 
22 AF309980.1_BD - - - - 
23 AF309981.1_ML - - - - 
24 AF309982.1_TS - - - - 
25 AF309983.1_FL - - - - 
26 AF309984.1_B-AL - - - - 
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27 AF309985.1_B-AS - - - - 
28 AF309986.1_PS - - - - 
29 AF309987.1_MS - - - - 
30 AF309988.1_Can10 - - - - 
31 AF309989.1_BO - - - - 
32 AF309990.1_LC - - - - 
33 AF309991.1_BC - - - - 
34 AF309992.1_ZV - - - - 
35 AF309993.1_HDu - - - - 
36 AF309994.1_SR - - - - 
37 AF309995.1_RL - - - - 
38 AF309996.1_SE - - - - 
39 AF309997.1_BR - - - - 
40 AF309998.1_LV - - - - 
41 AF309999.1_CR - - - - 
42 AF310000.1_GJ - - - - 
43 AF310001.1_RC - - - - 
44 AF310002.1_PN - - - - 
45 AF310003.1_VL - - - - 
46 AF310004.1_MN - - - - 
47 AF310005.1_BN - - - - 
48 AF310006.1_PM - - - - 
49 AF390748.1_CER - - - Clinical isolate 
50 AF390749.1_FR - - - Clinical isolate 
51 AF390750.1_LA10 - - - Clinical isolate 
52 AF390751.1_LA12 - - - Clinical isolate 
53 AF390752.1_LA14 - - - Clinical isolate 
54 AF390753.1_LA15 - - - Clinical isolate 
55 AF390754.1_LA16 - - - Clinical isolate 
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56 AF390755.1_LA19 - - - Clinical isolate 
57 AF390756.1_LA2 - - - Clinical isolate 
58 AF390757.1_LA20 - - - Clinical isolate 
59 AF390758.1_LA21 - - - Clinical isolate 
60 AF390759.1_LA22 - - - Clinical isolate 
61 AF390760.1_LA23 - - - Clinical isolate 
62 AF390761.1_LA25 - - - Clinical isolate 
63 AF390762.1_LA28 - - - Clinical isolate 
64 AF390763.1_LA33 - - - Clinical isolate 
65 AF390764.1_LA34 - - - Clinical isolate 
66 AF390765.1_LA38 - - - Clinical isolate 
67 AF390766.1_LA5 - - - Clinical isolate 
68 AF390767.1_LA9 - - - Clinical isolate 
69 AF390768.1_LA7 - - - Clinical isolate 
70 AF390769.1_LA8 - - - Clinical isolate 
71 AF390770.1_LS - - - Clinical isolate 
72 AF390771.1_m23 - - - Clinical isolate 
73 AF390772.1_PL - - - Clinical isolate 
74 AF390773.1_RZ - - - Clinical isolate 
75 AF390774.1_SA - - - Clinical isolate 
76 AF390775.1_SH - - - Clinical isolate 
77 AF390776.1_SV - - - Clinical isolate 
78 AF390777.1_RV - - - Clinical isolate 
79 AF390778.1_SF - - - Clinical isolate 
80 AF390779.1_DEL - - - Clinical isolate 
81 AF390780.1_BRT - - - Clinical isolate 
82 AF390781.1_CU - - - Clinical isolate 
83 AF390782.1_FC - - - Clinical isolate 
84 AF390783.1_GL - - - Clinical isolate 
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85 AF390784.1_KA - - - Clinical isolate 
86 AF390785.1_MD - - - Clinical isolate 
87 AF390786.1_MR - - - Clinical isolate 
88 AF390787.1_SG - - - Clinical isolate 
89 AF390788.1_SM - - - Clinical isolate 
90 AF390789.1_ST - - - Clinical isolate 
91 AF390790.1_VT - - - Clinical isolate 
92 AF390791.1_GS - - - Clinical isolate 
93 AF390792.1_RO - - - Clinical isolate 
94 AF390793.1_RF - - - Clinical isolate 
95 AF390794.1_GAR - - - Clinical isolate 
96 AF390795.1_PR - - - Clinical isolate 
97 AF390796.1_TR - - - Clinical isolate 
98 AF390797.1_A1-36A - - - - 
99 AF390798.1_A3-90B - - - - 
100 AF390799.1_A4-15F - - - - 
101 AF390800.1_A5-14B - - - - 
102 AF390801.1_A7-45E - - - - 
103 AF390802.1_A8-27F - - - - 
104 AF390803.1_A9-11F - - - - 
105 AF390804.1_A11-79A+ - - - - 
106 AF390805.1_A12-35A - - - - 
107 AF390806.1_A16-28B - - - - 
108 AF390807.1_A17-30A - - - - 
109 AF390808.1_A18-16B - - - - 
110 AF390809.1_A20-17F - - - - 
111 AF390810.1_A22-19F - - - - 
112 AF390811.1_A23-20F - - - - 
113 AF390812.1_A24-92A - - - - 
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114 AF390813.1_A25-17A - - - - 
115 AF390814.1_A26-41A - - - - 
116 AF390815.1_A27-38A - - - - 
117 AF390816.1_A28-99A - - - - 
118 AF390817.1_A29-37C - - - - 
119 AF390818.1_A30-48B - - - - 
120 AF390819.1_A32-96A - - - - 
121 AF390820.1_A33-70A - - - - 
122 AF390821.1_A34-49A - - - - 
123 AF390822.1_A35-55A - - - - 
124 AF390823.1_A37-6E - - - - 
125 AF390824.1_A10-11B - - - - 
126 AF390825.1_A13-73D - - - - 
127 AF390826.1_A14-84A+ - - - - 
128 AF390827.1_A15-96D - - - - 
129 AF390828.1_A2-28A - - - - 
130 AF390829.1_A21-18F - - - - 
131 AF390830.1_A31-64A - - - - 
132 AF390831.1_A36-3E - - - - 
133 AF390832.1_A39-19E* - - - - 
134 AF390833.1_A6-45B - - - - 
135 AF390834.1_A40-5A - - - - 
136 AF390835.2_P143 - - - - 
137 AF390836.2_209 - - - - 
138 AF390837.2_33spa - - - - 
139 AF390838.2_36YUEK - - - - 
140 AF390840.2_210 - - - - 
141 AF390841.2_236 - - - - 
142 AF390842.2_244 - - - - 
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143 AF390843.2_11PAN - - - - 
144 AF390844.2_20FI - - - - 
145 AF390845.2_7RO - - - - 
146 AF390846.2_7330ET - - - - 
147 AF390847.2_5929C - - - - 
148 AF390848.1_C13 - - - - 
149 AF390849.1_C16 - - - - 
150 AF390850.1_C22 - - - - 
151 AF390851.1_C35 - - - - 
152 AF390852.1_C7 - - - - 
153 AF390853.1_C9 - - - - 
154 AF390854.1_C69 - - - - 
155 AF390855.1_C14 - - - - 
156 AF390856.1_C32 - - - - 
157 AF390857.1_C33 - - - - 
158 AF395118.1_104M - - - Clinical isolate 
159 AF395119.1_109B - - - Clinical isolate 
160 AF395120.1_13B - - - Clinical isolate 
161 AF395121.1_2B - - - Clinical isolate 
162 AF395122.1_Vp293 - - - Clinical isolate 
163 AF396713.1_USA1 - - - Clinical isolate 
164 AF396714.1_USA2 - - - Clinical isolate 
165 AF396715.1_USA3 - - - Clinical isolate 
166 AF396716.1_USA4 - - - Clinical isolate 
167 AF396717.1_USA5 - - - Clinical isolate 
168 AF396718.1_USA6 - - - Clinical isolate 
169 AF396719.1_USA7 - - - Clinical isolate 
170 AF396720.1_USA8 - - - Clinical isolate 
171 AF396721.1_USA9 - - - Clinical isolate 
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172 AF396722.1_BH - - - Clinical isolate 
173 AF396723.1_BL - - - Clinical isolate 
174 AF396724.1_CL - - - Clinical isolate 
175 AF396725.1_CN - - - Clinical isolate 
176 AF396726.1_CS - - - Clinical isolate 
177 AF396727.1_DEL - - - Clinical isolate 
178 AF396728.1_DM - - - Clinical isolate 
179 AF396729.1_LA22 - - - Clinical isolate 
180 AF396730.1_ME - - - Clinical isolate 
181 AF396731.1_MS - - - Clinical isolate 
182 AF396732.1_NT - - - Clinical isolate 
183 AF396733.1_RL - - - Clinical isolate 
184 AF396734.1_SCG - - - Clinical isolate 
185 AF396735.1_SC - - - Clinical isolate 
186 AF396736.1_SN - - - Clinical isolate 
187 AF396737.1_SP - - - Clinical isolate 
188 AF396738.1_TD - - - Clinical isolate 
189 AF396739.1_TM - - - Clinical isolate 
190 AF396740.1_ZN - - - Clinical isolate 
191 AF396741.1_MCV - - - Clinical isolate 
192 AF396742.1_MR - - - Clinical isolate 
193 AF396743.1_CLZ - - - Clinical isolate 
194 AF396744.1_DLG - - - Clinical isolate 
195 AF396745.1_DG - - - Clinical isolate 
196 AY326987.1_A2u Urine - Malawi - 
197 AY326988.1_Bir Mouth rinse - Malawi - 
198 AY326989.1_Biu Urine - Malawi - 
199 AY326990.1_B1r Mouth rinse - Malawi - 
200 AY326991.1_B1u Urine - Malawi - 
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201 AY326992.1_B4r Mouth rinse - Malawi - 
202 AY326993.1_B4u Urine - Malawi - 
203 AY326994.1_Cir Mouth rinse - Malawi - 
204 AY326995.1_Dir Mouth rinse - Malawi - 
205 AY326996.1_Eir Mouth rinse - Malawi - 
206 AY326997.1_E2r Mouth rinse - Malawi - 
207 AY326998.1_E3u Urine - Malawi - 
208 AY326999.1_E4u Urine - Malawi - 
209 AY327000.1_F2r Mouth rinse - Malawi - 
210 AY327001.1_F1u Urine - Malawi - 
211 AY327002.1_F2u Urine - Malawi - 
212 AY327003.1_Gir Mouth rinse - Malawi - 
213 AY327004.1_G3r Mouth rinse - Malawi - 
214 AY327005.1_G3u Urine - Malawi - 
215 AY327006.1_I2u Urine - Malawi - 
216 AY327007.1_M3u Urine - Malawi - 
217 AY327008.1_Nir Mouth rinse - Malawi - 
218 AY327009.1_Niu Urine - Malawi - 
219 AY327010.1_Piu Urine - Malawi - 
220 AY327011.1_Riu Urine - Malawi - 
221 AY327012.1_R1r Mouth rinse - Malawi - 
222 AY327013.1_R2r Mouth rinse - Malawi - 
223 AY327014.1_R2u Urine - Malawi - 
224 AY327015.1_R3u Urine - Malawi - 
225 AY327016.1_Tir Mouth rinse - Malawi - 
226 AY327017.1_T3u Urine - Malawi - 
227 AY327018.1_T4r Mouth rinse - Malawi - 
228 AY327019.1_T4u Urine - Malawi - 
229 AY327020.1_Qiu Urine - Malawi - 
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230 AY327021.1_Uir Mouth rinse - Malawi - 
231 AY327022.1_U1r Mouth rinse - Malawi - 
232 AY327023.1_U3r Mouth rinse - Malawi - 
233 AY327024.1_Xir Mouth rinse - Malawi - 
234 AY327025.1_X2r Mouth rinse - Malawi - 
235 AY327026.1_X3r Mouth rinse - Malawi - 
236 AY327027.1_W4r Mouth rinse - Malawi - 
237 AY327028.1_W6r Mouth rinse - Malawi - 
238 AY327029.1_Zir Mouth rinse - Malawi - 
239 AY327030.1_Ziu Urine - Malawi - 
240 AY327031.1_Rir Mouth rinse - Malawi - 
241 AY327032.1_E4r Mouth rinse - Malawi - 
242 EU377503.1_M449/05 Clinical specimen - India - 
243 EU377505.1_VRF3754/06 Clinical specimen - India - 
244 EU377506.1_VRF2054/07 Clinical specimen - India - 
245 EU377509.1_VRF3053/06 Clinical specimen - India - 
246 EU377510.1_VRF2758/07 Clinical specimen - India - 
247 EU686416.1_N5a - - Zambia Genotype:gN1 
248 EU686417.1_N8c - - Zambia Genotype:gN1 
249 EU686418.1_N17a - - Zambia Genotype:gN1 
250 EU686419.1_N33a - - Zambia Genotype:gN1 
251 EU686420.1_N7c - - Zambia Genotype:gN2 
252 EU686421.1_N10c - - Zambia Genotype:gN2 
253 EU686422.1_N21b - - Zambia Genotype:gN2 
254 EU686423.1_N2b - - Zambia Genotype:gN3a 
255 EU686424.1_N9a - - Zambia Genotype:gN3a 
256 EU686425.1_N10a - - Zambia Genotype:gN3a 
257 EU686426.1_N19a - - Zambia Genotype:gN3a 
258 EU686427.1_N23a - - Zambia Genotype:gN3a 
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259 EU686428.1_N25a - - Zambia Genotype:gN3a 
260 EU686429.1_N34a - - Zambia Genotype:gN3a 
261 EU686430.1_N8a - - Zambia Genotype:gN3b 
262 EU686431.1_N6a - - Zambia Genotype:gN4a 
263 EU686432.1_N11a - - Zambia Genotype:gN4a 
264 EU686433.1_N21a - - Zambia Genotype:gN4b 
265 EU686434.1_N27b - - Zambia Genotype:gN4b 
266 EU686435.1_N28a - - Zambia Genotype:gN4b 
267 EU686436.1_N31a - - Zambia Genotype:gN4c 
268 EU686437.1_N32a - - Zambia Genotype:gN4c 
269 EU686438.1_N1c - - Zambia Genotype:gN4d 
270 EU686439.1_N12c - - Zambia Genotype:gN4d 
271 EU686440.1_N18a - - Zambia Genotype:gN4d 
272 EU686441.1_N24a - - Zambia Genotype:gN4d 
273 EU686442.1_N29a - - Zambia Genotype:gN4d 
274 EU686443.1_N30a - - Zambia Genotype:gN4d 
275 EU686444.1_N36a - - Zambia Genotype:gN4d 
276 EU686445.1_35M6 - 14-Nov-05 Zambia Genotype:gN3a 
277 EU686446.1_133M18 - 30-Mar-07 Zambia Genotype:gN3a 
278 EU686447.1_26M18 - 07-Nov-06 Zambia Genotype:gN3a 
279 EU686448.1_263M6 - 30-Aug-06 Zambia Genotype:gN3a 
280 EU686449.1_492M6 - 15-Jun-07 Zambia Genotype:gN3a 
281 EU686450.1_503M6 - 21-Jun-07 Zambia Genotype:gN3a 
282 EU686451.1_K68 - - Zambia Genotype:gN1 
283 EU686452.1_K33 - - Zambia Genotype:gN3a 
284 EU686453.1_K57 - - Zambia Genotype:gN4a 
285 EU686454.1_K60 - - Zambia Genotype:gN1 
286 EU686455.1_K135 - - Zambia Genotype:gN3a 
287 EU686456.1_K141 - - Zambia Genotype:gN4d 
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288 EU686457.1_K152 - - Zambia Genotype:gN3a 
289 EU686458.1_K103 - - Zambia Genotype:gN1 
290 EU686459.1_K110 - - Zambia Genotype:gN1 
291 EU686460.1_K61 - - Zambia Genotype:gN1 
292 EU686461.1_K190 - - Zambia Genotype:gN1 
293 EU686462.1_K137 - - Zambia Genotype:gN1 
294 GQ227753.1_HAN15 Bronchoalveolar lavage 2007 Germany Passaged twice in human fibroblasts 
295 GQ227755.1_HAN17 Bronchoalveolar lavage 2007 Germany Passaged twice in human fibroblasts 
296 GQ227760.1_HAN23 Bronchoalveolar lavage 2007 Germany Passaged 3 times in human fibroblasts 
297 GQ227761.1_HAN24 Bronchoalveolar lavage 2007 Germany Passaged 3 times in human fibroblasts 
298 GQ227762.1_HAN25 Bronchoalveolar lavage 2007 Germany Passaged twice in human fibroblasts 
299 GQ227765.1_HAN29 Bronchoalveolar lavage 2007 Germany Passaged twice in human fibroblasts 
300 GQ227770.1_HAN34 Bronchoalveolar lavage 2007 Germany Passaged twice in human fibroblasts 
301 GQ227780.1_U4 Urine from a congenitally infected infant 2003 United Kingdom Passaged 10 times in human fibroblasts 
302 GQ227785.1_W1 Post mortem lung tissue from an AIDS patient 2001 United Kingdom Sequenced directly from patient material, not passaged in  cell culture; two 
strains (W1 and W2) were detected in the same material 
303 GQ227786.1_W2 Post mortem lung tissue from an AIDS patient 2001 United Kingdom Sequenced directly from patient material, not passaged in  cell culture; two 
strains (W1 and W2) were detected in the same material 
304 GU376720.1_N3201 Plasma from bone marrow recipient  27-Jul-09 China Genotype:gN3b 
305 GU376721.1_N1802 Plasma from bone marrow recipient  23-Apr-09 China Genotype:gN4a 
306 GU376722.1_N3403 Plasma from bone marrow recipient  02-Jul-09 China Genotype:gN4a 
307 GU376723.1_N2701 Plasma from bone marrow recipient  20-Apr-09 China Genotype:gN4b 
308 GU376724.1_N1503 Plasma from bone marrow recipient  13-Apr-09 China Genotype:gN4d 
309 GU376725.1_N1507 Plasma from bone marrow recipient  13-Apr-09 China Genotype:gN2 
310 GU376726.1_N3405 Plasma from bone marrow recipient  02-Jul-09 China Genotype:gN3a 
311 GU376727.1_N1809 Plasma from bone marrow recipient  23-Apr-09 China Genotype:gN4b 
312 GU441773.1_N3408 Plasma from bone marrow recipient  02-Jul-09 China Genotype:gN1 
313 GU583628.1_102F - 11-Aug-08 India - 
314 GU583629.1_103F - 19-May-07 India Genotype:1 
315 GU583630.1_105F - 12-May-08 India - 
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316 GU583631.1_110F - 19-Mar-08 India Genotype:1 
317 GU583632.1_111F - 30-Oct-07 India Genotype:4b 
318 GU583633.1_113F - 11-Sep-07 India Genotype:4c 
319 GU583634.1_114F - 13-Sep-07 India Genotype:4b 
320 GU583635.1_115F - 19-Mar-07 India - 
321 GU583636.1_223F - 02-May-08 India - 
322 GU583637.1_261F - 28-May-08 India - 
323 GU583638.1_293F - 28-Jul-07 India Genotype:4b 
324 GU583639.1_323F - 16-Oct-07 India Genotype:4c 
325 GU583640.1_459F - 06-Aug-07 India Genotype:4b 
326 GU583641.1_1011F - 28-Aug-06 India Genotype:4b 
327 GU583642.1_1022F - 04-Mar-08 India - 
328 GU583643.1_1095F - 27-Dec-08 India Genotype:4c 
329 GU583644.1_1193F - 12-Dec-07 India Genotype:4a 
330 GU583645.1_1194F - 28-Dec-07 India - 
331 GU583646.1_1210F - 13-Jun-07 India - 
332 GU583647.1_1225F - 03-Sep-07 India - 
333 GU647095.1_N1592 Plasma from bone marrow recipient  30-Jul-09 China Genotype:gN4c 
334 KF875976.1_1 Inflammatory breast cancer tissue 20-Aug-13 Egypt Genotype:gN1 
335 KF875977.1_2 Non-inflammatory breast cancer tissue 20-Aug-13 Egypt Genotype:gN1 
336 KF875978.1_3 Inflammatory breast cancer tissue 24-Oct-13 Egypt Genotype:gN2 
337 KF875979.1_4 Non-inflammatory breast cancer tissue 24-Oct-13 Egypt Genotype:gN2 
338 KF875980.1_5 Inflammatory breast cancer tissue 13-Jun-13 Egypt Genotype:gN3 
339 KF875981.1_6 Non-inflammatory breast cancer tissue 13-Jun-13 Egypt Genotype:gN3 
340 KF875982.1_7 Inflammatory breast cancer tissue 08-Jul-13 Egypt Genotype:gN4 
341 KF875983.1_8 Non-inflammatory breast cancer tissue 08-Jul-13 Egypt Genotype:gN4 
342 KR261654.1_Ah14 HIV1-infected patient 04-Dec-14 China Genotype:gN4b 
343 KR992948.1_1C Urine 17-Jan-03 Spain H12VL:CMV2;genotype:1 
344 KR992949.1_1cCMV Urine 29-Jan-03 Spain H12VL:CMV1;genotype:1 
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345 KR992950.1_2C Urine 20-Jan-03 Spain H12VL:CMV4;genotype:1 
346 KR992951.1_2cCMV Urine 25-Feb-03 Spain H12VL:CMV3;genotype:3a 
347 KR992952.1_3C Urine 10-Apr-03 Spain H12VL:CMV6;genotype:1 
348 KR992953.1_3cCMV Urine 07-Jan-05 Spain H12VL:CMV5;genotype:4c 
349 KR992954.1_4cCMV Foetal blood 03-Feb-06 Spain H12VL:CMV7;genotype:1 
350 KR992955.1_5C Urine 23-Sep-04 Spain H12VL:CMV8;genotype:4b 
351 KR992956.1_6C Urine 20-Sep-05 Spain H12VL:CMV10;genotype:1 
352 KR992957.1_6cCMV Amniotic fluid 20-Oct-06 Spain H12VL:CMV9;genotype:4a 
353 KR992958.1_7C Urine 05-Jan-06 Spain H12VL:CMV12;genotype:2 
354 KR992959.1_7cCMV Urine 27-Mar-07 Spain H12VL:CMV11;genotype:4a 
355 KR992960.1_8cCMV Urine 04-May-07 Spain H12VL:CMV13;genotype:3a 
356 KR992961.1_9C Urine 04-Apr-06 Spain H12VL:CMV15;genotype:4c 
357 KR992962.1_9cCMV Foetal blood 05-Jun-07 Spain H12VL:CMV14;genotype:4a 
358 KR992963.1_10C Urine 08-May-06 Spain H12VL:CMV16;genotype:4b 
359 KR992964.1_11C Urine 09-Jan-07 Spain H12VL:CMV17;genotype:4b 
360 KR992965.1_12C Urine 11-Jan-07 Spain H12VL:CMV18;genotype:4c 
361 KR992966.1_13C Urine 31-Jan-07 Spain H12VL:CMV20;genotype:3a 
362 KR992967.1_13cCMV Amniotic fluid 05-Nov-07 Spain H12VL:CMV19;genotype:1 
363 KR992968.1_14cCMV Amniotic fluid 12-Feb-08 Spain H12VL:CMV21;genotype:1 
364 KR992969.1_15C Urine 23-Mar-07 Spain H12VL:CMV23;genotype:4c 
365 KR992970.1_15cCMV Dried blood spot 23-Feb-10 Spain H12VL:CMV22;genotype:1 
366 KR992971.1_16C Urine 08-Oct-08 Spain H12VL:CMV25;genotype:3b 
367 KR992972.1_16cCMV Urine 12-Apr-10 Spain H12VL:CMV24;genotype:2 
368 KR992973.1_17cCMV Foetal blood 13-Apr-10 Spain H12VL:CMV26;genotype:4c 
369 KR992974.1_19C Urine 09-Mar-09 Spain H12VL:CMV28;genotype:3b 
370 KR992975.1_19cCMV Urine 22-Feb-11 Spain H12VL:CMV27;genotype:3a 
371 KR992976.1_20cCMV Urine 15-Apr-11 Spain H12VL:CMV29;genotype:2 
372 KR992977.1_21C Urine 27-Oct-09 Spain H12VL:CMV31;genotype:3a 
373 KR992978.1_21cCMV Urine 01-Jul-11 Spain H12VL:CMV30;genotype:4c 
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374 KR992979.1_22C Urine 25-Nov-09 Spain H12VL:CMV32;genotype:3a 
375 KR992980.1_23C Urine 20-Mar-10 Spain H12VL:CMV34;genotype:3a 
376 KR992981.1_23cCMV Urine 06-Sep-11 Spain H12VL:CMV33;genotype:4a 
377 KR992982.1_24C Urine 23-Mar-10 Spain H12VL:CMV36;genotype:4a 
378 KR992983.1_24cCMV Foetal blood 13-Dec-11 Spain H12VL:CMV35;genotype:1 
379 KR992984.1_25C Urine 24-May-10 Spain H12VL:CMV38;genotype:3b 
380 KR992985.1_25cCMV Foetal blood 17-Jan-12 Spain H12VL:CMV37;genotype:4a 
381 KR992986.1_26cCMV Urine 31-Jan-12 Spain H12VL:CMV39;genotype:4c 
382 KR992987.1_27C Urine 22-Jul-10 Spain H12VL:CMV41;genotype:3a 
383 KR992988.1_27cCMV Urine 30-Mar-05 Spain H12VL:CMV40;genotype:4a 
384 KR992989.1_28C Urine 10-Aug-10 Spain H12VL:CMV42;genotype:4b 
385 KR992990.1_29C Urine 15-Sep-10 Spain H12VL:CMV43;genotype:1 
386 KR992991.1_30C Urine 25-Oct-10 Spain H12VL:CMV44;genotype:3a 
387 KR992992.1_31C Urine 05-Nov-10 Spain H12VL:CMV46;genotype:4c 
388 KR992993.1_31cCMV Urine 18-Oct-07 Spain H12VL:CMV45;genotype:1 
389 KR992994.1_32cCMV Amniotic fluid 01-Dec-09 Spain H12VL:CMV47;genotype:1 
390 KR992995.1_33C Urine 11-Jan-11 Spain H12VL:CMV49;genotype:2 
391 KR992996.1_33cCMV Dried blood spot 17-Dec-09 Spain H12VL:CMV48;genotype:1 
392 KR992997.1_34C Urine 01-Mar-11 Spain H12VL:CMV51;genotype:3b 
393 KR992998.1_34cCMV Urine 19-Jan-11 Spain H12VL:CMV50;genotype:2 
394 KR992999.1_35cCMV Foetal blood 07-Mar-11 Spain H12VL:CMV52;genotype:3b 
395 KR993000.1_35C Urine 28-Mar-11 Spain H12VL:CMV53;genotype:1 
396 KR993001.1_36C Urine 24-Jun-11 Spain H12VL:CMV55;genotype:4c 
397 KR993002.1_36cCMV Dried blood spot 10-Mar-11 Spain H12VL:CMV54;genotype:2 
398 KR993003.1_37C Urine 24-Jun-11 Spain H12VL:CMV56;genotype:4a 
399 KR993004.1_38C Urine 28-Nov-11 Spain H12VL:CMV58;genotype:4c 
400 KR993005.1_38cCMV Saliva 13-Jan-12 Spain H12VL:CMV57;genotype:3a 
401 KR993006.1_39cCMV Dried blood spot 22-Jun-10 Spain H12VL:CMV59;genotype:2 
402 KR993007.1_39C Urine 25-Jan-12 Spain H12VL:CMV60;genotype:1 
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403 KR993008.1_40C Urine 31-Aug-12 Spain H12VL:CMV61;genotype:1 
404 KR993009.1_41C Urine 01-Oct-12 Spain H12VL:CMV62;genotype:4c 
405 KR993010.1_42C Urine 11-Nov-13 Spain H12VL:CMV63;genotype:3b 
406 KR993011.1_43C Urine 28-Nov-13 Spain H12VL:CMV64;genotype:3b 
407 KR993012.1_44C Urine 31-Jan-14 Spain H12VL:CMV65;genotype:2 
408 KR993013.1_45C Urine 14-Apr-14 Spain H12VL:CMV66;genotype:4a 
409 KR993014.1_46C Urine 09-Jul-14 Spain H12VL:CMV67;genotype:4b 
410 KR993015.1_47C Urine 30-Jul-14 Spain H12VL:CMV68;genotype:4a 
411 KR993016.1_48C Urine 31-Jul-12 Spain H12VL:CMV69;genotype:4a 
412 KR993017.1_49C Urine 07-Apr-12 Spain H12VL:CMV70;genotype:4c 
413 KR993018.1_50cCMV Urine 18-Jul-11 Spain H12VL:CMV71;genotype:4a 
414 KR993019.1_56C Urine 10-Sep-14 Spain H12VL:CMV72;genotype:1 
415 KR993020.1_57C Urine 28-Apr-09 Spain H12VL:CMV73;genotype:3b 
416 KR993021.1_58cCMV Foetal blood 28-Aug-12 Spain H12VL:CMV74;genotype:3a 
417 KR993022.1_59cCMV Urine 28-Nov-12 Spain H12VL:CMV75;genotype:4b 
418 KR993023.1_60cCMV Urine 13-Jun-13 Spain H12VL:CMV76;genotype:3b 
419 KR993024.1_61C Urine 03-Dec-13 Spain H12VL:CMV78;genotype:4a 
420 KR993025.1_61cCMV Urine 26-Jun-13 Spain H12VL:CMV77;genotype:1 
421 KR993026.1_62C Urine 29-Oct-14 Spain H12VL:CMV79;genotype:4b 
422 KR993027.1_64C Urine 11-Jan-13 Spain H12VL:CMV80;genotype:1 
423 KR993028.1_65C Urine 22-Sep-05 Spain H12VL:CMV81;genotype:4b 
424 KR993029.1_66C Urine 03-Sep-12 Spain H12VL:CMV83;genotype:3b 
425 KR993030.1_66cCMV Urine 23-Apr-03 Spain H12VL:CMV82;genotype:3b 
426 KR993031.1_68C Urine 09-Feb-06 Spain H12VL:CMV84;genotype:3a 
427 KR993032.1_69C Urine 04-Mar-03 Spain H12VL:CMV86;genotype:4a 
428 KR993033.1_69cCMV Urine 31-Oct-13 Spain H12VL:CMV85;genotype:3a 
429 KR993034.1_70C Urine 12-May-03 Spain H12VL:CMV88;genotype:4c 
430 KR993035.1_70cCMV Urine 02-Dec-13 Spain H12VL:CMV87;genotype:1 
431 KR993036.1_71C Urine 02-Apr-12 Spain H12VL:CMV90;genotype:2 
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432 KR993037.1_71cCMV Urine 07-Oct-13 Spain H12VL:CMV89;genotype:4c 
433 KR993038.1_73C Urine 09-May-12 Spain H12VL:CMV91;genotype:3a 
434 KR993039.1_74C Urine 08-Mar-07 Spain H12VL:CMV92;genotype:4b 
435 KR993040.1_76C Urine 14-Nov-11 Spain H12VL:CMV94;genotype:3b 
436 KR993041.1_76cCMV Foetal blood 04-Jun-14 Spain H12VL:CMV93;genotype:1 
437 KR993042.1_77C Urine 24-Dec-12 Spain H12VL:CMV95;genotype:2 
438 KR993043.1_79C Urine 26-Dec-11 Spain H12VL:CMV97;genotype:2 
439 KR993044.1_79cCMV Urine 23-Jul-14 Spain H12VL:CMV96;genotype:4c 
440 KR993045.1_80C Urine 16-Oct-12 Spain H12VL:CMV99;genotype:3a 
441 KR993046.1_80cCMV Urine 13-Nov-09 Spain H12VL:CMV98;genotype:2 
442 KR993047.1_81cCMV Urine 14-Oct-09 Spain H12VL:CMV100;genotype:3b 
443 KR993048.1_82C Urine 12-Apr-04 Spain H12VL:CMV102;genotype:3b 
444 KR993049.1_82cCMV Amniotic fluid 16-Oct-14 Spain H12VL:CMV101;genotype:3b 
445 KR993050.1_83cCMV Urine 19-Aug-08 Spain H12VL:CMV103;genotype:2 
446 KR993051.1_83C Urine 24-Feb-10 Spain H12VL:CMV104;genotype:4a 
447 KR993052.1_84cCMV Urine 27-Nov-09 Spain H12VL:CMV105;genotype:2 
448 KR993053.1_85C Urine 06-Jul-06 Spain H12VL:CMV106;genotype:3a 
449 KR993054.1_86cCMV Urine 17-May-10 Spain H12VL:CMV107;genotype:4a 
450 KR993055.1_87cCMV Foetal blood 25-Nov-14 Spain H12VL:CMV108;genotype:4a 
451 KR993056.1_88C Urine 20-Jun-07 Spain H12VL:CMV110;genotype:2 
452 KR993057.1_88cCMV Urine 10-Jun-04 Spain H12VL:CMV109;genotype:2 
453 KR993058.1_89C Urine 11-Oct-07 Spain H12VL:CMV111;genotype:3a 
454 KR993059.1_90C Urine 14-Sep-08 Spain H12VL:CMV112;genotype:1 
455 KR993060.1_92C Urine 17-Jul-14 Spain H12VL:CMV113;genotype:3a 
456 KT987979.1_human-wt/ITA/PR219/1998 Urine 1998 Italy Genotype:gN1 
457 KT987980.1_human-wt/ITA/PR421/2001 Urine 2001 Italy Genotype:gN1 
458 KT987981.1_human-wt/ITA/PR217/1997 Urine 1997 Italy Genotype:gN3a 
459 KT987982.1_human-wt/ITA/PR691/1997 Urine 1997 Italy Genotype:gN3a 
460 KT987983.1_human-wt/ITA/PR2121/1995 Urine 1995 Italy Genotype:gN3b 
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461 KT987984.1_human-wt/ITA/PR2349/1997 Urine 1997 Italy Genotype:gN4a 
462 KT987985.1_human-wt/ITA/PR2724/1997 Urine 1997 Italy Genotype:gN4a 
463 KT987986.1_human-wt/ITA/PR1663/1996 Urine 1996 Italy Genotype:gN4b 
464 KT987987.1_human-wt/ITA/PR1749/2011 Urine 2011 Italy Genotype:gN4b 
465 KT987988.1_human-wt/ITA/PR1343/1995 Urine 1995 Italy Genotype:gN4c 
466 KT987989.1_human-wt/ITA/PR817/1998 Urine 1998 Italy Genotype:gN4c 
 
Appendix 12. This table depicts key features of the 466 partial and complete HCMV gO CDSs sequences available in GenBank release 211 that were 
analysed in this study. 
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RL5A Reverse Protein RL5A RL11 family 90 MTSGKSATLNTKLNSTWTFFNGTGSDVTVCNVVGTNNYTVSDSGLTGICNCTHSSLGFCNVSTKHEGSYDL
RRRFDNGPEDVGTWFVVVK 
RL8A Reverse Protein RL8A Contains potential transmembrane domain 90 MPHGHLRQALSPTSWTCEGLLLLLGLLVLFFHHHNQSAVERRRRVSFVEVDRLPHESGWYSSDDDGDRDG
DEETGESHNRNSVGLSAVFS 
RL9A Reverse Protein RL9A Contains potential transmembrane domain 47 MSLDAASHQPAARRLLDSALVRRVLSCMIIVIMIAISIWILTYVLFL 
RL10 Forward Envelope glycoprotein 
RL10 





RL11 Forward Membrane glycoprotein 
RL11 
Type 1 membrane protein; binds IgG Fc; involved in 











RL13 Forward Membrane protein RL13 Type 1 membrane protein; RL11 family; consensus is 







UL1 Forward Membrane protein UL1 Type 1 membrane protein; RL11 family 215 MSVQCNTKLLLLIALIPIAIILTGTLVPVILHEQKKAFYWRLFLQSQQSQHIDAPITVIQGDTVYLNASNNPCNY
SSFWYHGNCELCGWNGHLHNFTEYHTNTSCSPKFICINETKGLQLHNVTLNDSGTYTEDVYECDLLCNITNC
TYTINSTKYIITVLSPHHSKHTNSHVSTHVGWTAAVVTVIIICVLIYFNVPTTLRHKLQTRNNVNRIT 
UL2 Reverse Protein UL2 Contains potential transmembrane domain 60 MPEDSVSIFIVEDDDDTYPSFGTLPASHAQYGFRLLRGIFLITLVIWTVVWLKLLRDALL 
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UL4 Forward Envelope glycoprotein 
UL4 
Contains signal peptide; RL11 family 149 MMLRTWILLQMVLLAAYCHCVFGTCSISTTTAPVEWKSPDRRIPSNITCANYSGTVNGSVTFRGLQNKTEDF
LHWLLGWGHKSICSFFPKLQGNKEQHYRYGVTNLTYNCTHDSLTLLNLTTENSGKYYFKREDVNSTFYYSCY
NLTVS 









UL7 Forward Membrane glycoprotein 
UL7 
Type 1 membrane protein; modulates cytokine 






UL8 Forward Membrane glycoprotein 
UL8 





UL9 Forward Membrane glycoprotein 
UL9 








UL11 Forward Membrane glycoprotein 
UL11 
Type 1 membrane protein; disrupts T cell function 
via inhibition of CD45; involved in immune 
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UL14 Forward Membrane protein UL14 Type 1 membrane protein; possibly involved in 






UL15A Forward Protein UL15A Contains potential transmembrane domain 102 MKRMIRSHGRKTECQMTGAGERRGSAVGALICGSGTRRGSGANERRNSDVGPIAHSSGTRRGSANETSAC
TRTDHQKADIGLWFMFLFFGLCSWLSMRYRAQ 
UL16 Forward Membrane glycoprotein 
UL16 
Type 1 membrane protein; inhibits NK cell 
cytotoxicity; sequesters MICB, ULBP1 and ULBP2; 






UL17 Forward Protein UL17 Possibly related to UL19 104 MDHALLTHFVGRPRHCRLEMLILDEQVSKRSWDTTVYHRRRKHLPRRRAPCGPQRPAEIPKRRKKAAVLLF
WHDLCWLFRRLFFPREDSEPLMSDPARSPEEEE 
UL18 Forward Membrane glycoprotein 
UL18 
Type 1 membrane protein; inhibits NK cell 
cytotoxicity; acts on inhibitory receptor LIR-1 (ILT2); 







UL19 Forward Protein UL19 Possibly related to UL17 98 MTSNALYELFRRRLPRAPVNTVMFLTRRTRDGFCGRLTSIATNSHYTMFVLDHGSVRIERPSQSEVDCASLM
ETLKRIRLRNSWVASEDELDVSRRDA 





UL21A Reverse Protein UL21A Facilitates viral DNA synthesis 123 MGGSPVPQLTTVTQGLMPSVRMDFRARRPLRRLAFYAPRARRRLFQNHIHPEQRRVLVGEGDEEMLPGLP
MEIDIVIDRPPQQPLPNPLVLLLDDVPPHVPGFAPYRVPRPHPMIPEEHWDQF 
UL22A Forward Glycoprotein UL22A Contains signal peptide; secreted protein; binds CC 
chemokine RANTES; involved in immune regulation 
106 MARRLWILSLLAVTLTVALAAPSQKSKRSVTVEQPSTSTNSDGNNTTRNKDVTLSQGGSTTDGDEDYSGGD
YDVLITDTDGGNHQQPQKKTNEHKEEHTKENEKTQ 




UL24 Reverse Tegument protein UL24 US22 family 358 MEETRAGRYIVRAGFGGQTEDTASGAESVLATLAAVRTRRRSVVCDGAPGSPTDSARHMSDLASLALTAEF
GLGCLEAYVRINAGQVLPVVWPPGWNLVLQEIETDEDFKPEDVKAWSHYLCCETRLAFVGRFVNEAVLSPD
QQKKTAVCLISDEGYVFCYVREDTAVYYLARNLMEFARVGLRAVETLHCMRYLTSSLVKRYFRPLLRAWSLGL
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DTMARFIIRHHGQFMPLTYPPGTELRLCNLRCFENSVEGGHLLRNIKAAFGMRVLGLGTVSLKGENAPFPHL
RWPVDLIPIVVAYTGAVYACDVRDDRYIRVGDNLNTFMCLGLNLLFENRRFSGHNGIYDRVPDCPKGRQHR 









UL26 Reverse Tegument protein UL26 transcriptional activator of major immediate early 













UL29 Reverse Protein UL29 Interacts with components of the NuRD complex, 












UL30 Reverse Protein UL30 UL30 family 121 MTTSAMTAPDTRRQLQHVETLRRFLRGDSCFVHDLRGMMDYHDGLSRRQQRAFCRAGRVLTDPEPIQSET
EGENKQFTEHTHKVVSFFIKSVFVFPCLVLPNCCQVSVDRSRVPETGGRWL 
UL30A Reverse Protein UL30A UL30 family; alternative start codon 79 MACRDARWVRFIRLRTLWSVRPRAHVADLEDFAAFYRTLSDSEQQEFEQEAELASRSQRVRDLREARRQLK
MDLMCHGG 
 Page 290 of 338 
Gene  Orientation Product Product Features / Known functions AA length AA Sequence 
























UL33 Forward Envelope glycoprotein 
UL33 
Type 3 membrane protein; 7 transmembrane 
domains; putative chemokine receptor; involved in 















UL35 Forward Tegument protein UL35 UL25 family 641 MAQGSRAPSGPPLPVLPVDDWLNFRVDLFGDEHRRLLLEMLTQGCSNFVGLLNFGVPSPVYALEALVDFQ
VRNAFMKVKPVAQEIIRICILANHYRNSRDVLRDLRTQLDVLYSEPLKTRLLRGLIRLCRAAQTGVKPEDISVHL
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UL36 Reverse Tegument protein vICA Inhibitor of caspase-8-induced apoptosis; involved in 








UL37 Reverse Envelope glycoprotein 
UL37 
Type 1 membrane protein; involved in apoptosis; 
involved in gene regulation; major isoform 
(mitochondrial inhibitor of apoptosis, vMIA) 













UL40 Reverse Membrane glycoprotein 
UL40 
Type 1 membrane protein; sequence in signal 
peptide inhibits NK cell cytotoxicity; upregulates cell 
surface expression of HLA-E; acts on inhibitory 






UL41A Reverse Protein UL41A Contains potential transmembrane domain 78 MTLFCRTANSTAGYVDMNVCIGMIGVVCFVFGVFIIIFCSTLKAFYVRQKTYHLLGTESDDEETTVWEKRRM
ESDTDF 
UL42 Reverse Protein UL42 Contains potential transmembrane domain 122 MEPTPMLRDRDHDDAPPTYEQAMGLCPTTVSTPPPPPPDCSPPPYRPPYCLVSSPSPRHTFDMDMMEMP
ATMHPTTGAYFDNGWKWTFALLVVAILGIIFLAVVFTVVINRDNSTTTGTTSG 
UL43 Reverse Tegument protein UL43 US22 family 423 MEKTPAETTAVSAGNVPRDSIPCITNVSADTRGRTRPSRPATVPQRRPARIGHFRRCSASLSFLDWPDDSVT
EGVRTTSASVAASAARFDEIRRRRQSINDEMKERTLEDALAVELVNETFRCSVTADARKDLQKLVRRVSGTVL
RLNWPNGWFFTYCDLLRVGYFGHLNIKGLEKTFLCCDKFLLPVGTVSRCEAIGRPPLPILIGEGGRVYVYSPVV
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UL44 Reverse DNA polymerase 
processivity subunit 







UL45 Reverse Ribonucleotide reductase 
subunit 1 













UL46 Reverse Capsid triplex subunit 1 Complexed 1:2 with capsid triplex subunit 2 to 
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UL48 Forward Large tegument protein Complexed with tegument protein UL37; ubiquitin-


































UL48A Reverse Small capsid protein Located externally on capsid hexons; involved in 
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UL50 Reverse Nuclear egress 
membrane protein 
Type 2 membrane protein; interacts with nuclear 







UL51 Reverse DNA packaging protein 
UL33 
Interacts with DNA packaging terminase subunit 2; 




UL52 Forward DNA packaging protein 
UL32 












UL53 Forward Nuclear egress lamina 
protein 
Interacts with nuclear egress membrane protein; 







UL54 Reverse DNA polymerase catalytic 
subunit 
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UL55 Reverse Envelope glycoprotein B Type 1 membrane protein; possible membrane 
fusogen; binds cell surface heparan sulphate; 














UL56 Reverse DNA packaging terminase 
subunit 2 
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UL57 Reverse Single-stranded DNA-
binding protein 
Contains zinc-finger; involved in DNA replication; 



















UL69 Reverse Multifunctional 
expression regulator 
RNA-binding protein; shuttles between nucleus and 
cytoplasm; inhibits pre-mRNA splicing; exports virus 
mRNA from nucleus; exerts most effects post-
transcriptionally; involved in gene regulation; 












UL70 Reverse Helicase-primase primase 
subunit 
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UL72 Reverse Deoxyuridine 
triphosphatase 






UL73 Forward Envelope glycoprotein N Type 1 membrane protein; complexed with 
envelope glycoprotein M; involved in virion 
morphogenesis; involved in membrane fusion 
135 MECNTLVLGLLVLSVVASSNNTSTASTPRPSSSTHASTTVKATTVATTSTTTATSTSSTTSAKPGSTTHDPNV
MRPHAHNDFYNAHCTSHMYELSLSSFAAWWTMLNALILMGAFCIVLRHCCFQNFTATTTKGY 
UL74 Reverse Envelope glycoprotein O Contains signal peptide; associated with envelope 
glycoprotein H and envelope glycoprotein L; 








UL74A Forward Envelope glycoprotein 24 Type 2 membrane protein 70 MALTRGGDPAPSVCLVVWLACVYSLLILVVLLLIYRCCIGFQDDLVSRTLAVYRACIQGPICNQTHNSTS 
UL75 Reverse Envelope glycoprotein H Type 1 membrane protein; possible membrane 
fusogen; complexed with envelope glycoprotein L; 
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UL77 Forward DNA packaging tegument 
protein UL25 
Located on capsid near vertices; possibly stabilizes 











UL78 Forward Envelope protein UL78 Type 3 membrane protein; 7 transmembrane 
domains; putative chemokine receptor; possibly 












UL80 Forward Capsid maturation 
protease 
Serine protease (N-terminal region); minor scaffold 
protein (remainder of protein, clipped near C 
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UL82 Reverse Tegument protein pp71 Upper matrix protein; involved in gene regulation; 
transcriptional activator; targeted to ND10; targets 
Rb proteins for ubiquitin-independent proteosomal 









UL83 Reverse Tegument protein pp65 Lower matrix protein; involved in immune 
regulation; suppresses interferon response; inhibits 









UL84 Reverse Protein UL84 Involved in gene regulation; involved in DNA 










UL85 Reverse Capsid triplex subunit 2 Complexed 2:1 with capsid triplex subunit 1 to 







UL86 Reverse Major capsid protein 6 copies form hexons, 5 copies form pentons; 
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UL89 Reverse DNA packaging terminase 
subunit 1 
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UL91 Forward Protein UL91  111 MNSLLAELNRLGVAHATTEDVFIFVDRLFQHFSFLFQAEESGPRRLELVASVFEHLTVECVNDILDACSHPDV
NVAETSNSCRPCPSPVPSAPKTVSGAQTSCATPRAPVT 
UL92 Forward Protein UL92  201 MCDASGACDMRHVQNAFTEEIQLHSLYACTRCFRTHLCDLGSGCALVSTLEGSVCVKTGLVYEALYPVARSH
LLEPIEEAALDDVNIISAVLSGVYSYLMTHAGRYADVIQEVVERDRLKKQVEDSIYFTFNKVFRSMHNVNRISV
PVISQLFIQLIIGIYSKQTKYDACVIKVSRKKREDALLKQMRSEYGNAPVFGSGV 
UL93 Forward DNA packaging tegument 
protein UL17 
Capsid-associated; involved in DNA encapsidation; 























UL96 Forward Tegument protein UL14 Involved in virion morphogenesis 127 MTSVNKQLLKDVMRVDLERQQHQFLRRTYGPQHRLTTQQALTVMRVAAREQTRYSQRTTQCVAAHLLEQ
RAAVQQELQRARQLQSGNVDDALDSLTELKDTVDDVRATLVDSVSATCDLDLEVDDAV 
UL97 Forward Tegument 
serine/threonine protein 
kinase 
Involved in protein phosphorylation; resistance to 
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UL99 Forward Myristylated tegument 
protein 





UL100 Reverse Envelope glycoprotein M Type 3 membrane protein; 8 transmembrane 
domains; complexed with envelope glycoprotein N; 
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UL104 Reverse Capsid portal protein Dodecamer located at one capsid vertex in place of 











UL105 Forward Helicase-primase helicase 
subunit 
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UL115 Reverse Envelope glycoprotein L Contains signal peptide; complexed with envelope 

















UL119 Reverse Membrane glycoprotein 
UL119 
Type 1 membrane protein; IgG Fc-binding; similar to 
OX-2; involved in immune regulation; possibly 






UL120 Reverse Membrane protein 
UL120 
Type 1 membrane protein; UL120 family 197 MYRAGVTLLVVAVISVGRWDVVAVAIGWYEPQVSVAYMYEHNDTNLTIFCNTTACDSPFLASGMMISIPQ
NTQFLTSKVNYSDDMYNDRKNYTHELKRMLTGAPGAYVNGSVTCWGSNGTFGAKTFLVKSMINTTAGNT
STSIIHFVQQDELVENPAYFRRSNHRAFMIVILTQVVFVVFIINASFIWSWTFKRHKR 
UL121 Reverse Membrane protein 
UL121 
Type 1 membrane protein; UL120 family 180 MWGCGWSRILVLLPLMCMALMARGTHGAYICSPNPGRLRISCALSVLDQRLWWEIQYSSGRLTRVLVFHD
EGDEGDDLHLTDTRHCTSCTHPYVISLVTPLTINATLRLLIRDGMYGRGEKELCIAHLPTLRDIRTCRVDADLGL
LYAVCLILSFSIVAAALWKVDYDRSVAVVSKSYKS 
UL122 Reverse Regulatory protein IE2 Interacts with basal transcriptional machinery and 
cellular transcription factors; specific DNA-binding 
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UL123 Reverse Regulatory protein IE1 Enhances activation by IE2; interacts with basal 
transcriptional machinery and cellular transcription 








UL124 Forward Membrane protein 
UL124 
Type 1 membrane protein 152 MERNSLLVCQLLCLVARAAATSTAQTTLPSTVNSTATGVTSDSYQNTTTQLPASSSAAALSLPSASAVRAQSP
SSFSDTYPTATALCGTLVVVGIVLCLSLASTVRSKELPSDHEPLEAWDQGSDVEAPPLPEKSPCPEHVPEIRVEI
PRYV 
UL128 Reverse Envelope protein UL128 Contains signal peptide; similar to CC chemokines; 
complexed with envelope glycoproteins H and L; 




UL130 Reverse Envelope glycoprotein 
UL130 
Contains signal peptide; complexed with envelope 
glycoproteins H and L; essential in non-fibroblast 





UL131A Reverse Envelope protein UL131A Contains signal peptide; complexed with envelope 
glycoproteins H and L; essential in non-fibroblast 
cells; involved in cell entry 
129 MRLCRVWLSVCLCAVVLGQCQRETAEKNDYYRVPHYWDACSRALPDQTRYKYVEQLVDLTLNYHYDASHG
LDNFDVLKRINVTEVSLLISDFRRQNRRGGTNKRTTFNAAGSLAPHARSLEFSVRLFAN 
UL132 Reverse Envelope glycoprotein 
UL132 




UL148 Reverse Membrane protein 
UL148 





UL147A Reverse Membrane protein 
UL147A 
Type 1 membrane protein 75 MSLFYRAVALGTLSALVWYSTSILAEINENSCSSSSVDHEDCEEPDEIVREEQDYRALLAFSLVICGTLLVTCVI 
UL147 Reverse Chemokine vCXCL2 Contains signal peptide; putative secreted 
glycoprotein; possibly involved in immune 
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UL146 Reverse Chemokine vCXCL1 Contains signal peptide; putative secreted 




UL145 Reverse Protein UL145 RL1 family 130 MYGVLAHYYSFISSPSVMVNFKHHNAVQLLCARTRDGTAGWERLTHHASYHANYGAYAVLMATSQRKSLV
LHRYSAVTAVALQLMPVEMLRKLDQSDWVRGAWIVSETFPTSDPKGFWSDDDSSMGGSED 
UL144 Reverse Membrane glycoprotein 
UL144 
Type 1 membrane protein; similar to TNFR; interacts 
with BTLA and inhibits T cell proliferation; does not 
bind TNF superfamily ligands; activates NFkappaB via 
TRAF6-dependent mechanism to upregulate CCL22; 




UL142 Reverse Membrane glycoprotein 
UL142 
Type 1 membrane protein; similar to MHC-I; inhibits 
NK cell cytotoxicity; downregulates MICA; acts on 
activating receptor NKG2D; involved in immune 






UL141 Reverse Membrane glycoprotein 
UL141 
Type 1 membrane protein; inhibits NK cell 
cytotoxicity; sequesters CD155; acts on activating 
receptor DNAM-1, CD96; involved in immune 






UL140 Reverse Protein UL140 Contains potential transmembrane domain 191 MTPAQTNATTTVHPHDAKNGSGGSALPTLVVFGFIVTLLFFLFMLYFWNNDVFRKLLRCAWIQHCCDRFDA
WQDEVIYRRPSRRSQSDDESRTNSVSSYVLLSPASDGGFDNPALTEAVDSVDDWATTSVFYATSDETADAE
RRDSQQLLIELPPEPLPPDVVAAMQKAVKRAVQNALRHSHDSWQLHQTL 
UL139 Reverse Membrane glycoprotein 
UL139 
Type 1 membrane protein 135 MLWILVLFALAASASETTTGTSSNSSQSTSATANTTVSTCINASNGSSWTVPQLALLAASGWTLSGLLLLFTCC
FCCFWLVRKICSCCGNSSESESKTTHAYTNAAFTSSDATLPMGTTGSYTPPQDGSFPPPPR 
UL138 Reverse Protein UL138 Contains potential transmembrane domain; possibly 
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UL148A Reverse Protein UL148A Contains potential transmembrane domain 79 MSSQSLDPWIPVCVVVVMTSVVLFAGLHVYLWYVRRQLVAFCLEKVCVRCCGKDETTPLVEDAEPPAELEM
VEVSDECY 
UL148B Reverse Protein UL148B Contains potential transmembrane domain 80 MALDTLAGLAICVGLVMGVTVIASCALLVFYYCDEREDGRPSKLLQRSIRRWRHGLSTESLTAILPDGSSTEQE
IYHTRL 
UL148C Forward Protein UL148C Contains potential transmembrane domain 77 MLTPAVFPAVLYLLALVVWVEMFCLVAVAVVEREIAWALLLRMLVVGLMVEVGAAAAWTFVRCLAYQRSF
PVLTAFP 
UL148D Forward Protein UL148D Contains potential transmembrane domain 62 MTAPKCVTTTTYLVKTKERPWWPDNAIRRWWISVAIVIFIGVCLVALMYFTQQQARSGSSSG 













IRS1 Forward Tegument protein IRS1 Transcriptional activator; blocks phosphorylation of 
eIF2alpha and host shutoff of protein synthesis; 
binds dsRNA; involved in gene regulation; involved in 
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US1 Reverse Protein US1 Contains duplicated TT virus ORF2 motif; US1 family 156 MASGLGDLSVGVSSLPMRELAWRRVADDSHDLWCCCMDWKAHVEYAHPASELRPGSGGWPEHAEAQ
WRQQVHAAHDVWCNCGDWQGHALRSRSRTAESGRSSLSSSVSVLSDGDQQPWWRRLRVKRPKFPSWA
RRWTQRHDSEERASQQAENDSTS 
US2 Reverse Membrane glycoprotein 
US2 
Contains potential transmembrane domain; causes 
selective degradation of MHC-I and MHC-II; involved 




US3 Reverse Membrane glycoprotein 
US3 
Type 1 membrane protein; inhibits processing and 
transport of MHC-I and MHC-II; involved in immune 




US6 Reverse Membrane glycoprotein 
US6 
Type 1 membrane protein; inhibits TAP-mediated 





US7 Reverse Membrane glycoprotein 
US7 
Type 1 membrane protein; possibly involved in 





US8 Reverse Membrane glycoprotein 
US8 
Type 1 membrane protein; binds to MHC-I; involved 





US9 Reverse Membrane glycoprotein 
US9 
Type 1 membrane protein; possibly involved in 





US10 Reverse Membrane glycoprotein 
US10 
Type 1 membrane protein; delays trafficking of 




US11 Reverse Membrane glycoprotein 
US11 
Type 1 membrane protein; causes selective 
degradation of MHC-I; involved in immune 




US12 Reverse Membrane protein US12 Type 3 membrane protein; 7 transmembrane 






US13 Reverse Membrane protein US13 Type 3 membrane protein; 7 transmembrane 
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US14 Reverse Membrane protein US14 Type 3 membrane protein; 7 transmembrane 







US15 Reverse Membrane protein US15 Type 3 membrane protein; 7 transmembrane 






US16 Reverse Membrane protein US16 Type 3 membrane protein; 7 transmembrane 







US17 Reverse Membrane protein US17 Type 3 membrane protein; 7 transmembrane 






US18 Reverse Membrane protein US18 Type 3 membrane protein; 7 transmembrane 






US19 Reverse Membrane protein US19 Type 3 membrane protein; 7 transmembrane 






US20 Reverse Membrane protein US20 Type 3 membrane protein; 7 transmembrane 






US21 Reverse Membrane protein US21 Type 3 membrane protein; 7 transmembrane 
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US27 Forward Envelope glycoprotein 
US27 
Type 3 membrane protein; 7 transmembrane 
domains; putative chemokine receptor; possibly 






US28 Forward Envelope protein US28 Type 3 membrane protein; 7 transmembrane 
domains; broad spectrum CC chemokine receptor; 
354 MTPTTTTAELTTEFDYDEAATPCVFTDVLNQSKPVTLFLYGVVFLFGSIGNFLVIFTITWRRRIQCSGDVYFINL
AAADLLFVCTLPLWMQYLLDHNSLASVPCTLLTACFYVAMFASLCFITEIALDRYYAIVYMRYRPVKQACLFSI
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constitutive signalling; mediates cellular migration; 
















US31 Forward Protein US31 Contains duplicated TT virus ORF2 motif; US1 family 161 MSLLEREESWRRVVDYSHNLWCTCGNWQSHVEIQDEEPNCEQPEPAHWLEYVAVQWQARVRDSHDRW
CLCNAWRDHALRGRWGTAYSSGSSASSSGFVAESKFTWWKRLRHSTRRWLFRRRRARYTPSNCGESSTSS
GQSSGDESNCSLRTHGVYTRGEQH 
US32 Forward Protein US32 Contains duplicated TT virus ORF2 motif; US1 family 183 MAMYTSESERDWRRVIHDSHGLWCDCGDWREHLYCVYDSHFQRRPTTRAERRAANWRRQMRRLHRLW
CFCQDWKCHALYAEWDGKESDDESSASSSGEAPEQQVPAWKTVRAFSRAYHHRINRGLRGTPPPRNLPGY
EHASEGWRFCSRRERREDDLRTRAEPDRVVFQLGGVPPRRHRETYV 
US33A Forward Protein US33A  57 MSLRFPERAGYEKLGYRPHAKRVRVHDSLGLTRFIMRQLMMYPLVLPFTFPFYVPRS 
US34 Forward Protein US34 Contains signal peptide 163 MNLEQLINVLGLLVWIAARAVSRVGPHGSGLVYRELHDFYGYLQLDLLGPVVAGNRSVRTWREQADRAKG
TFARRSGLNTSHILPVGSMYRGSDTLSAGLYRPEEEVFLLLNRCHGPLSTPKNACLAEVGVANSTFLSRFNVG
DFHGASWENGTAPDGELGVC 
US34A Forward Protein US34A Contains potential transmembrane domain 64 MLKFLLRFRKRRRPVVVPRFVRFIVYVVLFTVAVQRVKQERDAHLRRYEERLRKNRARRRQSFP 
TRS1 Reverse Tegument protein TRS1 Transcriptional activator; blocks phosphorylation of 
eIF2alpha and host shutoff of protein synthesis; 
binds dsRNA; involved in gene regulation; involved in 
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Appendix 13. This table outlines the annotated genes in ZM240 and the amino acid sequences of their products. 
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